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Cancer Survivorship
I001
MYOCARDIAL INFARCTION MORTALITY RISK AFTER TREATMENT FOR HODGKIN DISEASE:
A COLLABORATIVE BRITISH COHORT STUDY
A.J. Swerdlow,1 C.D. Higgins, P. Smith, D. Cunningham, 
B.W. Hancock, A. Horwich, P.J. Hoskin, A. Lister, J.A. Radford, 
A.Z.S. Rohatiner, D.C. Linch
1Section of Epidemiology, Institute of Cancer Research, Sutton, UK
Risk of myocardial infarction mortality has been ascertained in a
cohort of 7033 patients with Hodgkin disease who were treated at cen-
tres in Britain during 1967-2000. Mortality was compared with expec-
tations from general population rates. 2441 deaths occurred during fol-
low-up, of which 166 were from myocardial infarction. Risks of myocar-
dial infarction in relation to age, field of radiotherapy and type of
chemotherapy will be presented and the implications discussed.
I002
RISK FACTORS FOR CARDIOVASCULAR DISEASE; DUTCH RESULTS
B.M.P. Aleman,1 A.W. van den Belt-Dusebout,2 M.L. De Bruin,2
M.B. van ’t Veer,3 M.H.A. Baaijens,4 F.E. van Leeuwen
1Department of Radiotherapy, the Netherlands Cancer Institute, Amsterdam;
2Department of Epidemiology, the Netherlands Cancer Institute, Amsterdam;
3Department of Hematology, the Dr. Daniel den Hoed Cancer Center, Rotterdam;
4Department of Radiotherapy, the Dr. Daniel den Hoed Cancer Center, Rotter-
dam, the Netherlands
Introduction. Over the past decades, survival of patients treated for
Hodgkin's lymphoma (HL) has improved dramatically. This improved
prognosis of HL has, however, been accompanied by long-term toxici-
ty, like elevated risks of cardiovascular disease (CVD). The purpose of
this analysis was to assess incidence of and risk factors for CVD in 5-year
survivors of HL.
Methods. We compared CVD incidence with general population rates
in 1,474 survivors of HL treated before the age of 41 years in two Dutch
centres (1965-1995). Multivariable Cox regression and competing risks
analyses were used to quantify treatment effects on CVD risk. 
Results. After a median follow-up of 18.7 years, risks of myocardial
infarction (MI) and congestive heart failure (CHF) were strongly
increased compared to the general population [Standardized Incidence
Ratios (SIRs)=3.6 and 4.9, respectively], resulting in 35.7 excess cases of
MI and 25.6 excess cases of CHF per 10,000 patients/year. SIRs of all
CVDs combined remained increased for ≥25 years and were more
strongly elevated in younger patients. Mediastinal radiotherapy signifi-
cantly increased the risks of MI, angina pectoris, CHF and valvular dis-
orders (2- to 7-fold). Anthracyclines significantly added to the elevated
risks of CHF and valvular disorders from mediastinal RT (Hazard Ratios
(HRs): 2.81 and 2.10, respectively). The 25-year cumulative incidence of
CHF after mediastinal radiotherapy and anthracyclines in competing
risk analyses was 7.9%. Established cardiovascular risk factors, except
hypertension, increased the risk of most CVDs, but did not appear to
interact with treatment effects.
Discussion. Risks of several CVDs are 3- to 5-fold increased in HL-sur-
vivors compared to the general population, even after prolonged follow-
up, leading to increasing absolute excess risks over time. Anthracyclines
further increase the elevated risks of CHF and valvular disorders from
mediastinal radiotherapy. While treating patients with HL the radiation
dose to the heart should be limited as much as possible. In addition,
especially in young HL survivors at increased risk of CVD, physicians
should consider appropriate risk reducing strategies such as treatment of
hypertension and hypercholesterolemia, and life-style advice such as
refraining from smoking.
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CLINICAL APPLICATIONS OF MODELLED SECOND CANCER RISK AMONG HODGKIN 
LYMPHOMA SURVIVORS
D.C. Hodgson
Department of Radiation Oncology, Princess Margaret Hospital, and Depart-
ment of Health Policy, Management and Evaluation, University of Toronto,
Canada
Introduction. It has been known for several years that Hodgkin lym-
phoma (HL) survivors are at increased risk of developing second cancers
(SC). Modeling the complex interaction of factors that contribute to SC
risk could facilitate the appropriate management of survivors as well as
treatment modifications to improve the long-term outcome of HL
patients. 
Methods. Advances in the modelling of SC risk will be discussed, with
emphasis on the clinical applications of screening for SC among sur-
vivors, and modifying RT fields and doses in contemporary patients.
Results. Age at treatment, attained age, latency, sex, treatment, and
competing risks of death all influence the risk of SC. Data are accumu-
lating regarding the radiation dose-risk relationship at doses used in the
treatment of HL, indicating that this risk varies for different exposed
organs. Additional biologic factors of presumed importance are not well
understood. Results of an international registry study support the initi-
ation of breast cancer screening among female HL survivors starting 8-
10 years after HL diagnosis, and also indicate that some survivors have
risks of colorectal cancer comparable to the screening- eligible general
population at attained ages 10-15 years before colorectal cancer screen-
ing would normally be recommended.
Discussion. Modeling SC risk can facilitate the development of ration-
al strategies for cancer screening among survivors and also reducing the
late effects of modern therapy. 
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SCREENING FOR LUNG CANCER IN PATIENTS AT HIGH RISK OF THIS SECOND CANCER
AFTER TREATMENT FOR HODGKIN LYMPHOMA (HL)
J.A. Radford,1 H. Roberts,2 R. Banks,3 P. Lorigan1
1Cancer Research UK Department of Medical Oncology, Christie Hospital and
University of Manchester, Manchester, UK; 2Department of Medical Imaging,
University Health Network and University of Toronto, Toronto, Canada; 3Clin-
ical and Biomedical Proteomics Group, Cancer Research UK Clinical Centre, St
James’s University Hospital, Leeds, UK
Lung cancer is a common second tumour after treatment for HL with
a relative risk (RR) of 2.2 and absolute excess risk (AER) of 9.7 (for female
breast cancer RR is 2.0 and AER 10.5). Unfortunately it is usually asso-
ciated with a poor prognosis because the disease is often far advanced
when diagnosed and responds poorly to treatment. Risk factors for lung
cancer in this setting are age over 40 years at treatment for HL, time
since treatment (risk increases to a maximum at 25 years) thoracic irra-
diation (RT) and alkylating agent containing chemotherapy (CT). With-
in the RT category, dose, fractionation and field size are important and
the effects of combination CT/RT are additive. Smoking has a synergis-
tic effect but here is no clear impact on risk of gender, HL stage or
whether or not the patient has been splenectomised. Reducing the bur-
den of lung cancer in HL survivors is a priority and apart from measures
to encourage smokers to quit and to fully utilise technologies such as PET
imaging to define more precisely patients requiring RT, screen detection
of small asymptomatic tumours when these are potentially curable by
surgical resection warrants investigation. Considerable interest has been
expressed in such a study the proposed entry criteria for which are: 
- Males/females first treated for HL aged ≥40years;
- Treatment for HL comprising a minimum of thoracic RT alone, any 
CT plus thoracic RT or alkylating agent containing CT alone;
- ≥10 years since first treatment and ≥5 years since completed any treat
ment for HL;
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WORKSHOPS, SCIENTIFIC SESSIONS AND MAIN PROGRAM: ORAL SESSIONS
- No evidence of active HL for ≥5 years;
- Age at study entry ≤70 years
Following informed consent, study entrants will be asked to complete
a lifestyle questionnaire with particular emphasis on smoking history.
This will be supplemented by details of previous treatment for HL
extracted from the case-notes. Low dose, helical CT scanning of the
thorax will be performed at baseline, 2 and 4 years and blood
drawn/stored for subsequent proteomic analysis. Following each
planned CT scan patients will be managed according to an algorithm
that will determine the need for no further action for two years, a repeat
CT scan after a shorter interval, a PET scan or immediate surgery. The
1y endpoint will be prevalence/incidence of resectable cancers detected
by screening and 2y endpoints, incidence of interval cancers, proteomic
data associated with early stage lung cancer, molecular pathology of
resected cancers, patient acceptability and health economic parameters. 
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BREAST MAGNETIC RESONANCE IMAGING (MRI) SCREENING IN FEMALE SURVIVORS
OF HODGKIN LYMPHOMA (HL): PRELIMINARY FINDINGS 
A.K. Ng, R.L. Birdwell, L.R. Diller, D. Neuberg, J.E. Garber, 
D.C. Fisher, M.A. Stevenson, P.M. Mauch
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Med-
ical School, Boston, MA, USA
Introduction. Women who received mantle irradiation at a young age
for Hodgkin lymphoma (HL) are at increased risk for breast cancer. The
American Cancer Society recommends annual magnetic resonance
imaging (MRI) screening as an adjunct to mammography in women
who have received chest irradiation between ages 10-30. The aim of this
study is to compare the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) of mammography versus
breast MRI for breast cancer detection in survivors of HL
Methods. Women treated with mantle irradiation for HL at age ≤35,
and are now ≥ 8 years out from treatment are eligible for the study. Par-
ticipants undergo yearly breast MRI and mammogram for 3 years. We
plan to recruit 168 patients over 4 years, which will allow an 80% pow-
er to detect a difference of sensitivities of 0.9 for MRI versus 0.5 for
mammogram, at a one-sided significant level of 0.1. 
Results. To date, 90 patients have been enrolled. The median age at
enrollment was 42 (range, 22-62), the median age at HL treatment was
24 (range 8-34), and the median time from treatment was 18 years
(range, 8-39). Seven patients withdrew for the following reasons: insur-
ance coverage denial (3), moved out-of-state (1), lack of time (1), fear of
IV contrast (1), bladder implant (1). 63 patients have completed the first
set of mammogram and breast MRI, and 10 patients have completed the
second set of studies. 13 patients had abnormal radiographic breast find-
ings on both MRI and mammogram (5), MRI alone (7), or mammogram
alone (1), leading to a biopsy. Six of the 13 biopsies were positive for
malignancy. Of the 5 biopsies based on both MRI and mammogram
abnormalities, 3 were positive [2 invasive cancer and 1 ductal carcino-
ma-in-situ (DCIS)]. Of the 7 biopsies for MRI abnormalities alone, 2
were positive (1 DCIS and 1 phyllodes tumor). The 1 biopsy based on
abnormal mammogram alone showed DCIS. 1 patient had incidental
finding of a 3 cm right lung mass on the breast MRI and was subsequent-
ly found to have stage IIB lung cancer
Discussion. Preliminarily, breast MRI as an adjunct to mammogram
detected 2 malignancies that were missed by mammogram among
screened patients (3.2%). It also led to 5 biopsies with negative findings
that would otherwise have been avoided with mammogram screening
alone (7.9%). We will formally compare the sensitivity, specificity, PPV
and NPV of breast MRI versus mammogram when target accrual is
reached. 
Pathology
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CYTOKINE GENE EXPRESSION AND T-CELL TRANSCRIPTION FACTOR PROFILE OF THE 
T-CELLS OF THE NODULAR LYMPHOCYTE PREDOMINANCE TYPE OF HODGKIN'S 
LYMPHOMA
Ç. Atayar,1 S. Poppema,1 T. Blokzijl,1 M. Boot,1 R.D. Gascoyne,2
L. Visser,1 A. van den Berg1
1Department of Pathology & Laboratory Medicine, University of Groningen and
University Medical Centre Groningen, The Netherlands; 2Department of Pathol-
ogy, University of British Columbia and British Columbia Cancer Agency, Van-
couver, BC, Canada
Introduction. Both subtypes of Hodgkin lymphoma (HL) are character-
ized by an ineffective immune response that is predominantly mediat-
ed by CD4+ T-cells. We studied the expression of the fundamental T-cell
transcription factors (TFs) and the cytokines in the T-cells of HL involved
tissues to assess the nature of the T-helper immune response and the sig-
nificance of the characteristic rosetting CD4+/CD57+ T-cells in nodular
lymphocyte predominance type of Hodgkin lymphoma (NLPHL).
Methods. We used immunohistochemistry to evaluate the expression
of the T-cell TFs. We analysed different T-cell populations isolated by
FACS from lymph node cell suspensions from NLPHL, cHL, normal ton-
sil, follicular hyperplasia and progressive transformation of germinal
centres (PTGC). The T-cells were sorted based on expression of CD3,
CD4 and CD57. The cytokine mRNA profiles of the T-cell subsets were
determined with quantitative RT-PCR. 
Results. GATA3 was strongly expressed in a subset of interfollicular
lymphocytes in the reactive lymphoid tissues, whereas T-bet was
expressed exclusively in interfollicular lymphocytes. In cHL, that is gen-
erally located in the interfollicular zones, a predominance of T-bet+ T-
cells were found with a low percentage of GATA3+ and c-Maf+ T-cells.
In reactive lymphoid tissues, c-Maf expression was observed mostly in
T-lymphocytes within the germinal centres (GCs). NLPHL and PTGC
cases showed a majority of c-Maf+ T-cells, consistent with the pattern
in normal GCs. NLPHL cases uniformly showed c-Maf+/CD57+ T-cell
rosettes around the neoplastic cells. The overall percentage of T cells was
similar in NLPHL and cHL cases, but all NLPHL cases had a much high-
er frequency of CD4+/CD57+ T-cells. In contrast to the CD4+/CD57+ T-
cells from tonsils, IL2 and IL4 mRNAs were consistently absent from the
CD4+/CD57+ T-cells of NLPHL. Even after stimulation, no IL4 transcripts
could be detected in the CD4+/CD57+ T-cells of NLPHL. On the other
hand, IFNγ transcripts were elevated in NLPHL and PTGC T-cell subsets
as compared to the tonsillar T-cell subsets. 
Discussion. T-cell TF expression profiles of the reactive T-cells in both
subtypes of HL are in accordance with the expression profile observed
in the distinct lymphoid compartments. Elevated levels of CD4+/CD57+
T-cells are characteristic of NLPHL and these T-cells display a distinctive
cytokine mRNA profile consistent with the characteristics of CD4+ T
regulatory type 1 cells. 
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DOUBLE-POSITIVE CD4+CD8+ T-CELL POPULATIONS IN NODULAR LYMPHOCYTE 
PREDOMINANT HODGKIN LYMPHOMA: FURTHER CHARACTERIZATION AND 
RELATIONSHIP TO OTHER ENTITIES
A. Rahemtullah,1 K.K. Reichard,2 M.E. Dorn,1 F.I. Preffer,1 N.L. Harris,1
R.P. Hasserjian1
Departments of Pathology, 1Massachusetts General Hospital and Harvard Med-
ical School, Boston, MA; 2University of New Mexico, Albuquerque, NM, USA
Introduction. Nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL) is a distinct subtype of Hodgkin lymphoma composed of a rel-
atively small number of neoplastic L&H Reed-Sternberg variant cells in
a background of reactive small B and T cells. The immunophenotype of
the background cells had not been well-characterized until recently,
when we demonstrated that a double-positive (DP) CD4+CD8+ T-cell
population is commonly found in NLPHL. 
Methods. In an initial frequency analysis, we reviewed 24 cases of
NLPHL from 2 independent laboratories and compared flow cytomet-
ric (FC) results with those of 13 progressively transformed germinal cen-
ters (PTGC) cases, 78 nonspecific reactive hyperplasia (RH) cases, and
31 classical Hodgkin lymphoma (CHL) cases. Additional NLPHL cases
received in consultation were also reviewed for the presence of DP T
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cells. Subsequently, additional staining of DP T cells for T-cell activation
markers (CD25, CD38, CD57, CD69, CD71, HLA-DR) was performed
in a lymph node involved by NLPHL (n=1), bone marrow (n=7) and
peripheral blood (n=1) samples in which DP T cells were identified. 
Results. The frequency analysis revealed the presence of a DP T-cell
population in 58% of NLPHL cases, constituting 10-38% of T cells. The
cells were brightly CD4+, exhibited variable positivity for CD8, and were
CD2+, CD3+, CD5+, CD7+, CD1a– and TdT–. Similar DP T cells were
identified in 38% of PTGC cases (p=0.31), but only 4% of RH
(p<0.00001) and 6% of CHL (p<0.0001) cases. DP T cells were identified
in 7 NLPHL consultation cases on which FC had been performed at 5
independent laboratories (not included in frequency analysis). Subse-
quent FC analysis of DP T cells in bone marrow, peripheral blood, and
NLPHL cases for coexpression of T-cell activation antigens showed that
CD57 was consistently expressed on >50% of the DP T cells in all 9 sam-
ples, while expression of the other antigens was less consistently seen
on a minority of the DP T cells. 
Discussion. DP T cells constitute a significant number of background
cells in a majority of NLPHL cases. The DP T cells commonly coexpress
CD57. Their presence in NLPHL and PTGC may reflect an activated or
reactive T-cell subset and should not lead to a misdiagnosis of T-cell
lymphoma. This population may be a clue to the diagnosis of NLPHL,
particularly in cases with limited tissue. The role of these cells in the
pathogenesis of NLPHL and PTGC and their localization within involved
lymph nodes require further study.
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CD4/CD8-DOUBLE POSITIVE T CELLS IN NODULAR LYMPHOCYTE PREDOMINANCE
HODGKIN LYMPHOMA (NLPHL)
Y.H. Oh, A. Weng, J. Connors, R.D. Gascoyne
British Columbia Cancer Agency and University of British Columbia, Depart-
ment of Pathology and Medical Oncology, Vancouver, British Columbia, Cana-
da
Introduction. Double CD4+/CD8+ T cells are not normally present in
the peripheral blood or lymph nodes of healthy individuals. They have
been described as probable effector memory T cells and have been asso-
ciated with viral infections. A significant elevation of these cells has
recently been described as a unique finding in the lymph nodes (LN) of
patients with NLPHL (Rahemtullah et al., Am J Clin Pathol, 2006; 126:
805-14).
Patients and Methods. We studied a total of 311 LN biopsies, including
33 NLPHL, 58 classical HL (cHL), 200 with reactive hyperplasia (RH), 15
with progressive transformation of germinal centers (PTGC) and 5 with
T cell-rich B cell lymphoma (TCRBCL) using 3-color flow cytometry for
CD4/8 double-positive T cells. Patients with NLPHL and clinical data (n
= 30) were further analyzed in an attempt to correlate the presence of
these cells with survival.
Results. Double positive T cells, defined as ≥2% of the CD4 and CD8
T cells, were identified in 14 of 33 (42%) NLPHL, 4 of 15 (27%) PTGC,
33 of 200 (16.5%) RH, 1 of 5 (20%) TCRBCL and 1 of 58 (1.7%) with
cHL. These differences were highly significant. The characteristic
immunophenotype of these cells was CD4 bright and CD8 dim. Cases
with > 6% CD4/8 double-positive T cells were identified only in RH
(2/200, 1%) and NLPHL (5/32, 16%). Clinical data and follow-up were
available for 30 patients with NLPHL. This included 22 males and 8
females with a median age of 36 years and 60% with limited-stage dis-
ease. Treatments were variable (see Savage et al., abstract this meeting),
with a median follow-up of living patients of 46 months. Using a thresh-
old of ≥2% CD4/8 double-positive T cells, there was no significant dif-
ference in overall or progression-free survival between patients deemed
negative (n = 19) vs positive (n = 11). However, the number of patients
is too small to make definitive conclusions. 
Conclusions. In summary, the finding of CD4/8 double-positive T cells
in LN biopsies is strongly correlated with NLPHL and to some extent,
PTGC. These findings confirm those of the previous study. These results
do not support an obvious relationship between NLPHL and TCRBCL,
although the number of analyzed cases is small. The function of these
cells is unknown, but studies are continuing using fresh-frozen cell sus-
pensions. Although the presence of CD4/8 double-positive T cells lacks
clinical significance, further studies of additional patient cohorts are
required
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T REGULATORY CELLS IN CLASSICAL HODGKIN’S LYMPHOMA
R. Bosch, M. Lejeune, J. Jaén, L.l. Pons, M.T. Salvadó, C. López, 
P. Escrivá, T. Álvaro
Department of Pathology, Hospital de Tortosa Verge de la Cinta, Tortosa, Spain
CD4+ T lymphocytes present in the reactive microenvironment of
Hodgkin Lymphoma (HL) have been described to express typical mark-
ers of regulatory T cells (Treg), including FOXP3, GITR, LAG3, CD25 and
CTLA-4. Macrophage-derived chemokine MDC/CCL2, expressed by
HL tumor cells, has demonstrated to be able to mediate Treg trafficking
probably through their specifiv CC chemokine receptor (CCR4). Cur-
rently, immunohistochemical and flow cytometric techniques have per-
mitted the detection of mainly two forms of Treg in the tumor microen-
vironment of HL: the natural CD4+CD25+ T cells (FOXP3+/GITR+/
LAG3+) and the adaptive interleukin (IL)-10 producing T regulatory 1
(Tr1) cells. These migratory Treg cells, induced by the HL tumor cells,
appear to be able to create a favourable environment for the tumor cells
to escape from host immune system. Tr1 cells appear to inhibit antitu-
mor immunity mainly by cytokines-dependent mechanisms although
CD4+CD25+ cells mediate suppression by cell-cell contact, delaying or
blocking the antitumoral cytotoxic immune response. Functional assays
have demonstrated that these Treg are also able to suppress INF-Á pro-
duction and PBMC response to mitogens and recall antigens. Moreover,
in patients with EBV-associated HL, the presence of infiltrated Treg
LAG3+ and FOXP3+ in the microenvironment of the tumor has demon-
strated to be linked to the impairment of LMP-specific T cell responses.
Few studies have been focused on the prognostic role of Treg in lym-
phomas. Recently, we have demonstrated the utility of Treg cells con-
tent as a prognostic factor in HL patients. Contrary to what happens in
carcinomas and what it would be expected in HL, we found that an
increased numbers of infiltrating FOXP3+ Treg cells in conjunction with
decreased infiltration of cytotoxic T lymphocytes predicted a favourable
clinical outcome of HL patients. Other authors have also found a simi-
lar improvement of survival when high Treg number where observed in
some types of lymphomas, particularly follicular and cutaneous T-cell-
lymphomas. At present, new therapeutic modalities are being designed
in order to manipulate Treg pathway. Nevertheless, before using these
new approaches in humans it is mandatory to clarify the real prognos-
tic impact of Treg in the lymphoma tumor microenviroment. 
Supported by grants FIS 04/1440, 04/1467 and 05/1527 from the Ministe-
rio de Sanidad y Consumo, Spain.
I011
BIOLOGIC PROGNOSTIC MARKERS IN CHL: EVALUATION OF CHARACTERISTICS OF RS
CELLS AS WELL AS THE TUMOR INFILTRATING LYMPHOCYTES
E.D. Hsi
Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH USA
Classical Hodgkin lymphoma (CHL) is a neoplasm of post-germinal
center B-cells that appear to avoid apoptotic cell death. Characteristics
of the Reed-Sternberg (RS) cell are being elucidated that help explain its
ability to survive. However, the non-neoplastic immune cells in CHL
make up over 95% of the lymph node infiltrate and these cells also play
a role in lymphomagenesis. Prognostic factors in HL are primarily clini-
cal factors. Biologic factors that may yield added information and pro-
vide clues for targeted therapies are needed. To this end, we and others
have studied constituents of the non-neoplastic infiltrate. In particular,
we were interested in the balance of regulatory T-cells (Treg) and cyto-
toxic T-cells (CTLs) in CHL. In a series 94 biopsies from newly diagnosed
CHL patients treated with curative intent, we evaluated the number of
FOXP3+ Tregs and granzyme B+ (GzB) CTLs by immunohistochemistry
to evaluate Treg and activated CTLs within the tumor. The median age
of patients was 29 years, 51% were male, and the 5-year failure free sur-
vival (FFS) and (OS) are estimated to be 76±4% and 86±4%, respective-
ly. The number of Tregs correlated with lower stage (p=.02) and age <45
years (p=.01). Increased GrB+ CTLs were significantly associated with
male sex (p=0.006), age≥45 years (p=0.02), histologic subtype other than
nodular sclerosis (p=0.001). FOXP3+ Tregs <25/hpf was associated with
shorter FFS (P=.05) while GrB was not associated with outcome. How-
ever, the ratio of FOXP3/GzB >1 was associated with a favorable FFS and
OS (p<.001). In multivariable analysis this association remained, with
other unfavorable clinical factors being presence of bulky disease and IPS
>2. In previous studies, we had shown BCL2 and MAL expression in RS
cells were independent factors that were associated with shorter survival.
Interestingly, when also considering the FOXP3/GzB ratio, a FOXP3/GzB
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ratio ≤1 and MAL in RS cells remained independently associated with
an unfavorable FFS and OS. These studies suggest that evaluation of
biologic factors in CHL, including features of the non-neoplastic tumors
cells, may yield important prognostic information.
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IDENTIFICATION AND PURIFICATION OF HODGKIN CELLS FROM LYMPH NODES
INVOLVED BY CLASSICAL HODGKIN LYMPHOMA BY FLOW CYTOMETRY AND FLOW
CYTOMETRIC CELL SORTING
J.R. Fromm,1 M. Roshal,1 S.J. Kussick,2 B.L. Wood1
1Laboratory Medicine, University of Washington, Seattle, WA; 2PhenoPath Lab-
oratories, Seattle, WA, USA
Introduction. Purification of Hodgkin and Reed-Sternberg (HRS) cells
from lymph nodes involved by classical Hodgkin lymphoma (CHL) has
historically employed microdissection as methods like flow cytometry
(FC) and flow cytometric cell sorting (FCCS) have not been able to iden-
tify and purify these cells. As HRS cells are ringed (rosetted) by benign T
cells, we hypothesized that in cell suspensions HRS cells will be bound
to T cells (forming rosettes) and that the rosettes would have a compos-
ite T-cell/HRS immunophenotype by FC (CD3+/CD15+/CD20–/
CD30+/CD45+). We further hypothesized that specific antibodies to the
adhesion molecules known to be involved in T cell/HRS cell binding
might result in naked (unbound) HRS cells, enabling us to use FC and
FCCS to identify and purify HRS cells with the expected immunophe-
notype.
Methods/Results. Initial FC studies of the HRS cell line L1236 demon-
strated that CD15, CD30, CD40, CD71, and CD95, but not CD3 or
CD20, were brightly expressed on these cells and may be useful in iden-
tification and purification of HRS from lymph nodes. In mixing experi-
ments, L1236 cells spontaneously bound normal T cells, analogous to T
cell rosetting of HRS cells in CHL; these interactions could be blocked
specifically using unlabeled antibodies to CD2, LFA-1, CD54, and CD58.
Among 27 lymph nodes involved by CHL (250,000 to 500,000 lymph
node cells assessing up to ten antigens simultaneously), HRS cells were
identified in 89% of cases. 82% of these cases demonstrated HRS cell/T
cell interactions that could be disrupted with blocking antibodies. None
of 29 non-CHL neoplasms and none of 23 reactive lymph nodes, demon-
strated HRS populations by FC. With the exception of CD45 (expressed
at a low level in most cases), antigen expression was similar to that
described in tissue sections. Three to six color FCCS experiments (exam-
ple: CD15-FITC, CD30-PE, CD45-ECD, and CD40-PeCy5.5) resulted in
T cell-HRS cell rosettes or naked HRS cells when sorting in the absence
or presence of blocking antibodies, respectively.
Discussion. These results confirm that 1) the populations identified by
FC have the cyto-morphology HRS cells, 2) rosettes can be disrupted by
blocking antibodies, and 3) HRS cells can be isolated with greater than
90% purity yielding more than 1,000 cells in a single sort. These FCCS
and FC techniques offers a rapid means of purifying HRS cells and a
potential alternative to immunohistochemistry in confirming the diag-
nosis of CHL.
Allogeneic Stem Cell Transplantation
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HODKGIN LYMPHOMA
G.G. Laport
Division of Blood and Marrow Transplantation, Stanford University Medical
Center, Stanford, CA, USA
High dose chemotherapy with autologous hematopoietic cell trans-
plantation (HCT) is the standard of care for patients with relapsed or
refractory Hodgkin lymphoma (HL). The role of allogeneic HCT for
patients with HL however, remains under debate as the existence of a
graft-vs-tumor (GVT) effect against HL is controversial although donor
leukocyte infusions have induced durable remissions anecdotally. A
handful of studies have detailed the experience with myeloablative allo-
geneic HCT but overall, results have been disappointing. Treatment-
related mortality (TRM) has ranged from ~20-60% with progression-free
survival (PFS) varying from ~15-25% with relapse rates as high as 65%.
Most results originate primarily from registry data from the European
Bone Marrow Transplant Registry (EBMT)and the International Bone
Marrow Transplant Registry. Although the relapse risk appears to be
somewhat lower compared to autologous HCT, the suggested benefit
of a GVT effect is consistently diminished by TRM. In an effort to reduce
the TRM associated with myeloablative allogeneic HCT, reduced inten-
sity conditioning (RIC) regimens have recently been offered to patients
with relapsed/refractory HL. This modality relies more on the GVT
effect for curative potential rather than upfront cytoreduction. There
are several published reports with moderate sample sizes and heteroge-
nous conditioning regimens although most regimens are fludarabine-
based. All reports utilize both related and unrelated donors with no
apparent difference in outcome based on donor type. A consistent result
seen is reduced upfront TRM at 100 days ranging from 4-17%. The PFS
of 18%-32% is encouraging as most of these series included a large pro-
portion of patients who had failed prior autologous HCT. The incidence
of disease progression, however, remains a major cause of treatment
failure and varies from 43-64%. Prognostic factors reported to influence
outcome after allogeneic HCT are nearly identical to the prognostic fac-
tors affecting outcome after autologous HCT such as chemosensitivity,
performance status and number of prior regimens. The EBMT has the
largest published RIC series with 311 patients with 45% of patients
who had failed a prior autologous HCT. With a 1 year median followup,
the 2 year PFS, overall survival and relapse incidence was 26%,46% and
64%, respectively. The incidence of acute graft vs host disease (grade 2-
4) and chronic graft vs host disease was 24% and 20%, respectively. The
100 day TRM was 17% with chemoresistant disease being an adverse
prognostic factor affecting TRM. Investigators from the M. D. Anderson
Cancer Center have reported one of the largest series(n=40) from a sin-
gle center and found that intensity of the RIC regimen affected survival.
Patients who had received a less intensive regimen consisting of flu-
darabine, cyclophosphamide + antithymocyte globulin had a less
favourable OS compared to patients who had received the more cytore-
ductive regimen of fludarabine and melphalan(73% vs 39%, respective-
ly, p=03). Thus, the data detailing the feasibility of RIC transplantation
has been gradually accumulating with cautiously optimistic results.
Heavily pretreated patients including those who had failed prior autol-
ogous HCT may benefit from RIC HCT with acceptable early TRM.
Overall, the current data regarding the efficacy of RIC conditioning war-
rants the continued investigation of this modality for patients with
chemosensitive HL. However, the optimal RIC regimen remains to be
determined. 
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ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT) IN HODGKIN’S LYMPHOMA
(HL): THE EUROPEAN POINT OF VIEW
A. Sureda,1 C. Canals,1 S. Robinson,2 A. Claviez,3 N. Schmitz,4 on
behalf of the Lymphoma Working Party (LWP) of the European Group
for Blood and Marrow Transplantation (EBMT)
1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 2Bristol Children’s
Hospital, UK; 3University Hospital Schleswig-Holstein, Kiel, Germany; 4AK St.
Georg, Hamburg, Germany
Allo-SCT remains an experimental therapeutic procedure in HL
patients (pts). Nevertheless, although the high non-relapse mortality
(NRM) of myeloablative protocols prevented the widespread use of allo-
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SCT in this disease, the development of reduced intensity conditioning
(RIC) regimens has resulted in a significant increase in the number of allo-
geneic procedures performed over the last 10 yrs (Figure 1). 
Figure 1. Event free survival for stage 3 and 4 of LPHL.
To evaluate the impact of these RIC regimens, the LWP of the EBMT
sought to determine the outcomes of pts with HL undergoing allo-SCT
either after a myeloablative (n=79) or a RIC protocol (n=89). NRM was
significantly decreased in the RIC group. OS was better in the RIC group
and there was a trend for better PFS in the RIC group. The development
of cGVHD decreased the incidence of relapse, which translated into a
trend for a better PFS. Considering the potential advantages of these RIC
regimens, an analysis of the long-term outcome of 374 pts undergoing
this procedure was performed [21% were in CR, 39% had chemosensi-
tive (CS) disease and 40% had chemoresistant (CRf) disease]. 80% of the
patients had failed a prior ASCT. NRM rate at 100 days and 3 yrs was
11.8% and 22.5% respectively. The development of either aGVHD or
cGVHD was associated with a lower rate of disease progression. The dis-
ease progression rate at 1 and 5 yrs was 39% and 60% respectively. PFS
and OS rates at 1 yr were 40% and 65% and at 3 yrs were 24% and 39%
respectively and were superior in pts with a good performance status (PS)
and CS disease. Finally, specific attention was given to paediatric pts
and adolescents with HL (n=151) undergoing an allo-SCT. A myeloab-
lative regimen was given to 40% of pts. Disease status was CS in 59%
and CRf in 41%. PFS at 2 and 5 yrs were 39% and 29%, respectively.
Relapse rates (RR) at 1, 2 and 5 yrs were 29%, 37% and 44%, respec-
tively, whereas NRM at 1, 2 and 5 yrs were 20%, 24% and 27%. PFS and
NRM of pts without adverse prognostic factors (allo-SCT >2001,
matched donors and good PS), PFS at 1, 2 and 5 yrs was 67%, 50% and
43%, and 11%, 17% and 17%, respectively. In summary, allo-SCT has
increasingly being performed in relapsed HL pts in Europe due to the
development of RIC regimens. Its use has been associated to a signifi-
cant reduction in NRM, an improvement in OS and the possibility to bet-
ter demonstrate the existence of a GVL effect associated to the develop-
ment of GVHD after allo-SCT. Results are significantly better in those
pts undergoing the allo-SCT in good PS and with CS disease.
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IMPROVED OUTCOME FOLLOWING REDUCED INTENSITY ALLOGENEIC TRANSPLANTATION
IN HODGKIN’S LYMPHOMA RELAPSING POST-AUTOLOGOUS TRANSPLANTATION
S. Mackinnon, K.J. Thomson, A.H. Goldstone, D.C. Linch, K.S. Peggs
Royal Free and University College London School of Medicine, UK
Hodgkin’s Lymphoma is curable with primary therapy in the majori-
ty of patients. For those with relapsed or refractory disease, salvage with
high dose chemotherapy plus autologous stem cell rescue is effective for
a significant proportion. Patients relapsing following autologous stem cell
transplantation, however, have an extremely poor prognosis. Allogene-
ic transplantation with conventional conditioning has proved excessive-
ly toxic in this setting, and reduced intensity conditioning has therefore
been introduced, with encouraging preliminary results. This is a study
of 72 patients relapsing following autologous transplantation, analysed
in 2 groups. One group (A: n=38) then underwent allogeneic transplan-
tation with reduced intensity conditioning at 6 UK centres (1998-2004),
with alemtuzumab 100 mg, fludarabine 150 mg/m2 and melphalan 140
mg/m2. Donors were HLA-matched related in 63% of cases, and unre-
lated in the remaining 37%. The second group (B: n=34) is a control
cohort, who relapsed before the advent of reduced intensity condition-
ing, and were treated with chemotherapy ± radiotherapy alone. The
groups were equivalent in age (median- A 31yrs [20-51]; B 29yrs [13-47]),
disease subtype (>85% nodular sclerosing both groups), time from diag-
nosis to autograft (median-A 18mo [7–139]; B 20mo [4-185]), and lines
of prior therapy pre-autograft (median 3 both groups). Median time from
autograft to relapse for group A was 13mo (2-56) and for group B 10mo
(3-40), and patients were only selected for inclusion in group B if they
responded to further salvage therapy, attained at least a stable response
to treatment, and lived for >12 months following relapse (median time
from relapse to allogeneic transplant for group A is <12 months). In this
way, it was intended to include only those patients who would have
been eligible for reduced intensity allogeneic transplantation had this
been available at the time. Indeed, the entry criteria for group A were
arguably less stringent, as patients with chemorefractory disease were
included (n=14, 37%). Overall survival from diagnosis was significant-
ly better in group A, with actuarial survival at 10yrs of 48% compared
to 15% in group B (p=0.0014), and overall survival from autograft was
65% at 5 yrs in group A and 15% in group B (p=<0.0001). Of group B
patients treated with chemotherapy/RT alone, only 2/34 patients remain
alive at a median follow-up of 22 months from relapse, one of whom has
progressive disease. For group A receiving reduced intensity transplan-
tation, actuarial survival from the time of allograft was 50% at 5 yrs. In
the chemoresponsive patients, OS at 5yrs was 57% at 5 yrs with current
progression-free survival of 39% at 5 yrs. This demonstration of the
potential efficacy of reduced intensity transplantation in a group of heav-
ily pre-treated patients who have failed autograft and whose outlook is
otherwise extremely poor, strongly suggests further studies of reduced
intensity allogeneic transplantation in Hodgkin’s Lymphoma are war-
ranted. 
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ALLOGENEIC/SYNGENEIC/AUTOLOGOUS TRANSPLANTATION FOR HODGKIN 
LYMPHOMA - A COMPARISON
P. Bierman
Department of Internal Medicine, University of Nebraska Medical Center, Oma-
ha, NE, USA
Introduction. High-dose therapy followed by autologous hematopoiet-
ic rescue has become accepted therapy for patients with relapsed and
refractory Hodgkin lymphoma. Allogeneic transplantation has potential
advantages over autologous transplantation, but this approach is limit-
ed by donor availability and the high risk of transplant-related morbid-
ity and mortality. It is unclear when allogeneic (including syngeneic)
transplantation should be considered for patients with Hodgkin lym-
phoma, as compared to autologous transplantation.
Methods. The results of autologous (n=10,471), allogeneic (full inten-
sity HLA-identical sibling; n=532), and syngeneic (n=26) transplants for
Hodgkin lymphoma that were registered with the Center for Interna-
tional Blood and Marrow Transplant Research (CIBMTR) from 1990-
2005 were reviewed. Patients who had failed a prior transplant were
excluded. 
Results. The actuarial 4-year progression-free survival was 67% follow-
ing syngeneic transplantation, 44% following autologous transplanta-
tion, and 18% following allogeneic transplantation (p<0.01). The actu-
arial 4-year overall survival rates were 72%, 61%, and 30%, respective-
ly (p<0.01). 
Discussion. These results demonstrate that progression-free survival
and overall survival following autologous transplantation for Hodgkin
lymphoma is superior to allogeneic transplantation. It is possible that
allogeneic transplantation might be preferred in some circumstances,
however. Syngeneic transplantation should be considered in the rare cir-
cumstances when a donor is available. Additional analyses from the
CIBMTR data will be presented, as well as analyses from other registry
and single-institution databases. The data presented here are prelimi-
nary and were obtained from the Statistical Center of the Center for
International Blood and Marrow Transplant Research. The analysis has
not been reviewed or approved by the Advisory or Scientific Commit-
tee of the CIBMTR.
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CURRENT PROTOCOL AND CONCEPTS FOR CLASSICAL HODGKIN DISEASE (HD) IN THE USA
C.L. Schwartz, L.S. Constine
Department of Oncology and Pediatrics, Sidney Kimmel Oncology Center at
Johns Hopkins University, Baltimore, MD; and Department of Radiation Oncol-
ogy and James P. Wilmot Cancer Center, University of Rochester School of Med-
icine and Dentistry, Rochester, NY, USA
Introduction. The COG HD Committee has developed novel paradigms
of therapy that strive to bring HD treatment from a simple empirical
model toward one of biologically based therapeutics. Our efforts focus
on understanding response, postulating that early response reflects the
complex interplay between tumor, host and therapeutic factors. Legacy
trials showed that early response after 3 chemotherapy cycles (not after
6 cycles) was predictive of outcome.1 On this basis we developed an ear-
ly response based paradigm for tailoring the therapy of advanced HD.
Dose dense ABVE-PC delivered every 3 weeks enhanced early response
and thus supported therapeutic reduction.2 61% of patients were rapid
early responders (RER), achieving a 3 year EFS =88.3% with 3 ABVE-PC
cycles (9 wks) and consolidative RT (21 Gy), Slow early responders (SER)
achieved 86.8% EFS with 5 cycles and RT. 
Methods. Dose dense ABVE-PC is now the standard backbone thera-
py for ongoing COG studies. Doxorubicin, bleomycin, and etoposide are
limited. No procarbazine is used. i) AHOD0031 for intermediate risk
HD3 will accrue > 1500 children. It compares RT vs. No RT for rapid RER
who achieve CR. SER receive Ifosfamide/vinorelbine augmentation; ii)
AHOD0431 evaluates 3 AV-PC for low risk HD.4 RT is used only for
residual disease. Chemotherapy and low dose RT for disease recurrence
avoid high intensity salvage treatment; iii) The high risk protocol will
deliver ABVE-PC* with intensified cyclophosphamide.5 Success of
C59704 (escalated BEACOPP with response based, gender specific mod-
ifications) led to the cyclophosphamide dose escalation. SER will receive
augmented ifosfamide/vinorelbine, an efficacious COG retrieval regi-
men; 6 iiii) We have shown efficacy of gemcitabine/vinorelbine.7 A cur-
rent retrieval study evaluates NFκB inhibition with bortezomib, an
approach to biologically targeted therapy.
Discussion. The use of response-based treatment algorithms, based on
dose dense ABVE-PC, has allowed for short duration, highly effective
regimens that limit cumulative therapy, particularly for RER. Targeted
therapies that may enhance toxicity and avoid the long term complica-
tions of therapy are in process. 
References
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STRATEGY OF THE EURONET-PHL-C1 PROTOCOL FOR THE TREATMENT OF CLASSICAL
HODGKIN’S LYM-PHOMA IN CHILDREN AND ADOLESCENTS
D. Körholz,1 J. Landman-Parker,2 D. Hasenclever,3 M. Nékolna,4
E. Bergsträsser,5 J. Karlen,6 G. Mann,7 A. Fernández-Teijeiro,8
A. Hraskova,9 A. Fossa,10 H. Thomassen,11 C. Mauz-Körholz,1
W. Balwierz,12 W.H. Wallace,13 for the EuroNet-PHL-Study Group 
1Dpt. Ped. Martin Luther University Halle/Wittenberg; 2Hopital d’Ènfants
Armand Trousseau, Paris; 3Institute for Med. Informatics, Statistics and Epidemi-
ology, University of Leipzig; 4Dpt. Ped. Hematology and Oncology, Fa-culty
Hospital Motol, Prague; 5Dpt. Ped. University of Zürich; 6Ped. Cancer Unit,
Astrid Lindgrens Childrens Hospital, Karolinska University Hospital, Stock-
holm; 7St. Anna Kinderspital, Wien; 8Ped. Haematol./Oncol. Unit, Hospital de
Cruces-Baracaldo, Vizcaya; 9University Children’s Hospital, Bratislava; 10Dpt.
Med. Oncol./Radio-therapy,Rikshospitalet, Oslo; 11Rigshospitalet, Copenhagen
University Hospital, Copenhagen, 12Dpt. Ped. Oncol. Jagiellonian University,
Krakow, 13Royal Hospital for Sick Children, Edinburgh 
Since the late 1970s children and adolescents with Hodgkin’s lym-
phoma have been treated in different national protocols using different
strategies. While the overall survival rates are excellent (>90%), a signif-
icant number of patients will develop severe late effects many years lat-
er. Second malignancies related to radiation exposure, or infertility and
premature menopause after chemotherapy regimens that include procar-
bazine . To reduce the prevalence of these late effects the European Net-
work for Pediatric Hodgkin’s Lymphoma agreed on a common European
protocol for the treatment of children and adolescents with Classical
Hodgkin’s lymphoma. The treatment includes two cycles of OEPA (vin-
cristine, doxorubicin, etoposide and prednisolone), for early stage dis-
ease, two cycles of OEPA and two cycles of COPP (cyclophosphamide,
vincristine, prednisone and procarbazine) or COPDAC (cyclophos-
phamide, vincristine, prednisone and dacarbazine) for intermediate stage
disease and for advanced stage disease two cycles of OEPA and four
cycles of either COPP or COPDAC. Those patients with an inadequate
response to two cycles of OEPA (etoposide, doxorubicine, prednisone,
vincristine) chemotherapy, assessed by response assessment analysis of
cross-sectional imaging (CT/MRI) and FDG-PET scanning, will receive
modified involved field radiotherapy. Patients in the GPOH group and
in the UK will have central review of response assessment carried out
in Halle/Leipzig. Patients with an adequate response will not receive
involved field radiotherapy in the hope of reducing the prevalence of late
onset second cancers.. To reduce the prevalence of male infertility or pre-
mature menopause in patients with intermediate and advanced stage
disease the effect of dacarbazine (COPDAC) vs procarbazine (COPP) on
fertility and tumour response will be assessed in a randomised study.
The study opened in January 2007 in Germany and is due to open in the
UK and other European countries soon. Currently 97 patients have been
enrolled.
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FIRST INTERNATIONAL INTER-GROUP STUDY FOR LYMPHOCYTE PREDOMINANT
HODGKIN’S LYMPHOMA IN CHILDREN AND ADOLESCENTS. FOR EURONET-PAEDIATRIC
HODGKIN’S LYMPHOMA GROUP 
J. Landman-Parker
Pediatric Hematology Oncology, Hopital d’Enfants Armand Trousseau, APHP,
Université Pierre et Marie Curie-Paris, France
Lymphocyte predominant Hodgkin's lymphoma (LPHL) is a rare
CD20-positive good prognostic lymphoma in children. Patients typical-
ly present with early stage disease, mainly IA, with peripheral lymph
node involvement i.e. cervical, axillary, and inguinal rather than medi-
astinal involvement which is rarely seen. There is a striking male pre-
dominance. The prognosis is favorable with an indolent course of dis-
ease and the rare patients deaths are related to secondary (treatment
related) malignancies or transformation to aggressive B cell lymphoma
or classical Hodgkin’s. In the past LPHL patients have often been treat-
ed with chemotherapy and radiotherapy according to standard classical
Hodgkin’s lymphoma (HL) protocols. Early stage patients treated with
radiotherapy alone usually received extended field radiation, chemother-
apy alone or more recently in adults monoclonal antibody therapy using
Rituximab. With these modalities, long term progression free survival
between 80% and 95% and overall survival between 83% and 100%
has been reported although delayed relapses may occurs. Early stage
LPHL patients successfully treated by surgical node resection alone have
been reported by the French Society of pediatric Oncology in 2003. In
order to clarify the optimum treatment strategy in children, European
study groups were asked to report their experience of surgery alone
used in the treatment of pediatric LPHL and results have been recently
reported (.Mauz-Koerholz C et al Cancer. 2007 Jul 1;110(1):179-85). With
a median follow up of 43 months, overall survival is 100% and PFS 57%
in 58 pts treated by surgery alone and 67% (95% CI 51%; 82%) in the
patients in CR after initial surgical treatment. This study confirm that,
when complete resection is achieved, a substantial proportion of surgi-
cally treated early stage LPHL cases experience long-term remission and
may actually be cured. In patients with residual disease after initial sur-
gery, the proposal is to used limited doses of antimitotics and few or not
expected toxicity. A pilot study with CVP (3 courses) (cyclofosphamide,
vinblastine, prednisone) regimen confirm a high rate of complete remis-
sion (Ananth G. Shankar. Blood 2006 108: Abstract 2471). Based on these
results the Euronet Hodgkin lymphoma group has recently proposed a
treatment strategy for Stage I and IIA patients including TEP evaluation
strategy and this will be presented in details at the meeting . 
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Future Studies/Intergroup Trials (including PET)
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THE NEW TRIAL GENERATION OF THE GERMAN HODGKIN STUDY GROUP (GHSG)
M. Fuchs, P. Borchmann, M. Dietlein, H. Eich, H.P. Müller, B. Pfistner,
V. Diehl
A. Engert for the German Hodgkin Study Group, Germany
As a result of continuous improvement of therapeutic options and
subsequent validation in large multicenter trials, Hodgkin lymphoma
(HL) has become one of the best curable cancers in adults. Nowadays,
about 80-90% of all patients achieve long term survival. The ongoing tri-
al generation (G5) focussed on detoxification of therapy and minimiz-
ing late effects by omitting single cytostatic drugs, reducing the number
of chemotherapy cycles given or using reduced doses in a time intensi-
fied schedule (HD13 for early favourable stage HL, HD15 for advanced
stage HL). Improvement of therapy results was the aim of the HD14 tri-
al for early unfavourable/intermediate HL by combining BEACOPPesca-
lated and ABVD (two cycles each) to further intensify first line treat-
ment for these patients. Over the last years, positron emission tomog-
raphy (PET) has become available and published data indicates that PET
could be used to individualize treatment to the specific risk of the patient
by determining an early response to therapy as predictive factor. Thus,
PET has been integrated in the new generation of trials planned (G6).
These trials (HD16, 17, 18) will be launched by late 2007 (HD18) or ear-
ly 2008 (HD16, 17).
HD16 for early favourable stages. All patients will receive two double-
cycles of ABVD and PET after the end of chemotherapy. Patients in the
standard arm will receive a 30Gy involved field radiotherapy (IF-RT)
irrespective of the PET result. Patients in the experimental arm will
receive IF-RT only if PET is positive after chemotherapy; no further treat-
ment will be given in patients with negative PET.
HD17 for early unfavourable/intermediate stage. 4 double-cycles of ABVD
will be compared with 4 cycles of EACOPP-14, a novel BEACOPP-vari-
ant without Bleomycin and increased antracyclin dose (50 mg/m2).
Patients will be randomized between the standard of radiotherapy in IF
technique and involved node (IN) technique.
HD18 for advanced stage. All patients receive two cycles of BEA-
COPPesc and thereafter a PET. Patients with negative PET will be ran-
domized between standard treatment (six additional cycles of BEA-
COPPesc) and only two additional cycles of BEACOPPesc. Patients with
positive PET will be randomized between standard treatment and inten-
sification of therapy by adding Rituximab to the following six cycles of
BEACOPPesc. Patients with residual PET-positive lymph nodes (> 2.5
cm) will receive an additional 30Gy radiotherapy.
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THE H10 EORTC/GELA RANDOMIZED INTERGROUP TRIAL ON EARLY FDG-PET SCAN
GUIDED TREATMENT ADAPTATION VERSUS STANDARD COMBINED MODALITY 
TREATMENT IN PATIENTS WITH SUPRADIAPHRAGMATIC STAGE I/II HODGKIN’S 
LYMPHOMA
M. André, J. Raemaekers, R. Van der Maazen, O. Reman, 
M. Van ‘t Veer, E. Lutgenburg, T. Girinski, C. Fermé, P. Brice, 
O. Casasnovas, M. Meignan, J. Auduin, J. Bosq, N. Mounier, 
M. Van Glabekke
GELA and EORTC lymphoma group
Design. All eligible stage I-II supradiaphragmatic patients will be strat-
ified according to the classic EORTC clinical prognostic factors into the
favourable (F) and unfavourable (U) subsets. 
The F group will be randomized between:
1. Standard arm: ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy
(+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD
for comparison with the experimental arm will be performed but no
treatment adaptation will take place; 2. Experimental arm: ABVDx2 cycles;
then FDG-PET evaluation: PET negative: ABVDx2 without further RT
(total of 4 cycles!); PET positive: presumed poor-risk: switch to escalat-
ed BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions).
The U group will be randomized between:
1. Standard arm: ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual
lesions). FDG-PET after two cycles of ABVD for comparison with the
experimental arm will be performed but no treatment adaptation will
take place; 2. Experimental arm: ABVDx2 cycles; then FDG-PET evalua-
tion: PET negative: ABVDx 4 cycles, without RT (total of 6 cycles); PET
positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT
30Gy (+boost 6Gy to residual lesions).
Primary objective. To evaluate whether chemotherapy alone is as effec-
tive, but less toxic, as combined modality treatment, in patients with
stage I/II Hodgkin’s lymphoma who are FDG-PET scan negative after
two cycles of ABVD. This question will be addressed in the group of
patients with favorable stages I/II disease (F) as well as in those with
unfavorable stage I/II disease (U).
Secondary objective. To evaluate whether chemotherapy with escalat-
ed BEACOPP improves the outcome of PET positive patients – after 2
cycles of chemotherapy - when compared with standard therapy
Methodology. Phase III non inferiority (primary objective in PET- pts);
Phase III superiority (secondary objective in PET+ pts)
Number of patients. At least 1576 pts, to be simultaneously accrued in
all groups; 608 to 750 pts in group A (F/PET-); 720 to 850 pts in group B
(U/PET-); 248 pts expected in group C (PET+). The trial has started end
of 2006 and the accrual is in line with estimations (147 patients end of
july 2007). Additional informations http//:www.eortc.beor http//:H10.
gela.org
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RESPONSE-ADAPTED THERAPY USING FDG-PET SCANNING AFTER INITIAL ABVD: THE UK
NCRI, ITALIAN AND NORDIC TRIAL IN ADVANCED HODGKIN LYMPHOMA
P. Johnson,1 M. Federico,2 G. Enblad,3 C. Burton,4 P. Smith,5 W. Qian,6
M. O’Doherty,7 J. Radford8
1Cancer Research UK Clinical Centre, Southampton, UK; 2Università di Mod-
ena e Reggio Emilia, Italy; 3Akademic Hospital,Uppsala, Sweden; 4HMDS,
Leeds, UK; 5Lymphoma Trials Office, London, UK; 6MRC Clinical Trials Unit,
London, UK; 7PET Imaging Centre, St Thomas’s Hospital, London UK; 8CR UK
Department of Medical Oncology, Christie Hospital, Manchester, UK
Advanced Hodgkin lymphoma can be cured in many cases, but with
standard ABVD chemotherapy the treatment still fails in around one
quarter, and in those cured, late toxicity remains a significant problem.
Cure rates might be increased using more intensive initial treatment,
but the resulting toxicity will be unacceptably high if even those with a
good chance of cure are subjected to it. 
Figure 1. Response-Adapted Therapy Using FDG-PET Scanning After Initial
ABVD: The UK NCRI, Italian and Nordic Trial In Advanced Hodgkin Lym-
phoma: Trial Outline.
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Baseline clinico-pathologic characteristics have proven poor discrim-
inators in this respect, but there is increasing evidence that FDG-PET
functional imaging can give highly accurate prognostic information if
performed early during the course of treatment. The specific aim of this
study is to prospectively evaluate the use of CT-FDG-PET to permit ear-
ly assessment of tumour response. This will allow selective escalation
of therapy for those with a poor prognosis, and test de-escalation of
treatment to minimise long-term toxicity for those with a good initial
response. All patients will receive 2 courses of ABVD chemotherapy
and then undergo a CT-PET scan. Patients who become CT-PET nega-
tive will be randomised between ABVD and AVD, the omission of
bleomycin aiming to reduce lung toxicity whilst achieving an equivalent
outcome. Those who remain CT-PET positive will undergo treatment
escalation with the BEACOPP-14 regimen for 4 cycles before a third
CT-PET scan. Those with negative CT-PET scans at this point will com-
plete a further 2 BEACOPP-14. Those with a persistently positive scan
will be treated off-study with alternative salvage regimens. Radiother-
apy will be used according to local protocols, but in general will be
reserved for those with positive CT-PET scans and residual nodal mass-
es at the completion of therapy. An important issue for FDG-PET scan-
ning that has been little studied to date is reproducibility. A particular
advantage of conducting a large collaborative study is the opportunity
to develop a standardised approach to the reporting of PET scan results,
validated by using them to guide subsequent therapy. This is one of the
important secondary goals of this trial. Central review of PET scans has
been established in the current UK NCRI trial in early stage Hodgkin
lymphoma and an International Committee has already agreed a proto-
col for standardised reporting in this study.
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DEVELOPMENT OF ABVD AS STANDARD TREATMENT FOR HODGKIN’S LYMPHOMA (HL)
B.D. Cheson
Georgetown University Hospital, Washington, D.C. and Cancer and Leukemia
Group B, USA
The treatment of patients with HL is one of the great successes of
modern Hematology/Oncology. The first major advance was the intro-
duction of the combination of mechlorethamine mustard, vincristine,
prednisone and procarbazine (MOPP) by DeVita et al, which was cura-
tive for about half of treated pts with advanced stage disease (Ann Intern
Med 92:587, 1980). However, not only did more than 20% of pts fail to
enter a complete remission, but another third experienced a relapse.
Moreover, MOPP was associated with an unacceptably high rate of
infertility and secondary malignancies. Bonadonna and coworkers first
demonstrated that ABVD (adriamycin, bleomycin, vinblastine, dacar-
bazine) was successful in salvaging MOPP failures, and subsequently
that this regimen was highly effective as front-line therapy, with about
90% of patients attaining a complete remission, and two-thirds of pts
remaining free from progression with prolonged follow-up (Ann Intern
Med 104:739, 1986). Encouraging data were subsequently published
with regimens in which MOPP alternated with ABVD and a MOPP/ABV
hybrid (Klimo and Connors, J Clin Oncol 3:1174, 1985). These encour-
aging results led to several important US intergroup studies. The first of
these compared three regimens: ABVD, MOPP, and MOPP alternating
with ABVD, The overall survival at 5 yrs was 50% for MOPP, 61% for
ABVD, and 65% for MOPP-ABVD (Canellos et al, New Engl J Med
327:1478, 1992). In a second study conducted by Glick et al, MOPP/ABV
hybrid chemotherapy was shown to be superior to sequential MOPP-
ABVD (J Clin Oncol 16:19, 1998). Finally, Duggan et al compared ABVD
with the MOPP/ABV hybrid and demonstrated comparable efficacy but
with reduced treatment related toxicities associated with the ABVD (J
Clin Oncol 21:607, 2003). These trials in aggregate demonstrated that,
not only does ABVD have superior efficacy compared with MOPP, but
has at least comparable efficacy to MOPP/ABVD or the MOPP/ABV
hybrid. Moreover, ABVD is associated with fewer acute toxicities and
secondary malignancies. The efficacy and favorable toxicity profile of
ABVD in this series of studies, defined ABVD as the standard
chemotherapy regimen for patients with early or advanced stage HL.
Nevertheless, almost 20% of pts do not achieve a complete remission
with ABVD, and almost 40% fail therapy with prolonged follow-up.
Results from a recently completed comparison of Stanford V vs ABVD
in pts with locally extensive or advanced stage HL are eagerly awaited.
Whether the German BEACOPP regimens will improve on this regimen
is the subject of an ongoing clinical trial. Continued research is essential
to improve pt outcome while reducing treatment-related toxicities.
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Chronic Inflammation
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RNA EXPRESSION ANALYSES OF WHOLE TISSUE SECTIONS IN CLASSICAL HODGKIN LYM-
PHOMA
A. Sánchez-Aguilera,1 C. Montalban,2 B. Sánchez,1 M.A. Piris,1
J.F. Garcia1,3
1Molecular Pathology Programme, Spanish National Cancer Institute (CNIO);
2Internal Medicine Department, Hospital Ramon y Cajal, Madrid; 3Pathology
Department, MD Anderson, International, Madrid, Spain
The neoplastic HRS cells usually represent less than 1-5% of the cells
in classical Hodgkin Lymphoma tumour tissues, since the vast majority
of cells is represented by a mixture of T cells, B cells, macrophages,
eosinophils, plasma cells and others. This fact has been classicaly con-
sidered as the main limitation for molecular analysis of cHL. Thus, the
majority of efforts have been aimed to identify biological alterations of
the HRS cells revealing pathogenic mechanisms. In the last years, it have
been published a limited number of reports of gene expression of cHL
using systematic analysis of differential gene expression, most of them
comparing these HL-derived cell lines with normal B cells and B cell non-
Hodgkin lymphomas. These studies revealed a global loss of the B cell
identity of HRS cells, with decreased mRNA levels for nearly all B-line-
age-specific genes. This is probably the most relevant feature of the neo-
plastic cells, but also a large number of concurrent alterations in the reg-
ulation of cell cycle, apoptosis, and signalling pathways have been
reported. The reason and consequences for this downregulation of genes
important for B cell function and survival is presently unclear. It is also
known that HRS cells produce a variety of cytokines and chemokines,
including Il-6, Il-10, Il-13, and TARC, and there are clear indications for
the role that these factors play in HL. For example, expression of both
Il-13 and its receptor appears to represent an autocrine proliferation stim-
ulus. Since TARC is a chemokine attracting TH2 cells, its strong expres-
sion by HRS cells may be the main cause for the attraction of CD4 T cells
into the tissue. HRS cells also express a number of molecules that are
important for TH cell-B cell interaction (CD40, MHC class II, CD80,
CD86), and for HRS cell survival. Contribution of these non-tumoral
cells to the pathogenesis of HL is still obscure, but a high proportion of
activated cytotoxic T-cells has been described to be associated with an
unfavourable outcome. Eosinophilic granulocytes are frequently
observed in lymphatic tissue of Hodgkin's patients, and tissue
eosinophilia have been proved to be also a prognostic factor in cHL. The
presence of follicular dendritic cells has also been suggested as being an
element of prognostic value. Current therapeutic approaches using
ABVD and more recent protocols such as BEACOPP in combination
with radiotherapy are, in general, very effective for the treatment of HL,
but about 20-30% of patients will nevertheless eventually die of the dis-
ease, more notorious in advanced stage cases. The ultimate reasons for
this unsuccessful outcome have not yet been elucidated. Moreover, these
therapies have additional consequences, since treatment-associated late
toxicities may develop. In this scenario, important goals in HL research
are the identification of reliable biological factors that allow risk strati-
fication of HL patients, and the discovery of new therapeutic targets.
Aimed to the identification of predictive markers related with both
tumor components, neoplastic HRS cells and reactive background, we
have used gene-expression analysis for the identification of specific gene
signatures associated with favorable or unfavorable clinical outcome in
cHL patients with advanced stages. We initially found 145 genes whose
expression was associated with treatment response. These experiments
demonstrated the feasibility of gene expression analysis using RNA
extracted from whole-tissue samples in cHL tumors following a stringent
selection of samples with clearly defined clinical and pathological crite-
ria, and using appropriate supervised methods based on class compari-
son. As a result, we identified clusters of functionally related genes asso-
ciated with clinical outcome and expressed by either the reactive cell
component or the neoplastic H/RS cells. The main conclusion is that it
can be described specific gene signatures associated with treatment
response in HL patients. Our results have identified: 1) general process-
es affecting treatment response, such as specific immune responses and
alterations of the spindle checkpoint; 2) potential prognostic biological
markers, as demonstrated by immunohistochemical techniques in an
independent series of HL samples; 3) potential therapeutic targets. The
biological variables identified could potentially be included, after fur-
ther validation, in a predictive system combining features of the H/RS
cells and their cellular microenvironment.
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THE ROLE OF INFLAMMATORY BYSTANDER CELLS IN HODGKIN LYMPHOMA
G. Enblad
Department of Oncology, Radiology and Clinical Oncology, Uppsala Universi-
ty Hospital, Sweden
Hodgkin lymphoma (HL) is characterized by only a few malignant
cells and an abundance of inflammatory cells. The sparse Hodgkin and
Reed Sternberg (HRS) cells are surrounded by a reactive infiltrate com-
posed of T and B cells mixed with cells of the innate immune system,
e.g., neutrophils, macrophages, eosinophils and mast cells. A complex
network of interactions mediated by cytokines, chemokines and cell-cell
contact exists between the different cell types in this disease and appears
vital for its development and progression. 
Eosinophils. HL has been associated with eosinophilia in the blood,
bone marrow and tumour tissue. Patients with many eosinophils in the
tumour tissue have a poorer prognosis. The exact mechanisms behind
the presence of numerous eosinophils in HL tumours is as yet unclear
but could be due to e.g., secretion of IL-5, IL-9, CCL28 and GM-CSF by
the HRS cells, or eotaxin (CCL11), secreted from fibroblasts and
macrophages.
Neutrophils. Neutrophils are distributed among other infiltrating cells.
The role of neutrophils has not as yet been thoroughly studied. Howev-
er, there is an increase in neutrophil number in the blood of many HL
patients and an increase in leukocyte counts is correlated to a poor prog-
nosis.
Mast cells. The majority of HL cases (>90%), and all histopathological
subtypes, show mast cell infiltration. The highest numbers of mast cells
and eosinophils are seen in the NSHL and the cross-talk between mast
cells, eosinophils and fibroblasts can contribute to the development of
fibrosis. Increased mast cell number in HL is associated to high white
blood cell counts, and low blood haemoglobin and a worse survival.
One important pathway for the interaction between inflammatory cells
and HRS cells is the CD30 - CD30ligand (CD30L)/CD153 interaction.
The CD30 molecule belongs to the TNF receptor superfamily (TNFR).
The CD30L (CD153) is expressed on eosinophils and mast cells but mast
cells constitute the majority, 66%, of the CD30L positive cells in HL. The
activation of HRS-cells by CD30L results in a proliferative response in
the tumor cells that might be one reason for the negative prognostic
impact. Interaction between CD30 and its ligand constitutes a bidirec-
tional interaction, where not only CD30-positive cells can be activated
by CD30L, but also the CD30L-postive cell can be activated by CD30.
CD30-activation of mast cells constitutes a unique mechanism of cell
activation/triggering since they do not degranulate, nor release
leukotrienes, but secrete only a very specific set of chemokines includ-
ing IL-8, MIP-1α and MIP-1β. These chemokines are involved in the
recruitment of granuloctes, lymphocytes and monocytes, cells common-
ly found in HL. Thus, through this bidirectional interaction mast cells
have dual roles by stimulating the growth of tumor cells and by con-
tributing to the recruitment of inflammatory cells to the tumor.
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GENE EXPRESSION PROFILING OF MICRODISSECTED HRS CELLS IN CLASSICAL
HODGKIN LYMPHOMA 
C. Steidl, T. Nayar, T. Lee, A. Telenius, N. Johnson, D. Horsman, 
J. Connors, R.D. Gascoyne
British Columbia Cancer Agency and University of British Columbia, Depart-
ment of Pathology, Medical Oncology and the Genome Sciences Centre, Van-
couver, British Columbia, Canada
Introduction. Hodgkin Lymphoma (HL) is characterized by the presence
of only a small fraction of Hodgkin Reed Sternberg cells (HRS cells)
which represent the malignant clone. Thus far, the molecular under-
standing of the disease is mainly based on studies of whole clinical biop-
sy samples or Hodgkin cell lines. Recently, the analysis of microdissect-
ed HRS from primary biopsy material has allowed a better understand-
ing of the disease.
Patients and Methods. 12 patients with classical HL who were prima-
rily treated at the BC Cancer Agency in Vancouver between 1985 and
2005 have been included into the study. Treatment response was defined
as absence of disease progression (n=5) and treatment failure as disease
progression or relapse at any time (n=7). Cells were collected by laser
capture microdissection using Molecular Machines & Industries (MMI)
technology. Gene Expression profiling (GEP) and Array Comparative
Genomic Hybridization (aCGH) were performed on these 12 clinical
specimens (1000 HRS cells each), 5 Hodgkin cell lines (L-1236, HDLM-
2, L-428, KM-H2, L-540) and germinal centers of 5 reactive lymph nodes.
RNA was extracted and amplified in a two-cycle target labeling assay
and hybridized onto Affymetrix GeneChip HG U133 2.0 Plus arrays.
Extracted DNA was whole genome amplified and hybridized to Sub-
megabase Resolution Tiling Arrays (SMRT) comprising of 26,363 over-
lapping Bacterial Artificial Chromosomes (BACs).
Results. Correlating GEP with outcome data, we found differentially
expressed genes that indicate a higher expression of antigen processing
and presentation as well as of humoral immune response genes in the
treatment failure group. By integrating aCGH and GEP data of the HRS
cells we could identify regions that harbor genes with a clear gene-
dosage-effect. When comparing the GEP of the clinical samples and the
Hodgkin cell lines to the profiles of the germinal center cells we found
genes that are common among both sets. The largest expression differ-
ences were observed in genes involved in cell cycle regulation, metabo-
lism, and receptor signaling.
Conclusions. GEP and aCGH of microdissected HRS cells identified
genetic markers that could be used as predictive markers for treatment
response. Further validation using tissue microarrays is needed. These
approaches offer the possibility of improved understanding of the bio-
logical underpinnings of treatment failure in classical HL.
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GALECTIN 1 MEDIATES TUMOR ESCAPE IN HL
P. Juszczynski,1 J. Ouyang,1 S. Monti,2 S. Rodig,3 K. Takeyama,1
J. Abramson,1 W. Chen,1 J.L. Kutok,3 G.A. Rabinovich,4 M.A. Shipp1
1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Mass-
achusetts, USA; 2Broad Institute, Cambridge, Massachusetts, USA; 3Depart-
ment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts,
USA; 4Institute of Biology and Experimental Medicine, IBYME; CONICET
and Faculty of Exact and Natural Sciences, University of Buenos Aires, Buenos
Aires, Argentina
Introduction. Classical Hodgkin lymphomas (cHLs) contain small num-
bers of neoplastic Reed-Sternberg (RS) cells within an extensive inflam-
matory infiltrate which includes abundant T helper (Th)-2 and T regu-
latory (Treg) cells. The skewed nature of the T-cell infiltrate and the lack
of an effective host anti-tumor immune response suggest that RS cells
utilize potent mechanisms to evade immune attack. This study was
designed to identify T-cell inhibitory molecules in cHL.
Methods and Results. Using cHL cell lines and primary cHL tumors, we
found that RS cells selectively overexpressed the immunoregulatory gly-
can-binding protein, galectin-1 (Gal1), via an AP1-dependent enhancer.1
In co-cultures of activated T cells and Hodgkin cell lines, RNAi-mediat-
ed blockade of RS cell Gal1 increased T-cell viability and restored the
Th1/Th2 balance.1 In contrast, Gal1 treatment of activated T cells
favored the secretion of Th2 cytokines and the expansion of
CD4+CD25high FOXP3+ Treg cells.1
Discussion. These data directly implicate RS cell Gal1 in the develop-
ment and maintenance of an immunosuppressive Th2/Treg-skewed
microenvironment in cHL and provide the molecular basis for selective
Gal1 expression in RS cells. Thus, Gal1 represents a novel therapeutic
target for restoring immune surveillance in cHL.
Reference
1. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of
galectin-1 by Reed-Sternberg cells fosters immune privilege in classical
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T-CELLS IN HODGKIN LYMPHOMAS
S. Poppema
Department of Pathology, University Medical Center Groningen, The Nether-
lands
Lymph nodes involved by HL generally contain only a minority of RS
cells surrounded by an abundant inflammatory infiltrate, suggesting that
immunological mechanisms contribute to HL pathogenesis. What caus-
es the extensive infiltrate of lymphocytes and other inflammatory cells
in HL? An important part of the explanation may be that RS cells pro-
duce and secrete high amounts of chemokines, in particular TARC and
MDC, that attract cells expressing the CCR4 receptor, such as activat-
ed Th2 lymphocytes and CD4+CD25+ regulatory T cells. Another ques-
tion is why there is no effective immune response against the tumor
cells? HL infiltrating lymphocytes are anergic to stimulation with some
mitogens and primary as well as recall antigens, but also suppress periph-
eral blood mononuclear cell (PBMC) responses. This appears to be
caused by IL-10 secreting T cells as well as CD4+CD25+ regulatory T
cells. The immunosuppressive effect of the HL infiltrating cells can be
neutralized with anti IL-10, by preventing cell to cell contact and by anti
CTLA-4. The lymphocytes in HL do not produce cytokines, such as IL-
2, IL-4 and IFN-γ with primary (KLH) and recall (PPD) antigens and the
mitogen ConA. However, when stimulated with PHA or with phorbo-
lester (PMA)-ionomycin, the lymphocytes in HL are capable of produc-
ing these cytokines. Specifically, when the CD26 negative CD4 cells
immediately surrounding the Reed-Sternberg cells were purified and
stimulated with PMA ionomycin, these produced IL-4 and IFN-γ. The
potential to produce IL-4 was the reason why these cells were previous-
ly considered Th2 like. Absence of IL-2 production upon stimulation is
also associated with anergy. The exact nomenclature of these cells is thus
a matter of semantics. In addition to the IL-10 producing cells (Tr1) there
are also TGF-β producing cells (Th3) present in the infiltrate. There are
variations in the lymphocyte populations involved in different cases. It
can be concluded that as an overall population the infiltrating lympho-
cytes do not have Th1 type functions and are probably attracted into the
tissues by chemokines TARC and MDC as CCR4 expressing Th2 cells
and T-regulatory cells. These cells do not spontaneously produce IL-2 or
IL-4, but do secrete IL-10 despite not being fully activated and therefore
function as Tr1 cells. The major remaining question is what causes the
predominance of T cells with suppressor activity in Hodgkin Lym-
phoma. It appears that Reed-Sternberg cells, although they have the
genotype of B cells, execute a functional program with expression of
molecules like CD40, CD80 and CD86, that is similar to that of antigen
presenting cells and is resulting in tolerance. Mechanisms include the
production of immunosuppressive cytokines like IL-10, especially in
Epstein-Barr virus positive cases, and IL-13, and of TGF-β, especially in
Nodular Sclerosis cases. In addition, R-S cells express FAS ligand that
induces cell death in FAS expressing activated T-cells, while the R-S cells
themselves are protected by over-expression of cFLIP or infrequently
by FAS mutation. The relevance of these findings is that they may allow
a better design of new treatment modalities. There are indications that
the infiltrating cells in fact support the growth and survival of the R-S
cells and therefore blocking chemokines like TARC and MDC to prevent
the influx of T cells may be effective. Also interference with binding or
signaling of IL-13 or other cytokines might be effective. On the other
hand, blocking of the immunosuppressive signals, such as provided by
IL-10 and TGF-β or the removal of the suppressor regulatory T cells, may
enhance cytotoxic T-cell responses. 
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AUTOIMMUNITY AND HODGKIN LYMPHOMA
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Introduction. Autoimmunity is consistently associated with elevated
risk of non-Hodgkin lymphoma (NHL). Based on small numbers,
rheumatoid arthritis has been associated with improved NHL survival
and a lower risk of relapse or progression. Recently, we reported
increased risk of Hodgkin lymphoma (HL) following autoimmune dis-
eases. In contrast, there are no data addressing whether a personal his-
tory of autoimmunity impacts survival in HL patients. Documenting the
impact of autoimmunity on HL onset and survival might provide clues
to exploiting the host immune reaction for HL therapy or prevention.
Aims of this study were to assess risk of HL following autoimmune dis-
ease and to define the prognostic significance of autoimmunity in HL
patients. The expanded study size allows for analyses of age, sex, and
latency effects; designed to provide clues on mechanisms.
Methods. Using population-based central registries we identified 9,299
HL patients diagnosed in Sweden 1964-2005 and 37,064 frequency-
matched controls. HL patients and controls were linked to the nation-
wide Inpatient Registry to capture hospital records including data on
autoimmunity and the Cause of Death Registry to retrieve mortality
data. We fit logistic regression models and Cox proportional hazards
models to compute relative risks (RRs) and 95% confidence intervals to
assess associations between autoimmune conditions and survival in HL
patients.
Results. We found increased risks of HL associated with personal his-
tories of several autoimmune conditions, such as Sjögren’s syndrome,
systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis,
immune cytopenias (immune thrombocytopenic purpura and autoim-
mune hemolytic anemia), celiac disease, and Wegener’s granulomatosis
(RRs ranged from 1.2 to 11.5). HL patients with (vs. without) a history
of rheumatoid arthritis had a poorer survival (RR~2).
Discussion. We found strong associations between personal history of
certain autoimmune disorders and HL risk. Our observation that HL
patients with a personal history of rheumatoid arthritis had a poorer
survival requires further follow-up. In addition to furthering our under-
standing of lymphomagenesis, such information can advance etiologic
knowledge, improve understanding of pathogenesis, and lead to more
informed risk assessments of novel autoimmune drugs implicated in
playing causal roles in lymphomagenesis. Additional results on HL risk
and survival in relation to autoimmunity will be presented at the meet-
ing.
Characterization of HRS Cells and Stem Cells in
Hodgkin Lymphoma
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MOLECULAR IMMUNOGENETICS OF B CELLS AND HRS CELLS
R. Küppers
Institute for Cell Biology (Tumor Research), University of Duisburg-Essen, Med-
ical School, Essen, Germany
Constitutive nuclear activity of NF-κB represents a key feature in the
pathogenesis of Hodgkin lymphoma (HL), primary mediastinal B cell
lymphoma (PMBCL) and activated B cell-like diffuse large cell lymphoma
(ABC-DLBCL). We sequenced the complete coding region of TNFAIP3,
an inhibitor of NF-κB, from cell lines and tumor cells of primary biop-
sies of HL, PMBCL and ABC-DLBCL. Inactivating mutations in the
TNFAIP3 gene were found in several PMBCL, but were rare in the DLB-
CL. TNFAIP3 gene mutations were also detected in 3 of 6 HL cell lines
analyzed, and in microdissected HRS cells of 9 of 21 cases of classical HL.
The mutations included nonsense mutations, deletions causing
frameshifts and replacement mutations. The somatic origin of muta-
tions in HL was verified. These results suggest that TNFAIP3 acts as a
tumor suppressor gene in HL and PMBCL. Whereas own work and stud-
ies from other groups further support an important role of Epstein-Barr
virus in the pathogenesis of a fraction of classical HL, an involvement of
measles virus, as it had been suggested, could not be confirmed in a
study of microdissected HRS cells for the presence of measles virus RNA.
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CHROMOSOMAL TRANSLOCATIONS IN HODGKIN AND REED-STERNBERG CELLS
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Applying a wide range of molecular cytogenetic techniques like FISH,
M-FISH, subtelomere M-FISH, FICTION and chromosome- and array-
based CGH, we could recently show that Hodgkin and Reed-Sternberg
(HRS) cells of classical Hodgkin lymphoma (cHL) are characterized by
the presence of highly complex and chromosomally instable karyotypes.
In spite of this chromosomal complexity, several recurrent genetic
changes have been identified, like gene amplifications in 2p13-16 (REL)
and 9p24 (JAK2). Some of the gene amplifications in cHL are caused by
segmental chromosomal aberrations, by which multiple copies of a cer-
tain chromosomal segment are translocated or inserted into different
parts of the genome. Moreover, we could show that HRS cells, similar-
ly to tumor cells of other B-cell lymphomas, harbor recurrent chromo-
somal translocations affecting the immunoglobulin loci IGH, IGL and
IGK. In an ongoing study, we have evaluated the HRS cells from a total
of 242 cHL for chromosomal breakpoints affecting IG loci. We identified
38 cHL (16%) displaying breakpoints in the IGH locus. Variant rearrange-
ments in IGL or IGK were also found in 3 of 77 cases investigated. The
IG translocation partners could be identified in 10 cHL and involved
chromosomal bands 2p16 (REL), 3q27 (BCL6, 2 cases), 8q24.1 (MYC),
14q24.3, 16p13.1, 17q12, 18q21 (BCL2, 2 cases) and 19q13.2
(BCL3/RELB). Furthermore, our interphase cytogenetic analyses showed
evidence for deletions in the IGH constant region of HRS cells, suggest-
ing the presence of class switch recombination. In spite of the presence
of various recurrent chromosomal imbalances and translocations in cHL,
their pathogenetic significance is still unclear. These alterations arise in
a highly instable genome in which many tumor suppressor genes and
oncogenes can be simultaneously deregulated. Unraveling the causes of
this marked chromosomal instability in cHL is a major topic for future
research.
Supported by the Deutsche Krebshilfe (Grant 107736)
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THE PLASTICITY OF HODGKIN-/REED-STERNBERG CELLS
S. Mathas
Charité, Hematology/Oncology, Medical University Berlin, and Max-Delbrück-
Center for Molecular Medicine, Berlin, Germany
It has been shown in mouse models that differentiated lymphoid cells
can display a broad developmental potential, and might even differen-
tiate into other cell types. These models revealed a high degree of plas-
ticity in the hematopoietic system and challenged the previous rigid
view of cellular differentiation. Whether such processes occur during
the physiological process of B cell differentiation or malignant transfor-
mation is currently unclear. Recent data implicate such processes in the
pathogenesis of classical Hodgkin lymphoma (HL), a common human
malignancy. In the malignant, B cell-derived Hodgkin-/Reed-Sternberg
(HRS) cells of HL the expression of B cell-specific genes is lost, and B lin-
eage-inappropriate genes are upregulated. Experimental evidence has
been presented in recent years that epigenetic modification of lineage-
specific genes and functional disruption of the B lineage-specific tran-
scription factor program contributes to this process. The disruption of
the B lineage-specific transcription factor program, consisting of tran-
scription factors E2A, EBF and Pax5, is in HRS cells mediated by the
aberrantly expressed helix-loop-helix (HLH) proteins activated B cell
factor 1 (ABF-1) and inhibitor of differentiation 2 (Id2). These proteins
repress B-cell specific genes and allow for upregulation of non-B-lineage
genes in HRS cells. As a result, HRS cells express genes of different
hematopoietic lineages, which is reminiscent of the low-level multilin-
eage gene expression found in hematopoietic progenitor cells. These
processes might require strong cell-intrinsic proliferative and antiapop-
totic signaling pathways, as reflected by the unique activation pattern
of transcription factors nuclear factor kappa B (NF-κB), AP-1, and STAT
family members. These data offer an explanation for the unique HL
phenotype and reveal a high degree of plasticity of human lymphoid
cells. 
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Introduction. PRDM1 is a master regulator in plasma cell differentiation
inactivated by a classic mechanism for tumor suppressor gene in diffuse
large B-cell lymphomas (DLBCL) of the activated B-cell (ABC) type. No
PRDM1 inactivating mutations were identified in HRS cell lines. Since
HRS cells share genetic similarities with ABC-DLBCL, we hypothesize
whether PRDM1 accumuation in HRS cells may be down-regulated by
epigenetic mechanisms such as microRNAs (miRNA).
Methods. miRNAs with the potential to regulate PRDM1 expression
in HRS cells were initially identified by cloning-based miRNA profiling,
in conjunction with computer algorithms that predict potential miRNA
binding sites. Additional supporting experimental evidence was
obtained by correlative PRDM1 and miRNA expression studies in HRS
cell lines (L428, KMH2 and L1236) vs. cell lines with plasmacytic differ-
entiation (U266 myeloma and primary effusion lymphoma [PEL] cell
lines), reporter assays, and regulation of endogenous PRDM1 expression
by miRNA manipulation.
Results. In HRS cell lines, miR-9 and let-7a constitute a relatively high
percentage (up to ~5% for miR-9 and ~2.5% for let-7a) of the total miR-
NA population. Three miR-9 and one let-7a binding sites were predict-
ed in PRDM1 3’ UTR. miR-9 and let-7a levels are significantly higher in
HRS cell lines compared to U266 and PEL cell lines (p<0.05), whereas the
former have significantly lower PRDM1 expression (p<0.05). However,
no significant difference was detected in PRDM1 transcript levels
between these cell lines. Both miR-9 and let-7a repressed reporter
luciferase activities by at least 50% in a binding site-dependent manner
via translation inhibition. Co-operativity exists between the three miR-
9 binding sites, as well as between miR-9 and let-7a. We also demon-
strated, as proof of principle, that alterations in miR-9 and/or let-7a lev-
els can result in changes in endogeous PRDM1 expression. L428 trans-
fected with anti-sense miR-9 and/or let-7a RNA oligonucleotides result-
ed in an increase in PRDM1 up to ~3 fold. Over-expression of miR-9 or
let-7a in U266 cells reduced PRDM1 by about 40 to 50%.
Conclusions. miR-9 and let-7a can target the tumor suppressor gene
PRDM1 in HRS cells and down-regulate its expression. This miRNA-
mediated interference of PRDM1-associated functions may help abort
terminal B-cell differentation that has been initiated in HRS cells, and
thus may contribute to the pathogenesis of Hodgkin lymphoma by
maintaining HRS cells at the activated B-cell differentiation stage. 
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BIC AND OTHER MIRNAS IN HODGKIN LYMPHOMA
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Introduction. Since the first publication about the markedly increased
levels of BIC RNA transcripts in the nuclei of HRS cells, many studies
have been performed to gain insight into the function of this gene in nor-
mal B cells and its potential pathophysiological role in B cell lymphomas.
The BIC gene encodes a primary (pri-) micro-RNA (miRNA) transcript,
which is processed to a mature miRNA, miR-155. In normal B cells, BIC
and miR-155 are expressed predominantly in germinal centre B cells.
Indeed, recent studies in transgenic mice demonstrated that miR-155
plays an important role in B and T cell functioning, including the regu-
lation of T-helper 2 cells and T cell dependent antibody responses. In B
cell lymphomas, miR-155 expression levels are strongly increased not
only in HL, but also in DLBCL, PMBL and CLL. In transgenic mice, EÌ-
enhancer driven miR-155 expression resulted in a marked increase in
pre-B cells in spleen and bone marrow supporting a role in oncogenic
transformation.
Methods. Profiling of miRNA levels in HL cell lines and confirmation
of HL specificity by RNA-ISH on tissues and qRT-PCR on a panel of 33
cell lines containing DLBCL, PMBL, BL, CLL and EBV transformed B
cells. Experimental validation of miR-155 predicted target genes in var-
ious HL cell lines.
Results. Profiling of HL, NHL and normal B cells indicated that the
overall micro-RNA expression levels were markedly increased in B cell
lymphomas in comparison to normal B cell subsets. Specifically, most
members of the oncogenic C13ORF25 pri-miRNA cluster and the pre-
viously reported miR-155 were highly expressed. For a selection of the
miRNAs detected in the profiling, expression in HRS cells could be con-
firmed by RNA-ISH. 7/13 miRNAs, differentially expressed between
cHL and PMBL & cHL and EBV transformed B were confirmed as dif-
ferentially expressed miRNAs in a panel of 33 cell lines. Experimental
validation of 11 putative miR-155 target genes in a luciferase reporter
assay expressed in HL cell lines resulted in reduced luciferase activity for
5 sequences, derived from ZIC3, ZNF537, AGTR1, IκBκε and KGF.
Conclusions. In contrast to the reduced miRNA levels identified in most
cancer types, HL displays a marked increase in overall miRNA expres-
sion levels when compared to normal B cells. Besides miR-155, several
other miRNAs are also differentially upregulated in HL. 5 genes were
identified as putative miR-155 targets in HL. 
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HODGKIN’S LYMPHOMA (HL): EVIDENCE FOR A CANCER STEM CELL AND THERAPEUTIC
IMPLICATIONS
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Introduction. As new approaches to targeting therapy become avail-
able, should we focus on the characteristics of Reed-Sternberg (RS) cells
to guide therapies in HL or might there be cancer stem cell precursors
with different morphology and patterns of gene expression that might
be more fruitfully targeted? In chronic myelogenous leukemia, it is
established that mature granulocytes although characteristic of the dis-
ease, do not sustain the malignancy. In MM, Matsui et al have present-
ed evidence that malignant plasma cells have very modest proliferative
and clonogenic capacity. Cells with a memory B cell phenotype have the
proliferative and clonogenic capacity. We sought to determine whether
in HL patients there was a similar phenomenon - cells with a different
phenotype than RS cells that carried the same Ig rearrangements and that
had proliferative capacity.
Methods. RS cell lines (L428 and KMH), HL biopsy specimens, as well
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as peripheral blood mononuclear cells (PBMC) from HL patients were
studied. PCR, capillary electrophoresis and sequencing were used to
characterize IgH gene rearrangements. Cell separations were achieved
with magnetic beads and flow cytometry. Flow cytometry with Alde-
fluor was used to characterize likely populations of stem cells.
Results. In HL cell lines, although more than 95% of cells were CD30+
by flow, there were small populations of cells that were CD30–. These
latter cells expressed CD19, CD20 and were Aldefluor+, and harboured
virtually all of the clonogenic capacity. In patients, isolation of tumor cells
allowed characterization of Ig rearrangements characteristic of the malig-
nancy. Lymphocytes from PBMC that were Aldefuor+expressed CD20
and were clonal as determined by surface light chain expression. In sev-
eral cases, this was confirmed by Ig rearrangement studies.
Discussion. In HL cell lines and patients, there is a subpopulation of cells
that is clearly related to RS cells that do not express CD30 but do express
CD20. Targeting this specific population of cells in patients may lead to
therapeutic benefit. The encouraging results reported by Younes et al in
clinical trials using rituximab in HL patients may be explained by the tar-
geting of a cancer stem cell population.
Translational Approaches
I040
KLHDC8B: A CANDIDATE HODGKIN’S LYMPHOMA SUSCEPTIBILITY GENE
M.E. Mealiffe,1 L.R. Goldin,2 M.L. McMaster,2 P.H. Wiernik,3
H.T. Lynch4 M.A. Tucker,2 M.S. Horwitz1
1U. Washington, Seattle; 2National Cancer Institute, DCEG, Bethesda; 3New
York Medical College, Bronx; 4Creighton University, Omaha, USA
Introduction. Both Epstein-Barr virus (EBV) exposure and heritable fac-
tors contribute to Hodgkin’s lymphoma (HL) risk. However, the specif-
ic gene(s) responsible for the majority of this heritable HL susceptibility
are yet to be defined. We have ascertained a family with multiple HL cas-
es co-segregating with a constitutional, balanced translocation:
t(2;3)(q11.2;p21.31) and have molecularly cloned the translocation break-
points.
Methods. The breakpoints were mapped with FISH and Southern blot-
ting, followed by long-range PCR amplification and sequencing.
KLHDC8B expression was assessed with Taqman quantitative RT-PCR
and via western blotting. For miRNA target prediction, we used the
online implementation of the Rna22 algorithm, and miRNA:target pairs
were confirmed with transfected miRNA precursors, real-time PCR, and
luciferase assays.
Results. Molecular cloning of the breakpoints shows that the 2q break-
point is intergenic, but the 3p breakpoint disrupts the first intron of a pre-
viously uncharacterized gene, KLHDC8B (Kelch domain-containing 8B),
resulting in significantly decreased expression in lymphoblastoid cells
from translocation carrying individuals. We sequenced the six KLHDC8B
exons in affected individuals from 52 HL families revealing no coding
region mutations. However, we did identify a novel variant (+42C>T)
in a conserved region of the 5’UTR that was present in 3 of 52 familial
HL probands (5.8%) compared to 4 of 307 controls (1.3%; Odds Ratio
[95% C.I.]=4.6 [1.0-21.4]). Interestingly, Rna22 predicts that 20 of 32 of
the known EBV microRNAs target KLHDC8B with 1-4 target sites each.
The EBV-related rhesus macaque herpesvirus, rLCV, similarly contains
miRNAs predicted to target rhesus Klhdc8b. We have experimentally val-
idated targeting of KLHDC8B by a subset of the EBV miRs and valida-
tion of the rLCV/rhesus Klhdc8b targets is ongoing. 
Discussion. We have demonstrated that a constitutional balanced
translocation cosegregating with HL disrupts KLHDC8B. A novel
KLHDC8B 5’UTR variant identified in ~6% of affected probands from
families with two or more HL cases is associated with familial HL with
borderline significance. Although further studies in larger cohorts of HL
patients and in animal models will be necessary to validate KLHDC8B’s
role in HL, the targeting of its 3’UTR by a large percentage of the known
EBV miRNAs suggests that it is an intriguing candidate gene for this
EBV-associated disease. 
I041
ANALYSIS OF GENETIC PREDISPOSITION TO HEMATOTOXICITY IN HODGKIN LYMPHOMA
PATIENTS
T. Zander , R. Fürst, J. Franklin, J. Hampe, P. Nürnberg, S. Schreiber,
J. Wolf ,  V. Diehl , R.K. Thomas , D. Re
Cologne, Germany
Using aggressive multimodal treatment protocols, Hodgkin Lym-
phoma (HL) has become a curable disease over the last decades. Never-
theless, acute and late toxicities are a major concern of dose intensifica-
tion. We here investigate the possibility that genetic polymorphisms in
drug metabolizing genes constitute genetic susceptibility factors for tox-
icities and might correlate with remission status. We conducted an asso-
ciation study in Hodgkin Lymphoma patients to identify susceptibility
genes predicting acute hematoxicity and treatment repsonse. Patients
with first presentation of HL that were randomized to the HD13, HD14,
or HD15 trial of the German Hodgkin Study Group were included for
this analysis. 27 SNPs in 14 candidate genes were genotyped using
germline DNA extracted from peripheral blood mononuclear cells. Can-
didate genes were selected using public databases. Genetic polymor-
phisms were typed by SNPlex™ technology. Polymorphisms will be
presented as a descriptive analysis and associated with clinical factors
such as leukopenia, thrombocytopenia and anemia. Repsonse rate and
progression-free survival will be also associated. Mature data of this tri-
al will be presented at the conference.
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TARGETED TREATMENT APPROACHES IN HODGKIN LYMPHOMA
M. Janz,1,4 T. Stühmer,2,4 L.T. Vassilev,3 B. Dörken,1 R.C. Bargou2
1Department of Hematology and Oncology, Charité, University Medicine Berlin,
Campus Virchow-Klinikum and Campus Buch, and Max Delbrück Center for
Molecular Medicine; 2Department of Internal Medicine II, Division of Hema-
tology, University, Berlin, Germany
Despite considerable advances in the treatment of Hodgkin lym-
phoma (HL), disease relapse and long-term treatment-related toxicity
remain significant clinical problems. Therefore, it is a crucial task to
identify signaling pathways in Hodgkin/Reed-Sternberg (HRS) cells
which can serve as therapeutic targets. The p53 pathway is central to the
cellular response to oncogenic signaling and DNA damage, and inacti-
vation of p53 is a common event in malignant transformation. In HRS
cells however, often high expression levels of p53 protein contrast with
a low frequency of detectable p53 mutations, a finding that has made it
difficult to estimate the functional status of the p53 pathway in HL and
its significance for tumorbiology and response to treatment. To address
these questions, we employed a small-molecule antogonist of MDM2,
designated nutlin-3a, that disrupts p53-MDM2 interaction. Nutlin-3a
efficiently increased the level of p53 and induced expression of p53
downstream targets in Hodgkin cell lines with wild-type p53, whereas
no effects were observed in Hodgkin cell lines that harbour p53 muta-
tions. Activation of the p53 pathway led to strong induction of apopto-
sis in p53 wild-type Hodgkin cell lines. In addition, MDM2 inhibition
enhanced the activity of traditional cytotoxic drugs, such as doxoru-
bicin, etoposide, or vincristine. In view of the fact that HRS cells display
high constitutive NF-κB activity, we analyzed the effects of the HSP90
inhibitor geldanamycin which has been shown to block IKK/NF-κB sig-
naling in Hodgkin cells. Similarly to IKK inhibition by arsenite, gel-
danamycin induced a strong apoptotic response in Hodgkin cell lines
with wild-type IκB. Hodgkin cells that contain wild-type IκB but lack
functional p53 (through mutation or siRNA knock-down) are resistant
to nutlin treatment, but still respond to geldanamycin, indicating that
inhibitors of HSP90 induce apoptosis in HRS cells in a p53-independent
manner. Therefore, combined targeting of central survival pathways
could be a promising approach to develop highly effective therapies for
patients with HL. Moreover, since nutlins and HSP90 inhibitors act by
non-genotoxic mechanisms, they exemplify a class of agents which
might be utilized to reduce the genotoxic burden of current therapeutic
regimens. 
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I045
SCREENING AND INTERVENTION IN HIGH RISK GROUPS AFTER TREATMENT FOR
HODGKIN LYMPHOMA (HL)
J.A. Radford,1 G. Brabant2
1Cancer Research UK Department of Medical Oncology; 2Department of
Endocrinology, Christie Hospital and University of Manchester, Manchester, UK
The majority of patients with HL can be cured and for these survivors
the late effects of treatment are relevant to both quality of life and long
term survival. Our challenge over the next decade is therefore twofold.
First, to develop treatments that are effective yet lower in toxicity and
second (the subject of this talk), design follow-up strategies that
acknowledge some late toxicity is inevitable with a view to identifying
problems early and making appropriate interventions wherever possible.
Second cancers (and in particular carcinomas of the breast, lung and
upper gastro-intestinal tract) have a major impact on long term survival
and early detection of small, potentially curable tumours has the poten-
tial for significant benefit. Screening of women at risk of breast cancer
as a result of supra-diaphragmatic radiotherapy (RT) at a young age is
now quite common but screening for lung cancer in both sexes is rare
and efforts are underway to set up an international study to evaluate the
effectiveness of this. Endoscopy of the oesophagus/stomach may also be
appropriate in some patients. All HL survivors should be actively encour-
aged to stop smoking and advised to make contact if new symptoms
develop so that investigations can be arranged as a matter of urgency -
and structures put in place to facilitate this. Cardiovascular disease is an
important cause of premature mortality due to the impact of RT and
anthracycline drugs on the coronary arteries and myocardium. This
excess mortality is the tip of a cardiovascular iceberg the size of which is
currently unknown and studies to define this are urgently required. In
addition, screening to identify and treat other known risk factors (obe-
sity, inactivity, smoking, diabetes mellitus, hyperlipidaemia) should be
considered and there may also be a case for the routine use of statins and
low dose aspirin in this population. Endocrine disturbances primarily
affect quality of life but may also increase the risk of cardiovascular dis-
ease. Regular assessments of ovarian, testicular and thyroid function and
bone mineral density are relevant to all survivors who have received
chemotherapy and/or RT to the abdomen/neck and appropriate inter-
ventions determined by the results of these. Some late effects of treat-
ment may be the price of success in HL but if individual risk is formally
assessed and linked to a programme of screening/intervention it should
be possible to minimise these and optimise the quality and duration of
survival.
I046
PULMONARY AND CARDIAC TOXICITY IN HL SURVIVORS
B.M.P. Aleman,1 F.E. van Leeuwen2
1Department of Radiotherapy, the Netherlands Cancer Institute; 2Department of
Epidemiology, the Netherlands Cancer Institute, Amsterdam
Introduction. Survival of patients treated for Hodgkin's lymphoma (HL)
has improved dramatically. Treatment has, however,been associated
with pulmonary and cardiovascular toxicity. 
Pulmonary toxicity. Both chemo- and radiotherapy may be associated
with pulmonary toxicity. Bleomycin-related toxicity usually presents
with pulmonary symptoms and/or bilateral interstitial infiltrates during
or shortly after chemotherapy. Bleomycin-related toxicity has been
shown to result in a significant decrease in 5-year overall survival in
patients treated for HL. Gemcitabin has also been reported to be associ-
ated with severe pulmonary toxicity in a study where etoposide was
substituted by gemcitabine in the escalated BEACOPP schema. Radia-
tion-related toxicity has an acute and a late phase. Patients may present
with pulmonary symptoms and infiltrates. The chance of radiation pneu-
monitis may be further increased if patients have also been treated with
chemotherapy (reported rates of 3% and 11% for radiation alone and
chemo- and radiotherapy, respectively). 
Cardiovascular toxicity. Cardiovascular diseases (CVDs) can arise after
both radio- and chemotherapy. Radiation-induced heart disease includes
a wide spectrum of cardiac pathologies, such as coronary artery disease,
valvular heart disease, myocardial dysfunction, pericardial disease and
electrical conduction abnormalities. In comparison with the general pop-
ulation 3- to 5-fold increased risks of several CVDs have been reported,
even after prolonged follow-up, leading to increasing absolute excess
risks over time. Risks are more strongly elevated in patients younger at
radiation. Anthracyclines may further increase the elevated risks of con-
gestive heart failure and valvular disorders from mediastinal radiother-
apy. Whereas cardiotoxicity following radiotherapy is usually observed
from 5-10 years of follow-up, anthracycline-related toxicity may be
observed at different intervals after therapy. The occurrence of anthra-
cycline-associated cardiotoxicity is strongly related to the cumulative
dose. The total dose of anthracyclines during first-line therapy for HL in
adults is relatively low compared to treatment regimens for breast can-
cer and pediatric malignancies. 
Discussion. Monitoring of acute and late pulmonary and cardiovascu-
lar toxicity is important during and after treatment for HL. Ongoing tri-
als examine whether reduction of treatment intensity is possible. Patients
should be advised to maintain a healthy life-style.
I047
HOW TO PRESERVE FERTILITY IN HL PATIENTS
M. von Wolff
Department of Gynaecological Endocrinology and Reproductive Medicine, Uni-
versity of Heidelberg, Germany
Increasing survival rates in cancer, new reproductive techniques, and
the growing interest in life quality after cancer therapy has put fertility
protection into the focus of oncologists and patients. Several studies
have shown that the risk for the mother and the baby is apparently not
increased after a cytotoxic therapy of the parents. However, a consider-
able proportion of patients loose their fertility due to the gonadal toxi-
city of chemotherapies and radiotherapies. Due to the current progress
in reproductive medicine patients can be offered a broad range of pro-
cedures to preserve their fertility. However, whereas the cryopreserva-
tion of sperm or testicular tissues is well established in men, the situa-
tion in women is far more complex. Women can be offered the cryop-
reservation of unfertilized oocytes, fertilized oocytes or ovarian tissue,
the injection of GnRH-analogues and the transposition of the ovaries.
Some of these techniques are already established, others are still exper-
imental. The ideal procedure must be individually chosen by an experi-
enced specialist in reproductive medicine in co-operation with oncolo-
gists, psychologists, geneticists and others in an interdisciplinary setting.
The integration of these disciplines and the evaluation of all new fertil-
ity preserving techniques is co-ordinated in Germany by a unique Net-
work on Fertility Preservation, called FertiPROTEKT (www.fertipro-
tect.de). The lecture will give basic information on the risk of cytotoxic
therapies for patient’s fertility and their offspring, provides an overview
of the currently available fertility preserving techniques and will give
insight in the work of the network FertiPROTEKT.
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I048
EARLY STAGE HODGKIN’S DISEASE (HD) – DEFINING THE ROLE OF RADIATION THERAPY (RT)
R.T. Hoppe
Stanford University, Palo Alto, USA
RT has more than 100 years of success in the treatment of HD. How-
ever, in the past century its role has changed dramatically. Its effects were
described as almost magical by WA Pusey, the first physician to apply
Roentgen rays to a patient (pt) with HD, in 1902. But palliation was its
first role in pt management, as pts were treated to individual sympto-
matic sites. Later, benefited by technological advances, R Gilbert
described more comprehensive programs of RT that he demonstrated in
a few cases could lead to prolonged disease control, These approaches
were adopted later by G Richards and Vera Peters in Toronto and Hen-
ry Kaplan at Stanford. Both groups were able to demonstrate that RT was
truly curative when applied aggressively to pts with early stage HD. The
identification of effective chemotherapy (CT) for the disease in the 1960s
and recognition of many potential late effects of RT in the 1970s led to
new concepts of combined modality therapy whereby the risks associ-
ated with RT could be reduced. Brief CT and limited RT has now become
the standard of care for classical HD throughout most of the world. Lim-
ited RT alone is the standard for lymphocyte predominance HD. Since
the few trials of CT alone versus combined modality therapy demon-
strate significant benefit in freedom from progression (NCIC HD6 Trial)
and failure-free survival (EORTC-GELA H9F Trial) by incorporation of
RT, efforts now are focused on identification of the minimum dose and
fields of RT to achieve this benefit. Trials of the GHSG identify doses as
low as 20 Gy to be sufficient. Although most trials have utilized fields
described as involved field, more restricted fields, limited to the involved
node(s), are now being tested by the EORTC group. Additional refine-
ments in RT technique are being incorporated into standard practice that
will further reduce RT associated risk. These include respiratory gating
and intensity modulated radiation therapy (IMRT). An additional tech-
nical advance that promises an advantage for pts with HD is proton ther-
apy, a means for further reducing RT dose to unaffected areas. Finally, pre-
treatment FDG PET scanning is essential to defining the involved node(s)
in combined modality programs and early re-evaluation PET scans (after
completion of a partial course of CT) may be helpful in defining RT dose
more precisely, or even in the identification of pts who do not require RT
to achieve a cure with the first round of treatment.
I049
BRIEF CHEMOTHERAPY WITHOUT RADIATION IS OPTIMAL TREATMENT FOR MOST
PATIENTS WITH LIMITED STAGE HODGKIN LYMPHOMA (HL)
J.M. Connors
Division of Medical Oncology, University of British Columbia and the British
Columbia Cancer Agency, Vancouver, British Columbia, Canada
Background. Radiotherapy (RT) for limited stage HL is associated with
clinically significant late toxicity including second neoplasms of the head
and neck, breast, lung, gastrointestinal and thoracic soft tissues, cardio-
vascular and pulmonary dysfunction, dental caries and hypothyroidism.
Maintenance of very high cure rates following combined modality
chemo-radiotherapy despite reduction of radiation field size from
extended to, most recently, involved nodal fields prompts us to question
the need for any radiation in the management of limited stage HL. The
experimental arm of the NCIC CTG/ECOG HD.6 trial and accurate
assessment of mid-treatment response with FDG-PET provide the evi-
dence and tools needed to design treatment consisting of chemothera-
py alone, without radiation, for 90% of patients while maintaining very
high cure rates.
Methods. HD.6 included 182 patients with stage IA or IIA, non-bulky
(<10 cm) classical HL in the experimental arm consisting of 2 cycles of
ABVD followed by complete re-assessment including CT but not PET
scanning. Patients with a complete response then received 2 more cycles
of ABVD; those with < CR received 4 more cycles.
Results. Among the 182 patients on the experimental arm of HD.6, 69
(~40%) had a CR after 2 cycles of ABVD, completed treatment with
another 2 cycles of ABVD and had a 5 y freedom from progression (FFP)
of 95%. The 113 (~60%) patients with < CR after 2 cycles of ABVD
completed treatment with 4 more cycles and had a 5 y FFP of 80 %.
However, we know from the standard arm of HD.6 that if the patients
with < CR had been treated with radiation instead of further chemother-
apy they would have had a 5y FFP of ~95%. Combining these results it
is clear that ~12% of patients with limited stage HL have a better chance
of cure if radiation is included in their treatment (20% of the 60% des-
tined to have < CR after ABVD x 2). Of the first 40 patients assessed at
our center with FDG-PET after 2 cycles of ABVD, ~ 10% had a positive
PET scan and received involved nodal RT, with the other 90% complet-
ing treatment with 2 more cycles of ABVD. 2 y FFP is 97% (see poster,
this meeting).
Conclusions. These results indicate that ~90% of patients with limit-
ed stage HL can be cured without radiation. The ~10% who require
radiation can be accurately identified with FDG-PET and its integration
into the management of limited stage HL allows almost all patients to
be successfully treated with chemotherapy alone.
I050
COMBINED MODALITY TREATMENT FOR EARLY-STAGE HODGKIN LYMPHOMA: THE GHSG
EXPERIENCE 
A. Engert, V. Diehl
German Hodgkin Study Group, University Hospital of Cologne, Germany
On the basis of clinical staging and risk factors, patients with early-
stage Hodgkin lymphoma are classified into early-favourable (CS I/II
without risk factors) or early-unfavourable stages (CS I/II with risk fac-
tors). Until recently, these patients were usually treated with extended
field (EF) radiotherapy or similar large-field techniques. Though the over-
all survival (OS) depending on stage and risk group ranged between 80
and 90%, up to 25-30% of patients relapsed and were in need of salvage
chemotherapy. The introduction of combined modality treatment
(CMT) significantly improved disease-free survival in this group of
patients. This was demonstrated in prospectively randomized trials per-
formed by the EORTC and GELA (H7F; H8F) and the HD7 trial per-
formed by the GHSG in the group of early-favourable HL patients. Here,
two cycles of ABVD followed by EF radiotherapy were significantly
superior to EF radiotherapy alone in terms of tumour control. In early-
unfavourable HL patients, CMT consisting of four to six cycles of
chemotherapy followed by radiotherapy has become the treatment of
choice. This was based on the H8U trial performed by the
EORTC/GELA and the HD8 trial by the GHSG demonstrating that addi-
tional radiotherapy or after four cycles of chemotherapy either in the
larger EF technique or the smaller involved field technique are equally
effective. Thus, most groups would consider four cycles of ABVD fol-
lowed by EF radiotherapy standard of care in these patients. Currently
open questions when using CMT is the dose of radiotherapy needed and
the possible use and effectiveness of a new radiation technique (involved
node). In addition, the prognostic impact of early PET in this group of
patients is being discussed. 
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I055
PREDICTING OUTCOME IN CLASSICAL HODGKIN LYMPHOMA: 
THE ROLE OF THE MICROENVIRONMENT?
R.D. Gascoyne, T. Nayar, T. Lee, N. Johnson, J.M. Connors, C. Steidl
British Columbia Cancer Agency and University of British Columbia, Depart-
ment of Pathology and Medical Oncology, Genome Sciences Center, Vancouver,
British Columbia, Canada
Introduction. Two previous publications have attempted to correlate
whole biopsy sample gene expression profiling with clinical outcome
and response to therapy in classical HL, reaching somewhat differing
conclusions (Devilard et al., Oncogene 2002 and Sanchez-Aguilera et al.,
Blood 2006). The aim of this study was to find genes correlated with
treatment response by studying the HRS cells, the microenvironment
and their interactions.
Patients and Methods. 70 patients with classical HL who were primari-
ly treated at the BC Cancer Agency in Vancouver between 1985 and
2005 have been included in the study. All patients received at least 4
cycles of polychemotherapy and stage-dependent radiotherapy if indi-
cated. Treatment response was defined as absence of disease progression
(n=45) and treatment failure as disease progression or relapse at any time
(n=25). We also analyzed purified normal centroblasts and 5 HL cell
lines. We performed gene expression profiling using RNA extracted from
70 total lymph nodes (referred to as microenvironment profiling) and
microdissected HRS cell extracted RNA (n=12) (Affymetrix GeneChip
HG U133 2.0 Plus), including 5 treatment responders and 7 treatment
failures. 
Results. Using supervised analysis methods, significant differences
between the two outcome groups were detected. Gene expression pro-
filing of the HRS cells revealed differentially expressed genes that indi-
cate elevated expression of antigen processing and presentation as well
as of humoral immune response genes in the treatment failure group.
Microenvironment profiling mainly showed significant differences for T
cell, fibroblastic and neo-angiogenesis genes, most prominently featur-
ing over-expression of T cell genes in the favorable treatment response
group.
Conclusions. Treatment response is coded in both the HRS cells and the
microenvironment of pretreatment lymph node specimens of classical
HL. We identified markers that could predict outcome for potential clin-
ical use. Studying microdissected HRS cells offers the possibility of deter-
mining the molecular mechanisms controlling gene expression in these
cells and understanding the interaction of HRS cells with the microen-
vironment.
I056
ANALYSING DIFFERENTIAL GENE EXPRESSION AND GENETIC LESIONS IN HRS AND L&H
CELLS TO IDENTIFY NEW THERAPEUTIC TARGETS
R. Küppers
Institute for Cell Biology (Tumor Research), University of Duisburg-Essen, Med-
ical School, Essen, Germany
We generated gene expression profiles from laser-microdissected
tumour cells of 16 cHL (10 EBV+, 6 EBV–), 30 peripheral B-cell non-HLs
(B-NHLs, of different types), and 5 lymphocyte-predominant HL (LPHL)
biopsies. Following two rounds of linear amplification, RNA was
hybridized to Affymetrix chips. Expression profiles were similarly gen-
erated from comparable cell numbers of FACS/MACS-sorted HL cell
lines and normal B-cell subsets of peripheral blood or tonsil (plasma cells,
naïve, memory and germinal centre B cells, as well as CD30+ B cells). A
supervised comparison between primary and cultured HRS cells revealed
a highly differential expression of ~1300 probe sets, including upregula-
tion in primary HRS cells of several genes involved in interactions with
the microenvironment. Primary HRS cells showed little similarity with
germinal centre B or plasma cells but, interestingly, a more consistent
relatedness to CD30+ B cells. Only few genes with significantly differ-
ent expression in EBV+ vs. EBV– HRS cells were identified, suggesting
that EBV infection does not markedly imprint the fully established cHL
clone at the transcriptional level. Further analyses will be performed to
highlight genes and pathways that are specifically activated in primary
HRS cells and that could be of pathogenetic importance. Unsupervised
hierarchical clustering showed that L&H cells of LPHL cluster as a dis-
tinct entity close to HRS cells. Supervised comparison of L&H and HRS
cells confirmed a low number of significantly differentially expressed
genes. Comparison of differentially expressed genes between L&H cells
and germinal centre B cells as their putative normal counterpart revealed
a partial downregulation of B cell marker expression. Moreover, L&H
cells have upregulated multiple anti-apoptotic as well as downregulated
pro-apoptotic molecules. The further analysis of genes aberrantly
expressed in HRS and L&H cells may reveal deregulated genes and sig-
nalling pathways that may become novel therapeutic targets.
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I057
DOSE AND FIELD SIZE: THE EORTC EXPERIENCE
T. Girinsky,1 R. Van Der Maazen, L. Specht, B. Aleman, P. Poortmans,
P. Meijnders, Y. Lievens, E. Noordijk, On Behalf Of The Eortc Lym-
phoma Group
1Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
Background. With the increasing recognition that late complications are
linked to the size of the radiation doses and fields, the EORTC lym-
phoma group initiated randomized trials testing the feasibility of reduc-
ing them.
Lower radiation doses. In 1998, the H9 trial tested the efficacy of reduced
radiation doses (20 Gy instead of 36Gy) and assessed the possibility of
foregoing radiation treatment in the early favorable Hodgkin lymphoma
group in complete response or CRu after 6 cycles of EBVP. Five-year
progression-free survival was 89%, 86% and 70% in the 36 Gy, 20 Gy,
and no radiation groups respectively. The H3-4 trial also used small radi-
ation doses (30 Gy) in most patients in PR after 6 cycles of MOPP/ABV.
Five-year overall survival was similar to that of the group of patients in
CR.
Smaller radiation fields. Large radiation fields were used in the early
unfavorable group until 1988 and until 1998 in early favorable Hodgkin
lymphoma because of a more limited use of combined modality treat-
ments. In the ongoing H10 EORTC-GELA trial, a new radiation field
concept is applied in which radiation treatment is delivered exclusively
to the initially involved lymph nodes. This new concept is mostly based
on 2 fundamental facts. The first is that the vast majority of local recur-
rences occur in initially involved lymph nodes. The second is that small-
er radiation fields are more likely to beget fewer late complications.
However, there is a caveat. There is a risk of local recurrences if the con-
cept is not properly implemented. To avoid this risk, a number of points
must be emphasized. The use of a prechemotherapy PET/CT is of para-
mount importance. It has been shown that in 25 to 36% of the patients,
one or more of the initially lymph nodes were not included in radiation
fields, when CT scan was used alone. In addition, proper training of
radiation oncologists is required through workshops and quality control
programs. A prospective quality control program using the Internet net-
work to link various cancer centers and treating hospitals has started to
be implemented in Europe. Retrospective quality control sessions are
also being organized to allow the exchange of ideas and experience.
The benefits of new radiation field concepts will be further increased
with the use of modern radiation delivery techniques such as intensity-
modulated or respiratory-gated radiotherapy.
Conclusions. Reduced radiation fields and doses in conjunction with
modern radiation delivery techniques. are redefining the role of radio-
therapy in the treatment of Hodgkin lymphoma 
I058
DOSE AND FIELD SIZE, THE GHSG EXPERIENCE
R.P. Müller, H.T. Eich
Department of Radiation Oncology, University of Cologne, Germany
Since its beginning, more than 13.000 patients with Hodgkin’s lym-
phoma (HL) have been enrolled into the multicentre randomized trials
of the GHSG. Within 5 study generations the treatment of HL has been
developed stepwise by using the results of the completed protocols.
According to radiotherapy (RT), the study group successfully evaluated
different dose-effect relationships and could also prove the efficacy of
involved field (IF)-RT in early stages in combination with effective
chemotherapy. The first protocol with a radiotherapeutic question was
the HD4 trial (1988-1994). The major aim of HD4 was to show whether
the radiation dose to the non-involved extended field (EF) could be
reduced while maintaining effective tumor control. Thus patients in
stage I or II without risk factors were randomized between standard
treatment consisting of 40 Gy EF-RT (arm A) and 30 Gy EF-RT plus
additional 10 Gy to the IF (arm B). The results showed no statistically
significant differences in recurrent free survival and overall survival (OS)
between the two treatment arms. The HD8 protocol (1993-1998) for
patients with early-unfavourable stages tested in a randomized two arm
study the question of EF-RT versus IF-RT after two cycles of
COPP/ABVD. Of 1204 patients randomized, 1064 patients were inform-
ative for the arm comparison. The median observation time was 54
months. The OS for all eligible patients was 91% and freedom from
treatment failure (FFTF) was 83%. Survival rates at five years after start
of RT revealed no differences in terms of FFTF (85.8% and 84.2%) and
OS (90.8% and 92.4%). However, patients with IF-RT reported a signif-
icant lower acute toxicity compared to those with EF-RT. The aim of the
HD10 trial (1998-2002) was to reduce acute and long term toxicities
while maintaining optimal tumor control. According to RT, the HD10
trial represents a very decisive step, since irradiation was performed as
IF-RT in all treatment arms. The HD10 trial was designed to investigate
the optimal intensity of both, chemotherapy and radiotherapy. There-
fore patients in stages PS I or II without risk factors were randomized
in a four-arm study between an IF-RT dose of 30 Gy versus 20 Gy and
2 versus 4 cycles of ABVD. After 4 years, FFTF was similar in all groups
– 94%, and overall survival was 97%. Reducing chemotherapy appeared
safe, and at this point, there was no difference between the different
radiation doses. In the EORTC/GELA-Intergroup study H10F for
patients with early stages the IF-RT was recently replaced by the
involved node (IN)-RT concept as a consolidation after ABVD
chemotherapy. Since this concept has never been tested in a randomized
trial the GHSG aims to compare it with standard IF-RT in their future
study generation (HD17).
I059
RADIOIMMUNOTHERAPY (RIT) APPLIED TO HODGKIN LYMPHOMA – A USEFUL TOOL?
T.M. Illidge
School of Cancer and Imaging Sciences, Christie hospital, University of Man-
chester, UK 
Although the outcome for the primary treatment of Hodgkin lym-
phoma with polychemotherapy has continued to improve, salvage
chemotherapy options require improvement with only around 30-40
% of those whose lymphoma relapses remaining disease-free after sec-
ond-line treatment. For patients unfit for high dose chemotherapy and
autologous stem cell transplantation and for those patients who relapse
after transplantation procedures, effective treatment options are cur-
rently limited. Given the sensitivity of Hodgkin lymphoma to radiation,
there has been a longstanding interest in using antibodies to deliver sys-
temic radiation to tumour. The earliest attempts at radioimmunotherapy
(RIT) used 90Y radiolabelled polyclonal rabbit anti-ferritin targeting the
ferritin rich surrounding milieu of the tumour. These early clinical trials
produced impressive response rates in relapsed and chemorefractory
patients. More recently the lymphoid activation markers CD25 and
CD30 have been targeted. The antigens are present on Hodgkin/Reed-
Sternberg (H-RS) cells but only on a small minority of normal cells. The
CD30 receptor antigen was originally discovered on cultured
Hodgkin/Reed-Sternberg (H-RS) cells using the monoclonal antibody
(mAb) Ki-1 and appears a promising target antigen for immunotherapy
of Hodgkin lymphoma. A murine mAb (Ki-4)-based 131I conjugate
showed efficacy in refractory HL patients, however, toxicity was a prob-
lem and less toxic constructs using alternate mAb or isotopes need to be
designed. A humanized and a fully human anti-CD30 mAb are current-
ly being evaluated in phase I/II clinical trials. These mAbs could engage
the human immune system against the HL and are capable of directly
inducing apoptosis of H-RS cells. CD25 (IL-2R alpha) also appears to be
a potentially good target antigen in H-RS cells. Promising results have
been achieved using 90Y daclizumab (anti-CD25). It is likely that these
radioimmunconjugates will need to be combined with conventional
chemotherapy to further improve responses and response durations in
relapsed disease or used in conjunction with high dose chemotherapy
as part of conditioning prior to autologous stem cell transplantation in
high risk disease. The current progress in RIT of Hodgkin lymphoma and
strategies to incorporate radioimmunoconjugates for further develop-
ment in the therapy of HL will be reviewed.
I060
YTTRIUM-90 RADIOLABELED HUMANIZED ANTI-CD25 MONOCLONAL ANTIBODY,
DACLIZUMAB, PROVIDES EFFECTIVE THERAPY FOR REFRACTORY AND RELAPSED
HODGKIN’S LYMPHOMA
D.O’Mahony, J.E. Janik, J.A. Carrasquillo, M. Brechbiel, C.H. Paik, 
N. Le, M. Whaley, E. Jaffe, T.A. Fleischer, C. Lee, D. Gao, 
S. Fioravanti, D. O’Hagan, T.A. Waldmann, J.C. Morris
Metabolism Branch, Laboratory of Pathology, NCI, Nuclear Medicine Radia-
tion Oncology and Clinical Pathology Department, CC, NIH, Bethesda, Mary-
land USA
Although with standard therapy Hodgkin’s lymphoma is one of the
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most curable neoplastic diseases, a proportion of cases are refractory or
relapse and respond poorly to salvage treatment.  The scientific basis for
the present study involving Yttrium-90 labeled anti-CD25 monoclonal
antibody, daclizumab therapy was that the majority of normal resting
cells do not display CD25 (IL-2R alpha) whereas it is expressed by most
malignant Reed-Sternberg cells.  However, there are very few (less than
1%) Reed-Sternberg cells in the malignant lesions.  However, many
tumor-associated T-cells express CD25 which dramatically increases the
antigenic target of this monoclonal antibody; thus the targeting of CD25
represents a major advance over other strategies that target antigens
(CD30) that are expressed largely on the Reed-Sternberg cells alone.  A
monoclonal antibody, daclizumab was armed with the radionuclide
Yttrium-90 which provides a beta emission that cures cells by a cross-
fire effect, thereby providing effective therapy for cells at a distance
including those that do not express CD25. Materials and Methods. In the
present study 23 patients with refractory or relapsed Hodgkin’s lym-
phoma were treated with intravenous infusions of 15 mCi of 90Y-
daclizumab (anti-CD25). 90Y-daclizumab treatment was repeated every
6-10 weeks depending on tumor response provided that there was hema-
tological recovery (platelet counts > 100,000, ANC > 1,000/mm3) for up
to 7 total doses. Results. In the 23 patients with Hodgkin’s lymphoma
treated with Yttrium-90-daclizumab there were 2 patients with progres-
sive disease, 5 with stable disease, 2 with partial responses and 14
patients who manifested a complete response. Responses were observed
both in patients whose malignant Reed-Sternberg cells expressed the
target antigen, CD25, as well as those whose Reed-Sternberg cells were
CD25 negative provided that the associated infiltrating T-cells expressed
this antigen. Toxicities of the radioimmunotherapy were limited to bone
marrow suppression manifested at 5 to 10 weeks following the infusion
that predominantly involved thrombocytopenia with an ultimate return
to normal platelet values in all cases. Conclusions. Repeated 90Y-daclizum-
ab infusions provided effective therapy for patients with refractory and
relapsed Hodgkin’s lymphoma with acceptable toxicity.
Allogeneic Transplantation
I062
DO WE NEED ALLOGENEIC TRANSPLANTATION IN HL? 
J.G. Gribben
Professor of Experimental Cancer Medicine, St. Bartholomew’s Hospital, Barts
and The London School of Medicine, London UK
Autologous stem cell transplantation (SCT) can lead to long-term dis-
ease-free survival in HL,1 even in high-risk patients,2 but the role of allo-
geneic (allo-) SCT remains controversial. The use of allo-SCT has been
restricted to very high risk patients because of prohibitive treatment-
related mortality (TRM) and lack of definitive evidence for a therapeu-
tic graft-versus-lymphoma (GVL) effect in this disease and it was not pos-
sible to demonstrate any advantage of allo- compared to auto-SCT. 3
Despite these problems, a minority of patients have experienced long-
term remissions and presumably cure. Reduced-intensity conditioning
(RIC) is being evaluated as a treatment approach in HL and has reduced
TRM4 and produced encouraging results,5 which together with respons-
es to donor lymphocyte infusions demonstrates evidence of a GVL effect
in HL.5 Now that RIC allogeneic SCT,4 or tandem autologous followed
by RIC allogeneic SCT6 have been shown to be feasible and result in an
acceptable TRM, these approaches now merit incorporation into care-
fully designed prospective clinical trials. The challenges remain how best
to identify which patients merit consideration of allo-SCT and to design
suitable trials to determine whether RIC allo-SCT has any role to play
in the management of select subgroups of patients with HL, compared
to single or tandem autologous SCT.7,8 The use of prognostic scores 9 will
be required to identify suitable patients. We are fortunate that results of
standard approaches are good and continue to improve in HL, so the
number of patients who merit consideration of allo-SCT remains small
and is unlikely at the present time that allogeneic SCT will become a rou-
tine part of the management of this disease.
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I063
NEW FRONTIERS IN ALLOGENEIC TRANSPLANTATION FOR HODGKIN’S LYMPHOMA
P. Anderlini
Department of Stem Cell Transplantation and Cellular Therapy, The Universi-
ty of Texas M.D. Anderson Cancer Center, Houston, Texas, USA 
Allogeneic stem cell transplantation (allo-SCT) with reduced-intensi-
ty conditioning (RIC) is gaining increasing acceptance in relapsed/refrac-
tory (R/R) Hodgkin s lymphoma (HL). There is accumulating experience
with matched related donors (MRDs), and this area has recently been
reviewed in detail (BBMT 12: 599, 2006). Unfortunately, while most
studies have shown that (early) transplant-related mortality has now
been reduced to less than 20%, progression-free and overall survival
(PFS/OS) for many patients continue to lag behind expectations, and
early disease progression after transplant is still common. In addition,
only about 25-30% of patients will have an HLA-identical sibling, there-
fore only a minority of patients may ultimately be eligible for the pro-
cedure itself. Many open questions therefore remain regarding the dif-
ferent aspects of this procedure, and how to improve patient outcome.
Some of the more relevant and current issues can be outlined as follows.
Results with matched unrelated donors (MUDs). Accumulating experience
suggests that, at least in selected centers, RIC allo-SCT outcome employ-
ing MUDs is comparable to the one achieved with MRDs. If unrelated
donors are employed more widely, more patients are likely to be eligi-
ble for transplant.2
Optimization of response status pre-transplant. Published data clearly indi-
cate superior outcome for patients transplanted in complete remission.
Therefore, every effort should be made to effectively cytoreduce these
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patients prior to transplant. A suggested approach here is the autolo-
gous/RIC allo-SCT combination. Alternatively, newer and investiga-
tional chemotherapy combinations should be considered.
The role of donor leukocyte infusions (DLIs). Several reports have shown
that the response rate for DLIs in HL is in the 30-40% range, and the like-
lihood of response may be affected by the chimeric status of the patient.
These responses are not always durable, however, and disease progres-
sion ultimately occurs in many patients. Whether earlier or prophylactic
DLIs or concurrent chemotherapy administration will increase this
response rate deserves further study. Preliminary data suggest a correla-
tion between CD3+ cell dose infused and development of acute GVHD,
as it is the case in chronic myeloid leukemia.
Alternative stem cell sources. Novel stem cell sources are now being
explored, and they include umbilical cord blood (UCB) units, as well as
haploidentical donors. Preliminary data have shown the feasibility of
this approach, which would significantly expand the donor pool avail-
able.
Novel conditioning regimens. Two main approached have been employed
so far. The first has contemplated the use of fludarabine-alkylating
agents (e.g. cyclophosphamide, melphalan) ± alemtuzumab or antithy-
mocyte globulin. The second has relied on low-dose total body radia-
tion (TBI) with the addition of fludarabine. Mixed chimerism is common
after alemtuzumab-based conditioning. There is a need to explore new
combinations and agents as part of the conditioning regimen. Gemc-
itabine, for instance, is active as a single-agent and in combination in HL,
and appears to have limited and manageable non-hematological toxici-
ties. The inclusion of gemcitabine in the preparative regimen is current-
ly being explored.
I064
REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION (RIC-ALLO) FOR
REFRACTORY / RELAPSED HODGKIN’S LYMPHOMA (HL). PRELIMINARY RESULTS OF AN
EBMT PROSPECTIVE TRIAL.? 
A. Sureda
Clinical Hematology Division, Hospital de la Santa Creu I Sant Pau, Barcelona,
Spain, on behalf of the Lymphoma Working Party (LWP) of the EBMT.
Autologous stem cell transplantation (ASCT) constitutes the standard
therapeutic approach for patients with HL who relapse after first line
therapy. Nevertheless, long term outcome of patients with primary
refractory disease as well as those relapsing after an ASCT is very poor.
Allo-SCT offers the potential benefit of a graft-versus-HL effect.
Although myeloablative allo-SCT has always been associated to a high
NRM in HL patients, it has been significantly reduced with the recent
introduction of reduced intensity conditioning protocols (RIC-Allo). The
LWP of the EBMT developed a prospective clinical trial to assess the
effectiveness of RIC-Allo in patients with relapsed or refractory HL.
Conditioning regimen consisted on the combination of FLU (150 mg/m2
iv) plus MEL (140 mg/m2 iv). CsA and Mtx were used as acute GVHD
prophylaxis and 4 monthly donor lymphocyte infusions were planned
after RIC-Allo in case of mixed chimerism or disease progression. Up to
now, 49 pts (31M/18F, median (range) age at diagnosis of 28 (13–54)
years and at RIC-Allo of 31 (18-63) years] have been included. Pts includ-
ed constituted a heavily pre-treated population [prior RT: 32 (65%), > 2
lines of therapy before the RIC-Allo: 34 (69%), previously failed ASCT:
40 (81%)]. 33 pts (67%) were allografted with sensitive disease and 16
(23%) with resistant disease. A HLA matched sibling donor was used in
31 pts (63%). Hematopoietic recovery was fast and complete in all pts
and 100% of the pts were complete chimera on day +28. aGVHD (44
pts at risk) was present in 20 (45%) [Grades ≥ 2 in 14 (32%)]. cGVHD
(34 pts at risk) was present in 13 (38% [extensive cGVHD in 9 (27%)].
NRM was 13%, 16% and 16% at 1, 2 and 3 yrs, without differences
between sensitive and refractory pts. With a median follow-up for sur-
viving pts of 26 (3-69) mo, OS was 71%, 62% and 43% at 1, 2 and 3 yrs
[sensitive pts: 80% and 68% at 1 and 2 yrs vs refractory pts: 56% and
49%, p=0.01]. PFS was 50%, 35% and 25% at 1, 2 and 3 yrs with sig-
nificantly better results in sensitive pts [64% and 50% at 1 and 2 yrs vs
25% and 12%, p=0.01]. Relapse rate was 37%, 49% and 59% at 1, 2 and
3 yrs with also better results in sensitive pts (23% and 33% at 1 and 2
yrs) in relation to refractory ones (62% and 75%, p=0.01). In summary,
RIC-Allo is a feasible procedure in heavily pre-treated HL pts that car-
ries a low NRM. Results are promising in those pts with sensitive dis-
ease with a better PFS and significantly lower relapse rate in relation to
resistant pts.  
Positron Emission Tomography
I066
PET-CT FOR TREATMENT RESPONSE ASSESSMENT IN LYMPHOMA
S. Stroobants, L. Brepoels, J. Thomas, G. Verhoef
University Hospital Gasthuisberg, Leuven, Belgium
Lymphomas are highly sensitive to therapy and substantial cure-rates
are expected with standard therapies. However, some patients have
residual lymphoma after therapy and early identification of these
patients is important since better outcome can be expected if treated
with lower tumour burden. At the same time, late treatment-related
diseases are increasingly recognized in cured patients. So, tailoring the
intensity of the treatment to the individual patient has become very
important. At the end of treatment, residual masses are frequent
although these masses often consist of benign fibrotic tissue only. Struc-
tural imaging as Computed Tomography (CT) does not allow differen-
tiation of fibrosis and viable lymphoma, but numerous studies have
shown the effectiveness of Fluorine-Deoxyglucose Positron Emission
Tomography(PET) in the detection of residual lymphoma. A systemat-
ic review1 showed a pooled sensitivity and specificity of 84% and 90%
in Hodgkin’s lymphoma (HL, 350 patients), respectively 72% and 100%
in non-Hodgkin’s lymphoma (NHL, 408 patients). In HL, a negative end-
of-treatment PET clearly identifies patients with an excellent prognosis
while a positive PET in NHL is highly suggestive for relapse. However,
false positive lesions can occur and a close correlation with clinical and
other imaging data and/or biopsy is mandatory before starting new
treatment. The high prognostic value of PET resulted in new response
criteria including both PET and CT results.2,3 PET is also an important
prognostic tool after a few cycles of chemotherapy as persistent abnor-
malities at interim PET are associated with a short progression-free sur-
vival. However, no published reports have demonstrated that PET-
response-adapted therapy also improves outcome yet. Finally, only lim-
ited data are available on the use of PET in the follow-up of asympto-
matic patients. The high rate of false positive findings, especially in HL,
and the lack of evidence that early detection of recurrence also improves
overall survival, warrants further studies before this can be implement-
ed in routine clinical practice.
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PET FOR EARLY RESPONSE ADAPTED THERAPY
M. Hutchings
Departments of Oncology and Haematology, Copenhagen University Hospital,
Denmark
FDG-PET and FDG-PET/CT have become standard imaging modali-
ties in the staging of Hodgkin lymphoma and the revised international
response criteria for malignant lymphoma include FDG-PET in the rec-
ommended response evaluation procedures. The improved quality of
staging and the better prognostic value of restaging are likely to benefit
the patients, although this remains unclear. Early stage HL has excellent
survival rates which are seriously tainted by late treatment-related mor-
bidity and mortality. Overall survival is markedly reduced in patients
who relapse, so it is of utmost importance to achieve a lasting remission
with the initial therapy. There is yet no known prognostic factor to iden-
tify a group of patients for whom radiotherapy can be avoided. On the
other hand, considerable mortality is caused by the fraction of advanced
stage HL patients who respond poorly to therapy. It is generally accept-
ed that more patient-tailored, risk-adapted strategies are needed to
address these problems. A number of studies have shown that FDG-PET
performed early during chemotherapy for HL is an accurate marker of
tumour response and indicator of survival. Being stronger than other
known prognostic markers, FDG-PET could have an important role as
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a determinant for risk-adapted therapeutic strategies. A number of stud-
ies are in progress or in the planning stages, which use early FDG-PET
results directly as a determinant for early therapeutic adaptation. In ear-
ly stage HL, a negative early FDG-PET is used to identify good-risk
patients for less intensive therapy (without radiotherapy), while in
advanced stage HL, A positive early FDG-PET identifies patients at high
risk who are selected for early treatment intensification. The back-
ground, rationale and progress of these trials will be addressed and future
perspectives discussed.
I068
CURRENT ROLE AND FUTURE OF PET IN HODGKIN’S LYMPHOMA (HL)
B.D. Cheson 
Georgetown University Hospital, Washington, D.C., USA
PET is widely used in the staging and response assessment of patients
with HL. Recently published guidelines regarding the standardization of
PET technique and interpretation (Juweid et al, J Clin Oncol, 25:571,
2007) and recommendations for response assessment (Cheson et al J
Clin Oncol, 25:579, 2007) have provided a framework for the incorpo-
ration of this new and important technology in the clinical research set-
ting. Nevertheless, the optimal use of this procedure remains to be
defined. Whereas stage is altered by PET in 10-30% of patients, in only
10%-30% of those is therapy changed on the basis of these results, with
no data to support a difference in outcome. The clearest role for PET is
in post-treatment assessment, distinguishing persistent disease from
fibrosis or scar tissue, although even this use requires prospective vali-
dation, which is currently ongoing. No clearly defined role exists for
PET in routine post-therapy surveillance scans. Numerous studies have
suggested that PET performed after 1 or more cycles of therapy may
predict outcome; however, no data are currently available that demon-
strate a positive impact of altering therapy on the basis of this informa-
tion. Clinical trials are currently focusing on taking advantage of PET dur-
ing therapy to modify treatment and reduce toxicity or, hopefully
improve survival. In patients with early stage disease, those with a neg-
ative PET scan may be spared additional cycles of treatment, limiting the
number of cycles of combination chemotherapy to 3 (British Lymphoma
Study Group) or even 2 (German Hodgkin’s Study Group). A study to
determine whether PET can identify those patients with bulky disease
who do not require radiation therapy is in development. Whether inten-
sifying therapy in patients with advanced disease will result in improved
clinical benefit is a critical clinical question and an international study is
under development that will address this issue. The conduct of large
randomized studies has been hampered by a number of factors: the rel-
atively small number of patients (~10-20%) who remain PET-positive
after 1-4 cycles of chemotherapy, the lack of unanimity of opinion on
what new therapy should be initiated, and the reluctance of treating
physicians to keep a patient on the same therapy in the setting of a per-
sistently positive scan. Thus, whereas PET has great potential for
improving the outcome for patients with HL, additional study in care-
fully conducted clinical trials is essential for further progress.
Advanced Stage Hodgkin Lymphoma
I071
GERMAN HODGKIN STUDY GROUP
V. Diehl
German Hodgkin Study Group, Cologne, Germany
Introduction. The HD9 trial compared baseline and dose escalated ver-
sions of the novel chemotherapy regimen BEACOPP in advanced
Hodgkin lymphoma. The previous analysis with a median follow-up of
5 years showed improved tumor control and overall survival for BEA-
COPPescalated. The present 10 year analysis in March 2007 aimed to
update and confirm these results and to monitor late effects.
Methods. Patients aged 16-65 years with previously untreated
advanced Hodgkin lymphoma (stage IIB/IIIA and risk factors or stage
IIIB/IV) were randomized to (A) 4 double cycles COPP/ABVD, (B) 8
cycles BEACOPPbaseline or (C) 8 cycles BEACOPPescalated (doxoru-
bicin, cyclophosphamide and etoposide at 140%, 192% and 200% of
standard doses, respectively). For all treatment arms the chemotherapy
was followed by irradiation of initial bulky and/or residual disease. The
trial was planned so as to detect a 9-10% improvement in the primary
endpoint, freedom from treatment failure (FFTF), by accrual of at least
900 patients.
Results. 1196 of 1201 eligible, randomized patients were evaluable
(261, 469 and 466 in arms A, B and C, respectively). The median follow-
up times were 122, 111 and 107 months in arms A, B and C, respective-
ly (29-32 months longer than in 2004). Corresponding 10-year FFTF rates
were 64%, 70% and 82% respectively (p<0.0001). FFTF was significant-
ly better in the BEACOPPescalated arm than in the BEACOPPbaseline
arm (p<0.0001). 10-year overall survival rates were 75%, 80% and 86%
respectively (p<0.001). Overall survival was also significantly better in
the BEACOPPescalated arm than in the BEACOPPbaseline arm
(p=0.0053). The death rates for HL were 11,5%, 8,1% and 2,8% in arms
A, B and C respectively. A total of 74 second malignancies were docu-
mented: 1, 7 and 14 acute myeloid leukemias (AML); 7, 8 and 5 non-
Hodgkin lymphomas (NHL); 7, 16 and 9 solid tumors/others in arms A,
B and C respectively. The corresponding overall secondary malignancy
rates were 6,7% , 8,9% and 6,8%.
Conclusions. After 10 years of follow-up dose escalation of BEACOPP
chemotherapy results in a stabilized significant improvement in long-
term FFTF and OS. The risk of secondary AML, although increased in
this study after BEACOPPescalated, amounts to 0.9% in the succeeding
HD12 study with BEACOPPescalated in 1502 randomized patients and
4 years median follow-up.
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Bonadonna Lecture
FROM THE ABSORBENT GLAND TO THE MOLECULAR CURE OF HODGKIN LYMPHOMA
V. Diehl
University of Cologne, Germany
Today, the clinical situation for patients with Hodgkin Lymphoma is
a unique example for a victory over a fatal tumor disease with a 170
years history of expanding knowledge from a mere pathology speci-
men representing mediastinal lymph nodes of a 10-year old boy,
described by Thomas Hodgkin in 1832, to the understanding of the plas-
ticity of abnormal B-cell lymphomagenesis leading to the breath taking
possibility of approaching an era of targeting molecules to revert the
malignant process. The transformation of a normal germinal center B-
lymphocyte to the peculiar, though fragile Reed-Sternberg (stem)-cell is
possibly caused by ubiquitous virus (es) (EBV) or hitherto undetected
other virus actions and molecular-genetic malfunctions of transcription
factors controlling cell growth and differentiation and is, furthermore,
highly dependent upon a sophisticated crosstalk between the  surround-
ing bystander cells consisting of cells of the innate immunity (mast cells,
eosinophils, macrophages, regulatory T-cells) that on one side inhibit the
programmed cell death of the Reed-Sternberg cells, on the other side
exhibit a feeder effect for the very fragile Hodgkin tumor cell that,
deprived of this help, would die immediately, a fact which is exempli-
fied by the scarcity of only 14 Hodgkin derived in vitro cell lines existing
today. Hodgkin Lymphoma patients after being treated with age adjust-
ed, risk adapted, response modulated and protocol based modern treat-
ment can experience a lifespan as a non-lymphoma age matched healthy
individual in the same geographical and socio-economical setting. The
hazards of not experiencing this fortune is the even in 2007 not achiev-
able rapid tumor cell kill due to a thus far unexplained resistance/high
biological malignant potential of the Hodgkin-Reed-Sternberg (stem-)
cells, a hostile tumor-micro-environment, a fragile comorbid host situ-
ation, an incompetent doctor who is not willing or unable to give the
best therapy at the right time and last but not least in developing coun-
tries the unavailability of effective drugs and or radiation sources. There
is an additional hazard for the patient not to reach the modern statisti-
cally expected lifespan: this is the situation where the tumor cells are
irradicated ab origine but the treatment induced somatic damages
become incompatable with  normal functions of a physiologically unaf-
fected organism and the patient dies due to the iatrogenic impact. Efforts
are undertaken globally today within and outside clinical trials to reach
the goal of curing patients with Hodgkin lymphomas with the least tox-
ic treatment strategy, short and long term, but the highest efficacy with
a strategy plan that is agreed upon in an interdisciplinary consensus and
implies: 1. a risk adapted therapy using the IPS or new molecular param-
eters; 2. response adaptation, using FDG-PET as prognosticator and ther-
apy- modulator; 3. combine conventional strategies (chemo-radiother-
apy) with new modalities like antibodies (rituximab, anti- CD30/25-
Moabs), or molecular targeting (avastin, linalidomid, avastin etc); 4. treat
patients – if possible – only in prospective controlled clinical trials; 5. use
age adjustment for the elderly patient group (PVAG, ABVD, AVG); 6. as
an unexperienced doctor: refer the patient to the specialist who partic-
ipates in clinical trials; 7. observe and screen the survivors for iatrogenic
damages like secondary neoplasms, cardio-pulmonary toxicity, hormon-
al dysfunctions and psycho-social problems.
Keynote Lecture
INFLAMMATION AND CANCER: ORGAN-SPECIFIC REGULATION OF CANCER
DEVELOPMENT
L.M. Coussens
Department of Pathology, Comprehensive Cancer Center, University of Califor-
nia, San Francisco, CA, USA
During the early development of cancer, many physiological process-
es occur in the vicinity of 'young tumor cells' that are similar to process-
es that occur during embryonic development and to healing of wounds
in adult tissue, e.g., inflammation, angiogenesis (development of new
blood supply) and tissue remodeling (Balkwill et al., 2005; Coussens and
Werb, 2002).  During wound healing, inflammatory cells are recruited
to sites of injury to eliminate potential bacterial infection as well as to
facilitate healing by providing growth factors and proteases that are
essential to the process. In so doing, a new blood supply is also formed
that further helps the tissue heal. When healing is complete, inflamma-
tion resolves and the tissue returns to its former state.  Several of these
parameters are conserved during tumor development; however, instead
of initiating a healing response, inflammatory cells provide growth-pro-
moting factors that help tumors grow.  These observations are signifi-
cant in light of the fact that individuals suffering from chronic inflam-
matory diseases harbor a greatly increased risk for cancer development
in tissues infiltrated by activated leukocytes (de Visser et al., 2006), and
indicate that by identifying molecular mediators regulating onset, acti-
vation and maintenance of inflammation in the neoplastic microenviron-
ment, we will reveal regulatory events/molecules that can be effective-
ly targeted with anti-cancer therapeutics. The concept that leukocytes
are components of malignant tumors is not new; however, their func-
tional involvement as promoting forces for tumor progression has only
recently been appreciated (Balkwill and Mantovani, 2001). We are inter-
ested in understanding the molecular mechanisms that regulate leuko-
cyte recruitment into neoplastic tissue and subsequent regulation those
leukocytes exert on evolving cancer cells. To address these issues, we
have taken several approaches to investigate mechanisms involved in:
i. induction and maintenance of chronic inflammatory microenviron-
ments in premalignant tissues, and ii. role of leukocytes and their solu-
ble mediators as regulators of cancer development. By studying mouse
models of skin, lung and breast cancer development, we have recently
appreciated that adaptive leukocytes differentially regulate of innate
immune cell recruitment, activation, and behavior, by organ-dependent
mechanisms. Thus, whereas chronic inflammation is B cell–dependent
during skin carcinogenesis, during mammary carcinogenesis, T cells
appear to play more of a dominant role. To be presented will be recent
insights into organ and tissue-specific regulation of epithelial cancer
development by adaptive and innate immune cells.
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EXPRESSION OF THE EBV-ENCODED EBNA1 IN HODGKIN'S LYMPHOMA CELLS 
MEDIATES UPREGULATION OF THE CHEMOKINE CCL20 AND THE MIGRATION OF 
REGULATORY T CELLS
K.R.N. Baumforth,1 A. Birgersdotter,2 G.M. Reynolds,1 W. Wei,1
J.R. Flavell,1 L.S. Young,1 I. Ernberg,2 C.B.J. Woodman,1 P.G. Murray1
1Cancer Research UK Institute for Cancer Studies, University of Birmingham,
UK 2Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska
Institute, Stockholm, Sweden
Introduction. A proportion of Hodgkin’s lymphomas (HL) carry the
Epstein-Barr virus (EBV), an oncogenic herpesvirus, in their tumor cells.
Although it is generally assumed that EBV contributes to the malignant
phenotype of HL cells, direct evidence in support of this is lacking. The
more frequent association of EBV with the mixed cellularity subtype
suggests that the virus may influence the nature of the tumor cell
microenvironment.
Methods. Microarray analysis was used to compare gene expression
profiles of EBV-positive and EBV-negative primary HL tumors with that
of normal germinal centre B cells. Differentially expressed genes were
compared to a list of EBV regulated genes derived from a microarray
analysis of paired EBV positive and EBV negative HL cell lines. RT-PCR,
ELISA and immunohistochemistry were used to validate gene expression
changes. Transwell assays were used to assess the chemotaxis of PBM-
Cs towards conditioned media from HL cell lines. Migrated PBMCs were
phenotypically characterised using flow cytometry.
Results. Microarray analysis revealed differences in gene expression
between EBV-positive and EBV-negative tumors, which included the
upregulation of CCL20 in EBV-positive tumors. CCL20 was also up-reg-
ulated in both EBV-positive HL cell lines. Furthermore, by immunohis-
tochemistry, CCL20 expression was also observed more frequently in
the HRS cells of EBV-positive primary tumors compared to EBV-negative
primary tumors (79% vs. 13%; Chi-square 31.721; p=0.000). EBNA1
expression in EBV-negative L428 & KMH2 cells up-regulated CCL20
expression. Higher levels of CCL20 in conditioned media from EBV-pos-
itive HL cells led to increased chemotaxis of CCR6 positive PBMC. The
migrated CD4-positive PBMC contained significantly more FOXP3-pos-
itive cells than either than the starting population or the non-migrated
PBMC (28.86% vs. 4.14% and 4.22%, respectively; Student's t-test;
p=0.026).
Discussion. EBV infection of HRS cells increases the migration of
CD4+FOXP3+ PBMCs through the up-regulation of CCL20. These regu-
latory T cells may induce a localised immunosuppression and suppress
CTL responses to EBV-infected tumor cells. 
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ABERRANT NOTCH1 ACTIVITY CONTRIBUTES TO PLASTICITY OF HODGKIN AND 
REED-STERNBERG CELLS
F. Jundt,1 O. Acikgoez,1 S.H. Kwon,2 M. Hummel,3 H.Y. Lim,2
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1Department of Hematology and Oncology, Charité, Campus Virchow-Klinikum,
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Germinal center-derived neoplastic B cells in Hodgkin lymphoma have
lost the B cell phenotype despite their mature B cell origin and show
aberrantly high Notch1 activity. The Notch1 receptor is essential for the
maintenance of the stem cell pool and for cell fate decisions in
hematopoietic lineages, but its role in germinal center B cell identity and
function is unknown. Here we report the Notch1 receptor-dependent
transdifferentiation of neoplastic B cells in Hodgkin lymphoma. The
development of B cells critically depends on a transcription factor net-
work. Our data demonstrate that Notch1 disrupts the B cell-specific
transcription factor network by antagonizing the B cell-specific tran-
scription factors Pax5, E2A and early B-cell factor (EBF) in Hodgkin and
Reed-Sternberg (HRS) cells. Co-immunoprecipitation experiments
showed that Notch1 binds directly to the B cell commitment factor Pax5.
Specific downregulation of Notch1 by siRNA revealed that aberrantly
expressed Notch1 suppresses the transcription of E2A and EBF. Recent-
ly, we demonstrated, that the key B cell-determining transcription fac-
tor E2A is antagonized in HRS cells by the deregulated expression of its
inhibitor activated B-cell factor (ABF)-1 (Mathas et al., Nature Immunol.,
2006). We now provide evidence, that Notch1 induces the expression of
ABF-1. As a result, expression of the E2A/EBF-dependent genes CD79a
and CD79b is suppressed. Concomitantly, Notch1 induces the expres-
sion of B lineage-inappropriate genes as shown by RT-PCR analysis of
the macrophage-associated gene colony-stimulating factor 1 (c-fms) and
T cell-associated transcription factors T-bet and TCF-1. These data sug-
gest that Notch determines the unique HRS cell phenotype through aber-
rant expression of B lineage-inappropriate genes. To further investigate
molecular mechanisms for aberrant Notch1 activity, we analyzed the
expression of Deltex-1. Deltex-1 is a key modulator and cytoplasmatic
inhibitor of Notch1, which is known to be expressed in germinal center
B cells. We analyzed its expression and observed that Deltex-1 is not
expressed in primary and cultured neoplastic B cells in Hodgkin lym-
phoma. These data indicate that the loss of Deltex-1 contributes to aber-
rant Notch1 activity in HRS cells. Taken together, our data suggest that
Notch1 contributes to plasticity of B cells in Hodgkin lymphoma and that
its aberrant activation is partly caused by absence of its inhibitor Deltex-
1.
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INDUCTION OF A HODGKIN-LIKE PHENOTYPE BY EPIGENETIC REPROGRAMMING OF 
B CELLS
A. Ehlers, E. Oker, S. Bentink, D. Lenze, H. Stein, M. Hummel
Department of Pathology, Charité-Universitätsmedizin Berlin, Campus Ben-
jamin Franklin, Berlin, Germany
Introduction. A characteristic feature of the tumour cells (Hodgkin/
Reed-Sternberg (HRS)) of classical Hodgkin lymphoma (cHL) is the loss
of their B-cell phenotype despite their B-cell origin. It is suggested that
epigenetic events such as DNA-methylation in the promoter region are
involved in this silencing of B-cell associated genes. Our research team
has shown that the up-regulation of B-cell inappropriate genes (i.e. Id2)
significantly contributes to the extinction of the B-cell program via block-
age of the B-cell determining transcription factor E2A. The mechanism
for the overexpression of B-cell inappropriate genes in cHL is obscure.
Methods. We subjected Hodgkin and B-cell cell lines to reagents which
cause DNA-demethylation and histone-acetylation. Treated and untreat-
ed cell lines were analysed by means of Affymetrix GeneChips and
numerous up- and down regulated genes were verified by quantitative
RT-PCR. Chromatin-Immunoprecipiation was carried out to determine
the epigenetic modifications in the promoter region of the corresponding
genes.
Results. The treatment of Hodgkin cell lines with demethylating and
acetylating reagents had no significant effect on the reactivation of the
B-cell expression program. Instead, the treatment of B cells resulted in a
complete loss of the B-cell phenotype and - in parallel - to an up-regu-
lation of cHL characteristic genes. 
Discussion. Our results indicate that demethylation and acetylation
are responsible for the up-regulation of B-cell inappropriate genes in
cHL which in turn down-regulate significant parts of the B-cell expres-
sion program. This indicates that epigenetic mechanism are involved in
triggering the transdifferentiation of B cells into HRS cells, a process
which is most likely associated with the oncogenic event leading to cHL
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3D NUCLEAR ORGANIZATION OF TELOMERES IN HODGKIN AND REED-STERNBERG
CELLS
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In both, Hodgkin (H) and Reed-Sternberg (RS) cells telomerase activ-
ity is high and abundant telomerase RNA template (hTR) is identified
by in situ hybridization. However, the molecular events associated with
the transition from the mononuclear H to the multi-nuclear diagnostic
RS are unclear and nothing is known about the three-dimensional (3D)
structure of the telomeres in H and RS. We analyzed the 3D structure
of telomeres in interphase nuclei in the Hodgkin cell lines HDLM-2, L-
428 and L-1236, where about 95% are mononuclear H and only 1 to 5%
are multinuclear RS. We also analyzed the 3D structure of telomeres
within 5 mu thin sections of three lymph node biopsies diagnostic for
Hodgkin's disease (HD). The stereometric (3D) organization of telom-
eres was investigated in 30 H and 30 RS of each cell line and in 30 H and
30 RS of each lymph node biopsy specimen as previously described
(Proc Natl Acad Sci USA, 102: 9613). Cellular localization of key-proteins
of the telomere localized shelterin-complex (TRF1 and TRF2), of the
mitotic spindle (centrin and tubulin), and of ds-DNA breaks (gamma-
H2AX), was also analyzed. In all three cell lines the multinuclear RS
showed overall significantly shorter and also significantly less telom-
eres in relation to the total nuclear mass when compared to their
mononuclear H precursors. Visualization of their 3D telomeric struc-
ture revealed that this difference was due to partial or nearly total loss
of telomeres within single nuclei of multinuclear RS; in particular, one
or two nearly telomere free nuclei were often adjacent to one or two
nuclei displaying several impressive telomeric aggregates. TRF1 and
TRF2 were mainly cytoplasmic in H and RS whereas gamma-H2AX
accumulated in the nuclei of RS but not H. Multiple pairs of centro-
somes not correlating with the number of nuclei, as well as high num-
bers of spindles and incomplete spindles were identified in RS. In the HD
lymph node biopsy specimen results analogous to those described in the
HD cell lines were found. Our results suggest that multinuclear RS rep-
resent end stage tumour cells, where further nuclear division gets impos-
sible due to sustained 3D telomere aggregation, shortening or loss. In
particular, the number of nuclei within RS correlates closely with the 3D
organization of telomeres. This process is initiated in H and advances
to end stage telomere free ghost nuclei as observed in many RS. The
shelterin complex appears to be disrupted and the mitotic cycle is pro-
foundly disturbed. 
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PROTEOMICS ANALYSIS OF HODGKIN LYMPHOMA: IDENTIFICATION OF NEW PLAYERS
INVOLVED IN THE CROSS TALK BETWEEN HRS CELLS AND INFILTRATING LYMPHOCYTES 
Y. Ma,1,2 L. Visser,1 H. Roelofsen,2 M. de Vries,2 A. Diepstra,1
G. van Imhoff,3 T. van der Wal,3 G. Alvarez-Llamas,2 H. Vos,1
S. Poppema,1 R. Vonk,2 A. van den Berg1
1Dept. of Pathology and laboratory Medicine, 2Centre for Medical Biomics,
3Department of Hematology, University of Groningen and University Medical
Centre Groningen, Groningen, The Netherlands
Introduction. Hodgkin lymphoma (HL) is characterized by the abnor-
mal cytokine and chemokine production. These cytokines and
chemokines may play an important role in the proliferation of the HRS
cells, the reactive background formation and the impaired immune
response encountered in patients with HL. To detect new proteins that
might be involved in the interaction between the HRS cells and the
inflammatory background cells, we analyzed the secretome of the HRS
cells. 
Methods. Four HL cell lines L428, L1236, KMH2 and DEV were cul-
tured in RPMI without serum for 24 hours. Cell culture supernatant was
separately concentrated and fractionated in 30-35 bands after size sep-
aration using SDS-PAGE. Each band was digested with trypsine and
analyzed by LC-MS/MS for identification of the proteins. Presence of
secreted proteins was indicated by application of SecretomeP2.0 soft-
ware. ELISA was performed to validate protein expression in HL cell
lines and HL patient plasma. 
Results. In total, 1296 proteins were identified with confidence level
of ≥95% in the four HRS cell line supernatants. 372 proteins were pre-
dicted to be secreted, including 86 proteins that follow a classical path-
way and 286 proteins follow a non-classical pathway. TARC, as a known
serum marker for HL, was among the identified protein list. The secret-
ed proteins were classified based on their function, which revealed four
main functional subgroups: metabolism, immune-response, cell growth
& proliferation and signalling. Nine of 37 proteins involved in immune
response were validated in HL cell line culture supernatant and HL
patient plasma by ELISA. All nine proteins tested (ALCAM, Cathepsin
S, CD26, Fractalkine, IL1R2, IP-10, MIF, RANTES, TARC) were con-
firmed to be present in HL cell line supernatant. Seven proteins
(ALCAM, Fractalkine, IL1R2, IP10, MIF, RANTES and TARC) revealed
significantly elevated levels in patient plasma compared to healthy con-
trols. There were no increased plasma levels of Cathepsin S and CD26
in HL patients. 
Conclusions. The use of proteomic approaches to analyze HL cell line
secretome allowed the detection of new proteins. Further analysis of
these proteins may add to our knowledge about the interaction between
HRS cells and the infiltrating lymphocytes.
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ELEVATED LEVELS OF HLA-B ASSOCIATED TRANSCRIPT 3 (BAT3) IN SERA FROM
HODGKIN LYMPHOMA PATIENTS
B. Böll, V. Simhadri, K.S. Reiners, H.P. Hansen, B. von Tresckow, 
D. Re, A. Engert, E.P. von Strandmann
University Hospital of Cologne, Department of Internal Medicine I, Laboratory
for Immunotherapy, Cologne, Germany
Introduction. Natural Killer (NK)-cells are lymphocytes of the innate
immunity, which provide a link to the adaptive immune responses.
Major receptors involved in tumor cell recognition and surveillance are
the NKG2D receptor and the Natural Cytotoxicity Receptors Nkp30,
Nkp44 and NKp46. However, sustained expression and the release of
soluble ligands for the NKG2D receptor negatively imprints the local and
systemic immune response and correlates with a poor prognosis for
haematological and epithelial malignancies. So far the cellular ligands for
NKp30 have remained elusive and nothing is known about their expres-
sion in the sera of Hodgkin Lymphoma (HL) patients. 
Methods and Results. Using a yeast two hybrid approach with the extra-
cellular NKp30 sequence as bait we were able to isolate a putative
NKp30 ligand from a tumor cDNA library. Sequence analysis revealed
that the cDNA encoded for BAT3 (HLA-B-associated transcript 3)
mapped to chromosome 6p21.3 within the inflammatory HLA com-
plex. By means of laser scanner microscopy and Western Blotting we
demonstrate that BAT3 is released from tumor cell lines into the extra-
cellular environment. Released BAT3 triggers NK cell-mediated cytokine
release and NKp30-dependent cytotoxicity. Hodgkin Lymphoma (HL)
patients have impaired NK cell activity in the peripheral blood and the
level of NK anergy correlates with a bad prognosis. Since spleen derived
NK cells exhibit normal or increased activity, a serum-derived factor is
probably involved in NK cell inhibition. We screened the sera of 36
healthy donors and 56 early and late stage HL patients using a BAT3 spe-
cific sandwich-ELISA and recombinant BAT3 as standard. The BAT3
serum level was significantly elevated in HL patients in comparison to
healthy donors (p=0.0002). Interestingly, the early stage patients had a
more pronounced increase compared to the advanced stage patients
(p=0.024).
Discussion. The BAT3 level is elevated in sera from HL patients sug-
gesting a role for the modulation of NK cell activity in this disease. The
analysis of released BAT3 using fractionation and Western blotting
revealed that different BAT3 isoforms were secreted, that may exhibit
distinct modulation of NK cell-activity. The BAT3 expression levels are
currently being tested for correlation with individual features (e.g. age,
gender) and clinical parameters (e.g. histology, response to treatment) in
order to evaluate BAT3 as a novel prognostic marker.
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EFFICACY AND TOXICITY OF TREATMENT OF HODGKIN'S DISEASE/MATURE DATA FROM
A SINGLE CENTRE
R. Ward, A. Wilson, N. Plowman, A.Z.S. Rohatiner, T.A. Lister
Department of Medical Oncology, St. Bartholomew's Hospital, London, UK
Introduction. The cure of Hodgkin's Disease for the majority of patients
became a reality with the widespread use of extended field megavolt-
age radiotherapy (EFRT) and combination chemotherapy,and began in
the 1960s. 
Methods. 526 patients (median age 32 years, range 13-79) with
Hodgkin's Disease, commenced curative treatment at St Bartholomew's
Hospital between 1968 and 1985. Only 12 patients (2%) have been lost
to follow up, all prior to 1985. 
Results. Treatment was assigned at presentation and progression
according to the Ann Arbor, later Cotswolds stage (I/91/ II/178, III/150,
IV/107, laparotomy in 272 (52%)). Treatment at presentation was either
EFRT, combination chemotherapy (MVPP) + EFRT, or MVPP alone, and
at progression, was dictated by individual circumstances. Only 8 patients
received myeloablative therapy. 81 patients have developed second
malignancy/ lymphoid (NHL 16, ALL 1), myeloid 10 (MDS/MPD 5,
AML 4, CML 1), lung 13, breast 11, and other 36. Myeloid malignancy
occurred between 3 and 21 years, 3 in each of 1st, 2nd and 3rd remission
(CML concurrent to diagnosis). Most (79%) breast (9/11) and lung
(10/13) malignancies occurred in 1st remission. 246 patients are alive, all
free of Hodgkin's Disease at between 20 and 40 years, 205 in first remis-
sion (overall response - 458/536, 87%), 36 in second remission (response
rate 128/163, 79%), 5 in third or later remission (response rate 44/54,
81%), the latest recurrence having occurred in first remission after 25
years, in second remission after 18 years, and third remission after 10
years. 15 patients had a first recurrence after >10 years, 11 of which had
the same histology at time of relapse (NS 4, LP 5, MC 2). 268 patients
have died, 105 of Hodgkin's Disease, 20 after failure of first therapy, 83
after failure of second therapy and 38 after failure of third therapy. 47/81
second malignancies were fatal; 29 in 1st, 16 in 2nd, and 2 in 3rd or
more remission respectively. There were 45 deaths from cardiac failure
(34 in first remission), 35 related to treatment (increasing with number
of therapies), 15 from late infection (laparotomy not significant) and 19
from other causes.
Discussion. These findings which reflect the outcome of the first era
of therapy given with increasing expectation of cure of Hodgkin's Dis-
ease, will be shown in relation to patient characteristics and specific
therapy.
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CAUSES OF DEATH AND EXCESS MORTALITY AFTER HODGKIN LYMPHOMA (HL): 
THE EORTC-GELA EXPERIENCE
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Introduction. To analyze cause-specific excess mortality in adult HL
patients.
Methods. We conducted a retrospective study with the objectives of
estimating excess mortality from causes other than HL and determining
their risk factors. The cohort was composed of 4401 patients included
in eight successive EORTC and GELA clinical trials conducted from 1964
to 2000 in Belgium, France and The Netherlands. General population
mortality data were issued from the WHO Mortality Database. Excess
mortality was expressed using standardized mortality ratio (SMR) and
absolute excess risk (AER). The relative survival was calculated and
analysed using the model described by Estève. In early stage disease,
variables tested (multivariate analysis) were gender, age (15-39, 40-49,
50 years), prognostic group (early stages), splenectomy and treatment
(radiotherapy: localised vs. extended; alkylating vs. no alkylating-con-
taining chemotherapy vs. no chemotherapy). 
Results. After a median follow-up of 7.8 years (34,334 person-years),
725 patients have died, 51% from progressive disease, 10% from treat-
ment-related toxicity, 18% from second cancer, 5% from cardiovascu-
lar disease, 2% from infection, 8% from other causes and 6% from
unspecified causes. Overall, SMR was 7.4 (95% CL: 6.9-8.0) and AER
182.8 (95% CL: 167-199). They were 3.8 (95% CL: 3.2-4.5) and 27.9
(95% CL: 20.6-35.2) for second cancer deaths, and 4.0 (95% CL: 2.3-6.7)
and 3.3 (95% CL: 0-5.8) for deaths from infection, respectively. After 15
years, observed survival was 75% and relative survival was 80%. In ear-
ly stage patients (N=2541, 1982-1999), excess mortality (all causes) was
associated with age ≥40 (p=0.007), male gender (p<0.001), unfavourable
prognosis features (p<0.001), and two treatment modalities: combina-
tion of no alkylating-containing chemotherapy (i.e. EBVP) and involved-
field radiotherapy (p=0.002), and mantle field irradiation alone (p=0.003).
When censoring follow-up at first relapse, no treatment modalities were
associated with excess mortality.
Conclusions. Progressive disease remains the first cause of death in
patients with HL in the first decade after treatment. Excess mortality is
significantly linked with treatment modalities associated with poor
treatment failure-free survival. Longer follow-up is needed to assess the
cure rate of patients who were given current standard treatments, i.e.
combination of 3 or 4 ABVD and limited radiotherapy.
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SURVIVAL PATTERNS AMONG HODGKIN LYMPHOMA PATIENTS WITH A FAMILY HISTORY
OF LYMPHOMA
L.A. Anderson,1,2 R.M. Pfeiffer,1 J.S. Rapkin,1 G. Gridley,1 L. Mellemk-
jaer,3 K. Hemminki,4,5 M. Bjorkholm,4 L.R. Goldin,1 O. Landgren1
1Division of Cancer Epidemiology and Genetics, NCI, NIH; 2Cancer Prevention
Fellowship Program, NCI, NIH; 3Danish Cancer Society; 4Karolinska Insti-
tutet; 5German Cancer Research Center
Introduction. Genetic contributions seem to play important roles in the
causation of Hodgkin lymphoma (HL). 2- to 3-fold excess HL risk is con-
sistently reported among HL patients with a family history (FH) of HL
or other lymphomas. We previously found similarly elevated risk in
first-degree relatives of HL cases compared to first-degree relatives of
controls and another study found increased risk of HL among monozy-
gotic twins. Further, common genetic polymorphisms have been sug-
gested to alter risks for various lymphoma subtypes. In contrast, there
are limited data available on clinical characteristics for familial HL cas-
es and no data addressing whether familial and sporadic cases have dif-
ferent prognosis.
Methods. Using population-based linked registry data from Sweden
and Denmark, we identified 7,476 HL patients (median age 38 yrs, range
2-91 yrs; 60.4% males) with linkable first-degree relatives diagnosed
between 1958 and 2001. We calculated hazard ratios (HRs) and 95%
confidence intervals (CIs) as measures of overall survival using Cox pro-
portional hazard models. We compared survival in HL patients with a
FH of HL or any lymphoma (HL, non-Hodgkin lymphoma, and chron-
ic lymphocytic leukemia) to those without a FH.
Results. We found 96 (1.25%) HL patients with a FH of any lymphoma;
among these there were 21 (0.28%) with a FH of HL. Patients with a FH
of any lymphoma were more likely to be male (p=0.015) and were
younger than those without a FH of lymphoma (p<0.001). HL patients
with a FH of HL were younger than patients without a FH of HL
(p=0.019). However, the gender distribution was similar in the two
groups (about 60% males and 40% females: p=0.18). Survival was sim-
ilar for HL patients with and without a FH of any lymphoma (HR=0.78,
95% CI 0.51-1.19). In analysis stratified by age (<45> yrs) at HL diagno-
sis the results were virtually the same. Survival was also similar for HL
patients with, compared to those without, a FH of HL (HR=0.92, 95%
CI 0.38-2.21). While FH of lymphoma was not associated with survival,
we found older age (p<0.001), male gender (p<0.001), and early calen-
dar periods of diagnosis (p<0.001) to be associated with worse outcome.
Conclusions. Consistent with other data, HL patients with a FH of lym-
phoma were more likely to be male and younger than cases without FH.
However, survival patterns for HL patients with and without a FH of
lymphoma were similar suggesting that familial HL is not associated
with a more aggressive course of disease.
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RESULTS OF THE EORTC-GELA H9 RANDOMIZED TRIALS: THE H9-F TRIAL (COMPARING 3
RADIATION DOSE LEVELS) AND H9-U TRIAL (COMPARING 3 CHEMOTHERAPY SCHEMES)
IN PATIENTS WITH FAVORABLE OR UNFAVORABLE EARLY STAGE HODGKIN’S LYMPHOMA
(HL)
J. Thomas, C. Fermé, E.M. Noordijk, M.B. van 't Veer, P. Brice, 
M. Diviné, F. Morschhauser, P. Carde, H. Eghbali, M. Henry-Amar
EORTC Lymphoma Group; Groupe d'Etudes des Lymphomes Adultes (GELA)
Background. EORTC and GELA aim at reducing acute and late side
effects of treatment in early stages HL, without jeopardizing high event-
free survival (EFS) and overall survival (OS) rates already achieved. 
Methods. From October 1998 to May 2004, 1591 patients with stage
I-II HL were enrolled into 2 trials based on 4 prognostic factors: age,
symptoms, number of involved areas, MT-ratio. The H9-F trial com-
pared 36 Gy involved field radiotherapy (IF-RT) vs 20 Gy IF-RT vs no RT
in patients in complete remission (CR(u)) after 6 cycles of EBVP. The
H9-U trial compared 6 cycles of ABVD vs 4 cycles of ABVD vs 4 cycles
of BEACOPP baseline, followed by 30 Gy IF-RT in all arms, in patients
with unfavorable clinical features. 
Results. In the H9-F trial, of the 783 patients enrolled, 619 (79%)
achieved a CR(u) and were randomized. Inclusion of patients in the no-
RT arm was stopped in May 2002, because stopping rules were met (ie.
>20% of events). Inclusion in the other 2 arms continued until May
2004. After a median follow-up of 33 months, the 4-year EFS rates were
87% in the 36 Gy and 84% in the 20 Gy arm; it was 70% in the 0 Gy
arm (p<0.001). The 4-year OS rate was 98% in all 3 arms. Until Septem-
ber 2002, 808 patients were randomized in the H9-U trial. The 4-year EFS
rates were 94%, 89% and 91% in the 3 arms, respectively (p=0.23) and
the 4-year OS rates 96%, 95% and 93% (p=0.89). Chemotherapy-relat-
ed toxicity (measured by antibiotics, transfusions, hospitalization, S.A.E.)
was higher with BEACOPP compared to ABVD. 
Conclusions. In favorable HL patients who achieve CR(u) after 6 cycles
of EBVP, omission of IF-RT leads to an unacceptable failure rate; in con-
trast, an IF-RT dose reduced to 20 Gy provides equivalent early results
as an IF-RT dose of 36 Gy. In unfavorable HL patients, similar early EFS
rates are observed when the number of ABVD cycles is reduced from 6
to 4. BEACOPP is not more efficient but more toxic.
C011
STAGE I/II HODGKIN'S DISEASE (HD) WITH BULKY MEDIASTINAL DISEASE OR OTHER
RISK FACTORS (RF); THE STANFORD V EXPERIENCE
R.H. Advani, R.T. Hoppe, S.A. Rosenberg, S.J. Horning
Stanford University Cancer Center, Stanford, CA, USA 
Introduction. In the U.S., stage I/II HD with a mediastinal mass ratio >1/3
(MMR) is considered unfavorable (U) & is generally treated like advanced
disease. However, in contrast to the GHSG or the EORTC, stage I/IIA dis-
ease without MMR but with other features such as > 3 nodal sites, ESR >
50 and extra-nodal involvement are not considered U nor used in risk strat-
ification. The purpose of this study is to evaluate & compare the outcomes
of patients (pt) with early stage disease considered to be U due to MMR to
those with other adverse RF as defined by the GHSG or the EORTC.
Methods. This is a retrospective analysis of pt treated uniformly at
Stanford. Pt with stage I/II disease with a MMR or stage I/IIA without
MMR but with 1 or more risk factors (> 3 nodal sites, ESR >50, extra-
nodal involvement) & a minimum follow-up of 2 y were identified from
our database. Pt with MMR were treated with 12 wk of Stanford V + 36
Gy to sites of disease >5 cm (SV-12 + 36 Gy). Stage I/IIA pt without
MMR but with other RF were treated on our early stage protocols with
8 wk of Stanford V + 20-30 Gy RT to involved sites (SV-8 + 20-30 IFRT).
Results. 120 pt were identified: 56 pt with Stage I/II and MMR were treat-
ed with SV-12 + 36 Gy and 64 stage I/IIA pt without MMR but with RF
were treated with SV-8 + 20 Gy (n=16) or SV-8+30 Gy (n=48). The estimat-
ed freedom from progression (FFP) & overall survival (OS) were 90.5% &
93% respectively at 10 y. At a median follow-up (FU) of 10.2 y for MMR
pt, the 10 y estimated FFP was 90.6% & OS was 89%. At a median FU of
7.1 y for non-MMR pt with RF, the 10 y estimated FFP was 90.4% & OS
was 96.7%. SV-12+36 Gy failed in 5 pt. Relapse was limited to the RT field
in 1 pt & combined with distant disease in 3 pt. Secondary therapy was suc-
cessful in 2 of the 5 pt. SV-8+20-30 Gy failed in 6 pt. Relapse was limited
to the RT field in 2 pt & combined with distant disease in 3 pt. Secondary
therapy was successful in all pt although 1 transplant related death occurred.
Data on fertility and secondary cancers will be presented.
Conclusions. In our series, SV-8+20-30 Gy treatment of stage I/IIA HD
pt without MMR but with RF identified by the GHSG and EORTC have
excellent outcomes comparable to those of the GHSG (HD11) and
EORTC (HD9U) using more intensive treatments. Stage I/II MMR pt
treated with SV-12+36 Gy also enjoyed excellent FFP and OS but second-
line treatment was less successful in this group. These results suggest dif-
ferences within the intermediate prognosis HD group identified by
GHSG and EORTC that have implications for balancing the risks and
benefits of highly successful treatment strategies
C012
ABVD CHEMOTHERAPY IS ESSENTIAL FOR OPTIMAL TREATMENT OF LIMITED STAGE
NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA
K.J. Savage, P. Hoskins, R. Klasa, L.H. Sehn, T. Shenkier, N. Voss, 
R.D. Gascoyne , B. Skinnider, J.M. Connors
Medical Oncology, Pathology and Radiation Oncology, BC Cancer Agency,
Vancouver, BC, Canada
Background. Limited stage nodular lymphocyte predominant Hodgkin
lymphoma (NLPHL) has traditionally been treated with radiation alone. We
attempted to improve outcomes by adding chemotherapy with ABVD.
Methods. We identified 92 consecutive adult (age 16-65 y) patients with
limited stage (IA or IIA, low bulk (<10 cm)) NLPHL evaluated and treated
in British Columbia between 1965 and 2006. During that time treatment
has evolved: involved field radiation (IFRT) (1965-70) (n=8); extended field
(EFRT) (1970-93) (n=46); combined modality therapy ABVD + EFRT (1993-
96) (n=4); ABVD + IFRT (1993-2003) (n=26); ABVD alone (2004-07) (n=8)
with the exception of isolated peripheral stage IA disease which has been
routinely treated with IFRT alone. This allows comparison of patients
who received RT alone (n=54) versus ABVD ± RT (n=38).
Results. Prognostic characteristics were similar in both treatment
groups except for a larger proportion of stage IIA patients in the ABVD
± RT group (p=.037).
Table 1.
n IA (%) IIA(%) Age y M:F Largest mass cm
med (range) Med (range)
RT alone 54 41 (76%) 13 (24%) 37 (17-63) 40:14 4 (2-8)
ABVD±RT 38 21 (55%) 17 (44%) 37 (17-64) 26:38 3 (2-8)
Table 2.
n Follow-up mos 5 y PFS 10 y PFS 5 y OS 10 y OS
med (range) (%) (%) (%) (%)
RT alone 54 198 (26-458) 82 71 90 84
ABVD±RT 38 49 (4-149) 100 100 100 100
Figure 1.
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Figure 2.
No relapses or deaths have occurred in the patients treated with
ABVD ± RT. Only 8 patients have been treated with ABVD alone and
follow-up is too short to draw conclusions for this small subgroup; how-
ever, no relapses or deaths have occurred.
Conclusions. Planned treatment with ABVD is superior to radiothera-
py alone and markedly improves both PFS and OS in patients with lim-
ited stage nodular lymphocyte predominant Hodgkin lymphoma.
Relapsed and Refractory Disease 
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IFOSFAMIDE, GEMCITABINE, VINORELBINE, PREDNISOLONE (IGEV) AND FIXED DOSE OF
LENOGRASTIM: AN EFFECTIVE MOBILIZATION REGIMEN IN PRETREATED’S LYMPHOMA
PATIENTS
M. Magagnoli,1 M. Balzarotti,1 M. Spina,2 L. Castagna,1 B. Sarina,1
B. Bernardi,2 E. Morenghi,1 A. Nozza,1 U. Tirelli,1 A. Santoro
1Oncologia Medica ed Ematologia-Istituto Clinico Humanitas-Rozzano (MI),
2Oncologia Medica A, Centro di Riferimento Oncologico, Aviano, Italy
Introduction. In this study we explored the efficacy of IGEV regimen
combined with fixed dose of lenograstim (263 ºg day) to mobilize
peripheral blood stem cells (PBSCs) in resistant/relapsing Hodgkin's lym-
phoma (HL). 
Methods. Ninety patients were treated prospectively with a salvage
regimen consisting of ifosfamide 2000 mg/m2 on days 1 to 4, gemc-
itabine 800 mg/m2 on days 1 and 4, vinorelbine 20 mg/m2 on day 1, and
prednisolone 100 mg on days 1 to 4 (IGEV). A fixed dose of lenograstim
(263 µg day) was given from day 7 to day 12 of each course or up to
apheresis during the mobilizing phase.
Results. Leukapheresis was performed after the first, second, third and
forth cycles of chemotherapy in four, seven, seventy-one, and eight
patients, respectively. The median total CD34+ cell/µL peak, CFU-GM
and white blood cells (WBC) for all individual sets of collection was
85/µL, 12×104/Kg, and 20700/µL, respectively. In all cases, stem cell har-
vesting started after a median of 13 days from the first day of IGEV
chemotherapy (range 10-17). An adequate CD34+ cells (over 3×106 or
6x106 CD34+ cells/kg according to single or tandem high-dose
chemotherapy procedures) collection was achieved in 89 out of 90
(98,7%) mobilized patients, the only failure pooling 2,3×106 CD34+ cells/
kg. The median number of CD34+ cells collected was 11×106/kg (range
2.3-39×106/kg) with a median of one (range 1-3) leukaapheresis for
patients elegible for single high dose treatment, and 10×106/kg (range 6-
22,0×106/Kg) with a median of 2 (range 1-3) leukaapheresis for candi-
dates to tandem transplant, respectively. Overall, the target yields were
reached in 71,43% and 49,09% of cases after the first apheresis proce-
dure and in further 17,14% and 43,64%, after the second apheresis,
respectively. There were no significant differences in the total number
of CD34+ cells per leukapheresis and total number of CD34+ cells in
patients weighting <or> 60 kg or <70> kg. Actually, 34 patients received
a single transplantation and 47 a tandem transplantation, with rapid
engraftment. 
Conclusions. These results confirm that IGEV regimen with lenogras-
tim support can be successfully and safely used to mobilize PBSCs.
C014
A PHASE II STUDY OF MGCD0103, A NOVEL ORAL ISOTYPE-SELECTIVE HISTONE
DEACETYLASE INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN
LYMPHOMA
A. Younes, B. Pro, M. Fanale, P. McLaughlin, S. Neelapu, L. Fayad, 
A. Wedgwood, Z. Li, R. Ward, R.E. Martell
Anderson Cancer Center, Houston, TX, USA; MethylGene Inc., Montreal,
Canada; Pharmion Corporation, San Francisco, CA, USA
Introduction. Hodgkin's lymphoma patients (pts) with recurrent pro-
gressive disease after autologous bone marrow transplantation have
poor prognosis regardless of salvage therapy. This observation, com-
bined with the high frequency of relapse (~50%) and relatively young
age of afflicted pts, highlights the need for new therapeutic agents in this
setting. MGCD0103 is an oral isotype-selective inhibitor of histone
deacetylases with significant biological activity in preclinical models of
hematopoietic cancers. 
Methods. A phase II trial of MGCD0103 is ongoing in pts with
relapsed/refractory Hodgkin's lymphoma (RRHL). MGCD0103 was
dosed at 110 mg 3x/week in 4-week cycles, with dose reductions to 85
and 60 mg in case of toxicities. Eligibility criteria included previous treat-
ment with autologous and/or allogeneic stem cell transplant, target
lesion ≥2 cm, and ECOG performance status of 0-1. 
Results. In total, 22 pts of a planned 12-35 have been enrolled (medi-
an age, 28 yr; range, 21-62 yr). Of these, 11 (50%) remained on study
treatment for ≥16 weeks (4 cycles). Among 20 evaluable pts, 2 (10%) had
CR and 6 (30%) had PR, for an OR rate of 40% (median time to
response, 2 cycles). One pt (5%) had SD ≥ 6 m and 8 (40%) had SD <6
haematologica/the hematology journal | 2007; 92(s5) | 29
7th International Symposium on Hodgkin Lymphoma, 3-7 November 2007 – Cologne, Germany
m. The rate of disease control (CR + PR + SD ≥6 m) was 45%. PD was
observed in 3 pts (15%). As assessed by CT scan, 15 pts (75%) exhibit-
ed tumor reductions: 12 (60%) had reductions of >30%, and 8 (40%) had
reductions of ≥50%. Six of 22 pts required a single dose reduction to 85
mg, and another 6 required 2 dose reductions to 60 mg (1 pt was reduced
directly from 85 mg to 35 mg). The most common drug-related non-
hematological toxicities were nausea (9/22), fatigue (8/22), diarrhea
(7/22), vomiting (5/22), anorexia (4/22), dyspnea (3/22), weight loss
(3/22), and pneumonia (3/22). There were 2 deaths on study, both in
heavily pretreated patients, one of unknown cause in a woman with h/o
mantle XRT, BMT, suffering from significant GI AEs and the other of
pneumonia/sepsis in a man with severe marrow compromise at base-
line. With the exception of 2 other cases of grade 3 pneumonia and 1 of
grade 3 fatigue, all other adverse events were ≤ grade 2. Dose modifica-
tion was effective in managing toxicities. Significant HDAC inhibition
(>20% of total activity) was seen in PBMCs from patients. 
Discussion. Interim results from this ongoing trial suggest that single-
agent MGCD0103 demonstrates significant anti-tumor activity in RRHL
and has a manageable side effect profile.
C015
PROMISING RESULTS FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN 
LYMPHOMA TREATED WITH THE ORAL MTOR INHIBITOR EVEROLIMUS (RAD001) 
P.B. Johnston,1 S.M. Ansell,1 J.P. Colgan,1 T.M. Habermann,1
D.J. Inwards,1 S.N. Markovic,1 I.N.M. Micallef,1 L.F. Porrata,1
C.B. Reeder,2 V. Roy,3 B.R. LaPlant,1 T.E. Witzig1
1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Scottsdale, AZ, 3Mayo Clinic,
Jacksonville, FL, USA
Background. mTOR inhibition with intravenous temsirolimus (Wyeth
Pharmaceuticals) has produced responses in mantle cell lymphoma (J
Clin Oncol 23;5347, 2005) as well as other lymphomas (Blood 108 (11)
2483; 2006). This phase II study tested the oral mTOR inhibitor
everolimus (RAD001, Novartis Pharmaceuticals) in three simultaneous
two-stage phase II lymphoma studies - aggressive (group 1), indolent
(group 2), or uncommon (group 3) including Hodgkin lymphoma. The
goals were to learn the toxicity profile and to assess the anti-tumor
response. A total of 16 patients have been enrolled in the uncommon
arm with Hodgkin lymphoma.
Methods. Patients (pts) received 10 mg PO daily for each 28 day cycle
(up to 12) and restaged after 2, 6, and 12 cycles. The primary endpoint
is the confirmed response rate, including CR, CRu or PR. Overall, the
treatment would be considered promising if 4 or more successes were
observed in all 37 pts in each group. 
Results. The median age of the 16 pts with Hodgkin lymphoma was
37 yrs (range: 27-68), with a median of 6 (range, 4-13) prior therapies.
Fourteen pts (87.5%) had a prior stem cell transplant (SCT). Pts complet-
ed a median of 6 (range, 1-13) cycles of therapy. Fouteen of 16 patients
were evaluable for response as of this analysis. The overall response
rate was 42% (6/14) - all partial responses, meeting the overall criteria
for promising results in this study. 9 patients are continuing on study
while 6 have gone off due to disease progression and 1 due to other rea-
sons. Common grade 3 adverse events (AEs) include thrombocytopenia
(7 pts), anemia (8 pts) and alkaline phosphatase elevation (7 pts). 3
patients were reported to have grade 4 neutropenia. 
Conclusions. Oral everolimus has activity in a spectrum of lymphomas
with acceptable toxicity, particularly in Hodgkin lymphoma. These
results provide the rationale for additional studies with this novel class
of agents and to integrate mTOR inhibitors into salvage treatment reg-
imens for Hodgkin lymphoma. 
Translational Research 
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LATENT EBV INFECTION OF HODGKIN REED-STERNBERG CELLS PREDICTS ADVERSE
OUTCOME IN OLDER ADULT CLASSICAL HODGKIN LYMPHOMA PATIENTS
A. Diepstra, G. W van Imhoff, H. Karim-Kos, M. Schaapveld, 
E. Bastiaannet, A. van den Berg, E. Vellenga, S. Poppema
Departments of Pathology and Hematology, University Medical Center Gronin-
gen, University of Groningen, the Netherlands and the Comprehensive Cancer
Center North Netherlands, Groningen, the Netherlands
Introduction. Epstein Barr virus (EBV) genomes are present in the neo-
plastic cells of classical Hodgkin lymphoma (cHL) in about one third of
cases in western countries. Latent EBV infection is considered to be the
transforming event in these cases. The impact of EBV status on clinical
outcome is controversial.
Patients and methods. We assessed failure free survival (FFS) and rela-
tive survival (RS) in 417 cHL patients from a population based clinical
database from the Comprehensive Cancer Center North Netherlands
(CCCN). Patients were diagnosed between 1989 and 2000 in the north-
ern part of the Netherlands and were treated with standard chemo-
radiotherapy according to CCCN guidelines. Median age at diagnosis
was 35 years (range 7-94); 63% had Ann Arbor stage I-II, 25% stage III,
and 12% stage IV disease. Subgroup analysis was performed in the age
groups of 7-14, 15-34, 35-49, 50-74 and 75-94 years The median follow
up time was 7.1 years. EBV status was determined by EBER in situ
hybridization on primary lymph node biopsies.
Results. EBV status was positive in 35% of patients. Factors influenc-
ing FFS in univariate analysis were: age, Ann Arbor stage and extranodal
disease. Five-years FFS was 74% for EBV positive cases compared to
79% for EBV negative cases (p=0.27). EBV status had prognostic signif-
icance only in the age group of 50-74 years (5 yrs FFS 57% in EBV pos-
itive vs. 83% in EBV negative cases; p=0.01). In multivariate analysis this
effect remained significant (p=0.03). RS was influenced by age, stage,
extranodal disease, B symptoms and histology in univariate analysis.
Five-years RS was 84% for EBV positive cases compared to 87% for EBV
negative cases (p=0.12). Again, EBV status had prognostic impact only
in the age group of 50-74 years (5 yrs RS 66% in EBV positive vs. 84%
in EBV negative cases; p=0.02). In this age group, multivariate analysis
showed that EBV status was an independent prognostic factor with a rel-
ative excess risk of death of 2.58 (95% CI 1.05-6.29; p=0.04).
Conclusions. In this retrospective population based study EBV positive
status of neoplastic cells was associated with treatment failure and
increased risk of death in classical Hodgkin lymphoma patients aged 50
to 74 years.
C017
A TAQMAN-LOW DENSITY ARRAY TO PREDICT OUTCOME IN HODGKIN LYMPHOMA
USING PARAFFIN EMBEDDED SAMPLES
B. Sanchez-Espiridion, A. Sanchez-Aguilera, C. Montalban,
M. Garcia-Cosio, C. Bellas, V. Romagosa, J. Menarguez, M.F. Fresno,
M.M. Morente, M.A. Piris, J.F. Garcia for de Spanish Lymphoma
Study group.
From the Molecular Pathology Program, Spanish National Cancer Centre
(CNIO), Madrid; Department of Pathology, MD Anderson International,
Madrid, Spain
Background. In spite of the good prognosis of Hodgkin Lymphoma
(HL) patients after appropriate treatment, around 30% of the cases do
not benefit from standard therapies, and may die as result of their dis-
ease. This fraction is even higher for advanced HL. The identification of
molecular events and biological processes associated with treatment
response are necessary to develop new predictive tools adding accura-
cy to classical clinical parameters, such as the IPS.
Methods. We used gene expression data from 29 samples of advanced
Classic HL patients and HL-derived cell lines in order to identify tran-
scriptional patterns from the tumoral cells and the non-tumoral microen-
vironment. Student t-test was used to detect genes overexpressed in cell
lines and in tumor samples creating two databases (tumor and microen-
vironment). Using Gene Set Enrichment analysis (GSEA) we identified
specific gene sets enriched in both databases in patients with favorable
and unfavorable outcome, respectively. To validate these pathways we
designed a novel Taqman low-density array (LDA) to examine the
expression of the most relevant genes in 52 formalin-fixed, paraffin
embedded (FFPE) tissue samples, and correlated the results with treat-
ment outcome. 
Results. Functional pathways related to unfavorable outcome signifi-
cantly enriched in the RS cells included the regulation of the G2/M
checkpoint of the cell cycle, S phase and G1/S transition, chaperons,
histone modification and other signaling pathways with an important
representation of the MAPK pathway. On the other hand, specific T-cell
populations (T-cytotoxic and T-regulatory cells) and macrophage activa-
tion were found to be overexpressed in the microenvironment data-
base. The final model presents a balanced representation of these genes,
and also genes encoding factors implicated in drug resistance (RRM2,
TYMS and TOP2A). RNA extracted from FFPE sections yielded analyz-
able data for 41 samples (79%). LDA analysis of the genes included in
the model showed heterogeneous gene expression patterns. Overall,
the results correlated with the clinical outcome, confirming the robust-
ness of the model. 
Conclusions. LDA technology provides an effective technique for ana-
lyzing gene expression in RNA isolated from FFPE tissues and it can be
used for clinical prediction in HL paraffin-embedded diagnostic sam-
ples, using a selection of genes identified after GSEA analysis of the ini-
tial molecular signatures. The novel Taqman LDA presented will be used
to develop a new molecular predictor of the outcome of patients with
advanced HL.
C018
ASSOCIATIONS BETWEEN PLASMA LEVELS AND PROMOTER GENOTYPES OF IL-10 AND
IL-6 WITH PATIENT CHARACTERISTICS AND OUTCOME IN HODGKIN LYMPHOMA
S. Hohaus, M. Giachelia, G. Massini, B. Vannata, M. Martini,1
F. D’Alò, M.T. Voso, L.M. Larocca,1 G. Leone
1Istituto di Ematologia e di Anatomia Patologica, Università Cattolica S. Cuore,
Rome, Italy
Background. Production of cytokines by Reed-Sternberg cells and the
surrounding tissue contribute to the biology of Hodgkin lymphoma. We
recently reported that cytokine genotypes can predict clinical outcome
in HL: in a group of 184 HL patients, homozygous carriers of the A allele
at position -592 in the IL-10 promoter and of the G allele at position -
174 in the IL-6 promoter had a significantly lower probability of failure-
free survival (Hohaus et al, Ann Oncol 2007). We now analyzed whether
genotypes and other patients characteristics are associated with cytokine
plasma levels.
Patients and methods. Cytokine plasma levels of IL-6 and IL-10 were
determined in 80 patients with HL and 74 controls, and associations to
the polymorphic allele variants in the IL-10 gene (T-3575A, G-2849A, C-
2763A, A-1082G and C-592A), and in the IL-6 gene (G-174C) were stud-
ied. Wilcoxon ranksum test was used to compare plasma levels between
patients and controls. Cytokine levels were dichotomized using the
receiver operating characteristics technique. Multivariable logistic regres-
sion analysis was used to determine patient characteristics which may
influence elevated cytokine levels. Logrank test was used for survival
analysis. 
Results. Plasma levels of IL-10 and IL-6 were significantly higher in
patients than in controls (IL-10, median 23.1 pg/mL in HL pts. vs 2,3
pg/mL in controls (p=0.01); IL-6 median 2.6 pg/mL in HL pts. vs <0.001
pg/mL in controls (p<0.001). IL-10 plasma levels were higher in male
controls and patients in comparison to the respective female group.
(p=0.02 and 0.06, respectively). IL-6 plasma levels higher than 9.5 pg/mL
were associated with an inferior failure-free and overall survival (p=0.002
and p=0.04), while IL10 plasma levels higher than 65 pg/mL were asso-
ciated with inferior overall survival (p=0.05). In the multivariable analy-
sis, stage IV disease (HR 4.8; 95% CI 1.07-21), male gender (HR, 3.1,
95% CI, 1.0-9.6), and the presence of the A allele at position -592 in the
IL10 promoter (HR, 2.2; 95% CI, 1.0-5.1) were factors associated with
elevated IL10 plasma levels. Advanced stage of disease was also associ-
ated with elevated IL-6 plasma levels (HR, 3.72; 95% CI, 1.15-12), while
we could not find an association between the IL-6 -174 genotype and
IL-6 plasma levels.
Conclusions. Stage of disease reflecting tumor burden appears to be
more important than the cytokine promoter genotypes studied to deter-
mine plasma levels of IL-6 and IL-10 in HL. 
Radiotherapy
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INVOLVED NODE RADIOTHERAPY: IMPACT ON DOSE TO PTV AND ORGANS AT RISK
R. Bart, S. Sylvie, L. Yolande
University Hospitals Leuven, Department Radiotherapy-Oncology, Leuven, Bel-
gium
Purpose. To study the impact of Involved Node Radiotherapy (INRT)
guidelines and of treatment position in Hodgkin lymphoma (HL)
patients on target volume and dose to organs at risk (OAR).
Methods. 10 consecutive female patients with mediastinally located
HL, in CR(u) after chemotherapy and referred for adjuvant radiothera-
py, were retrospectively reviewed. All were treated with an involved
field irradiation technique (IFRT) before the publication of the EORTC-
GELA INRT guidelines and had PET-CT data available before and after
chemotherapy. Two sets of CTscans were used for INRT delineation: the
CT in treatment position (arms along the body, CT1) and CT images of
the PET-CT after chemotherapy (arms above the head, CT2). INRT-
CTV's were enlarged with a 1cm isotropic margin to create an INRT-
PTV and OAR (heart, lungs and breasts) were defined. The originally
treated IFRT-plan on CT1 was compared to computed INRT plans on
CT1 and CT2 (all APPA 3D-CRT) regarding to PTV volume and dose
(VPTV95) and dose to OAR: lung volume ≥20 Gy (Vlung20), mean lung
dose (MLD), heart volume ≥30Gy (Vheart30) and mean dose to left
(MBDL) and right breast (MBDR). Nodal failure within the first 2 years
of follow-up was recorded.
Results. Means of volumes and doses and p-values (paired t-test, com-
paring INRT-CT1 and -CT2 to IFRT) are shown.
Table.
IFRT (CT1) INRT (CT1) INRT (CT2)
Volume CTV (cc) 175,4 77,5 p=0.0005 73,2 p=0.0003
Volume PTV (cc) 651,8 360,8 p=0.006 337 p=0.001
V95PTV (%) 95,6 96,3 ns 97,2 ns
MLD (Gy) 8,2 6,9 p=0.04 6,7 p=0.01
Vlung20 (%) 22,2 18,3 p=0.06 18,1 p=0.03
Vheart30 (%) 18,4 11,8 ns 18,0 ns 
MBDL 2,2 2,2 ns 2,7 ns 
MBDR 0,8 0,6 ns 1,1 ns 
INRT significantly decreases target volumes and doses to the lungs
(MLD) and heart (if arms are along the body). Overall no statistically sig-
nificant differences are observed between INRT-plans but raising arms
above the head tends to increase the dose to the breasts (gaining signif-
icance for MBDR in our cohort (p=0.02 comparing both INRT-plans), be
it minor in absolute figures). Also, the gain in Vheart30 using INRT is
offset by the arms above the head (p=0.02). So far no loco-regional
relapses were observed.
Discussion. CTV delineation following INRT guidelines for HL meets
it goal to reduce target volumes and dose to the OAR (lungs and heart,
doses to the breast being usually low). Caution should however be paid
not to jeopardise this gain by altering treatment position (arms above the
head vs. alongside the body). 
C020
CHEMOTHERAPY ALONE VERSUS CHEMOTHERAPY PLUS RADIOTHERAPY FOR EARLY
STAGE HODGKIN LYMPHOMA
F.A. Rehan,1 C. Brillant,1 I. Knaul,1 J. Bohlius,1 L. Specht,2 A. Engert1
1Department I for Haematology and Oncology, Cochrane Haematological Malig-
nancies Group (CHMG), University of Cologne, Cologne, Germany; 2Depart-
ments of Oncology and Haematology, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark
Introduction. Both chemotherapy (CT) alone and combined modality
therapy (CMT) are effective modalities for the treatment of early
favourable and early unfavourable (intermediate) stages of Hodgkin lym-
phoma (HL). However, the optimal choice of treatment is still debated.
Different research groups reported that ABVD-like CT followed by irra-
diation is highly effective for early stage HL. A recently conducted ran-
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domized trial, to determine whether CMT is superior to CT alone in ear-
ly stages of HL, showed no significant difference in 5 year overall sur-
vival (OS) and event-free survival in patients treated with either 4-6
cycles of ABVD alone or 2 cycles of ABVD plus radiotherapy (Meyer RM
et al. 2005). A systematic review with meta-analysis was initiated to get
more conclusive results, especially regarding OS.
Methods. Only randomized controlled trials (RCT) comparing CT
alone with CMT in newly diagnosed patients with early stages of HL (CS
IA, IB, IIA, IIB) were included. Medline and Cochrane Library were sys-
tematically searched for randomized controlled trials from 1975 to 2007.
Patients who received CMT were considered as experimental group and
patients who received ABVD-like CT alone were considered as control
group. Data were collected from full text publications and the treatment
effects for OS were calculated as hazard ratios (HR), using methods
described by Parmar (Parmar et al 1998).
Results. A total of 590 references were screened. Five eligible RCTs
were identified, including 1005 patients with early stages (early
favourable and early unfavourable stages) of HL, enrolled during Septem-
ber 1977 to April 2002. There were 507 patients in CMT group and 498
patients in CT alone group. A statistically significant difference regard-
ing OS in favour of CMT group compared to CT alone group was found
(HR:0.60; 95% CI [0.41-0.88]; p=0.009). There was no evidence for a
substantial heterogeneity between studies (I=37.9%).
Discussion. Initial results of our systematic review showed improved
OS for patients treated with CMT in early stage HL compared to patients
treated with CT alone. Further comprehensive analyses are ongoing and
will provide an explicit and precise scenario. 
Positron Emission Tomography
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Introduction. The prospectively randomized HD15 multicenter trial of
the German Hodgkin Study Group (GHSG) includes patients (pts.) in
advanced-stage Hodgkin lymphoma (IIB with risk factors: large mediasti-
nal mass and/or extranodal disease; III; IV). One study question investi-
gated the prognostic value of 18F-fluorodesoxyglucose (FDG) positron
emission tomography (PET) following chemotherapy. The aim was to
specify the negative predictive value of PET (NPV). 
Methods. Entry criteria for the PET question were partial remission
(PR) after end of chemotherapy with at least one involved nodal site
with more than 2.5 cm diameter by computed tomography (CT). Exclu-
sion criteria included diabetes, elevated blood sugar levels and skeletal
involvement with risk of instability. The analysis comprised 311 evalu-
able pts. Calculations were restricted to those cases with either progres-
sion and relapse within 12 months after PET panel or at least 12 months
follow-up (n=275). The negative predictive value (NPV) was calculated
based on those pts. assessed by an expert panel as PET-negative in resid-
ual tissues. CT verification was performed to identify false positive PET
findings. The NPV was defined as the proportion of patients without a
progression or relapse within 12 months of the panel date (method 1) or
the proportion of such pts. without progression, relapse or irradiation
within 12 months (method 2).
Results. 9/216 patients with PET-negative residues and 9/59 patients
with PET-positive residues had progression or relapse. The NPV using
method 1 was 0.958 (95% CI [0.931, 0.985]) or 0.940 (95% CI [0.907,
0.968]) using method 2. In 244/245 cases with PET-negative residues, no
irradiation was recommended. In the 62/66 cases with PET-positive
residues, irradiation was recommended. Progression/relapse rates were
significantly different between the pts. with residual tissue being PET-
negative or PET-positive (p=0.0053). PET-negative pts, who were
assessed as PR by CT, had a prognosis similar to those in complete remis-
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sion. There was no significant difference in the progression free survival
in HD15 and the prior GHSG trials HD12 (arms pooled) and HD9 (arm
C) for advanced stage HL. (p=0.266). Importantly, the proportion of pts.
receiving radiotherapy decreased from 70% (HD9-C) to 39% (HD12)
and 12% (HD15). 
Discussion. The high NPV of PET suggests that the use of radiothera-
py following 6 or 8 cycles of BEACOPP can be greatly restricted accord-
ing to response to chemotherapy seen by PET.
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Purpose. Starting from November 2001 260 newly diagnosed patients
with advanced-stage Hodgkin lymphoma (HL) were consecutively
enrolled in a joint Italio-Danish prospective trial to evaluate the prognos-
tic role of an early interim FDG-PET scan and the International Prognos-
tic Score (IPS) in advanced HL, treated with conventional ABVD thera-
py. 
Patients and methods. Patients were treated with standard ABVD ther-
apy x 6 courses. Consolidation radiotherapy was given in case of bulky
presentation or residual tumour mass. Conventional radiological staging
was performed at baseline. FDG-PET scan was performed at baseline
and after two courses of ABVD (PET-2). No treatment change was
allowed based on the PET-2 results except in case of overt disease pro-
gression. Positive and minimally positive PET-2 scans were reviewed.
PET 2 was considered negative if the scan was negative o minimally pos-
itive (MRU+). A study was defined as MRU+ in presence of a non-focal
uptake with a SUV lower, equal or slightly higher than mediastinum. 
Figure.
Results. After a median follow-up of 2.19 years (0.32-5.18), 205 patients
were in continued CR (cCR), 2 patients were in PR; 43 patients pro-
gressed during therapy, and 10 relapsed. Fifty patients were PET-2 pos-
itive and 210 patients were PET-2 negative. 43/50 PET-2 positive patients
(86%) showed treatment failure (progression/relapse) while 6 were in
cCR and one in PR at the latest follow-up. 199/210 PET-2 negative
patients (95%) were in cCR and one patient in PR at the latest follow-
up, while 10 patients had experienced treatment failure. The 2-year PFS
for PET-2 positive patients was 12.8% and for PET-2 negative 95.0%
(p<0.0001). The sensitivity, specificity and overall accuracy of PET-2 for
predicting 2-year PFS were 81%, 97%, and 92%, respectively. The pos-
itive predicting value (PPV) was 93% and the negative predicting value
(NPV) was 92%. In univariate analysis the treatment outcome was sig-
nificantly associated with PET-2 (p<0001), stage IV (p<0.0001), WBC >
15.000 (p<0.0001), Lymphopenia (p<0.001), IPS as a continuous variable
(p<0.0001), extranodal involvement (p<0.0001) and bulky disease
(p=0.012). In multivariate analyses, only PET-2 turned out to be signifi-
cant (p< 0.0001). In a matched 2-year PFS analysis, this study showed
no prognostic value of IPS when the information from PET-2 is added. 
Discussion. PET-2 overshadows the prognostic value of IPS and
emerges as the single tool for planning a risk-adapted treatment in
advanced HL.
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Introduction. In early stage HL the goal is to maximise chances of cure
whilst minimising late effects of treatment on incidence of endocrine
dysfunction, second cancers and cardiovascular disease. Abbreviated
chemotherapy (CT) followed by involved field radiotherapy (RT) is the
standard of care but it is likely that some patients (pts) are cured by CT
alone and if it were possible for these individuals to be identified, unnec-
essary RT could then be avoided. Positron emission tomography (PET)
offers this possibility but the impact on disease control of de-escalating
treatment based on PET results after CT has not been established. A ran-
domised trial comparing no further treatment with involved field RT fol-
lowing 3 cycles ABVD and a negative (-ve) PET scan is ongoing and inter-
im results are presented.
Methods. Consenting pts with histologically proven, previously untreat-
ed HL, stages IA/IIA above the diaphragm are eligible for trial entry. Fol-
lowing 3 cycles ABVD, responders have a PET scan performed and if this
is reported -ve for lymphoma (score 1 or 2 on a 5 point scale) following
central review at the Core Lab in London, randomisation between involved
field RT and no further treatment is performed. Patients with a PET scan
positive (+ve) for lymphoma (score 3, 4 or 5) have a 4th cycle of ABVD and
involved field RT. When 320 PET -ve pts have been randomised the trial
is powered to exclude a 10% difference in PFS with 90% power.
Results. At the time of analysis, 258 pts (131 male, 127 female; medi-
an age 34.5 yrs) have been registered into the trial. After 3 cycles ABVD,
215 have had a PET scan which at central review has been allocated a
score of 1 (n=131, 61%), 2 (n=43, 20%), 3 (n=21, 10%), 4 (n=10, 5%) or
5 (n=10, 5%) giving an overall PET -ve rate (score 1 or 2) of 81%. 171
PET -ve pts have been randomised to receive involved field RT (n=90,
53%) or no further treatment (n=81, 47%). 4 pts have not been ran-
domised (pt choice, 2; clinician choice, 1; error, 1). After a median of 6
months from randomisation, 166 of 171 (97%) randomised pts are alive
and progression free, 3 (2%) have progressed and 2 (1%) have died
(HL,1; treatment related,1).
Conclusions. (1) Trials involving a randomised question after confir-
mation of PET -ve status at central review are feasible (2) the PET +ve
rate of 19% after 3 cycles ABVD is at the upper end of the expected
range (3) the event rate after short follow-up is very low.
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Objectives. In 2000, we initiated a phase-II study to evaluate the safe-
ty and efficacy of the novel combination of rituximab and ABVD (R-
ABVD) chemotherapy in newly diagnosed patients with classical HL. 
Methods. Rituximab was given at 375 mg/m2 weekly for 6 weeks to
rapidly deplete reactive B lymphocytes from the microenvironment,
while ABVD was given at a standard dose and schedule for 6 cycles.
Patients with areas of bulky disease received involved field radiation at
the end of therapy. Patients were eligible if they were older than 16
years of age and had biopsy-confirmed classical HL irrespective of CD20
expression on HRS cells, bidimensionally measurable disease, adequate
bone marrow, cardiac and renal functions. They were excluded if they
had HIV infection, or were pregnant women. 
Results. As of July 2007, 81 newly diagnosed pts are enrolled, of whom
65 pts had at least 12 months of follow up and are evaluable for treat-
ment response and event free survival (EFS). Median age 28 years (Range;
18-72 years). Patients had stage II (50%), stage III (31%), stage IV (19%)
disease. Twenty-five percent of the patients had evidence of CD20
expression on HRS cells. Using the IPS prognostic score model, 36
patients (55%) had a score of 2 or higher. With a median follow up of
3.5 years, the estimated event-free survival (EFS) for the entire group is
85% and the overall survival is 98%. R-ABVD improved EFS in all IPS
scores with the biggest impact seen in patients with IPS >2 (EFS =77%)
or >3 (EFS =71%). Patients with IPS of 0-2 had EFS of 89%. The
improvement in EFS was seen seen regardless of CD20 expression by
HRS (EFS for CD20+ and CD20 were 87.5% and 83.5%, respectively). 
Discussion/Conclusions. We conclude that in patients with classical HL,
the addition of 6 weekly doses of rituximab to standard dose and sched-
ule of ABVD chemotherapy is effective in terms of remission rate and
remission duration irrespective of CD20 expression on HRS cells or IPS
category. The encouraging results of this pahse-II trial are likely to be due
to several factors including 1) depletion or reactive B cells from the
microenvironment, 2) possible direct killing effect on the recently report-
ed HRS stem cells, and 3) direct killing effect on CD20+ HRS cells. A mul-
ti-center randomized study comparing ABVD with R-ABVD in patients
with advanced stage classical HL and poor IPS score is scheduled to start
by the end of this year in the U.S. to confirm these results. 
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Purpose. to analyze the long-term outcome of patients enrolled in the
EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 trial, comparing
HDT with autologous stem cell transplantation (ASCT) versus conven-
tional chemotherapy for consolidation of patients responding to front-
line therapy (JCO, 21:2320-5, 2003). Although there is a general agree-
ment that combination chemotherapy is the treatment of choice for
patients with advanced Hodgkin's lymphoma the encouraging results
obtained with high-dose salvage therapy raised the question whether
was appropriate to consider high-dose therapy (HDT) as consolidation
treatment for responding patients at high risk of relapse.
Methods. Previously untreated patients aged 15 to 60 years were eli-
gible if they had, in addition to advanced stage disease, at least two out
of the following adverse prognostic factors: elevated serum LDH levels,
large mediastinal mass (greater than at least 33% of the thoracic diam-
eter measured at T5/T6 level on chest radiographs), stage IV with more
than one extranodal site of disease, low hematocrit (≤34% for women
and ≤38% for men), and inguinal involvement. Moreover, patients reg-
istered at GELA trial office were eligible in the presence of at least three
adverse prognostic factors of six (the same five parameters mentioned
above plus bone marrow involvement). Four courses of ABVD or ABVD-
like regimen were administered and then patients achieving at least a
partial remission were randomized to receive either HDT followed by
ASCT (HDT-ASCT Arm) or four additional courses of the same
chemotherapy used in the induction phase (CHT Arm). Between April
1993 and December 2000, 163 patients were randomised to receive
HDT-ASCT (83 patients) or CHT (80 patients). The efficacy of HDT-
ASCT compared with 4 courses of standard CHT was assessed in terms
of percentage of CR rate, Overall Survival (OS), Relapse Free Survival
(RFS) and Failure Free Survival (FFS). Study endpoints were analyzed
using the intention-to-treat principle.
Results. at a median follow-up of 7 years a total of 26 deaths, 14 in
HDT-ASCT Arm and 12 in CHT Arm were observed. The 10-year sur-
vival rates are 84% (95% C.I.: 77-89) for patients randomly assigned to
HDT-ASCT Arm and 79% (95% C.I.: 69-87) for patients assigned to
CHT Arm (p=0.8). At time of present analysis a total of 15 relapses were
recorded, three of them (one in HDT-ASCT Arm and two in CHT Arm)
during the extended follow-up period. The 10-year RFS rates are 90%
(95% C.I.: 84-94) and 91% (95% C.I.: 86-95) for patients assigned to
HDT-ASCT and CHT Arm respectively (p=0.5). During the extended
follow-up a total of 5 additional failures were observed, including three
relapses and two second malignancies. The 10-year FFS is 78% (95%
C.I.: 71-84) in HDT-ASCT Arm and 75% in CHT Arm (95% C.I.: 65-82)
(p=0.7). The results overlap those previously reported. No difference in
long-term toxicity appeared between the two Arms.
Discussion. the updated results of HD01 study confirm that also after
a long-term follow-up the outcome of patients with unfavourable
advanced Hodgkin's lymphoma responding to four courses of ABVD-
like therapy was similar regardless they were treated with HDT and
ASCT or with four additional courses of the same conventional
chemotherapy.
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Purpose. To compare ABVD with BEACOPP and CEC in patients with
advanced HL.
Methods. Between January 2000 and June 2007, 307 adult patients
with untreated advanced HL (stage II bulky disease, III and IV) were
enrolled in multicentre, randomised trial aimed at comparing the effica-
cy of 6 courses of ABVD (doxorubicin, bleomycin, vinblastine, and
dacarbazine) vs. 6 cycles of BEACOPP (4 escalated followed by 2 stan-
dard; bleomycin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine, procarbazine, and prednisone) vs. 6 cycles of CEC (cyclophos-
phamide, vincristine, procarbazine, prednisone, epidoxirubicin,
bleomycin, vinblastine, lomustine, doxorubicin, and vindesine). Eligi-
ble patients were randomized in a 1:1:1 fashion and were stratified by
stage. Radiotherapy was planned at the end of induction therapy on
residual masses or on sites of previous bulky lesions. Progression free
survival (PFS) was chosen as principal endpoint. 
Results. One hundred and three, 101, and 103 patients were random-
ized to CEC, BEACOPP, and ABVD, respectively. After enrolment 10
patients were excluded due to unconfirmed histology (2 cases) or miss-
ing data (8 cases). The records of 27 cases have not been verified yet by
trial data-center, thus the remaining 270 patients (90 CEC, 89 BEACOPP,
91 ABVD) are the subject of this report. Patients median age was 31
years (15 to 67), 53% were males, 23% had stage IV, 36% had bulky dis-
ease; and 39% were at high risk (IPS >3). Patients characteristics were
homogeneously distributed among treatment arms. After induction ther-
apy a complete response was observed in 90%, 82% and 79% of
patients treated with BEACOPP, ABVD and CEC, respectively (p=0,122).
After a median follow-up of 39 months (6 to 83 months) the 3-year PFS
was 90%, 80%, and 72% for BEACOPP, CEC , and ABVD respective-
ly; (BEACOPP vs ABVD p 0.024; all other comparisons p=NS). The 3-
year Overall Survival (OS) was 93% (95% CI 88% to 95%) without dif-
ferences among study arms. BEACOPP and CEC regimens resulted in
higher rates of grade III-IV neutropenia (55% and 46%) compared to
ABVD (34%; p=0,02); BEACOPP regimen was associated to higher rates
of severe infections (13%) compared to ABVD(1%) and CEC
(3%)(p=0,003). 
Conclusions. The preliminary results of the first 270 pateints enrolled
in the HD2000 study suggest the superiority of BEACOPP over ABVD
in terms of PFS but not OS. So far no statistically significant differences
have emerged between CEC and the two other regimens.
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Background and Aim. There are significant differences in the pattern of
Hodgkin lymphoma seen in developing countries. The purpose of our
prospective study is the assessment of the epidemiologic and clinico-
pathologic features of adult Hodgkin lymphoma (HL) seen in Morocco. 
Methods. During a 7 year period, from April 1998 to December 2005,
we studied all the cases with de novo HL proven according to the WHO
classification. A work up was done systematically, contained clinical
evaluation, blood tests (CBC, ERS, LDH, and albumin), bone marrow
biopsy, and CT-scan of the thorax, abdomen and pelvis. 
Results. 363 cases were enrolled, aged from 16 to 80 years old, the
mean age was 36 year old, and patients up to 60 represent 9%. The male
to female ratio was 1.3:1. The mean delay between first symptoms and
diagnosis was 8.5 months. Lymph nodes at presentation were common
(71%), thoracic manifestations, B symptoms or pruritis motivated con-
sultation respectively in 13%, 6% and 2% of the cases. The most fre-
quently pathohistologic pattern found, and for the first time, was the
nodular sclerosis (64%). The mixed cellularity, the lymphocyte deplet-
ed and the nodular lymphocyte predominant subtypes were found
respectively in 26%, 1% and 2% of the case (unspecified subtype in
7%). Early stage (stage I and II) disease was present in 42% of patients
at presentation, 91% among them had unfavourable group according to
the EORTC prognosis staging. 58% had an advanced stage (stage III and
IV) disease. Prognosis factors found were performance Status >2 (26%),
Bulky disease, peripheral >10 cm (29%) and mediastinum (26%), ane-
mia with haemoglobin <10 g/dL in 34%, elevated LDH rate (60%), lym-
phopenia (12,5%) and albumin <30 g/L in 18%.
Conclusions. The clinico-epidemiological pattern of HL in Morocco
(Annals of Oncology, 1999, 10: 159) is still similar to that observed in
developing countries, young patients, male predominance and advanced
stages. The only exception found in this study is the predominance of
the nodular sclerosis subtype, found for the first time in our country.
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WHO WERE TREATED INSIDE VS. OUTSIDE THERAPY OPTIMISATION PROTOCOLS:
RESULTS OF THE TOPICS-ML STUDY
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Introduction. Despite the improvements and knowledge that clinical
trials have brought to cancer treatment, it remained unclear how bene-
ficial participation in a clinical trial with Therapy Optimisation Protocol
(TOP) is for patients (pts) with Hodgkin Lymphoma (HL) in relation to
pts treated outside of trials. In the TOPiCS project, trial participants
(TOP) were compared with non-trial pts (non-TOP).
Methods. In the population-based survey NLL, 356 pts with HL were
recorded in six regions of northern Germany with a first diagnosis in
1988-1998. The dataset was screened for patients fulfilling inclusion and
exclusion criteria from clinical trials of the German Hodgkin Study
Group (GHSG). Additionally, data on staging, therapy, adverse reactions
and survival were collected. 328 pts were documented and 198 pts (60%)
met the inclusion criteria of the GHSG. Of these, those 125 pts (63%)
not randomised in GHSG trials (non-TOP pts) were compared retro-
spectively with 4972 TOP pts who were recruited nation-wide between
1988-1998 in the GHSG trials HD4-HD9. Survival analysis was per-
formed using Kaplan-Meier method and log-rank test. Cox regression
analysis was used for multivariable modelling of risk of death or progres-
sion and included 89 non-TOP pts and 4868 TOP pts.
Results. The demographic parameters were not well balanced between
the two groups: TOP pts were younger, had more often advanced stage
and diagnosis in the later study generation than the non-TOP pts. The
median observation time for overall survival (OS) was 7 yrs for the TOP
group and 10 yrs for the non-TOP group. The 5-yrs OS for TOP pts is
89% (95%-CI [88-89]) and for non-TOP 89% (95%-CI [82-94])(p=0.63).
The 5-year progression free survival (PFS) for TOP pts is 79% (95%-CI
[78-80]) and for non-TOP pts 68% (95%-CI [59-76])(p<0.001). Accord-
ing to a multiple Cox-regression analysis, 5 parameters were significant-
ly (p<0.01) associated with poor OS and PFS: male sex, older age, B-
symptoms, advanced stage and earlier study generation. Participation in
a TOP-trial did not contribute independently for OS (Hazard Ratio
(HR)=1.13, 95%-CI [0.65-1.97]) but contributed independently and pos-
itively for PFS (HR=0.56, 95%-CI [0.40-0.79]). The difference is reflect-
ed in the number of relapses.
Conclusions. The results demonstrate that in Germany, allowing for
the influence of other factors, HL-patients within TOP have a superior
PFS than patients who were treated out of TOP-trials. However, no dif-
ference was observed in OS.
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FAMILIAL CORRELATIONS OF ANTI-VCA IGG TITERS IN FAMILIES WITH EBV RELATED
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Markers of Epstein-Barr virus (EBV) infection include the quantitative
measure of the serological titer anti-VCA IgG. This titer is considered as
a marker of EBV reactivation. High titers have been shown to be predic-
tive of the EBV associated lymphoproliferative diseases, Burkitt (BL) and
Hodgkin lymphomas (HL). We studied the intra-familial segregation of
anti-VCA IgG in three different settings: 127 families recruited through
a case of HL in France (A), 31 families recruited through a case of BL in
Uganda (B) and 74 large families recruited on a geographical basis in
Cameroon (C). Titers were determined by ELISA (A and C) and by
immunofluorescence (B). We found significant intra-familial correlations
for anti-VCA IgG titers in the three settings. The titers of relatives of
patients with HL and BL increased significantly with those of the index
case (p=0.01 and <10–4, respectively). Concordant with a polygenic mod-
el, significant familial correlations were observed between genetically
related individuals (father-offspring, mother-offspring and sibling-sib-
ling) and not between spouses. This pattern of correlations was observed
in all studied populations. The heritability of anti-VCA IgG titers is esti-
mated between 24 and 48%. Our results suggest that anti-VCA IgG
titers have a strong genetic component. These findings pave the way to
the identification of the locus involved in the control of this phenotype.
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INCIDENCE RATE OF HODGKIN LYMPHOMA IN THE LYMPHOMA REFERENCE GROUP OF
THE ONCOLOGY HEMATOLOGY INSTITUTE OF CARACAS, VENEZUELA 
A. Muller, M.A. Torres, M. Morales, R. Somoza, G. Acquatella, 
A. Soyano, A.E. Soyano, M. Diaz, M. Villegas, L. Capote
Instituto Oncologìa y Hematologìa, MS-UCV, UCV Escuela de Medicina Luis
Razzetti, Clinica El Avila, Clinica Sta Sofia, IVIC, Razzetti, Caracas, Venezuela
757 Venezuelan patients with lymphoma were studied retrospective-
ly. The patients were classified in 46% Hodgkin and 54% no Hodgkin
lymphoma. The most common subtype of HD was nodular sclerosis
(62,57%) and were more common in female and young adults patients
The mixed cellularity HD was the second more common and the lym-
phocyte predominance and lymphocyte depletion were only 6,8% and
8,7%. The venezuelan population are integrated by different mix races:
indians, caucasians and blacks but it seems that HD in these patients fol-
lows the same pattern reported in other population.
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PEDIATRIC HODGKIN LYMPHOMA IN TWO SOUTH AMERICAN SERIES: A DISTINCTIVE
EPIDEMIOLOGICAL PATTERN AND LACK OF ASSOCIATION OF EPSTEIN-BARR VIRUS WITH
CLINICAL OUTCOME
M.H.M. Barros,1 P.A. Chabay,2 R. Hassan,1 L. Assumpção Dal-Lago,1
E. De Matteo,2 M.K. Carriço,2 G. Rey,2 I. Zalcberg,1 M.V. Preciado2
1Molecular Biology Laboratory, Bone Marrow Transplantation Centre (CEMO),
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Hodgkin lymphoma (HL) shows a bimodal distribution with a first
peak in developing countries during childhood. The causative role and
prognostic significance of Epstein Barr virus (EBV) association in patients
with HL is controversial. Our aim was to perform a comparative study
of EBV association in two Latin American pediatric HL series, and to cor-
relate it with patient's survival. EBERs in situ hibridization and LMP1
immunohistochemistry were performed on formalin-fixed paraffin-
embedded HL biopsies from 176 pediatric patients from 2 public insti-
tutions from Argentina and Southeast Brazil. All the patients received
antracycline-based treatments. The median age of Argentine patients
was 8 years (2-18) while in Brazilian patients was 14 years (3-18). MC
subtype was prevalent in Argentine HL (52%), and NS subtype in Brazil-
ian HL (83%). EBV expression was detected in 52% of cases, namely
54% Argentine HL and 48% Brazilian HL. EBV was significantly asso-
ciated with MC subtype in both populations. In Argentine HL, EBV pos-
itivity was significantly higher in patients <10 years (p=0.0011). Event
free survival did not attain statistical significance neither in Argentine HL
(p=0.5317), nor in Brazilian HL (p=0.8321). Our results do not support
EBV association stated for pediatric HL in developing countries. Corre-
lation of younger age with EBV infection only in Argentine patients
might be related to a different age background. Our findings give further
support the fact that HL is a heterogeneous disease and that the epidemi-
ological models proposed in the last decade need to be refined to include
new and contrasting evidences. In our pediatric series, EBV status can-
not be used as prognostic factor.
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SERUM CHEMOKINE LEVELS IN HODGKIN LYMPHOMA PATIENTS: HIGHLY INCREASED
LEVELS OF THYMUS AND ACTIVATION-REGULATED CHEMOKINE AND MACROPHAGE
DERIVED CHEMOKINE 
M. Niens,1 L. Visser,2 A. Diepstra,2 T. van der Wal,3 G. van Imhoff,3
R.F. Jarrett,4 S. Poppema,2 A. van den Berg2
Departments of 1Medical Genetics, 2Pathology, and 3Hematology, University
Medical Center Groningen, University of Groningen, The Netherlands; 4LRF
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Introduction. Hodgkin lymphoma (HL) is characterized by a minority
of neoplastic Hodgkin-Reed Sternberg (HRS) cells surrounded by a non-
neoplastic reactive infiltrate. Presence of reactive cells can be explained
by the production of multiple chemokines by either the HRS or infiltrat-
ing cells. Since immunological mechanisms appear to be crucial in cHL
pathogenesis, altered serum chemokine levels might be related to HL
prognosis or disease activity. 
Methods. Serum levels of nine chemokines, Eotaxin, Fractalkine, IP-10,
MCP1, MDC, Mig, MIP1alpha, RANTES, and TARC were examined in
163 untreated HL patients and 334 controls. A follow-up study was per-
formed on 11 patients before during and after therapy.
Results. Serum TARC and MDC levels were significantly increased in
82% and 57% of the HL patient group, respectively. Nodular sclerosis
cases showed increased serum TARC and MDC levels compared to the
mixed cellularity cases (p<0.001) and a significant correlation was
observed between serum TARC and MDC levels and Ann Arbor stage.
Of the nine patients with both pre- and post-treatment serum samples,
the majority showed decreased serum TARC and MDC levels after treat-
ment. In a follow-up study plasma levels of TARC and MDC positive
patients decreased fast after the start of treatment and remained low dur-
ing and after treatment. 
Conclusions. Of nine chemokines tested, TARC and MDC were the
only chemokines with increased serum levels in the vast majority of HL
patients and indicating that both might be useful markers to monitor
treatment efficiency. 
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FOLLICULAR T-CELL ROSETTES REVISITED: PD-1 (NAT-105), AN USEFUL MARKER FOR
THE DIFFERENTIAL DIAGNOSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN
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Introduction. The nodularity and the presence of T-cell rossettes sur-
rounding the neoplasic cells has been described as a defining feature of
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).
Progress in the recognition of Follicular T-cells has made possible the use
of multiple markers for its detection, including CD10, Bcl6, CXCL13,
CD57 and PD1. Here we have explored the potential diagnostic value
of a new marker (NAT105) recognising the antigen PD1. 
Material and methods. A monoclonal antibody identifying PD-1(NAT-
105), has been used in TMAs containing 152 cases diagnosed as Nodu-
lar sclerosis classical Hodgkin lymphoma (NSHL), Mixed cellularity clas-
sical Hodgkin lymphoma (MCHL) Lymhpocyte rich classical Hodgkin
lymphoma (LRCHL), NLPHL and T cell histiocyte-rich B cell lymphoma
(T/HRBCL). All the cases were immunostained with a panel of antibod-
ies against CD10, bcl-6, CXCL13, CD57 and PD-1 (NAT-105). The series
includes a set of cases diagnosed of NLPHL with diffuse areas, and a
group of cases with borderline features between NLPHL and T/HRBCL.
Results. The findings are summarised in Table 1. 
Table 1.
Type of N° cases CD57 PD-1 (Nat105) CXCL-13
lymphoma rosettes rosettes rosettes
0 (3 cases 0 (1 case
NSHL 43 positive tumoral 0 positive
cells) tumoral cells
MCHL 14 0 0 0
8 (1 case
LRCHL 13 positive tumoral 10 0
cells)
7 (7 cases
NLPHL 58 44 57 positive
tumoral cells
NLPHL with 7 Nodular areas=7 Nodular areas=5 0
diffuse areas Diffuse areas=0 Diffuse areas=0
NLPHL vs. 5 3 (1 case positive 4 0
T/HRBCL tumoral cells
0 (2 cases 
T/HRBCL 12 0 0 positive
tumoral cells
Discussion. PD-1 (NAT-105), a member of the CD28 costimulatory
receptor familiy, is really an excellent immunomarker of T-cell rosettes
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in NLPHL, but we encountered that the presence of rosettes is not a
unique and defining feature of NLPHL, but also of a subset of LRCHL,
supporting the interpretation that the neoplastic cells in NLPHL and
some LRCHL are in close association with the germinal center associat-
ed T-cells and presumably reflecting the origin of the tumoral cells in the
outer zone of the germinal centre, the area where PD1 positive cells are
selectively located, even forming rosettes in reactive hyperplastic germi-
nal centres. The presence of PD-1 (NAT-105) positive T-cell rosettes
seems to be really a useful feature to make a differential diagnosis
between NLPHL and T/HRBCL, which is normally a controversial and
difficult task for pathologists. The standard T/HRBCL cases lack T-cell
rosettes, while the cases borderline between both entities following this
criterion seems to fall more on the NLPHL group.
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CD4+CD26– T CELL POPULATION IN CLASSICAL HODGKIN LYMPHOMA DISPLAYS A 
DISTINCTIVE REGULATORY T CELL POPULATION 
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A. van den Berg
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Introduction. Hodgkin and Reed-Sternberg (HRS) cells in classical
Hodgkin lymphoma (cHL) are surrounded by a majority of infiltrating
reactive cells, which mainly consists of CD4+ T cells. These T cells
express several activation associated surface markers but lack expres-
sion of the T cell co-stimulatory molecule CD26. Little is known about
the significance of these rosetting CD4+CD26– T cells. 
Methods. To characterize these T cells, CD4+CD26– and CD4+CD26+
T cells were sorted from lymph node cell suspensions from 7 cHL and 5
reactive lymph nodes (LN). Of 5 HL cases and 3 lymph nodes, parts of
the cells were stimulated with PMA/ionomycin to get activated T cell
subsets. mRNA profiles of activated and non-activated T cell populations
were evaluated with quantitative RT-PCR for 46 selected genes.
Results. We observed a higher percentage of CD4+CD26– T cells in cHL
compared to reactive LN. For the non-activated T cell subsets,
CD4+CD26– T cells in cHL showed higher mRNA levels of IL2RA,
CTLA4, TNFRSF4 and CCR4 compared to LN. Moreover, these cells
displayed low or no expression of the Th1 or Th2 related cytokines IL2,
IFNγ, IL13, IL12B, IL4, IL5 and the chemoattractant receptor GPR44.
Overall, the profiling results support a regulatory T (Treg) cell type for
the CD4+CD26– T cells in cHL. Besides Tregs, Th17 cells may exist in cHL
based on the significantly higher IL17 mRNA level for both the CD26–
and CD26+ T cells in cHL than in LN. Upon activation, the lack of up-
regulation of mRNA levels of most cytokine genes (IFNG, IL2, IL8, IL21,
IL17, IL13, IL12A and IL4) indicated an anergic character for the
CD4+CD26– T cell subset in cHL. 
Conclusions. A high proportion of CD4+CD26– T cells is characteristic
for cHL. No evidence for a Th1 or Th2 cell type is found for these cells
but they display a regulatory T cell phenotype. Anergy fits with the reg-
ulatory T cell profile of these cells, probably explaining the immunosup-
pressive mechanism involved in cHL.
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EOSINOPHIL CATIONIC PROTEIN IS CYTOTOXIC TO HODGKIN REED STERNBERG CELLS
IN VITRO - BUT WHY DO THE EOSINOPHILS FAIL TO KILL THE TUMOUR CELLS IN VIVO?
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P. Venge,3 G. Enblad1
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Introduction. Prominent eosinophil infiltration is characteristic for many
Hodgkin lymphoma (HL) affected lymph nodes. This is strikingly differ-
ent from reactive lymph nodes where almost no eosinophils are present.
Eosinophils participate in the defense against parasites and viruses, and
they possibly have a protective role against carcinomas. One defense
mechanism by eosinophils is the release of cationic protein (ECP), a high-
ly cytotoxic protein that probably acts as a pore-forming protein. ECP
may vary in size and toxicity depending on post translational modifica-
tions, such as glycosylation. However, HL patients with abundant
eosinophils in their tumours have a poor prognosis and eosinophils stim-
ulate Hodgkin Reed Sternberg (HRS) cell proliferation. In addition, high
levels of ECP in patient sera correlate to negative prognostic factors. To
achieve deeper knowledge about the actions of eosinophils in HL, we
studied the effects of different ECP fractions on HRS cells in vitro.
Methods. A cell proliferation assay was used to measure the survival
index of the HL cell lines HDLM-2 and L-1236 cultured together with
ECP. ECP was purified from pooled buffy coats from healthy blood
donors and using a two step chromatography separated into different
fractions, depending on the level of glycosylation. The different frac-
tions were then used in the proliferation assay.
Results. A reduction in survival index for the cell line HDLM-2 was seen
for all fractions of ECP used. The reduction in survival index varied
between 15-53% among the different fractions when 1.25 µg/mL of ECP
was used. ECP fractions with relatively sparse glycosylation seemed to
be more cytotoxic. Notably, the cytotoxic effect was most obvious at
low concentrations of ECP (1.25 µg/mL) and only somewhat accentuat-
ed at higher concentrations (5, 10 and 20 µg/mL) for some fractions. In
other fractions rather a slight stimulatory effect could be noted for high-
er concentrations. Preliminary data on the cell line L-1236 showed sim-
ilar results.
Conclusions. Many eosinophils in the tumours are a negative prognos-
tic factor and they do not seem to provide protection against tumour
development. Surprisingly, however ECP is cytotoxic to HRS-cells in vit-
ro, especially at low concentrations. This raises the questions whether
the characteristic cytokine milieu makes eosinophils at the tumour site
inactive or if the tumour cells in vivo are insensitive to ECP.
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Introduction. Gene expression profiling has successfully identified the
prognostic significance of the host response in lymphomas. We endeav-
or to unravel the functional meaning of this host response, investigating
T cell/histiocyte rich large B cell lymphoma (THRLBCL), an aggressive
B cell lymphoma, on the one hand, and nodular lymphocyte predomi-
nant Hodgkin's lymphoma (NLPHL), an indolent lymphoma, on the oth-
er hand. Of note, the tumor cells of both lymphomas share several char-
acteristics, including expression of pan B cell markers, germinal centre B
cell origin, and common chromosomal imbalances. Their stromal com-
position in contrast is clearly different.
Methods. We collected 28 THRLBCL and 47 NLPHL cases, and per-
formed microarray expression profiling on 10 cases of each lymphoma.
Based on the results, we built a straightforward three-gene classifier and
applied it to the remaining cases.
Results. As the stromal component constitutes the majority of the
tumor cell mass in both NLPHL and THRLBCL, we performed expres-
sion profiling on entire tissue sections. Principal component analysis
demonstrated a clear-cut separation between these two lymphomas.
Surprisingly, we found that over 50% of the measured microarray probes
showed differential regulation, indicating that NLPHL and THRLBCL
expression profiles are extremely dissimilar. As expected, the gene
expression profile of NLPHL is characterized by a B cell signature. In
contrast, the profile of THRLBCL is hallmarked by up-regulation of
CCL8, IFN-gamma, STAT1, IDO, VSIG4 and Toll-like receptors. We
speculate that CCL8 and IFN-gamma are responsible for respectively
the recruitment and the activation of histiocytes, a main component of
the stromal reaction in THRLBCL. Furthermore, these mediators may,
in synergy with TLR-ligands, be responsible for the production of high
levels of IDO by these histiocytes. The production of IDO and the
expression of VSIG4 results in an immune tolerogenic microenviron-
ment for the tumor cells, explaining the bad prognosis of these patients.
In addition, our understanding of this particular stromal reaction offers
several potential targets for therapy. Based on the three genes most dif-
ferentially expressed in our microarray experiment, we constructed a
quantitative RT-PCR classifier to support the morphological diagnosis.
This classifier made the correct diagnosis in the remaining 55 THRLB-
CL and NLPHL cases.
Conclusions. THRLBCL can be clearly distinguished from NLPHL at
the molecular level, allowing the design of a three-gene classifier. The
particular signature of the aggressive THRLBCL offers potential targets
for therapy.
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Introduction. Nodular Sclerosis (NS) and Mixed cellularity (MC) sub-
types constitute most of classical Hodgkin Lymphoma (cHL) cases.
Hodgkin/Reed-Sternberg (H-RS) cells in both subtypes have the same
phenotype but the lymph node morphology differs. There are also dif-
ferences in epidemiological features and clinical characteristics between
the two subtypes. However, these differences have not been fully
defined or explained at the molecular level.
Material and methods. The Affymetrix platform was used to determine
gene expression profiles of 47 cHL samples (27 NS and 20 MC). Gene
expression profiles in cHL derived cell lines that originated from NS or
MC tumors were compared in order to identify possible subtype spe-
cific genes characteristic of the H-RS cells from these subtypes. The
results were validated on RNA level with Real-time PCR and on protein
level with immunohistochemistry. The data were analyzed in relation
to the morphological features of the tumors and clinical characteristics
of the patients.
Results. Microarray analysis clearly distinguished the NS specific fibro-
sis and identified the genes involved in this process. The NS specific
genes might also be dependent on EBV status. Some inflammatory
genes, such as complement subunits and chemokines, were weakly
associated with the MC subtype and with the frequency of macrophages
in the tissue. 
Discussion. Gene expression and morphology of NS and MC cHL sub-
types are linked with regard to tissue fibrosis and cell composition of
tumors. NS has features of a second phase wound-healing process while
MC samples lack these deposits of extracellular matrixes. Both subtypes
show variable expression of different types of inflammation-related
genes correlating to the numbers of macrophages.
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SELECTIVE METALLOPROTEINASE INHIBITION OF HUMAN CD30 SHEDDING INCREASES
SPECIFITY OF TARGETED IMMUNOTHERAPY
H. Hansen, V. Simhadri, D. Eichenauer, A. Engert, 
E. Pogge von Strandmann
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Introduction. The receptor CD30 is selectively overexpressed on many
human lymphoma cells and therefore an interesting target for antibody-
based immunotherapy. However, binding of therapeutic antibodies
stimulates CD30 shedding leading to a loss of target antigen and an
enhanced release of the soluble ectodomain (sCD30). We wanted to
know whether sCD30 levels are a clinical relevant problem. 
Results. Here, we show that sCD30 binds to membrane-anchored
CD30 ligand (CD153) on mast cells and neutrophils which are frequent-
ly found among the bystander cells in lymphoma tissue. Using sCD30
as a linker, CD30 antibodies are able to bind these non-target cells and
caused the release of interleukin-8 (IL-8) which is involved in angiogen-
esis and metastasis. To overcome this adverse shedding-dependent mis-
targeting we used loss-of-function experiments with cells lacking can-
didate releasing enzymes ADAM10 and ADAM17 and a selective
inhibitor to identify ADAM10 as the main enzyme responsible for the
antibody-stimulated shedding. In co-culture experiments, the antibody-
induced transfer of sCD30 from the human Hodgkin lymphoma cell
line L540 to the CD30-negative but CD153-expressing human mast cell
line HMC-1 was inhibited by the ADAM10-selective inhibitor
GI254023X. 
Discussion. These findings suggest that selective metalloproteinase
inhibitors blocking antibody-induced shedding of target antigens could
be of therapeutic value to increase the specificity and reduce side-effects
of immunotherapy with monoclonal antibodies.
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Introduction. The cytokine receptor CD30 is consistently expressed by
the tumor cells of classical Hodgkin lymphoma (cHL) and anaplastic
large cell lymphoma (ALCL) whereas its expression is low in and restrict-
ed to few lymphoid blasts in the human body. This expression pattern
implies that CD30 plays an important role in the pathogenesis of cHL
and ALCL. This hypothesis was investigated by different approaches.
Methods. We analyzed the signaling activity of CD30 in B cell-derived
cHL cell lines and ALCL cell lines by (i) CD30 stimulation, (ii) CD30
down-regulation, and (iii) the combination of both. The consequences
of these treatments were determined at RNA level (gene expression
microarray analysis and RT-RQ-PCR), protein level (EMSA,
immunoblotting, and flow cytometric analysis) and cellular level (pro-
liferation and cell death).
Results. Neither CD30 stimulation nor CD30 silencing of Hodgkin
cells had any significant effect demonstrating that Hodgkin cells are vir-
tually CD30 unresponsive. In contrast, CD30 stimulation of ALCL cells
activated NF-κB and regulated pro-apoptotic as well as anti-apoptotoic
factors, induced major transcriptional changes, and decreased prolifera-
tion whereas siRNA-mediated CD30 downregulation abrogated these
effects. Strikingly, CD30 stimulation of ALCL cells stable transfected
with a dominant-negative NF-κB inhibitor induced pronounced caspase
activation and massive apoptosis.
Discussion. Our data indicate that (i) CD30 signaling is not effective in
cHL cells but in ALCL cells, (ii) CD30 is probably not significantly
involved in the pathogenesis of cHL, and (iii) CD30 stimulation triggers
two competing effects in ALCL cells namely activation of caspases and
NF-κB-mediated survival. Based on these data we suggest that CD30-
targeted therapy in ALCL should be combined with NF-κB inhibitors to
induce effective tumor cell killing.
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U-HO1, A NOVEL CELL LINE DERIVED FROM A PRIMARY REFRACTORY CASE OF 
CLASSICAL HODGKIN LYMPHOMA
P. Möller, A. Mader, S. Brüderlein
Institute of Pathology, University of Ulm, Germany
The Hodgkin cell line U-HO1 was established from a malignant pleu-
ral effusion of the 23-yr-old patient Andreas Mader during the end stage
of refractory nodular sclerosing classical Hodgkin lymphoma. Since its
establishment, U-HO1 has maintained stable characteristics during the
last 2 years in vitro and has a doubling time of about 4 days under stan-
dard culture conditions. U-HO1 lacks HLA-ABC but expresses MHC
class II antigens and surface expresses CD15 and CD30 in the absence
of CD19 and CD20.Karyotype analysis of U-HO1 revealed an hyper-
diploid karyotype: 50,XY,del(1)(p13.2p31.1),der(2)t(2;10) (q35;q16.1)
add(2)(p11.2).rev ish amp(2)(p13p23), t(4;6)(p12;p11.1),t(5;22)
(q35.1;q13.2),+der(6)t(4;6) (p12;p11.1)del(6)(q22.3q26),der(10) t(2;10)
(q35;q26.1),+t(12;18)(p11.1;q11.2),del(15)(q11.2q15),+der(18)t(12;18)(p1
1.1;q11.2),+del(20)(q13.1),ins(21;15)(p11.2;q11.2q15),der(22)t(5;2)q35.1;
q13.2).ish t(9;19)(p24;?) [43]/ 50,sl,del(8)(q24.1)[6]/50,sl,del(7) (q36.3)[2]/
50,sl,del(7)(q11.23)[2].CGH analysis revealed the following
imbalances:ish cgh dim(1)(p13p31)(p12q21),enh(2)(p13p23),dim(4)
(q31.3qter),enh(6)(q22q27),enh(12), enh(18),enh(20)(q13.1pter). Fish
analysis showed an amplification of REL and BCL-11A of about six fold
on chromosome 2(p13p23).Thus, U-HO1 is prototypical for classical
Hodgkin lymphoma in every aspect tested so far. However, compared
to the conventional Hodgkin lymphoma cell lines, which have highly
complex karyotypes, U-HO1 proved far less genetically aberrant sug-
gesting that the few imbalances suffice to develop the full-blown phe-
notype of refractory Hodgkin's disease.We wish to fulfill the last will of
Andreas Mader who wanted to donate his tumor cell line to the scien-
tific community to foster Hodgkin lymphoma research.
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LACK OF PTPN1 (PTP1B) IN U-HO1, A NEW HODGKIN-DERIVED CELL LINE, PROTECTS
CELLS FROM APOPTOSIS
S. Wegener, A. Mader, I. Melzner, S. Brüderlein, P. Möller
Institute of Pathology, University of Ulm, Germany
Protein tyrosine phosphatases (PTPs), which catalyze dephosphory-
lation of tyrosyl phosphorylated proteins, play an important role in cel-
lular signaling by serving as antagonists of Protein Tyrosine Kinases
(PTKs). PTPs regulate multiple cytokine and growth factor activated sig-
naling pathways which are associated with malignancies like myelodys-
plastic syndromes and B-cell lymphomas. PTPN1 is a well studied non-
receptor phophatase. JAK2 was shown to be a substrate of PTPN1 which
results in a negative regulation of the kinase activity of JAK2 and the sub-
sequent activation of downstream targets like STAT5.Furthermore it has
been demonstrated that PTPN1 is involved in regulation of apoptosis in
different cell systems.The parental tumor of U-HO1, a nodular scleros-
ing classical Hodgkin lymphoma (cHL), and its resulting cell line proofed
negative for PTPN1 in Western blot and by immunomorphology. We
hence investigated the expression of PTPN1. PTPN1 cDNA
(NM_002827) of U-HO1 was markedly truncated: exon 2 to exon 8 were
skipped translating into the following predicted short protein of 26
amino acids: MEMEKEFEQIDKSGSWAAIYQHESRH. To examine the
role of lack in functional PTPN1 we transfected U-HO1 cells with wt-
PTPN1. Transient ectopic expression of PTPN1 caused an increased
dephosphorylation of phosphoSTAT5. Stable wt-PTPN1 transfectants
featured a very slow proliferation in contrast to cells transfected with the
empty vector. As evidenced by Nicoletti staining and cytomorphology
wt-PTPN1 undergo apoptosis to a much greater extent than mock trans-
fectants. To see whether PTPN1 deficiency is occuring in the HRS-cells
of cHL in vivo, we analyzed 61 samples from patients with cHL by
immunohistochemistry. Only 15 of 61 cHL samples tested had PTPN1-
positive neoplastic cells. Thus lack of PTPN1 is a common feature in
HRS-cells in vivo.In summary our results show that PTPN1 plays a major
role in deactivation of the JAK2-/STAT5 signaling pathway and its defi-
ciency saves HRS-cells from apoptosis.
P018
IDENTIFICATION OF MIR-155 TARGETS TO ELUCIDATE THE ROLE OF HIGH MIR-155 
LEVELS IN B CELL HODGKIN AND NON-HODGKIN LYMPHOMA 
J. Gibcus, R.N. Schakel, G. Harms, J. Kluiver, L.P. Tan, S. Poppema, 
B.J. Kroesen, A. van den Berg
Pathology & Laboratory Medicine, University Medical Center Groningen and
University of Groningen, Groningen, Netherlands
Introduction. MicroRNAs (miRNAs) are 19-25 nucleotide long RNA
molecules derived from precursor genes that inhibit the expression of tar-
get genes by binding to their 3' UTR region. Expression of miRNAs is
often tissue specific and miRNA profiling has shown overexpressed miR-
NAs in both B-cell development and carcinogenesis. The primary miR-
NA transcript BIC and its mature micro-RNA, miR-155, are highly
expressed in Hodgkin lymphoma (HL), diffuse large B cell lymphoma
(DLBCL) and primary mediastinal B cell lymphoma (PMBL) indicating a
potential role for miR-155 in malignant transformation of B cells. Over
expression of BIC in a transgenic mice model revealed all features of
high grade B cell malignancies, supporting this hypothesis. To study the
relevance of high miR-155 expression in B cell lymphoma, it is essential
to identify and validate the predicted miR-155 target genes. 
Methods. Twenty five targets for miR-155 were selected for experi-
mental confirmation from more than 2000 predicted target genes
obtained by 4 target prediction algorithms (TargetBoost, Miranda, Tar-
getscanS and Pictar). Putative target sites were amplified and cloned in
the 3'-UTR of a Renilla Luciferase gene in the psiCHECK-2 vector. The
construct, containing a Firefly luciferase gene for normalization, was
transfected into miR-155 positive cells. An antisense miR-155 specific
inhibitor (LNA probe), was cotransfected to confirm the miR-155
induced translational block. Three HL cell lines (L428, L1236 and DEV)
with an increasing expression level of miR-155 respectively were used
to validate the predicted target sites.
Results. The predicted targets ZIC3, ZNF537, AGTR1 and KGF showed
a reduced Renilla/Firefly luciferase ratio compared to the same genes
co-transfected with the miR-155 inhibitor. This indicates that these three
predicted target sequences might indeed be miR-155 targets. Construc-
tion of a site-directed mutagenesis control and analysis of the remaining
selected miR-155 targets are ongoing.
Discussion. Our data demonstrate that the predicted miR-155 target
sites from ZIC3, ZNF537 AGTR1 and KGF can indeed be repressed by
miR-155 binding. Yet the pathophysiological role of these genes in B cell
lymphomagenesis needs to be established in future experiments.
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EVIDENCE FOR A PATHOPHYSIOLOGICAL ROLE OF 15-LIPOXYGENASE AND CYSTEINYL
RECEPTOR 1 IN CLASSICAL HODGKIN LYMPHOMA
J. Sjöberg,1 F. Schain,1 Y. Tryselius,2 L. Backman,2 M. Malec,1,3
A. Porwit,3 D. Xu,1 P.G. Murray,4 M. Björkholm,1 H.E. Claesson2,5
1Department of Medicine, Division of Hematology, Karolinska University Hos-
pital Solna and Karolinska Institutet, Stockholm, Sweden; 2Biolipox AB,
Berzelius väg 3, Solna, Sweden; 3Department of Pathology, Karolinska Univer-
sity Hospital Solna, Stockholm, Sweden; 4CRUK Institute for Cancer Studies,
University of Birmingham, Edgbaston, Birmingham, United Kingdom; 5Depart-
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Introduction. Leukotrienes (LT) are biologically active metabolites
derived from arachidonic acid. The key enzyme in leukotriene synthe-
sis is 5-lipoxygenase (5-LO). The enzyme 15-LO is related to 5-LO, and
15-LO can also catalyze the formation of pro-inflammatory metabolites.
Hodgkin/Reed-Sternberg (H/RS) cells are surrounded by inflammatory
cells including T-cells, eosinophils, macrophages and mast cells. It is gen-
erally believed that various molecules released by the H/RS cells are of
great importance in the pathophysiology of classical Hodgkin lymphoma
(cHL). Methods and Results: Here, we report the expression of 15-LO
and functional cysteinyl leukotriene (CysLT)1 receptors in cHL cell lines.
Challenge of these cells with LTD4 led to a robust calcium signal, which
was completely blocked by zafirlukast, a specific CysLT1 receptor antag-
onist. Quantitative PCR analysis demonstrated up-regulation of tumor
necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and IL-13 mRNA after
stimulation with LTD4. Furthermore, the secretion of TNF-α, IL-6 and
IL-8 was markedly increased upon stimulation with LTD4. This metabo-
lite also stimulated the proliferation of HL cells in vitro. Immunohisto-
chemical studies of cHL biopsies showed H/RS cells positive for 15-LO
and the CysLT1 receptor in >70 % of the tumors. The presence of mRNA
for the CysLT1 receptor and 15-LO was confirmed by microarray analy-
sis of laser dissected H-RS cells. Primary mediastinal B-cell lymphoma
(PMBCL) showed a partial overlap, expressing the CysLT1 receptor, and
the functionality of this receptor was confirmed in the PMBCL-derived
cell line MedB1. Other indolent or aggressive lymphomas under study
were negative for 15-LO and the CysLT1 receptor. 
Discussion. The expression of 15-LO and cysLT1 in cHL might be use-
ful as biomarkers in this disease. Since H/RS cells are surrounded by
CysLT producing cells (eosinophils, macrophages and mast cells), these
results indicate that CysLT signalling may be of importance in the patho-
genesis of cHL by contributing to the disturbed cytokine features of this
tumor.
P020
TRANSCRIPTIONAL REGULATION OF HUMAN 15-LIPOXYGENASE-1 
IN HODGKIN/REED-STERNBERG CELLS 
C. Liu,1,4 F. Schain,1,4 D. Xu,1 M. Björkholm,1 H.E. Claesson,2,3
J. Sjöberg1
1Department of Medicine, Division of Hematology, Karolinska University Hos-
pital Solna and Karolinska Institutet, Stockholm, Sweden; 2Department of Med-
ical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden;
3Biolipox AB, Berzelius väg 3, Solna, Sweden; 4CL and FS contributed equally
to this work
Introduction. Lipoxygenases oxidatively metabolize polyunsaturated
fatty acids to a rich spectrum of biologically active metabolites. We have
only recently reported that one enzyme of the lipoxygenase family,
human 15-lipoxygenase type 1 (15-LOX-1), is over-expressed in certain
Hodgkin lymphoma (HL) derived cell lines and in Hodgkin/Reed-Stern-
berg (H/RS) cells of >70% of tumors from patients with classical HL. The
gene expression of this enzyme is highly controlled at both the tran-
scriptional and post-transcriptional level. Methods and Results: Studies
of the 15-LOX-1 5' promoter region demonstrated three putative bind-
ing sites for signal transducer and activator of transcription (STAT6) with-
in the proximal 1500 base pairs relative to the start codon. In order to
depict the mechanism/s underlying the control of 15-LOX-1 transcrip-
tion in H/RS cells, experiments were undertaken in HL cell lines. Analy-
sis by serial promoter deletions and STAT6 binding site mutants indicates
that all three STAT6 binding sites are required for full activation of the
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15-LOX-1 promoter. Electrophoretic mobility shift assay and chromatin
immunoprecipitation assay demonstrated that this region is occupied by
STAT6 in a 15-LOX-1 positive HL cell line but not in 15-LOX-1 negative
HL cell lines. Furthermore, we found DNA hypomethylation and histone
hyperacetylation within the core promoter region of 15-LOX-1 in 15-
LOX-1 positive cells. Discussion: Taken together, the present study indi-
cates that STAT6 activation and chromatin remodeling by DNA
demethylation and histone acetylation are important for transcription-
al activation of 15-LOX-1 in H/RS cells.
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INSIGHTS INTO THE PATHOGENESIS OF PRIMARY NODULAR 
LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA (NLPHL) BY GLOBAL GENE
EXPRESSION ANALYSIS OF ISOLATED L&H CELLS
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Introduction. Hodgkin lymphoma (HL), one of the most frequent malig-
nant lymphomas, is subdivided into classical HL (cHL) and nodular lym-
phocyte-predominant HL (NLPHL). NLPHL accounts for approximate-
ly 5% of HL cases in the Western world. Tumor cells of both subtypes
represent clonal populations that are derived from germinal center (GC)
B cells, but they are genetically and morphologically different. Only lit-
tle is known about the mechanisms involved in NLPHL pathogenesis.
To gain insights into the pathogenesis of NLPHL, and similarities and dif-
ferences to cHL and other B cell lymphomas, we performed systematic
large scale gene expression studies, comparing L&H (lymphocytic and
histiocytic) cells of NLPHL to normal B cells, Hodgkin Reed Sternberg
(HRS) cells of cHL and other B-non Hodgkin lymphomas (B-NHL).
Methods. RNA of 1000-2000 laser-microdissected lymphoma cells,
MACS- and FACS-sorted normal B cell subsets and HL cell line cells was
isolated, amplified by a two-rounded T7 RNA polymerase-based pro-
tocol and analysed using Affymetrix U133 Plus 2.0 microarrays.
Results. Unsupervised hierarchical clustering showed that L&H cells
cluster as a distinct entity surprisingly close to HRS cells. Supervised
comparison of L&H cells to HRS cells confirmed a low number of sig-
nificantly differentially expressed genes. Comparison of differentially
expressed genes between L&H cells and GC B cells as their putative
counterpart revealed amongst other aspects a partial loss of B cell mark-
ers, including B cell receptor signaling molecules and molecules impor-
tant for B cell development, lineage commitment and maintenance.
Moreover, L&H cells have upregulated multiple anti-apoptotic as well
as downregulated pro-apoptotic molecules.
Discussion. Our global gene expression analysis using Affymetrix
microarrays already pointed out some interesting and unexpected
aspects of L&H cells. Further detailed analysis will be done to identify
L&H cell-specific genes that might be involved in the pathogenesis of
NLPHL and that might represent new diagnostic or therapeutic mark-
ers. We also aim to identify signaling pathways active in L&H cells that
promote their growth and survival. 
P022
ARRAY CGH ANALYSIS OF SUBNANOGRAM QUANTITIES OF DNA USING WHOLE GENOME
AMPLIFICATION: OPPORTUNITIES FOR DETECTION OF COPY NUMBER ALTERATIONS IN
HODGKIN'S LYMPHOMA
T. Feys,1 B. Poppe,1 B. Verhasselt,2 P. De Paepe,3 B. Menten,1
J. Vandesompele,1 N. Van Roy,1 A. De Paepe,1 F. Speleman1
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Classical Hodgkin's lymphoma (cHL) is a common malignant lym-
phoma characterized by the presence of large, usually multinucleated
malignant Hodgkin and Reed Sternberg (HRS) cells which are thought
to be derived from germinal centre B cells. In cHL, HRS cells usually
constitute less than 1% of the entire tumor volume. In contrast to many
other malignancies, the profile of genetic aberrations in cHL is still poor-
ly understood. In order to determine the gene copy number alterations
underlying Hodgkin's lymphoma we have set out a strategy for array
CGH analysis on pure populations of HRS cells isolated from a series of
Hodgkin's lymphoma cases. Given the scarcity of HRS cells and the
requirement of 250-500 ng DNA for array CGH, this implies the need
to amplify DNA from isolated HRS cells Recently, several whole genome
amplification methods have been reported that can generate micrograms
of DNA starting from as little as a few nanograms of input DNA. In this
study, we obtained reproducible and reliable results on BAC arrays using
two different whole genome amplification (WGA) methods. First, Ran-
dom Prime Amplification (RPA) was performed on 0.2 ng (approximate-
ly 30 cells) of DNA from HL cell lines with several well characterised
chromosomal imbalances and amplifications. Next, we tested the
GenomePlex WGA kit (Sigma-Aldrich) for detection of genomic aber-
rations using as little as 5 ng of input DNA. Further down-scaling was
done with the GenomePlex single cell WGA kit which we applied to 10
laser capture microdissected cells. The GenomePlex single cell WGA kit
allowed detection of the known chromosomal imbalances but also pro-
duced considerable deviation from the normal ratio in normal to normal
hybridisations for chromosomal regions with high gene density (e.g.
distal 1p, 6p21.1-p22.1, 22q). This phenomenon seemed to be sup-
pressed when using amplified reference DNA. In conclusion, both test-
ed whole genome amplification methods allow the detection of chro-
mosomal imbalances starting from a very limited amount of cells. These
results demonstrate that it should now be possible to analyze the chro-
mosomal imbalances on laser capture microdissected Hodgkin and Reed
Sternberg cells.
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HLA CLASS II EXPRESSION BY HODGKIN REED-STERNBERG CELLS IS AN INDEPENDENT
PROGNOSTIC FACTOR IN CLASSICAL HODGKIN LYMPHOMA
A. Diepstra, G.W. van Imhoff, H.E. Karim-Kos, A. van den Berg, 
G.J. te Meerman, M. Niens, I.M. Nolte, E. Bastiaannet, M. Schaapveld,
E. Vellenga, S. Poppema
Departments of Pathology, Hematology, Genetics and Epidemiology, Universi-
ty Medical Center Groningen, University of Groningen and the Comprehensive
Cancer Center North Netherlands, Groningen, the Netherlands
Introduction. The neoplastic Hodgkin Reed-Sternberg (HRS) cells in
classical Hodgkin lymphoma (cHL) derive from B cells and are surround-
ed by a T cell rich reactive infiltrate. Absence of HLA class II expression
may provide escape from tumor immunosurveillance. The frequency
of HLA class II downregulation and its relation to prognosis is unknown.
Patients and Methods: Immunohistochemistry results for HLA class
II were evaluated on HRS cells in lymph node biopsy samples of 292
patients with primary cHL retrieved from a population based clinical
database from the Comprehensive Cancer Center North Netherlands
(CCCN). Patients were diagnosed between 1989 and 2000 in the north-
ern part of the Netherlands and were treated with standard chemo-
radiotherapy according to CCCN guidelines. Median age at diagnosis
was 38 years (range 8-88); 63% had Ann Arbor stage I-II, 24% stage III,
and 13% stage IV disease. For 168 of these patients HLA genotype data
were available. Median follow up was 7.1 years.
Results. Lack of HLA class II cell surface expression on HRS cells in the
primary lymph node specimen was observed in 41.4% of cases, more
often in patients with extranodal dissemination (stage IV), Epstein Barr
virus negative cases and HLA class I negative cases. Alleles of three
microsatellite markers in the HLA class II region were associated with
presence (D6S1666: allele 144, p=0.0042; D6S2665: allele 247, p=0.035
and allele 263, p=0.017) or absence (D6S2444: allele 144, p=0.011 and
D6S2665: allele 256, p=0.0094) of HLA class II protein expression. Fac-
tors influencing failure free and relative survival in univariate analysis
were age, stage (extranodal dissemination), and HLA class II expression.
Lack of membranous HLA class II expression coincided with adverse
outcome (5 years failure free survival 67% vs. 85%, p=0.0007; 5 years
age and sex matched relative survival 80% vs. 90%, p=0.03). This effect
remained after adjustment for age and extranodal (stage IV) disease in
multivariate analyses (failure free survival: hazard ratio 2.21, 95% CI
1.30-3.70, p=0.004; relative survival: relative excess risk of death 2.56,
95% CI 1.19-5.55, p=0.02).
Conclusions. These results indicate that lack of membranous HLA class
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II expression by Hodgkin Reed-Sternberg cells in diagnostic specimens
is an independent adverse prognostic factor in classical Hodgkin lym-
phoma.
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Signaling through the latent membrane protein 1 (LMP1) of the Epstein
Barr virus (EBV) is likely to be important for virally induced transforma-
tion of germinal center B cells leading to the development of tumors
such as Hodgkin lymphoma (HL). However, the contribution of LMP1
to the pathogenesis of these tumors is unknown. In this study, we
describe a non-viral vector based method for the expression of LMP1 in
primary human GC B cells. Comparative gene expression profiling of
LMP1-expressing and non-expressing GC B cells revealed that LMP1
downregulated B cell specific genes and B cell receptor components such
as CD79A, CD79B, CD19, CD20, CD22 and BLNK. LMP1 also activat-
ed the expression of ID2, a negative regulator of B cell differentiation.
Our results suggest that in EBV positive cases, LMP1 expression con-
tributes to the loss of B cell phenotype characteristic of Hodgkin/Reed-
Sternberg cells.
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Introduction. Constitutive nuclear activity of NF-κB represents a key
feature in the pathogenesis of Hodgkin's lymphoma (HL), primary medi-
astinal B cell lymphoma (PMBCL) and activated B cell-like diffuse large
cell lymphoma (ABC-DLBCL). 
Methods. We sequenced the complete coding region of TNFAIP3, an
inhibitor of NF-κB, from cell lines and tumor cells of primary biopsies of
HL, PMBCL and immunohistochemically classified ABC-DLBCL. Single
CD30-positive Hodgkin and Reed/Sternberg (HRS) cells were obtained
by laser microdissection and analyzed as single cells or in groups of cells.
Results and Discussion. In PMBCL, inactivating mutations affecting both
alleles of TNFAIP3 were found in 1 of 1 cell line and 4 of 13 primary biop-
sies analyzed. Among 6 HL cell lines analyzed, one showed a premature
nonsense mutation and one a gene truncation, in both instances in com-
bination with loss of heterozygousity (LOH) leading to aberrant tran-
scripts encoding truncated A20 proteins. Mutations of TNFAIP3 in HRS
cells of primary HL biopsies were found in 9 of 21 cases including non-
sense mutations, deletions causing frameshifts and replacement muta-
tions. The somatic origin of mutations in HL was verified by sequence
analysis of TNFAIP3 in non-neoplastic cells. In ABC-DLBCL, 1 of 3 cell
lines showed a monoallelic frameshift deletion, whereas none of 10 pri-
mary cases analyzed exhibited mutations of this gene. These results sug-
gest that TNFAIP3 acts as tumor suppressor gene in HL and PMBCL.
Supported by the Wilhelm Sander Foundation and the Deutsche Krebshilfe.
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Introduction. Classical Hodgkin lymphoma (cHL) and anaplastic large
cell lymphoma (ALCL) are neoplasms characterized by the expression
of CD30. Two ALCL subsets are recognized in the current WHO classi-
fication: one expressing an oncogenic ALK-fusion protein as a result of
a translocation involving the alk-locus. The second subset is morpholog-
ically similar to ALK-positive ALCL, also expresses CD30 but lacks ALK-
expression. Additionally, a primary cutaneous type of ALCL with CD30-
positivity exists. Little is known about the mechanisms involved in the
pathogenesis of the latter two. The differential diagnosis between cHL
and ALK-negative ALCL can be rather challenging since ALK-negative
morphology can closely resemble tumor-cell-rich cHL. Besides Pax-5
expression by the tumor cells of cHL, the immunophenotype of these
two neoplasms is very close and no specific molecular marker has been
identified yet. Therefore, we conducted gene expression profiling stud-
ies on cHL, ALK-positive, ALK-negative and cutaneous ALCL cells and
compared them to normal B, T and NK cell subsets and to each other.
Methods. RNA of 1000-2000 laser microdissected lymphoma cells,
MACS- and FACS-sorted normal B, T and NK cell subsets, HL and ALK
cell line cells was isolated, amplified by a two-round T7 RNA poly-
merase-based protocol and analyzed using Affymetrix U133Plus2.0
microarrays.
Results. Unsupervised hierarchical clustering clearly separates cHL from
all subtypes of ALCLs. ALK-positive ALCLs cluster separately from ALK-
negative and cutaneous ALCLs. A large number of genes was found to
be differentially expressed between cHL and ALK-positive ALCL. Sur-
prisingly, supervised comparison of cHL to ALK-negative ALCL showed
a low number of significantly differentially expressed genes, most of
which are expressed at higher level in cHL. Several of these genes are
NFκB target genes.
Discussion. Applying Laser microdissection and microarray techniques,
we show for the first time that even though cHL and ALK-negative
ALCL are derived from different precursor cells, these two lymphoma
entities resemble each other very much on expression level. Our data fur-
ther support the notion that ALK-positive ALCL is a lymphoma entity
distinct from other CD30-positive anaplastic large cell lymphomas. Fur-
ther detailed analysis might help to reveal common and different under-
lying molecular pathways and mechanisms contributing to pathogene-
sis in these lymphomas. New diagnostic or therapeutic markers might
be established from our data. 
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SERIAL ANALYSIS OF GENE EXPRESSION ON PRIMARY HODGKIN AND 
REED-STERNBERG CELLS
A. Gallagher,1 J. Kluiver,2 L. Andrew,1 A. Lake,1 A. van den Berg,2
S. Poppema,2 R.F. Jarrett1
1LRF Virus Centre, Institute of Comparative Medicine, University of Glasgow,
Glasgow, UK; 2Department of Pathology & Laboratory Medicine, University
Medical Center Groningen, University of Groningen, Groningen, The Nether-
lands
Introduction. A striking feature of classical Hodgkin lymphoma (cHL) is
the scarcity of the malignant cells, the Hodgkin and Reed-Sternberg
(HRS) cells which usually constitute less than 1% of the cells within the
tumour mass. The rarity of these cells has hindered the complete char-
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acterisation and our understanding of this disease. A number of studies
have attempted to determine the overall gene expression profile of HRS
cells, the majority of which have used cHL-derived cell lines or whole
cHL tissue. An advantage of using HL-derived cell lines for investigative
studies is that the material is abundant and readily available; however,
all of the cell lines have been derived from patients with end-stage dis-
ease and may not, therefore, be truly representative of primary HRS
cells. In addition, only the L1236 cell line has actually been shown to be
clonally related to original tumour material. The aim of this study was
to generate serial analysis of gene expression (SAGE) libraries from HRS
cells away from the reactive infiltrate of the tumour, in order to identi-
fy known or novel genes that are involved in the pathogenesis of cHL.
The primary aim was to determine differences in gene expression
between HRS cells and a normal counterpart for further investigative
analyses. 
Materials and Methods. SAGE libraries were generated from CD30-
positive cells enriched from an EBV-positive and EBV-negative case of
cHL. CD77-positive cells were enriched from a reactive lymph node for
use as a normal counterpart. SAGE tags were analysed and genes that
were up and down regulated in the cHL cases compared to the normal
control were considered for further analyses including quantitative PCR.
Results: A number of genes previously shown to be up-regulated in
HL had increased tag counts in the SAGE libraries, validating this
approach. Two genes chosen for further analysis were PKC eta and
Galectin 2 and relative quantitative PCR performed on the starting
cDNA samples confirmed their up-regulation. 
Conclusions. Preliminary data from our study suggest that PKC eta and
Galectin 2 mRNAs are up-regulated in HRS cells. Available information
on the encoded proteins suggest that they may play a role in the patho-
genesis of cHL. Further analyses on these SAGE libraries from sorted
HRS cells are required to maximise the potential of this valuable mate-
rial for the discovery of known or novel genes relevant to the pathogen-
esis of cHL.
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Introduction. In order to overcome some limitations of in vitro estab-
lished cell-line tumor models for Hodgkin lymphoma (HL), we explored
whether culturing in a three-dimensional (3D) matrix could improve the
quality of the model. 
Methods. We used a novel designer-peptide based self-organizing
matrix. The gene expression profile of the 3D-cultured HL derived cell-
line L1236 was compared to that of suspension-cultured (2D) L1236, as
well as to the gene expression profiles of 12 EBV negative HL tumor sam-
ples. To validate our results we also included a gene-expression data set
of laser captured Hodgkin Reed-Sternberg (H-RS) cells and laser cap-
tured non-malignant infiltrate from the same tumors. The gene expres-
sion profiles were analyzed using AffymetrixTM technology. 
Results. 3D culture affected the expression of 500 genes in L1236 by
up-regulating genes involved in immune response and apoptosis, and by
down-regulating genes involved in cell division. It also affected genes
involved in actin filament polymerization. We also found that the 3D
culture affected gene expression of the L1236 cell-line by inducing a
more tumor-related expression profile.
Discussion. Polarity is a tissue characteristic that is reintroduced to the
cell-lines grown in 3D culture. Thus 3D cultured cell-lines might have a
more tissue-like phenotype partly through the organization of the actin
filament. The 3D culturing increased the expression of several inflam-
matory proteins already reported to be expressed by the H-RS cell both
in vivo an in vitro, as well as their correlating receptors. Examples of
these were Il13, CCL3, CCL4, CCL17 and CCL22. These genes were
also expressed in the laser captured H-RS cells.
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JANUS KINASES ARE TARGETS OF TYRPHOSTIN AG17 AND HSP90-INHIBITOR 17-AAG IN
CLASSICAL HODGKIN LYMPHOMA
N. Schoof, F. von Bonin, L. Trümper, D. Kube
Universitätsmedizin der Georg-August-Universität Göttingen, Zentrum für
Innere Medizin, Abt. Hämatologie und Onkologie, Göttingen, Germany
Classical Hodgkin Lymphoma (cHL) is a malignancy originated of ger-
minal center (GC) B cells. Defective immunoglobulin rearrangement
should have destined these GC B cells for apoptosis. Chemotherapeu-
tic regimens for cHL are associated with stagnant rates of secondary
malignancies requiring the development of new therapeutic strategies.
Recently, we and others have shown that permanently activated Signal
Transducer and Activator of Transcription (STAT) molecules are essen-
tial for cHL cell proliferation and inhibitors of the tyrphostin-class are
capable of inhibiting STAT tyrosine phosphorylation. Here we focused
on the Janus kinases (Jaks), the major components involved in signal
transduction from cytokine receptors to STAT transcription factors. In
cHL cells we observed high levels of permanently tyrosine phosphory-
lated Jak1, Jak2, Jak3 and Tyk2. Tyrphostin AG17 reduced tyrosine phos-
phorylation of Jaks1-3 in cHL cell lines in vitro and decreased tumour for-
mation of L428 cHL cells in chorioallantoic membrane assay in vivo.
Since Jaks are known to be stabilised by heat shock protein 90 (HSP90)
and cHL cell proliferation is inhibited by HSP90-inhibitor 17-AAG, the
effects of 17-AAG on Jak-STAT signaling in cHL cells were investigat-
ed. 17-AAG led to a complete inhibition of STAT1, -3, -5 and -6 activa-
tion. Moreover, 17-AAG treatment was accompanied by significant
reduction of Jak protein expression. To further test the role of HSP90 in
Jak/STAT signaling in cHL cells RNA interference against HSP90 was per-
formed. Our results suggest that the effects of 17-AAG on cHL cell pro-
liferation are due to inhibition of Jak-STAT signaling. Therapeutics com-
prising inhibition of Jaks either by dephosphorylation or downregula-
tion, with tyrphostin AG17 and 17-AAG respectively, may be a prom-
ising strategy in cHL and other cancer entities associated with perma-
nent STAT activation.
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GENETIC IMBALANCES IN MICRODISSECTED HRS CELLS: PATTERNS OF ALTERATIONS
AND DIFFERENCES BETWEEN TREATMENT RESPONDERS AND FAILURES
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Introduction. Up-front clinical decision making in Hodgkin lymphoma
(HL) is still mainly based on clinical variables since the scarcity of the
malignant Hodgkin Reed Sternberg cells (HRS cells) hampered their
molecular characterization in the past. However, more recent investiga-
tions using laser capture microdissection (LCM) allowed a more detailed
analysis of these cells. 
Methods. 25 patients with classical HL who were primarily treated at
the BC Cancer Agency in Vancouver between 1989 and 2005 have been
included into the study. All patients received at least 4 cycles of poly-
chemotherapy and stage-dependent radiotherapy if indicated. Treat-
ment failure was defined as disease progression or relapse at any time
(n=11), treatment response as absence of progression (n=14). Whole
genome amplification (WGA) of pools from 500-1000 microdissected
HRS cells was performed and 200 ng of amplified DNA was hybridized
against sex-matched control-DNA using the 32k submegabase resolution
tiling array (SMRT). 
Results. On average WGA generated 500-fold amplification of genom-
ic DNA. When hybridizing amplified against unamplified reference
DNA, we found four telomeric regions (4p16.1 - tel, 4q35.2 - tel,
10q26.11 - tel, 20q13.31 - tel) that showed under-representation of the
respective regions. After excluding those regions from the analysis as
well as copy number polymorphisms, we identified copy number alter-
ations in every case (range 2-36, median 15). The most frequent gains
were +2p, +5p, +9p, +12q, +16p, +17q, +19p, +19q, +20q, and +21q, the
most frequent losses were -6q, -7q, -8p, -11q, -13q, and -Xq. Gains of
5p and 5q were significantly more frequent in treatment responders,
whereas gains of 16p were more frequent in treatment failures (Chi-
square analysis of intensity ratios: p<0.0001). Using unsupervised hier-
archical cluster analysis we found a strong correlation between the two
chromosomal imbalances +17q and +19q.
Discussion. The combination of laser capture microdissection with
subsequent WGA and high resolution array CGH provides a robust and
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sensitive platform for detecting chromosomal imbalances in microdis-
sected HRS cells. We identified new recurrent changes and specific alter-
ations that might play a role in the pathogenesis of HL. Furthermore, we
identified alterations that are significantly more or less frequent in
patients experiencing disease progression and therefore could serve as
predictive factors for treatment outcome.
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Introduction. Although valuable results have been obtained by gene
expression profiling of cHL cell lines, cultured HRS cells likely do not
reflect primary HRS cells in all aspects, being derived from anatomical
sites (e.g. pleural effusions, blood, bone marrow) which are not typical-
ly involved by cHL and where HRS cells lost their dependence on the
prominent inflammatory background of the lymph node.
Methods. ~1000-2000 HRS cells were laser-microdissected from H&E-
stained frozen sections of 16 cHL (10 EBV+, 6 EBV–), 30 peripheral B-cell
non-HLs (B-NHLs, of different types), and 5 lymphocyte-predominant
HL (LPHL) biopsies. Following two rounds of linear amplification, RNA
was hybridized to Affymetrix chips (HG-U133Plus2.0; ~54000 probe
sets). Expression profiles were similarly generated from comparable cell
numbers of FACS/MACS-sorted HL cell lines and normal B-cell subsets
of peripheral blood or palatine tonsil (plasma cells, naïve, memory and
germinal center B cells, as well as CD30+ B cells).
Results and Discussion. A supervised comparison between primary and
cultured HRS cells revealed a highly differential expression (≥4 fold) of
~1300 probe sets, including upregulation in primary HRS cells of sever-
al genes involved in interactions with the microenvironment such as
chemotaxis and extra-cellular matrix remodelling. On unsupervised hier-
archical analysis, cHL cases formed an own, tight cluster, showing on a
genome-wide basis that cHL represents a distinct patho-biological enti-
ty. This cluster is clearly distinct from B-NHLs (including primary medi-
astinal ones) and surprisingly closer to LPHL, a finding also confirmed by
supervised analyses. Supervised comparisons with the normal B-cell sub-
sets showed little similarity of primary HRS cells with germinal center
B or plasma cells and, interestingly, a more consistent relatedness (in a
large fraction of cHLs) with the transcriptional signature of CD30+ B
cells. Both unsupervised and supervised approaches revealed only few
genes with significantly different expression in EBV+ vs EBV- HRS cells,
suggesting that EBV infection, while likely important in the early phase
of cHL pathogenesis (e.g., by rescuing crippled germinal center B cells
from apoptosis), does not markedly imprint the fully established cHL
clone at the transcriptional level. Further analyses will be performed to
highlight genes and pathways that are specifically activated in primary
HRS cells and that could be of pathogenetic importance.
*Supported by a fellowship (F05/01) from the Deutsche José Carreras Leukämie-
Stiftung
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Previous studies showed that the HLA class I region is associated with
Epstein-Barr virus (EBV) positive Hodgkin lymphoma (HL) and that HLA-
A is the most likely candidate gene in this region. This suggests that anti-
genic presentation of EBV-derived peptides in the context of HLA-A is
involved in the pathogenesis of EBV-positive HL by precluding efficient
immune responses. We genotyped exons 2 and 3, encoding the peptide-
binding groove of HLA-A, for 32 single nucleotide polymorphisms in 70
EBV-positive and 31 EBV-negative HL patients and 59 controls. HLA-
A*01 was significantly overrepresented and HLA-A*02 was significant-
ly underrepresented in EBV-positive HL patients versus controls and EBV-
negative HL patients. In addition, HLA-A*02 status was determined by
immunohistochemistry or HLA-A*02 specific PCR on 154 EBV-positive
and 324 EBV-negative HL cases. The percentage of HLA-A*02 positive
patients in the EBV-positive HL group (35.2%) was significantly lower
than in 6107 general controls (53.0%) and the EBV-negative HL group
(51.2%). Our results indicate that individuals carrying the HLA-A*02
allele have a reduced risk of developing EBV-positive HL, while individ-
uals carrying the HLA-A*01 allele have an increased risk. It is known
that HLA-A*02 can present EBV-derived peptides and can evoke an effec-
tive immune response, which may explain the protective phenotype.
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A NOVEL T(4;9)(Q21;P24) FUSES SEC31A TO JAK2 IN NODULAR-SCLEROSIS HODGKIN
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Molecular mechanisms underlying the pathogenesis of classical Hodgkin
lymphoma (cHL) are poorly understood. Although no characteristic chro-
mosomal translocation has been identified in cHL, gain and amplification
of region 9p24 harbouring JAK2 is observed in up to 50% of cHLs. JAK2
encodes a protein tyrosine kinase (PTK) that plays a key role in the
JAK/STAT signalling pathway. Chromosomal translocations and gain-of-
function mutations involving JAK2 occur in several haematological malig-
nancies. We report here the molecular characterization of a t(4;9)(q21;p24)
identified in one case of NS-HL. The involvement of JAK2 was demonstrat-
ed by FISH with BAC clones flanking the gene. In order to identify the part-
ner gene, a BAC-walking interphase FISH strategy was used. Combining
a variety of 4q21 BACs labelled in red, with BACs covering the 3’ end of
JAK2 labelled in green, we narrowed down the breakpoint to a 450 kb
region harbouring three candidate partner genes: SEC31A, LIN54 and
PLAC8. Finally, interphase FISH with fosmid probes flanking the three
genes mapped the 4q21 breakpoint to the region of SEC31A, a gene which
is ubiquitously expressed in human cells and is known to play a role in ER-
to-Golgi vesicular transport. Molecular studies of the tumor sample led to
the identification of a SEC31A-JAK2 in-frame fusion transcript in which
exon 24 of SEC31A is fused to exon 17 of JAK2. A SEC31A-ALK fusion with
similar SEC31A breakpoint has been reported in one case of inflammato-
ry myofibroblastic tumor. The SEC31A-JAK2 fusion protein is likely to
function as a constitutively activated tyrosine kinase, due to SEC31A-medi-
ated oligomerization of JAK2. The transforming capacity of this fusion pro-
tein will be studied in IL3-dependent Ba/F3 cells. To determine the incidence
of the t(4;9) in cHL, we are screening large series of HL cases using both
FISH and cDNA-based nested PCR. In summary, we identified and mole-
cularly characterized the first JAK2-associated translocation in cHL.
Although aberrant expression of various PTKs including JAK2 has already
been documented in cHL on both RNA and protein level, our finding indi-
cates that at least in some cHL cases, chromosomal translocations may
underlie this event. Our finding also suggests that JAK2 could be a thera-
peutic target in NS-HL for small molecule inhibitors.
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THE MICRO-RNA EXPRESSION PROFILE IN HODGKIN LYMPHOMA
L. Ping Tan, G. Harms, T. Blokzijl, J. Gibcus, S. Poppema, 
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Introduction. Classical Hodgkin lymphoma (cHL) and nodular lymphocyte
predominant Hodgkin lymphoma (NLPHL) differs not only in the form of
histology and reactive background but also in the phenotypes of the tumor
cells. Although tumor cells from both HL subtypes are originated from the
germinal center B cell (CB), gene expression studies show that lymphocyt-
ic and histiocytic (L&H) cells from NLPHL resembles normal B cell while
Hodgkin/Reed-Sternberg cells (H/RS) from cHL demonstrate a loss of B
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cell phenotype and have significant overlap with primary mediastinal B cell
lymphoma (PMBL). Recently, a new class of small RNAs, namely the
micro-RNAs (miRNAs), has been identified. As miRNAs play important
roles in many cellular processes, it is proposed that there is a possible link
between aberrant miRNAs expressions and loss of B cell phenotype in HL. 
Methods. In this study, miRNA profiles from cell lines of various B cell
lymphoma subtypes were examined by qRT-PCR and some of the miR-
NAs are chosen for in situ hybridization (ISH). 
Results. From the miRNA profiling data, cHL cell lines cluster well with
PMBL while DEV, an NLPHL cell line, clusters together with CB. Upon val-
idation of differentially expressed miRNAs on cell line panel by monoplex
qRT-PCR, 8 miRNAs are identified as significantly differentially expressed
between cHL and EBV transformed centroblast while 6 miRNAs are sig-
nificantly differentially expressed between cHL and PMBL. Also, 18 miR-
NAs are found to be highly expressed in Hodgkin lymphoma cell lines and
some of them are confirmed by miRNA ISH on HL tissue samples. 
Conclusions. Several miRNAs that are expressed specifically in Hodgkin
lymphoma have been identified. However, the effect of the aberrant
expressions of these miRNAs in HL is yet to be elucidated, as the targets
of these miRNAs remain unknown.
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The Epstein-Barr virus (EBV) has been implicated as a contributing fac-
tor in the development of Hodgkin's disease (HD). The presence of EBV
varied according to the histological subtype, age of presentation and
geographic location. Mixed cellularity HD is more likely to be EBV-pos-
itive compared with nodular sclerosis. The purpose of our study is to
analyse the prevalence of EBV in this disease in a Moroccan population
using immunohistochemical detection of latent membrane protein LMP-
1. We studied a total of 234 cases of classical Hodgkin's disease. The dis-
tribution of histopathologic subtypes shows a predominance of Nodu-
lar sclerosis subtype 63% versus 23% of Mixed cellularity. Epstein Barr
virus was seen in 53% of our cases: 42 (75%) of the 56 mixed cellulari-
ty and 74 (48%) of 155 nodular sclerosis HD. None of our 10 lympho-
cyte predominant HD cases showed evidence of EBV. Epstein-Barr virus
was seen in 82% of HD cases in children below 15 years of age as
opposed to 42% of the young adult group. The results of the current
study showed that nodular sclerosis HD is more frequent (63%) than
mixed cellularity in Morocco. The findings suggest also, a strong asso-
ciation of EBV with Hodgkin's disease in Moroccans (53%), especially
in children when it reach 82%. This study shows a predominant asso-
ciation of EBV in mixed cellularity HD (75% MC versus 48% NS). Our
results need to be confirmed by in situ hybridization. 
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EPSTEIN-BARR VIRUS INFECTION
L. Jabri,1 A. Belbachir,1 A. Benkirane, M. Quachouh,2 A. Quessar,2
A. Madani,2 S. Zamiati1
1Pathology Department; 2Hematology department, Ibn Rochd University Hospi-
tal, Casablanca, Morocco
Background. The epidemiological data of Hodgkin Lymphoma shows
a predominance of Mixed cellularity in developing countries as well as
the high incidence in children in this countries Epstein-Barr virus (EBV)
has been associated with many hematopoietic malignancies including
Hodgkin's disease (HD). The association of HD correlates with the his-
tologic subtype, age of presentation and geographic location. This asso-
ciation is higher in developing countries compared with developed ones.
Objectives. the aim of this study is to determine the epidemiological
and histopathological profil of Moroccan Hodgkin Lymphoma and to
evaluate the incidence of EBV in this population. 
Methods. We evaluated the clinical and morphological data of 324
patients diagnosed between January 2000 et December 2005. Immuno-
histochemical features were available for 278 patients and 234 were
analyzed for Epstein-Barr virus (EBV) using latent membrane protein
(LMP1). 
Results. There were 53% males and 47% females, with a mean age of
32 years. Th peak of incidence was seen in the 15-39 years age group
(53%). 16% of the cases were seen in children under fifteen. Nodular
sclerosis was the most prevalent subtype (60% versus 24% for mixed
cellularity. Expression of CD30 was detected in 255 of 278 cases (92%),
CD15 was positive in 228of 278 (82%), Bcl2 was detected in 55% .
LMP1 was seen in 124 of 234 cases (53%): 74 of 155 (48%) with nodu-
lar sclerosis; 42 of 56 (75%) with mixed cellularity. There no difference
in LMP1 positivity between localised clinical stages and advanced clin-
ical stages. LMP1 positivity was higher in children and older adults than
in adults aged between 15-50 years. 
Conclusions. HD in Morocco showed a high incidence of nodular scle-
rosis subtype and a high prevalence of EBV. EBV detection showed cor-
relation with mixed cellularity subtype and age under Fifteen. LMP1
was more frequently seen in children and older adults, suggesting a dif-
ferent pathophysiology of HD among different age groups.
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Introduction. Age-related Epstein-Barr virus (EBV)-associated B-cell lym-
phoproliferative disorders (EBV+LPDs) are a disease group character-
ized by EBV-associated large B-cell lymphoma in elderly adults without
predisposing immunodeficiency. This disease group occurs as a mor-
phologically polymorphous subtype in nearly one-third of cases, which
show a small portion of EBV+ large cells in a background of extensive cel-
lular infiltration, a feature similar to that of classical Hodgkin lymphoma
(CHL). The aim of this study was to clarify the clinicopathological dif-
ferences between the polymorphic subtype of age-related LPDs and
EBV+CHL of middle and advanced age. 
Methods. Thirty-four patients with age-related EBV+LPDs and 108
with EBV+CHL aged 45 or older were enrolled. Paraffin-embeded tis-
sue blocks were available for all patients. Immunohistochemical assess-
ment was done as follows: CD3, UCHL-1/CD45RO, L26/CD20, Ber-
H2/CD30, LMP-1, EBNA2, LeuM1/CD15, TIA-1, and granzyme B. The
presence of EBV small ribonucleic acids was examined by in situ
hybridization using EBER oligonucleotides. The two groups were clin-
icopathologically compared with differences examined by the chi-
squared test and Mann-Whitney U test as appropriate. Patient survival
data were analyzed with the Kaplan-Meier method. 
Figure. Disease specific survival.
Results. Age-related EBV+LPDs were more closely associated with
aggressive clinical parameters than CHL: a higher age at onset (71 vs. 63
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years, p=0.0006), lower male predominance (male:female ratio, 20:14
vs.83:25, p=0.04), and a higher ratio of involvement of the skin (18% vs.
2%, p=0.002), gastrointestinal tract (15% vs. 4%, p=0.052) and lung (12%
vs. 2%, p=0.028). In pathologic comparison with CHL, this polymor-
phous subtype of age-related EBV+LPDs was further characterized by a
higher rate of geographical necrosis, a greater increase in background
cytotoxic cells, a higher positivity for CD20 and EBNA2, and an absence
of CD15 expression.As predicted by the clinical profile, patients with
age-related LPDs also had a significantly poorer prognosis than those
with EBV+CHL (p=0.0001). 
Conclusions. Age-related LPDs and CHL may pose a diagnostic and
therapeutic challenge to pathologists and hematologists, respectively.
This analysis clearly documented that the polymorphous subtype of the
former disease constitutes an aggressive group distinct from EBV+CHL.
Innovative therapeutic strategies for the treatment of aggressive age-
related EBV+ LPDs should be developed.
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CHOLESTASIS AS THE FIRST MANIFESTATION OF HODGKIN’S LYMPHOMA
Z. Vernerova, V. Eis, J. Polivka, J. Markova
Dep. of Pathology and Dep. of Clinical Haemathology, 3rd Faculty of Medicine,
Charles University, Prague, Czech Republic
Introduction. Hepatic involvement is quite frequent among patients with
advanced Hodgkin’s lymphoma (HL). However, only 3-13% of them pre-
sented clinically with jaundice. A cholestatic syndrome in HL can usual-
ly be attributed to infiltration of the liver, extrahepatic compression of bil-
iary tract by lymphoma or both. Nevertheless, about 25% of jaundiced
HL patients have no histological sings of liver involvement or extrahep-
atic obstruction. Possible mechanisms of such intrahepatic cholestasis
include a paraneoplastic effect and a vanishing bile duct syndrome.
Methods. A group of 325 patients with established diagnosis of
Hodgkin lymphoma referred to our hospital from 1995 to the end of May
2007 were reviewed and encountered in this study.
Results. 122/325 HL patients (37%) manifested with extranodal
involvement, but only 6 of them presented concomitantly with hepatic
involovement at the time of diagnosis (6/122). Laboratory investigations
showed (progressive) cholestasis. Liver biopsy was carried out in all
these patients. The leading cause of cholestasis was hepatic involvement
by lymphoma infiltration (4/6) in one case complicated by haemophago-
cytic syndrome. One patient developed vanishing bile duct syndrome
and the other intrahepatic cholestasis without vanishing bile duct syn-
drome 6 month prior to diagnosis of HL. All patients had neither previ-
ous history of alcohol or drug abuse nor liver disease. The link of liver
involvement to any histological subtype could not be estimated due to
small number of patients, however most frequent in our group was
mixed cellularity HL (5/6), followed by nodular sclerosis type (1/6). All
patients died within several weeks after the diagnosis, only one (HL
with hepatic involvement and haemophagocytic syndrome) has been
survived. 
Discussion. Several explanations have been proposed for the associa-
tion between HL and vanishing bile duct syndrome and idiopatic
cholestasis with the most likely one being the release of toxic cytokines
from lymphoma cells. These could cause hepatocyte or bile duct dam-
age ether directly or result in recruitment of effector cells leading to bile
duct destruction.
This work was supported by scientific program Oncology Nr. MSM
0021620808 by Ministry of Education of The Czech Republic
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DETECTION OF PROTEIN PATTERNS IN PLASMA WITH MASS SPECTROMETRY METHODS
FOR THE DIAGNOSIS OF HODGKIN LYMPHOMA
N. von Neuhoff,1 T. Oumeraci,1 M. Elsner,1 M. Kostrzewa,3 V. Diehl,2
B. Schlegelberger,1 D. Re2
1 Cell and Molecular Pathology Department, Medical School Hannover, Ger-
many; 2Department of Internal Medicine I, University of Cologne, Cologne, Ger-
many; 3Bruker Daltonik GmbH, Leipzig, Germany
Introductio. Proteomic profiling of body fluids is a promising novel tool
for early disease detection and therapy monitoring. It may allow early
diagnosis of disease, help to minimize the number of invasive medical
inspections (e.g. biopsies), and enable better risk and response adapted
therapeutic approaches. The present study describes the analysis of plas-
ma proteins by matrix assisted laser desorption/ionization-time of flight-
mass spectrometry (MALDI-TOF-MS). We show, that early and
advanced stage disease can be distinguished in HL patients by compar-
ing MALDI-TOF proteomic profiles created with the ClinProt system.
Methods. In a pilot study, pretherapeutic samples from 34 HL patients
treated within the 5th generation phase III trials of the German Hodgkin
Study Group were fractionated using magnetic beads. EDTA plasma
samples were processed with different surface functionalities (e.g.
hydrophobic interaction, cationic exchange and anionic exchange) to
enrich and purify different protein/peptide subclasses. Proteomic profiles
were acquired in a microflex MALDI-TOF mass spectrometer. To ensure
reproducibility, each purified sample was processed and spotted fourfold
onto the MALDI-target. For spectra acquisition, 500 single shots were
accumulated from each of the corresponding target positions. The
acquired patterns were analyzed using the ClinProTools 2.1 software to
discriminate both data sets and discover discriminating biomarker can-
didates. Data sets obtained with different bead functionalities were ana-
lyzed separately. Depending on the sample and magnetic bead function-
ality up to 150 peaks with high intensities could be detected in the mass
range from 1kDa to 10 kDa.
Results. Using these peak patterns, the best mathematical models
achieved a nearly complete segregation of early stage and advanced stage
HL patients. Discriminatory patterns could be identified for all applied
magnetic bead functionalities. Comparative analysis of the replicate
spectra of one sample from different spots showed a high reproducibil-
ity of the obtained data. The best classification was achieved after cation-
ic exchange fractionation of the samples. Biomarker patterns with the
corresponding biomarker candidates could be unambiguously visual-
ized. Nine masses were detected which discriminate both stages (recog-
nition capability overall 100%; cross validation 85%). Further work in
progress will help to identify the respective peptides and proteins detect-
ed specifically within the two identified signatures.
Discussion. Based on the Clinprot Bead technology, this study demon-
strates the presence of possibly novel biomarkers in the pretherapeutic
plasma of HL patients, which may be used both for initial diagnosis and
for therapeutic monitoring to allow application of more individualized
risk and response adapted therapeutic protocols.
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SOMATIC HYPERMUTATION OF SOCS1 IN LYMPHOCYTE-PREDOMINANT HODGKIN 
LYMPHOMA IS ACCOMPANIED BY HIGH JAK2 EXPRESSION AND ACTIVATION OF STAT6
A. Mottok, C. Renné, K. Willenbrock, M.L. Hansmann, A. Bräuninger
Senckenberg Institute of Pathology, University of Frankfurt, Frankfurt, Germany
Introduction. Hodgkin lymphoma (HL) is distinguished into the classi-
cal (c) and nodular lymphocyte-predominant (lp) forms. While the der-
ivation of the lymphocytic and histiocytic (L&H) tumor cells of lpHL
from germinal center (GC) B cells is well established, knowledge about
their pathogenesis is limited. JAK/STAT signaling pathways are consti-
tutively activated in several hematological malignancies. In a survey of
JAK2 expression in lymphomas we observed high JAK2 expression in
lpHL and analysed the causes and consequences of the high JAK2 expres-
sion in L&H cells.
Methods. Immunohistochemistry (IHC) was performed for JAK2, p-
Stat 3, p-Stat 5 and 6. For the analysis of SOCS1-mutations single CD20-
positive L&H cells from 12 cases of lpHL were micromanipulated and
then the complete coding region of SOCS1 (a single exon of 633 bp) was
amplified in 3 overlapping fragments and exon 12 of JAK2 as a single PCR
product from genomic DNA of single cells and negative controls in semi-
nested two round PCRs. All PCR products were directly sequenced.
Results. IHC revealed high JAK2 expression in the vast majority of
L&H cells in most lpHL cases (40/47 cases, 85%). While no activation of
STAT3 and STAT5 was observed, STAT6 was phosphorylated in 49%
of cases (21/43, 20 of the 21 p-STAT6 positive cases showed high JAK2
expression). Mutations of the SOCS1-gene were found in 6 of 12 cases.
In 3 cases inactivating mutations were observed and presence of sever-
al replacement mutations in functionally important regions in the 3 oth-
er cases suggest that SOCS1 function was also impaired in these cases.
Activating mutations in exon 12 of JAK2, which are frequent in myelo-
proliferative diseases, were not observed.
Discussion. In all cases with somatic mutations intraclonal diversity of
individual SOCS1 alleles with stepwise accumulation of mutations was
observed. These data suggest that in L&H cells SOCS1 function is
impaired by mutations which are in most cases likely due to activity of
somatic hypermutation (SHM). (hotspots of SHM (RGYW) were 4.5
times more frequently affected than expected). SOCS1 inactivation leads
to constitutive activation of the JAK2/p-STAT6 pathway in most lpHL
cases. 
46 | haematologica/the hematology journal | 2007; 92(s5)
7th International Symposium on Hodgkin Lymphoma, 3-7 November 2007 – Cologne, Germany
P043
PROGNOSTIC FACTORS IN PEDIATRIC HODGKIN LYMPHOMA: IS THERE A ROLE FOR
HISTOPATHOLOGY AND CLINICAL CHARACTERISTICS IN THE MOLECULAR ERA?
M.H.M. Barros, D.M. Guiretti, I. Zalcberg Renault, R. Hassan
Molecular Biology Laboratory, Bone Marrow Transplantation Centre (CEMO),
Instituto Nacional de Cancer (INCA), Rio de Janeiro, Brazil
Identification of prognostic factors in pediatric Hodgkin lymphoma
(HL) is relevant for tailoring therapy for the 20-30% of patients that will
ultimately relapse. Most prognostic systems used to date, including the
international prognostic score (IPS) fails to identify a proportion of those
cases. The objective of this study was to evaluate if morphologic vari-
ables and number of involved anatomic sites could be used as prognos-
tic factors in pediatric HL. A retrospective study was realized in a group
of 56 pediatric patients (5-18 years, yr, median age 14yr) treated with
anthracycline-based regimens. Ann Arbor stage and risk group (RG),
low RG (I, IIA, IIIA) and high RG (IIB, IIIB, IV) were determined. CD15,
CD30, CD20 and Ki-67 were study by immunohistochemistry (IHC).
High proliferative index (PI) was defined when >51% of Hodgkin and
Reed-Sternberg (H-RS) cells expressed Ki-67. EBV association was deter-
mined by EBER-ISH and IHC for LMP1 protein. Morphologic variables
were: histologic subtype, nodular sclerosing (NS) grading, degree of
interfollicular involvement, number of neoplastic cells, eosinophils and
mitosis (all of them at 10 high power fields, hpf). The univariate analy-
sis showed poor disease-free survival (DFS) for patients with >5 involved
anatomic sites (p=0.03), NS grade I (p=0.002), <40 H-RS cells at 10 hpf
in the cases of high RG (p=0.004) and low PI in the cases of high RG
(p=0.05). Stage, RG disease stratification (high risk vs. low risk), CD20
positivity, CD15 negativity, EBV status, LMP1 positivity and other mor-
phologic variables did not show prognostic impact. In the multivariate
analyses, only the number of involved anatomic sites had prognostic
impact for DSF (p=0.03, CI95% 0.007-0.08), while low number of H-RS
cells showed a trend for poor DFS (p=0.08). The prognostic value of H-
RS cell number deserves more investigation in childhood HL, since an
inverse relationship was determined between this variable and the high
PI in the studied group. The number of involved anatomic sites may be
a more accurate indicator of total tumor burden than stage, in the pedi-
atric setting. Our results pointed to the feasibility of refining clinical-
pathological prognostic factors applied to pediatric HL.
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TISSUE MICROARRAY TECHNOLOGY IN THE STUDY OF CELLULAR ANTIGEN EXPRESSION
AND EPSTEIN-BARR VIRUS ASSOCIATION OF HODGKIN LYMPHOMA
M.H.M. Barros,1 D.M. Guiretti,1 P.A. Chabay,2 M.V. Preciado,2
E. De Matteo,2 I. Zalcberg,1 R. Hassan1
1Molecular Biology Laboratory, Bone Marrow Transplantation Centre (CEMO),
INCA, Rio de Janeiro, Brazil; 2Molecular Biology Laboratory, Pathology Service,
Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina
The tissue microarray technology (TMA) allows the simultaneous
study of many tissues and it is increasingly applied in cancer research.
Hodgkin lymphoma (HL) is characterized by a low number of neoplas-
tic cells, raising the question if TMA methodology can warrant a suffi-
cient tumor representation for pathology studies. The objective of this
study was to validate TMA for studies of cellular antigen expression
and Epstein-Barr virus (EBV) association in HL. A TMA was construct-
ed using a tissue arrayer (Beecher Instruments) including 56 pediatric HL
diagnostic tumors, with 2 representative cores (1 mm diameter) of each
sample. The phenotype was evaluated by CD30 and CD15 immunos-
taining. EBV association was determined by EBER-ISH and expression
of EBV latent membrane protein LMP1 and LMP2A by immunohisto-
chemistry (IHC). CD30, LMP1 and EBER-ISH detection was also per-
formed in conventional slides, showing expression in 89%, 48% and
37% of the cases, respectively. Concordance between conventional and
TMA detection was 100%. Analysis of LMP2A was performed in 51 cas-
es; 12 cases showed membrane or para-nuclear (dot) immunostaining. All
LMP2A+ cases showed also LMP1 expression, while 10 were LMP2A-
negative/LMP1+. Core duplication allowed to improve the number of
available cases for CD30 (from 51 to 55 cases, p<0.001), LMP1 (43 to 54
cases, p=0.001) and EBER-ISH (43 to 56 cases, p=0.07). This study
showed that TMA is a reliable method to investigate cellular and viral
expression in HL. Core duplication is an important strategy to improve
TMA efficacy. Additionally, this study of LMP2A protein expression in
51 cases of pediatric HL showed low and discordant detection rates,
regarding EBER-ISH and LMP1, pointing to the need to further investi-
gate biological heterogeneity, as well as improving detection techniques.
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THE CORRELATION BETWEEN THE IMMUNOSTAINS FOR P53, KI67, PRB, BCL-6,
EBV-LMP EXPRESSION AND CLASSICAL PROGNOSTIC FACTORS IN 
HODGKIN LYMPHOMA
D. Antic, D. Tomin, V. Cemerikic, D. Boskovic
Institute of hematology, Clinical Centar of Serbia, Belgrade, Serbia
Background. Hodgkin's lymphoma (HL) is a curable malignanat lym-
phoproliferative disease in approximatly 80% of patients. Although
most patients are cured, there are groups of patients who fails primary
therapy and may die as a result of resistant disease. Detection of prog-
nostic factors and the adaptation of treatments to individual risk is one
of the primary aims of investigation in this disease. Age, stage, and oth-
er basic clinical and laboratory parameters, which comprise the Interna-
tional Prognostic Score (IPS), are used at diagnosis to predict survival.
Currently, there is no agreement on biologic markers that add value to
these parameters.
Aims. This study was performed to evaluate the clinical significance
of the expression of p53, Ki67, EBV-LMP, bcl-6 and pRb in Hodgkin and
Reed - Sternberg cells of patients with Hodgkin's lymphoma and to
identify any relation between these markers and several clasical prog-
nostic factors 
Methods. We evaluated 40 patients with a confirmed Hodgkin's lym-
phoma treated in a single institution for expression of p53, Ki67, EBV-
LMP, bcl-6 and pRb by immunohistochemistry and correlated the results
with overall survival, failure free survival (FFS), response to therapy, clin-
ical and laboratory parameters and IPS. HIV-positive patients were
excluded. The expression of these proteins was analised in pre-treat-
ment lymph-node biopsy specimens. Patients treated with ABVD or
BEACOPP chemotherapeutic regimens regarding to stage of disease. 
Results. The follow-up of the 40 patients was 36 monts. The median
age was 30.2 years (15-68), 40% were women, and 62.5% had
advanced-stage disease (III-IV CS). Half of patients were classified
according to the IPS in low-risk group. Complete remision after first line
chemotherapy was confirmed in 80% patients. Overall survival in this
series of patients was 29.7 months. Mean value of expression of p53,
Ki67, pRb, bcl-6 respectively was 2.9%, 34%, 8%, 21,8% and EBV-LMP
positivity was detected in 75% patients. Expression of oncogenes did not
significantly corelated with response to therapy and adverse events.
Only expression of pRb influenced to overall survival: patients with pRb
expression ≤20% had longer overall survival (29.8 month vs. 18.4
months, p=0.03). Patients with IPS <3 had significantly longer survival
too, 32.2 months vs 21.8 months. Also, patients with high IPS score had
significantly high expression of Ki67 and low expression of pRb. Medi-
astinal involvment significantly corelated with high expression of p53 i
low expression of pRb at same time. 
Conclusions. The expression of p53, Ki67, EBV-LMP, bcl-6 was not
associated with the response to therapy, FFS or OS. Expression of pRb
in HL is prognostic marker according to overall survival and can be used
in association with IPS to identify newly diagnosed patients with a good,
intermediate, or poor prognosis. 
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PREVENTION OF OVARIAN DAMAGE DURING CHEMOTHERAPY BY GONADOLIBERINE
ANALOGUES ADMINISTRATION
L. Smardova,1 M. Huser,2 Z. Kral,1 I. Crha,2 A. Simordova,1
J. Vorlicek1
University Hospital of Brno; 1Department of Internal Medicine and Hematoon-
cology; 2Department of Obstetrics and Gynecology, Czech Republic
Introduction. Frequent negative consequence of chemotherapy (CT) is
ovarian damage and premature ovarian failure (POF). The risk of POF
onset depends mainly on women’s age and foliculogenesis status, CT
regimen used and cumulative dose of single cytotoxic agents. Aim of this
prospective case-control study is evaluation of gonadoliberine analogues
(GnRH-a) administration to patients with Hodgkin’s lymphoma (HL)
during CT and prevention of ovarian damage depending upon CT dose
and regimen.
Methods. Study group consists of 72 pts in fertile age (28.4±4.1y) with
HL diagnosis treated in 2004-05 by curative CT together with GnRH-a
administration according standardized protocol. Pts were divided to 3
groups according clinical stage of disease and risk factors and treated by
three types of CT regimens with increased cytotoxicity (GHSG proto-
cols): group A - ABVD, group B - baseline BEACOPP and ABVD, group
C - escalated BEACOPP. Ovarian function of all pts was assessed by
gonadotrophins levels (FSH, LH) analysis from peripheral blood before
treatment and also 6 and 12 month after it. Number of women with POF
after CT in study groups was compared with control group (n=45, age
26.8±4.6y) of pts treated in 2002-03 according the same protocol, but
without protective GnRH-a application. In statistical evaluation two
sample binomial test with α=0.05 was adopted together with adjust-
ment of level of statistical significance by Bonferroni correction for mul-
tiple tests.
Results. In study group with GnRH-a administration during CT there
was statistical significantly (p<0.001) less cases with POF (38.2%) in 6
month after end of CT than in control group (73.4%). After 12 month
POF was detected in 48.8% of cases versus 69.3% in control group
(p<0.001). Comparative analysis depending on cytotoxicity of CT regi-
men used showed statistically significant differences in percentage of pts
with acquired POF between study and control group only in less aggres-
sive CT protocols (group A and B). Difference in number of cases with
POF in pts treated with CT regimen C was not statistically significant
(74.1% vs. 63.5%) in both observation periods.
Discussion. Study proved significant reduction of ovarian failure risk in
women with HL treated with less aggressive CT regimens. Reproduc-
tive functions protection in fertile women requires early and close coop-
eration between oncology department and assisted reproduction center.
Suppurted by Int. Grant Agency, Ministry of Health, No. NR8469-3.
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SPERM QUALITY BEFORE TREATMENT IN PATIENTS WITH EARLY STAGE HODGKIN'S
LYMPHOMA (HL) IN EORTC TRIALS
M.A.E. van der Kaaij, N. Heutte, J.M.M. Raemaekers, 
J. van Echten-Arends, P. Carde, E.M. Noordijk, C. Ferme, 
J. Thomas, H. Eghbali, M. Henry-Amar, J.C. Kluin-Nelemans
Haematology and Gynaecology, UMC Groningen, The Netherlands; GRE-
CAN and Clinical Research Unit, CFB, Caen; France, Haematology, UMC
Nijmegen, The Netherlands; Medical Oncology, IGR, Villejuif, France; Radio-
therapy, Leiden UMC, The Netherlands; Oncology, UZ Gasthuisberg, Leu-
ven, Belgium; and Haematology, Inst Bergonie, Bordeaux, France
Introduction. We investigated the quality of sperm and factors influenc-
ing sperm quality in a large cohort of patients with early stage disease
who delivered a sperm sample before start of treatment as part of a
gonadal toxicity study. 
Methods. Of 2410 males who participated in EORTC H6-H9 trials,
474 (20%) had data available. Median age was 26 years (range 15-57).
Sperm was considered of good quality if concentration of spermatozoa
was ≥20×106/mL and motility ≥50%; samples with concentration
<5×106/mL were considered of poor quality; all others were classified as
intermediate sperm quality. Azoospermia was defined as the complete
absence of spermatozoa in the ejaculate. Definitions and limits used are
in agreement with WHO guidelines. The contribution of clinical and
laboratory parameters to sperm quality was studied by logistic regres-
sion analysis.
Results. Median sperm concentration was 40×106/mL (range 0-345).
Median motility was 50% (range 0-90). Good sperm quality was
observed in 41% of patients whereas 3.4% were azoospermic. No rela-
tion was found between sperm quality, age, stage or ESR, but B symp-
toms contributed negatively (see Table). 
Table.
Sperm quality Good Intermediate Poor Azoöspermia# Total p
N (%) 195 (41%) 233 (49%) 46 (10%) 16 (3.4%) 474 value
Median age, yrs 27 26 26 25 26 0.518
(range) (15-51) (15-57) (15-45) (16-40) (15-57)
Clinical stage II (%) 133 (69) 162 (70) 36 (80) 12 (86) 331 (70) 0.316
B-symptoms (%) 46 (24) 75 (32) 24 (52) 9 (56) 145 (31) 0.001
Fever (%) 8 (4) 23 (10) 9 (20) 3 (19) 40 (8) 0.002
Median ESR*, mm/hr 17 25 30 26 21 0.005
ESR ≥50 mm/hr (%) 36 (19) 56 (24) 18 (39) 7 (44) 110 (24) 0.016
* ESR = erythrocyte sedimentation rate; #for statistics, azoöspermia was grouped within the category poor.
With logistic regression, the odds ratio (OR) associated with the pres-
ence of B-symptoms without fever was 2.33 (95% CI, 1.16-4.67;
p=0.018); that of B-symptoms and fever was 4.05 (95% CI, 1.72-9.56;
p=0.001), both predicting for poor sperm quality.
Discussion. Forty percent of patients with early stage HL have good
sperm at disease presentation. Median concentration and motility from
this population are in line with data from a normal (non-selected) pop-
ulation study (Denmark, Andersen, 2000). However, the percentage
azoospermic patients (3.4%) is elevated when compared to normal men.
The data confirm that sperm quality highly depends on the presence or
absence of B-symptoms (in particular fever), which might in part be
related to the familiar negative effect of elevated scrotal temperature on
spermatogenesis. Nowadays, IVF and ICSI are excellent options for all
qualities of sperm, even the very poor. Only azoospermia excludes cry-
opreservation. In conclusion, in most HL stage I-II patients, sperm qual-
ity before treatment is not a problematic issue and cryopreservation
should be encouraged.
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BREAST CANCER AFTER RADIOTHERAPY (RT) FOR HODGKIN LYMPHOMA (HL): 
IMPLEMENTATION AND RESULTS OF THE UK RISK ASSESSMENT AND SCREENING 
PROGRAMME IN A LARGE REGIONAL CENTRE
S.J. Howell, V. Goode, T. Gardener, R.A. Cowan, M.A. Harris, 
P. Hopwood, J. Ogden, R. Swindell, J. Kennedy, P. Chatterjee, 
A. Norman, A. Howell, J.A. Radford
Christie Hospital NHS Foundation Trust and University of Manchester, Man-
chester, UK
Introduction. Young women with HL treated with RT involving breast
tissue are at increased risk of breast cancer. In the UK a national patient
notification, assessment and screening exercise was undertaken in
November 2003. We report on the implementation and results at a large
regional cancer centre.
Methods. Women aged≤35 years when treated for HL between 1962-
2003 were identified using hospital and registry databases. Those who
had received supradiaphragmatic RT were invited to a clinic for risk
assessment and counselling. A telephone helpline was set up to aid the
recall of appropriate patients and deal with urgent concerns. Women
were referred to one of five local screening centres if >25 yrs old and >8
yrs since treatment for: annual breast MRI if 25-30 yrs; annual mammo-
gram (MG) if >30 yrs and 3-yearly MG on the National Health Service
Breast Screening Programme (NHSBSP) if ≥50 yrs. Further investigations
were arranged according to local screening protocols and reports from
all investigations were collated centrally.
Results. 287/405 (70%) women replied to the letter and 13 extra cas-
es were identified from helpline calls. 24/300 (8%) women declined
review and of the 276 that expressed initial interest in risk assessment
240 women were subsequently assessed. 44 women were already being
screened as part of the NHSBSP and 45 had screening deferred accord-
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ing to the protocol. 49 women had relocated and were referred to their
local cancer Networks. 102 women required annual screening locally
and so far have been screened a total of 213 times. 83% of MGs were
reported as normal with no further action taken. 9% of women with
mammographically normal dense breasts had normal ultrasound (4%)
or MRI scans (5%). 18 (8.5%) MGs were reported as abnormal although
15 of these cases were reclassified as normal following further imaging
alone. Three patients had FNA (1) or core biopsy (2) one of which con-
firmed a prevalence case of invasive breast cancer. In addition 10 breast
cancers and one breast sarcoma have been identified by history (3% of
cohort).
Conclusions. The feasibility of such an exercise has been demonstrat-
ed; response rates and levels of interest were relatively high and the
helpline was a valuable tool. The biopsy and false positive screen rates
are comparable to those in the NHSBSP but collation of the national
results is required to make accurate assessments of the validity of the
screening protocol in this population.
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THE INCIDENCE OF SECONDARY LEUKEMIA/MYELODYSPLASIA IN HODGKIN 
LYMPHOMA HAS DECREASED SUBSTANTIALLY OVER THREE DIFFERENT GENERATIONS
OF THERAPY REDUCING OR ABOLISHING MECHLORETAMINE AND PROCARBAZINE AND
LIMITING RADIOTHERAPY DOSES AND VOLUMES
E. Brusamolino
Clinica Ematologica, Fondazione Policlinico San Matteo IRCCS, University of
Pavia, Pavia, Italy
Introduction. Patients with Hodgkin lymphoma treated with alkylating
agents with and without radiotherapy have shown a long-term risk of
therapy-related myelodysplasia and leukemia (MDS/ANLL). To improve
on efficacy and to minimize the leukemogenic risk, we have modified
over time our therapeutic approach in Hodgkin lymphoma reducing and
eventually abolishing mechloretamine, and procarbazine and limiting
doses and volumes of radiotherapy. This study analyses the long-term
effect of this policy on the risk of secondary MDS/ANLL in different
cohorts of patients according to the era and type of treatment. Methods.
The first cohort (A) includes 202 patients treated from 1972 to 1983
(median FU: 20 yrs) with MOPP ± RT; 46% of patients received MOPP
alone for advanced disease, 37% MOPP and extended-field RT as adju-
vant, and 17% received MOPP at relapse after front-line RT for early-
stage disease. The second cohort (B) includes 231 patients treated from
1984 to 1995 (median FU: 16 yrs) with the alternating MOPP and ABVD
regimens (6-8 cycles) for advanced disease; 24% of patients were given
additional RT, limited to sites of bulky disease at diagnosis or to resid-
ual disease after chemotherapy. The third cohort (C) includes 207
patients treated from 1996 to 2003 (median FU: 10 yrs) with ABVD +/-
RT; 120 patients (58%) with early nonbulky disease received 4 ABVD
and limited RT, while 42% with advanced disease received 8 cycles of
ABVD and no RT. Results. The overall incidence of secondary
MDS/ANLL was of 17 cases over a total of 640 patients (2.6%). Both
incidence and 10-yr actuarial risk were significantly higher (p<0.001) in
the cohort A (6% and 5.5%, respectively) compared to cohort B (2.2%
and 2%), while no cases of MDS/ANLL occurred in the cohort C. In the
cohort A, the incidence of MDS/ANLL in patients given salvage MOPP
was identical to that of patients given adjuvant MOPP; whereas in the
cohort B, four of 5 cases developing MDS/ANLL had been given salvage
therapy with nitrosurea derivatives (two had received autologous stem
cells transplantation). 
Discussion. This long-term analysis indicates that reducing the cumu-
lative doses of mechloretamine and procarbazine (such as in the alter-
nating MOPP/ABVD program compared to MOPP alone) and limiting
RT doses and volumes produced a decline from 5.5% to 2% of the 10-
yr actuarial risk of secondary MDS/ANLL in Hodgkin lymphoma. Avoid-
ing mechloretamine and procarbazine and further reducing RT resulted
in no cases of secondary MDS/ANLL. The potential leukemogenic role
of salvage therapy was particularly evident in patients relapsing after
alternating MOPP/ABVD who had been given salvage therapy contain-
ing nitrosourea derivatives, whereas, the risk of secondary MDS/ANLL
was no longer a problem in patients with a sustained complete remis-
sion after ABVD therapy.
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LONG-TERM OUTCOME OF SURVIVORS OF AUTOLOGOUS HEMATOPOIETIC-
CELL TRANSPLANTATION FOR REFRACTORY AND RELAPSED HODGKIN LYMPHOMA
K.A. Goodman, E. Riedel, V. Serrano, A.M. Gonzales, S. Gulati, 
C. Moskowitz, J. Yahalom
Departments of Radiation Oncology, Biostatistics, and Medicine, Memorial
Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, Weill
Cornell Medical College, New York, NY, USA
Background. High-dose chemo-radiotherapy and autologous hemato-
poietic-cell transplant (AHCT) has significantly improved survival of
patients with refractory/ relapsed Hodgkin Lymphoma (HL). Late mor-
tality related to causes other than HL was reviewed in patients treated
with AHCT and the incidence of second malignancy (SM) in this pop-
ulation was compared with the SM incidence among HL patients from
the SEER Registry.
Methods. From 1985-1998, 218 refractory/relapsed HL patients were
treated on high dose chemo-radiotherapy and AHCT salvage protocols.
153 (70%) surviving ≥2 years after AHCT were analyzed. Primary end-
point was non-HL mortality, defined as mortality due to cardiac causes,
infection or SM. Competing risk methods were used to calculate cause-
specific mortality rates and examine its predictors. Events were calcu-
lated from 2 years post-AHCT to date of death/last follow-up. Risk
ratios (RR) were calculated to compare observed SM rates in the AHCT
population with the expected SM rates for age- and sex-matched con-
trols from both the general population and from HL patients registered
in the SEER database.
Figure. Cumulative incidence of death due to HL, 2nd cancer or other causes.
Table. Risk Ratios of Second Malignancies after AHCT in Comparison to the
General Population and to Hodgkin Lymphoma Patients.
Time since AHCT Person-Years
Observed Expected Ratio 95% CI
Reference Group: General Population from SEER Database.
≤5 years 3.0 0.54 5.51 1.11 16.10
5-10 years 5.0 0.93 5.36 1.73 12.50
>10 years 7.0 0.83 8.45 3.39 17.41
Total 15.0 2.31 6.50 3.64 10.73
Reference Group: HL Patients from SEER Database.
≤5 years 3.0 1.51 1.99 0.40 5.82
5-10 years 5.0 1.84 2.72 0.88 6.35
>10 years 7.0 2.77 2.53 1.01 5.21
Total 15.0 6.11 2.45 1.37 4.05
Results. Median follow-up time was 11.5 years. There have been 54
deaths, 33 due to HL and 21 due to other causes. Fourteen deaths were
due to SM: AML/MDS (6), NHL (3), NSCLC (2), colon cancer (2), and
gastric cancer (1). One patient is alive with a diagnosis of adenocarcino-
ma of unknown primary. Median age at diagnosis of SM was 46 years
and median time from AHCT to SM was 9 years (range 3-18 years).
There were 7 non-SM deaths: cardiac toxicity (4), infection, suicide,
unknown cause (1 each). The 10 and 15-year overall survival rates are
70% and 59%, respectively. The 15-year cumulative incidence of death
from HL and from non-HL causes were 22% and 18.2% (Figure). By
univariate analysis, increased risk of death due to SM was associated
only with higher age at AHCT (p=0.03). The RR of SM was 6.5 (CI: 3.6-
10.7) when compared to the general population, but only 2.4 (CI: 1.4-
4.05) when compared to HL patients (Table). Conclusions. HL initially
accounts for the majority of deaths among patients surviving high-dose
therapy, however, the HL mortality rate plateaus and risk of death from
other causes increases after 5 years. When compared to the general pop-
ulation, patients who underwent AHCT had a significantly higher risk
of SM, yet when compared to just the cohort of HL patients, the excess
risk of SM was less pronounced in the first decade after therapy, but
became significant beyond 10 years. Continued follow-up is necessary
in this heavily treated population to fully evaluate the risk of late SM and
other non-HL mortality.
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CANCER-RELATED FATIGUE (CRF) THERAPY: AN UNMET MEDICAL NEED NOT ONLY FOR
HODGKIN-PATIENTS
H.H. Bartsch,1 M. Roessig,2 S. Huppertz-Helmhold2
1Clinic for Oncological Rehabilitation at the Clinic for Tumor Biology, Universi-
ty of Freiburg, Freiburg; 2sigma-tau Arzneimittel GmbH, Duesseldorf, Germany
The impact of Fatigue on the quality of life of oncology patients is sub-
stantial and underestimated by many clinicians. Fatigue is a common
symptom occurring in 78-96% of cancer patients, particularly during
and immediately after the conclusion of active treatment. Although there
is a clear unmet medical need there are still no established strategies for
the treatment of cancer-related fatigue (CRF) including drugs and food
supplements. Therefore we started to investigate the effect of Levocar-
nitine (LC) treatment on CRF in a randomized, double blind, placebo-
controlled, multicentre trial in German rehabilitation centres.
Methods. Different approaches of interventions for Fatigue during and
following cancer and its treatment like exercise, treatment of anaemia,
Methylphenidate therapy have been clinically investigated in the last
several years. Results of three small open-label pilot-trials suggested effi-
cacy of LC supplementation for treatment of CRF. LC is a small, water-
soluble compound with an indispensable function for fuel metabolism
of heart and skeletal muscle. Since cancer-treatment with cytostatics like
ifosfamide and cisplatine results in a LC-loss, the impact of LC on CRF
is reasonable. De Greve et al asked in a prospective study in patients with
early breast cancer receiving adjuvant anthracycline-based chemothera-
py if a decrease in LC might be responsible for Fatigue symptoms. In
order to investigate the promising effect of LC in more detail a random-
ized, placebo-controlled, double-blind, multicentre phase II/III trial with
LC treatment of CRF in patients with breast cancer has been initiated.
A study-population of 60 non-anaemic patients in 10 rehabilitation cen-
tres in Germany will be evaluated. Primary endpoint of the trial will be
the efficacy of daily 3×1 g LC drinking solution (L-Carn®) after a 16±2
days treatment period on the General Fatigue Subscale of the Multidi-
mensional Fatigue Inventory (MFI). The secondary endpoints are: To
evaluate the change in Fatigue using the remaining subscales of the MFI,
to assess anxiety and depression using the HADS, and to assess QoL
with the EORTC-QLQ-C30.
Results. Our clinical trial will show as a prospective approach whether
LC treatment might be a validated treatment option in the future to
improve CRF.
Discussion. Due to Fatigue up to 65% of the effected patients taking a
mean of 4,5 days off work in a typical month. Hopefully we will iden-
tify an orally taken and cheap treatment option with no expected side
effects in order to improve QOL for cancer patients.
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LONG-TERM EVENTS OTHER THAN SECONDARY MYELODYSPLASIA/LEUKEMIA AND
CAUSES OF DEATH IN ADULT PATIENTS TREATED FOR HODGKIN LYMPHOMA
E. Brusamolino, M. Gotti, M. Lazzarino
Clinica Ematologica, Fondazione Policlinico San Matteo IRCCS, University of
Pavia, Italy
Introduction. Patients treated for Hodgkin lymphoma have a significant
risk of developing late complications related to prior therapy including
second malignancies, cardiovascular and pulmonary diseases. Beyond 12
years of follow-up, treatment-related mortality exceeds mortality from
relapse of Hodgkin lymphoma. This study evaluates the risk of therapy-
related events other than secondary myelodysplasia/leukemia and the
cause-specific mortality in two cohorts of patients treated, respectively,
for early and advanced disease Hodgkin lymphoma and observed for a
median follow-up longer than 12 years. 
Methods. We monitored late events and causes of death in two cohorts
of patients treated for Hodgkin lymphoma in our Institution. Cohort A
includes 120 patients treated from 1990 to 2003 for stage IA-IIA non-
bulky disease with four cycles of ABVD and involved-field RT (median
FU: 12.5 yrs). Cohort B includes 231 patients treated from 1984 to 1996
with alternating MOPP and ABVD regimens (6-8 courses) for advanced-
stage disease (median FU: 16 yrs); 24% of patients were given addition-
al radiotherapy to sites of bulky disease at diagnosis or residual disease
after chemotherapy. Pulmonary and cardiac function tests were per-
formed throughout the follow-up. Outcome measures included cause-
specific mortality, standardized mortality ratio and standardized inci-
dence ratio for secondary neoplasms. 
Results. Ten percent and 3% of patients in cohorts A and B, respective-
ly, developed late cardiovascular complications including myocardial
infarction, restrictive cardiomyopathy, valvular stenosis, pericarditis and
congestive heart failure. Median age of patients developing late cardiac
events was 45 years (range: 16-60) and median time from the end of
therapy 64 months (range: 33-179). In these patients, the median RT
dose to mediastinum (in cohort A, only) was 40 Gy and median cumu-
lative dose of doxorubicin 200 mg/m2 (range: 200-300 mg/m2). The 12-
yr actuarial risk of cardiac complications was 15% in cohort A and 4%
in cohort B, with no cases of pericarditis, valvular stenosis or restrictive
cardiomyopathy in this latter. Second solid tumors developed in 5% of
patients in cohort A (12-yr risk of 7%) and in 9% of patients in cohort
B (12-yr risk of 14%). Five of 6 tumors observed in the cohort A occurred
in an irradiated area (breast, thyroid, lung, gastric carcinoma, one case
each, and one case of diffuse large B-cell lymphoma). Neoplasms occur-
ring in cohort B included malignant lymphoma, lung, colon, larynx and
breast carcinoma, and melanoma. Late pulmonary and respiratory events
occurred in 8% and 3% of patients in cohorts A and B, respectively. All
patients developing late pulmonary symptoms had received mediastinal
irradiation (median dose: 40 Gy) and bleomycin (dose range: 60-120
mg/m2). Median time from end of RT to pulmonary events was 76 weeks
(range: 50-123). Overall, 9% and 26% of patients in cohorts A and B have
died, so far; the large majority of patients with early disease died from
causes other than progression or relapse of Hodgkin lymphoma, where-
as, two thirds of patients with advanced disease died from active disease.
Discussion. In both cohorts, the excess mortality was due to cardiovas-
cular events and second neoplasms. In the early-stage cohort, late events
and second malignancies were mostly RT-related (restrictive cardiomy-
opathy and solid tumors in irradiated sites). In the advanced disease
cohort, the occurrence of a second neoplasia (including secondary
leukemia) was the most frequent cause of death, with no evidence of a
decreasing risk for solid tumors over time. 
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CURE FROM HODGKIN'S LYMPHOMA-LIFE WITH THE CONSEQUENCES
I. Arpad, S. Zsofia, M. Zsofia
3rd Department of Institute for Internal Medicine, Medical and Health Science
Center, University of Debrecen, Hungary 
Introduction. More and more late complications of treatment can be
recognized in Hodgkin's lymphoma patients - due to the prolonged sur-
vival period - which determine survival and the quality of life of these
patients. We investigated the late complications in Hodgkin's lymphoma
patients, who are in complett remission at least 10 years.
Methods. 90 patients who are in complett remission at least 10 years
from Hodgkin's lymphoma between 1975 and 1994 were examined.
The study was accomplished in January 2005. The mean ages of patients
at the time of the diagnosis Hodgkin's lymphoma and the mean period
of survival after treatment(s) were 32 (11-70) and 17 (10-30) years, respec-
tively. Among the 90 patients: today 73 are still alive, we have no infor-
mation about 9, and 8 patients died (4 of them with second malignant
disease). 24 patients had relapse, of which 19 recovered after relapse
and were included in the study then. Five patients had a late relapse
(after 10 years). The investigations included physical examination, chest
X-ray (possibly CT), respiratory function, ECG, ergometry, echocardio-
graphy, myocardial perfusion SPECT (when necessary), laboratory tests
(renal-, thyroid function, tumour markers), mammography, breast,
abdominal, cervical and carotid ultrasonography and EORTC QLQ- C30
questionnaire for the investigation of fatigue.
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Results. In the majority of cases, 38% of patients, cardiovascular
changes (myocardial infarct, valvulopathy, pericarditis etc.), while in
32% pulmonary and pleural damage were observed. Disorders of the
thyroid gland, predominant hypothyroidism, were found in 24%.
Carotid artery disease was diagnosed in 19% of the patients. Less fre-
quently, a second malignant tumour (breast, colon, thyroid etc. in 9%
of patients), damage to the skin, musculature, bones, and genitourinary
system (6%), as well as the gastrointestinal system could be detected.
Mean fatigue score was 41,26 in the 52 patients who completed the
questionnaire. No late complications have been observed only in 16 cas-
es (18%) yet.
Discussion. Treatment based on modern therapeutic approaches (risk
adapted and not overtreatment) is expected to decrease the incidence of
complications. Still the aim is increased attention and early detection
through close patient follow-up, which may improve the quality of life
and decrease mortality as a result. We must aim to provide our patients
that their quality of life is not differ from normal population.
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FATIGUE IN HODGKIN'S LYMPHOMA PATIENTS
M. Zsofia, S. Zsofia, I. Arpad
3rd Department of Institute for Internal Medicine, Medical and Health Science
Center, University of Debrecen, Hungary 
Introduction. Complete remission and recovery have been achieved in
the majority of Hodgkin's lymphoma patients. Their life is determined
by their disease itself, its treatment and the early and late complications
of the therapy. Fatigue is the most frequent symptom, and it associates
morbidity, failure of quality of life. Fatigue occurs in 60-96% of treated
cancer patients. 
Methods. We examined the frequency and severity of fatigue in 168
Hodgkin's lymphoma patients (85 women, 83 men) with the EORTC
QLQ-C30 questionnaire. They were treated with Hodgkin's lymphoma
from 1972 to 2005. Median age was 43,11 years at the time of the exam-
ination, in 2005. If fatigue levels <20 on the fatigue scale of the EORTC
QLQ-C30 is probationary normal level, and if >40 is pathological level, as
an earlier GHSG study showed.
Results. Only 23,8% of the patients had normal fatigue level. We found
that fatigue level was significantly higher in patients who were treated
more than 20 years ago /fatigue score (FA): 53,37, during treatment FA:
29,35 (p<0,03). Significantly higher fatigue score was observed in
patients who suffered from late complications (cardiovascular, pul-
monary, thyroid, second tumour etc.) of the treatment (FA: 48,72, no
complications FA: 31,88, p<0,001). We didn't find any associations
between each of these complications and fatigue. Those patients who
were in complete remission for at least ten years /mean period of sur-
vival after the treatment(s) was 16,61 year (10-33 years/ had higher FA
than whose were during treatment, or who were after the treatment
within 10 years. The difference was significant. Who had lower hemo-
globin level than normal also had significantly higher fatigue score. No
significant associations were found with gender, B symptom, stage of
the disease, hystological subtype, treatment modality (only chemother-
apy versus only radiotherapy versus combined modality treatment).
Increased FA was found in patients who had relapse, but difference
between relapsed and no relapsed patients was not statistically signifi-
cant.
Discussion. More co-morbidity (cardiovascular disease, hypothyreosis
etc.) can cause higher fatigue score that observed in these groups of
Hodgkin's lymphoma patients. Fatigue is more frequent than we think
it, and has a strong effect on quality of life, so its early recognition and
treatment is important and needs multidisciplinar cooperation. Both
nonpharmacological and pharmacological strategies are possible.
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FAMILY HISTORY OF CANCER AS A RISK FACTOR FOR DEVELOPING SECOND 
MALIGNANCIES IN HODGKINS LYMPHOMA
A. Andersson,1 G. Enblad,2 B. Tavelin,1 M. Björkholm,3 J. Linderoth,4
I. Lagerlöf,5 M. Merup,6 M. Sender,7 B. Malmer1
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Karolinska University Hospital and Institute; 4Department of Oncology, Lund
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gy, Sahglrenska University Hospital, Sweden
Purpose. This study estimates the risk for developing secondary can-
cers for patients treated with extended radiation fields for Hodgkin lym-
phoma (HL) in Sweden between 1965 and 1995 in relation to their fam-
ily history of cancer, age at diagnosis, and latency. 
Patients and methods. Patients treated for HL and their second malig-
nancies were identified through the Swedish Cancer Register (SCR)
(n=6,946). A cohort of first-degree relatives (FDR) to the HL patients
were created by linking the HL cohort with the Multi Generation Reg-
ister at Statistics Sweden and linked back to SCR to identify cancer cas-
es in the relative cohort. The HL patient cohort was stratified on the
number of FDRs with cancer in the analyses of the risk of second malig-
nancy (SM). Standardized incidence ratios (SIR) of developing second
malignancies were analysed.
Results. In the HL cohort during the follow-up, 614 solid tumours were
observed. The risk for developing SM after treatment of HL was
increased with the number of FDR with cancer, SIR 2.28, SIR 3.09
respectively SIR 3.45 if 0, 1 or >2 FDR with cancer. The association was
strongest for HL patients diagnosed at 40 years or younger.
Conclusions. Risk for developing cancer in HL long term survivors is sig-
nificantly increased compared to the normal population. Patients treat-
ed at a young age with a family history of cancer carry a particularly
increased risk and could be proposed as a subgroup where standardized
screening for the most common cancer sites could be offered in a strin-
gent surveillance program. 
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EFFECTIVENESS OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN PREVENTION
OF OVARIAN FAILURE IN HODGKIN LYMPHOMA: UPDATE ON CURRENT PRACTICE AND
REVIEW OF LITERATURE
M. Gilliam, M. Fanale, C. Patterson
Anderson Cancer Center. Department of Lymphoma, Houston, Texas USA
Introduction. Premature ovarian failure (POF) is side effect of chemo in
female (F) Hodgkin lymphoma (HL) pts of childbearing age. Risk factors
are older age, multiple chemo, HL, alkylating agents, or pelvic radiation.
POF refers to the loss of fertility and loss of estrogen production of the
ovaries which can lead to difficulty with conception, menopause, osteo-
porosis. Gonadotropin releasing hormone agonists (GnRH-a) have
shown effectiveness in decreasing POF and preserving fertility. Early
studies have shown that GnRH-a can induce ovarian shutdown,
decrease follicular insult, and preserve ovarian function (OF) (Ataya et al.
1995) . 
Methods. A review of literature was performed utilizing PubMed with
key search words of fertility, HL, GnRH agonists, antagonists, ovarian
failure, ovarian preservation, spermatogenesis. This search generated
18 articles which discussed ovarian preservation, fertility options, rate
of infertility, administration, effectiveness, tolerability, & success of con-
traception with GnRH-a.
Results. The literature emphasizes the role of GnRH-a in OF by induc-
ing a prepubertal state. 240 children (M and F) age<15 treated with
MOPP showed 13% of F experienced POF. Achieving prepubertal state
prior to chemo has benefit in preventing POF (Blumenfeld 2003). 90 pts
injected with Qmos GnRH-a vs 100 pts in control (age 14-40) without
GnRH-a. <7% in GnRH-a group vs 50% in control had POF (Blumen-
feld et al. 2002). Similar efficacy in 56 F pts age 14-45.30 pts received
GnRH-a 1-2 wks prior & Q4wk intervals. Serum E2 & inhibin B levels
were measured to mark ovarian recovery. 27 of 30 in GnRH-a group
returned to normal menses in 4-30 wks. One achieved pregnancy. 20 of
26 in control developed POF (Castelo-Branco et al. 2007) 
Discussion. GnRH-a is effective in preserving OF in F HL pts undergo-
ing chemo. Utilizing GnRH-a do have side effects-osteoporosis &
hypoestrogenia. Associated symptoms can be controlled with low dose
estrogen with GnRH-agonists (Castelo-Branco et al 2007). Eligible F pts
are not routinely being offered GnRH-a. Certain factors have prevented
option of GnRH-a therapy-lack of insurance coverage, lack of knowledge
of benefits, prior chemo in relapsed setting. Discussion of appropriate
time to initial dosing (7d vs. 14d) , frequency (Qmos vs Q3mos), & age
at diagnosis (younger vs older) has any direct correlation with rate of
POF. In conclusion, GnRH-agonists are effective in preserving OF and
should be considered for all HL patients prior to chemo.
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THE OUTCOME IN PATIENTS WITH CLASSICAL HODGKIN'S LYMPHOMA ACCORDING TO
INTERNATIONAL PROGNOSTIC SCORE, ELEVATED SEDIMENTATION RATE, TISSUE
EOSINOPHILIA AND BULKY DISEASE
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The outcome in patients (pts) with classical Hodgkin's lymphoma
(cHL) treated with conventional therapy, leads to durable remissions
and high survival rate. It is still necessary to define prognostic parame-
tres wich will initially identify high risk patients (pts) who may benefit
from more agressive therapeutical approach. The aim of the study was
to determine the prognostic value of International Prognostic Score (IPS),
elevated sedimentation rate (ESR>50), tissue eosinophilia and bulky dis-
ease in newly diagnosed pts with cHL. Their significance was evaluat-
ed regarding response to treatment and survival period. A retrospective
study was performed on cohort of 112 pts with cHL (WHO). In all pts,
initial IPS (serum albumin <4 g/dL, hemoglobin <10.5g/dL, male sex,
stage IV disease, age>45 years (yrs), WBC>16.000/µL and lymphocyte
count <600/µL), presence of bulky disease (tumor >7 cm), ESR>50 and
tissue eosinophilia were determined. The median follow-up was 7 years
(ranging from 6 to 100 months). All pts were treated according to stan-
dard ABVD regimen. The mean age was 33.39±12.36 yrs, range 15-74
(79.46% of pts were <45 yrs). Gender distribution was 55 male / 57
female. On presentation early disease (CS I, IIA) had 12.5% pts and
advanced disease (CS IIB-IV) was present in 87.5% pts. Initial bulky dis-
ease was confirmed in 34.82%, ESR>50 in 62.5% and tissue eosinophil-
ia in 32.14% pts. The IPS distribution of HL pts was as follows: 0-2 in
58.93% and IPS 3-5 in-41.07%. After the first line therapy complete
remission (CR) was achieved in 100 pts (89.28%) and 12 pts (10.71%)
failed to therapy. The overall survival (OS) rate was 76% after 8 yrs of
follow up. Patients with high IPS (3,4,5) had more progresive disease and
shorter overall survival (OS8y of 57% compared to OS8y of 89% in pts
with low IPS, log rank p<0.01). Univariate statistical analysis showed
that pts with bulky disease vs non bulky had worse OS8y (43% vs 94%,
log rank p<0.01). Patients with tissue eosinophilia had shorter OS8y
(58% vs 85%, p<0.01). ESR>50 had also negative influence on OS8y
(66% vs 93%, p<0.01). Multivariate analysis (Cox's model) has revealed
that bulky disease, tissue eosinophilia, ESR>50 and IPS>3 were inde-
pendent prognostic parameters (p<0.05). The patients with bulky dis-
ease, tissue eosinophilia, ESR>50 and IPS>3 are at higher risk of treat-
ment failure, and could be eligible for more aggressive initial therapeu-
tic approach.
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QUALITY OF LIFE (QL) IN HODGKIN'S DISEASE (HD): RESULTS FROM THE GHSG 
MULTICENTRE TRIALS HD10-12
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Introduction. a) To study and compare the quality of life (QoL) of
patients on various QoL dimensions during, after therapy and during
follow-up after the end of active treatment; b) to identify longitudinal
patterns of QoL dimensions during re-adaptation to normal life and c)
to obtain comparisons between treatment arms and prognostic groups.
Methods. Within the randomised trials HD10-12, patients receive a
QoL questionnaire for completion after chemotherapy/radiotherapy and
during follow-up after the end of the first-line therapy. The EORTC
QLQ C-30 is used for quality of life assessment, the MFI20 for assess-
ment of fatigue, and further aspects include sexuality, specific side
effects, and subjective retrospective evaluation of treatment. Overall,
the instruments include 68 questions relating to 15 functional, symp-
tom, and fatigue scales plus 17 additional single items, and 3 open ques-
tions. In addition, the German shortened version of the life situation
questionnaire (LSQ) is used for the evaluation of objective parameters of
the patients life situation after end of treatment.
Results. For the current analysis 14.762 questionnaires from 3955
patients enrolled into the HD10-12 trials are available. Replication of
the psychometric properties of the scales revealed satisfactory results
using factor analyses and reliability testing. Feasibility analysis showed
a good acceptance of the questionnaire by both patients and physicians
resulting in a high return rate during follow-up. Regarding the function-
al and fatigue scales, patients report a mixed pattern of responses but
indicate severe limitations in their perceived QoL during the first years
of follow-up. Emotional functioning recovers fully only in 50% of
patients 3-5 years after end of treatment and 25% report constantly
severe strain. The same is true for fatigue and global QoL. In physical
functioning 85% recover fully and only 5% report low functioning. In
general, women report a lower QoL functioning and higher symptom
scores over time than men. Patients with more advanced disease report
lower functioning and higher symptom levels during follow-up.
Discussion. QoL assessment within multicentre trials in HD is feasible.
QoL data from the reintegration process of patients into normal life dur-
ing the first years of follow-up reveal substantial strain and limitations
of QoL, particularly in specific subsets of patients. QoL assessment with-
in the fourth trial generation is ongoing. Results regarding also socio-
demographic variables and the longitudinal analysis of various subgroups
will be presented in detail.
P059
BREAST SCREENING FOLLOWING RADIOTHERAPY IN HODGKIN LYMPHOMA
C. Jordan, E.M.L. Gallop-Evans
Velindre Cancer Centre, Cardiff, UK
The risk of breast cancer after supradiaphragmatic irradiation for
Hodgkin lymphoma at a young age is the largest of any non-genetic risk
factors identified to date. In 2004, the UK Royal College of Radiologists
produced guidelines for surveillance for women at risk. We describe the
notification and screening exercise carried out for the South East Wales
Cancer Network, UK. 300 female patients with Hodgkin Lymphoma
were identified through the Welsh Cancer Intelligence and Surveillance
Unit. 100 women who had received supradiaphragmatic radiotherapy
under the age of 35 years were considered to be at risk. 83 women who
had radiotherapy between 1968-2004 were eventually traced. To date,
14 women have died, 5 of relapsed Hodgkin lymphoma, 3 of breast can-
cer, 2 with brain metastases, unknown primary, 1 of lung cancer, and 3
of unknown causes. 3 women are alive with breast cancer diagnosed pri-
or to the screening programme, and 1 woman was diagnosed with breast
cancer on her first screening mammogram. 1 patient is known to have
had breast and thyroid cancer but has moved away. Our current prac-
tice is to commence screening 8 years following supradiaphragmatic
radiotherapy. Annual screening is by MRI for patients <30 years, and by
mammography for patients aged 30-50 years. After the age of 50, 3 year-
ly mammography is performed. A database has been set up to ensure
that all eligible patients are screened appropriately. Data with respect to
radiotherapy dose and site of breast cancer is currently being collated in
a national study.
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Introduction. i) To study and compare the fatigue levels of patients on
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different fatigue dimensions during, after therapy and during follow-up
after the end of active treatment; ii) to identify longitudinal patterns of
fatigue dimensions during re-adaptation to normal life and iii) to obtain
comparisons between treatment arms and prognostic groups.
Methods. Within the randomised trials HD10-12, patients receive an
extensive self-report questionnaire for completion after chemo-
therapy/radiotherapy and during follow-up after the end of the first-
line therapy. The EORTC QLQ C-30 is used for quality of life (QoL)
assessment, the MFI20 for multidimensional assessment of fatigue, and
further aspects include sexuality, specific side effects, and subjective ret-
rospective evaluation of treatment. Overall, the instruments include 68
questions relating to functional, symptom, and 6 fatigue scales plus 17
additional single items, and 3 open questions. In addition, the German
shortened version of the life situation questionnaire (LSQ) is used for the
evaluation of objective parameters of the patients life situation after end
of treatment.
Results. For the current analysis 14.762 questionnaires from 3955
patients enrolled into the HD10-12 trials are available. Replication of the
psychometric properties of the scales revealed satisfactory results using
factor analyses and reliability testing. Feasibility analysis showed a good
acceptance of the questionnaire by both patients and physicians result-
ing in a high return rate during follow-up. Regarding the functional and
fatigue scales, patients report a mixed pattern of responses but indicate
severe limitations in their perceived QoL during the first years of follow-
up. Reported fatigue levels recover fully only in 50% of patients 3-5
years after end of treatment and 25% report constantly severe fatigue.
In contrast physical functioning recovers fully in 85% of patients and
only 5% report long term low functioning. In conjunction with higher
fatigue, patients report lower general QoL and elevated emotional dis-
tress. In general, women report higher fatigue symptom scores over
time than men. Patients with more advanced disease report higher
fatigue symptom levels (30% vs. 20%) during follow-up.
Discussion. Fatigue assessment within multicentre trials in HD is fea-
sible and reveals necessary complementary findings to QoL data from
the reintegration process of patients into normal life during the first
years of follow-up. Relevant subgroups of patients report constantly
high fatigue levels although their physical functioning has recovered.
Related to high fatigue levels are low emotional functioning, indicating
general strain and low QoL. This points towards substantial strain and
limitations of QoL, particularly in specific subsets of patients. Fatigue
and QoL assessment within the fourth trial generation is ongoing.
Results regarding also socio-demographic variables and the longitudinal
analysis of various subgroups will be presented in detail.
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FERTILITY IN MALE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA TREATED WITH
BEACOPP REGIMEN IN THE GERMAN HODGKIN STUDY GROUP (GHSG) CLINICAL TRIALS
M. Sieniawski,1,2 T. Reineke,2 L. Nogova,1,2 A. Josting,1,2 B. Pfistner,2
V. Diehl,2 A. Engert1,2
1Department I Internal Medicine, University Hospital Cologne, Cologne; 2Ger-
man Hodgkin Study Group, University Hospital Cologne, Cologne, Germany
To date, there is little information on the impact of more aggressive
treatment regimen such as BEACOPP (bleomycin, etoposide, doxoru-
bicin, cyclophosphamide, vincristine, procarbazine, and prednisone) on
the fertility of male patients with Hodgkin Lymphoma (HL). We evalu-
ated the impact of BEACOPP regimen on fertility status in 38 male
patients with advanced stage HL enrolled into trials of the German
Hodgkin Study Group (GHSG). Before treatment, 6 (23%) patients had
normozoospermia and 20 (77%) patients had dysspermia. After treat-
ment, 34 (89%) patients had azoospermia, 4 (11%) other dysspermia
and no patient had normozoospermia. There was no difference in
azoospermia rate between patients treated with BEACOPP baseline and
those given BEACOPP escalated (93% vs. 87%, respectively; p=1.000).
After treatment most of patients (93%) had abnormal values of follicle-
stimulating hormone but number of patients with abnormal levels of
testosterone and luteinising hormone was not so pronounced - 57%
and 21%, respectively. In univariate analysis, none of the evaluated risk
factors (i.e. age, clinical stage, elevated erythrocyte sedimentation rate,
B symptoms, large mediastinal mass, extranodal disease and ≥3 lymph
nodes) were statistically significant. Male HL patients are at high risk of
infertility after treatment with BEACOPP, further prospective studies
with long follow-up are needed.
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SELECTION OF PATIENTS FOR MINIMAL INITIAL CHEMOTHERAPY (MIC); THE IMPACT OF
HASENCLEVER SCORE ON OUTCOME IN PATIENTS RECEIVING MIC AND INVOLVED
FIELD RADIOTHERAPY FOR CLINICAL STAGE IA/IIA SUPRA-DIAPHRAGMATIC HODGKIN 
LYMPHOMA IN THE UK NCRI LY07 TRIAL
F. Thistlethwaite,1 W. Qian,2 M.V. Williams,3 B.W. Hancock,4
P. Hoskin,5 H. Sun-Mynt,6 P. Smith,2 J.A. Radford1 on behalf of all LY07
collaborators
1Christie Hospital, Manchester, 2Cancer Research UK and University College
Trials Centre, London 3Addenbrookes Hospital, Cambridge, 4Weston Park Hos-
pital, Sheffield, 5Mount Vernon Hospital, Northwood, 6Clatterbridge Hospital,
Wirral, UK
Introduction. Individualising treatment in Hodgkin lymphoma (HL)
based on risk assessment offers the possibility of maximising the
chances of cure whilst minimising the incidence of late effects includ-
ing cardiovascular disease. Relevant to this is the cumulative dose of
doxorubicin but reductions may undermine disease control and appro-
priate selection of patients is therefore critical. In this analysis of the
LY07 trial, the impact of Hasenclever score on outcome in patients (pts)
receiving minimal initial chemotherapy (MIC) plus involved field radio-
therapy (RT) for early stage HL is explored. 
Methods. Between November 1996 and June 2001, 226 pts with clin-
ical stage I/II supra-diaphragmatic HL (no B symptoms or mediastinal
bulk) were randomised to receive either mantle field RT (arm A, n=115)
or MIC comprising 4 wks of VAPEC-B chemotherapy (doxorubicin 35
mg/m2 iv at wks 1 and 3, cyclophosphamide 350 mg/m2 iv at wk 1,
etoposide 100 mg/m2 po days 1-5 at wk 3, vincristine 1.4mg/m2 iv at wks
2 and 4 and bleomycin 10,000 IU/m2 iv at wks 2 and 4 with prednisolone
50mg daily for 4 wks and prophylactic cotrimoxazole/ketoconazole)
followed by involved field RT (arm B, n=111). In both arms RT dose was
30-40 Gy in daily fractions of 1.8-2 Gy. 
Results. At completion of treatment CR/CRu had been achieved by
91% pts in arm A and 90% in arm B, and PR by 7% in arm A and 9%
in arm B. After a median follow-up of 84 months, 5 year progression-
free survival (PFS) is 72% in arm A and 88% in arm B (Hazard ratio
(HR)=0.38, 95%CI=0.23-0.65, p=0.0004) and 5 year overall survival is
93% in arm A and 97% in arm B (HR=0.45, 95%CI=0.17-1.20, p=0.11).
There is an interaction between Hasenclever score (0,1 vs ≥2) and treat-
ment on PFS (p=0.058). The HR=0.26, p<0.001 in patients with Hasen-
clever score of 0,1 and HR=0.87, p=0.79 in patients with a score of ≥2.
In arm B, a Hasenclever score of 0,1 was associated with 5 year PFS of
92% and survival of 99% whereas a score of ≥2 was associated with a
5 year PFS of 77% and survival of 96%
Conclusions. Patients with stages IA/IIA HL and a Hasenclever score of
0 or 1 have an excellent prognosis after MIC (cumulative dose doxoru-
bicin 70 mg/m2 over 4 weeks) and involved field RT. Additional treat-
ment is required for those with a Hasenclever score of 2 or greater. These
data inform a risk adapted approach designed to maximise disease con-
trol and minimise exposure to doxorubicin with its attendant risk of
cardiovascular disease
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PRELIMINARY EVALUATION OF THE NORDIC STUDY FOR EARLY STAGE 
HODGKIN LYMPHOMA 
C. Raud,1 G. Enblad,1 L. Klint,2 D. Molin1
Department of Oncology 1Uppsala and 2Gothenburg, Sweden
Introduction. Between 1999 and 2005 patients with early stage HL, 18-
70 years of age, in the Nordic countries were treated according to a
phase II study with less extensive treatment than earlier protocol recom-
mended. 
Methods. The design of the study was prospective and population
based. Patients without risk factors (RF) were treated with two ABVD
followed by 30 Gy IFRT (if bulky disease 35 Gy). Those with RF were
given four ABVD before RT. Initially some patients where treated with
MOPP/ABV. Primary endpoints were disease free survival, over-all sur-
vival and late side effects.
Results. Only a small number of the included patients from Sweden are
updated until now. Median follow up is 35 months. Of 95 patients 22
patients were in stage IA and 73 in stage IIA. RF were found in 52 cas-
es. Mean age 39 years (range 18-70). The histology was NSHL in 68 cas-
es, MCHL in 20, 6 not classifiable and 1 LRCHL. After treatment 47
patients were in CR and 44 in CR(u). Relapse occurred in 7 cases (7%).
Salvage treatment was high-dose CT followed by autologous stem-cell
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transplantation (SCT) in all cases but two. Case no 3 did not want any
treatment and case no 7 preferred BEACOPP esc x 6 and RT 20 Gy. Case
no 6 has had several relapses and currently receives palliative treatment
in SD. One patient, 69 years old, died after one reduced ABVD of a heart
attack without HL at autopsy.
Discussion. With reservation for short follow-up time outcome is com-
parable to older treatment regimes and similar treatment in controlled
studies. Only one (14%) of the seven cases with recurrence had a good
early radiological response compared to 33% in those without recur-
rence. This is well corresponding with FDG-PET studies that show a
clear correlation between early response and final outcome. We also
notice large radiation-fields in several cases which might indicate large
tumour burden. Only a small fraction of the included cases are analysed
so far but we hope to soon have more data. 
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HIGH RELAPSE RATE AFTER A BRIEF CHEMOTHERAPY COURSE AND INVOLVED-FIELD
RADIOTHERAPY IN EARLY-STAGE HODGKIN' S LYMPHOMA
M. Magagnoli,1 M. Balzarotti,1 M. Spina,2 L.V. Siracusano,1 L. Isa,3
P. Navarria, E. Morenghi,1 U. Tirelli,2 A. Santoro1
1Oncologia Medica ed Ematologia-Istituto Clinico Humanitas-Rozzano (MI);
2Oncologia Medica A, Centro di Riferimento Oncologico, Aviano; 3Divisione di
medicina Interna, ospedale San Luigi, Gorgonzola, 2Divisione di radioterapia e
radiochirurgia, Italy
Introduction. A new regimen, VEBEP was developed at our institutions
with the primary aim to reduce short and long-term toxicity and, if pos-
sible, to improve therapeutic outcome. 
Mrthods. From May 1998 to May 2003, 26 consecutive patients with
newly diagnosed HL with Ann Arbor stage I or II, and no bulky disease,
symptoms, a mediastinal involvement, were prospectively enrolled. The
treatment consisted of two courses of VEBEP followed by low-dose (30
Gy) IF-RT. The regimen consisted of epidoxorubicin 30 mg/m2 iv day 1-
3, cyclophosphamide 1000 mg/m2 iv day 1, vinorelbine 25 mg/m2 iv day
2, bleomycin 10 mg/m2 iv day 3, and prednisone 100 mg iv day 1-3.
Courses were given on an outpatient basis every 21 days without growth
factor support. Radiotherapy was delivered within four weeks from the
end of the chemotherapy program and only if complete remission (CR)
was demonstrated at the end of VEBEP. 
Results. All patients completed the chemotherapy program and RT as
planned. Complete remission (CR) was achieved in 26/26 (100%) after
VEBEP chemotherapy. With a 5-year FFP of 74%, seven patients relapsed
at a median time of 33 months (range 19-63 months) from the comple-
tion of treatment. Only one relapse occurred during the first two years
of follow-up. Three patients had a relapse in a previously irradiated
nodal areas. Among several prognostic factors analyzed, (age, stage, sex,
number of involved sites, supra-vs infradiaphragmatic disease) no cor-
relation with FFP emerged. All seven patients received salvage
chemotherapy, and in three of them this was followed by high-dose
chemotherapy and peripheral blood stem cell support. At a median fol-
low-up of 73 months (range 32-104), 23 patients are disease free for a
five-year FFP from second relapse of 84%. All patients are alive. Toxic-
ity was globally mild. To date, no cases of secondary myelodysplastic
syndrome/acute leukemia, solid tumor, severe cardiovascular events, or
major respiratory symptoms have been documented 
Conclusions. In this study, despite the very low toxicity profile and the
high percentage of CR, the observed relapse rate was not satisfactory,
with an excess of late recurrences. In HL, treatment should be delivered
over as short a period as feasible in order to reduce the risk of long term
toxicity; nonetheless, a relapse rate in excess of 25% does not justify this
approach until the results of large randomized trials give us mature
results with a very long follow-up.
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COMBINED MODALITY THERAPY FOR EARLY STAGE HODGKIN DISEASE. ONE CENTER
EXPERIENCE
A. Manaka, M. Tsirogianni, M. Michael, C. Balotis, M. Vagia, 
K. Liapis, S. Gigantes, M. Pagoni, J. Apostolidis, G. Baltadakis, 
S. Delibasi, D. Karakasis, T. Karmiris, M. Bakiri, N. Harhalakis, 
E. Nikiforakis
Department of Hematology, Lymphoma and BMT, Evangelismos Hospital,
Athens, Greece
Introduction. Evaluation of treatment of clinical staged early stage (favor-
able and unfavorable) Hodgkin disease (HD), according to German
Hodgkin Study Group (GHSG), with ABVD (Adriamycin, Bleomycin,
Vinblastine, Deticene) and radiotherapy (RT). 
Methods. First group evaluated was consisted of 36 patients with favor-
able early stage HD, with median age 31 years (range 15-70) and medi-
an follow-up 52 months (range 5-146). All patients received 2-4 cycles
of ABVD. Thirty-three patients received involved field (IF) radiation
(median dose 27 Gy, range 15-30), and three received extended field (EF)
(median dose 33 Gy, range 30-36). Second group evaluated was consist-
ed of 57 patients with unfavorable early stage HD, with median age 27
years (range 15-73) and median follow-up 64 months (range 10-172). All
patients received 4-6 cycles of ABVD. Forty-five patients received IF
radiation (median dose 30 Gy, range 16-36), and twelve patients received
EF (median dose 36 Gy, range 30-45). 
Results. In the favorable group 34 patients are still in complete response
(CR) and 2 patients relapsed at 33 and 73 months from the diagnosis, and
were rescued with salvage chemotherapy and autologous stem cell trans-
plantation (ASCT). Disease free survival (DFS) was 95% at 5 years, and
overall survival (OS) was 100%. In the unfavorable group 48 patients are
still in CR and 8 patients relapsed, where all were rescued with salvage
chemotherapy and 5 underwent ASCT. One patient died from disease.
DFS was 84% at 5 years, and OS was 98%. No patients from both
groups developed secondary solid tumor or hematological malignancy.
Discussion. Our results are comparable with all recent literature data.
Patients after treatment failure can be effectively rescued with salvage
therapy and ASCT.
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A PROSPECTIVE TRIAL OF INVOLVED FIELD RADIATION (IFRT) + CHEMOTHERAPY VS
EXTENDED FIELD (EFRT) RADIATION FOR FAVORABLE HODGKIN'S DISEASE (HD): 
LONG-TERM FOLLOW-UP AND IMPLICATIONS FOR CURRENT COMBINED MODALITY
THERAPY
S.J. Horning, R.T. Hoppe, R.H. Advani, S. Breslin, E. McCormick, 
J. Allen, S.L. Hancock, S.A. Rosenberg
Stanford University Cancer Center, Stanford, CA, USA
Introduction. Brief chemotherapy and IFRT is the standard for early
stage, favorable HD. This approach is highly effective but there is uncer-
tainty about late effects and overall survival (OS). From 1980-88 IFRT
plus VBM (vinblastine, bleomycin, methotrexate) chemotherapy was
compared to EFRT in patients (pt) with favorable stage I-IIIA HD in a
prospective randomized trial. The experimental arm was designed to
limit RT exposure and define a chemotherapy regimen that was neither
sterilizing nor leukemogenic. 
Methods. Favorable, laparotomy-staged HD was defined as: no bulky
mediastinal disease, no or minimal abdominal disease (<5 cm), no or
minimal splenic disease, and <1 extranodal site. EFRT was subtotal lym-
phoid for stage I-IIA and total lymphoid irradiation for I-IIB, IIIA pt.
VBM was given for 6 cycles after 44 Gy IFRT. In 1988 we reported no
survival differences in this study (J Clin Oncol 1988;6:1822). For the cur-
rent analysis, follow-up was supplemented by an approved SSA Epi-
demiologic Vital Status Data Record application. 
Results. 72 pt were randomized, 38 to EFRT and 34 to IFRT + VBM.
Median follow-up is 21.5 yr with current status (within 2 yr) for 88%.
Twenty-two yr freedom from progression (FFP) is 94% for IFRT + VBM
vs 76% for EFRT (p= 0.037). There were 14 deaths among EFRT pt and
3 deaths among IFRT + VBM pt. OS at 22 yr is 88% for IFRT + VBM vs
66% for EFRT (p=0.006). Six of 14 EFRT deaths occurred in pt requiring
secondary therapy for HD. Notably, observed survival was significant-
ly less than expected, based on mortality tables, for EFRT pt (p<0.001)
but not for IFRT + VBM pt (p=NS).
Conclusions. The reduction of radiation to IFRT, combined with a less
toxic chemotherapy, resulted in long-term OS superior to EFRT in this
study. These results have implications for current combined modality
therapy where much lower doses of RT, more limited RT fields, and
brief chemotherapy should lead to even less late morbidity and mortal-
ity.
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ABVP PROTOCOL FOR EARLY STAGES OF HODGKIN LYMPHOMA
A STUDY ABOUT 88 CASES
A. Quessar, M. Quachouh, H. Hafiane, L. Jabri,1 M. Zidani, 
S. Benchekroun
Service d’Hématologie et d’Oncologie Pédiatrique, CHU Ibn Rochd, Casablanca;
1Laboratoire d’Anatomie Pathologique, CHU Ibn Rochd, Casablanca, Morocco
Background and Aim DTIC is unavailable in Morocco and in 2000, we
faced the shortage of Procarbazine. The ABVP protocol, a modification
of ABVD in which prednisone is given to substitute DTIC, was pro-
posed to treat patients with Hodgkin lymphoma (HL). We present the
results of prospective study, spanning the period from April 1998 to June
2005, our aim objectives are to analyse the efficacy and toxicity of this
combination in the treatment of patients with early stages of HL. 
Methods. During a 7 year period, 88 cases were enrolled; HL was con-
firmed according to the WHO classification, early stages considered
after staging procedures done systematically: clinical exam, ESR, CBC,
blood chemistry, bone morrow biopsy, chest x-ray and CT scans. The
chemotherapy program was ABVP: Doxorubicin, Vinblastine and
Bleomycin were administered on days 1 and 8, Prednisone given at dose
of 40 mg/m2 from day 1 to 14 of each cycle, a new cycle was started on
day 28. The number of cycles was determined according to the prognos-
tic group (EORTC prognostic staging). Patients with favourable group
received 4 ABVP cycles and 6 cycles for those with unfavourable group;
all patients received radiation therapy after chemotherapy to involved
fields. 
Results. 88 patients aged from 16 to 60 years old, the mean age was
31, more female (48 cases) than male (40 cases). Nodular sclerosis sub-
type was predominant (65, 5%) followed by the mixed cellularity sub-
type (24%). Stages I and II found respectively in 18% and 82%; only
15% of the cases had a favourable prognostic group and 85%
unfavourable. Complete response was archived in 84%, 29% among
these patients were not in CR after 2 to 3 cycles. 11, 5% failed to achieve
CR, all of them are with an unfavourable prognostic group; we deplore
one toxic death. 100% of the patients in favourable group achieved CR,
and 81% in the unfavourable group. 15% cases relapsed, 7/11 cases
before 12 months. The overall survival at 60 months was 86% and the
EFS 73%.
Conclusions. The ABVP protocol is simpler, not expensive with accept-
able toxicity. It could be a treatment option for the early stage Hodgkin
lymphoma, in the absence of bulky disease. 
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CONVENTIONAL PROGNOSTIC FACTORS IN CLINICAL STAGE (CS) IA/IIA HODGKIN’S
LYMPHOMA (HL) AFTER ABVD-BASED COMBINED MODALITY THERAPY (CMT) 
T.P. Vassilakopoulos, M.K. Angelopoulou, S. Sachanas, A. Zorbala,
M.P. Siakantaris, S.I. Kokoris, E.M. Dimitriadou, M.N. Dimopoulou, 
S. Masouridis, C. Kalpadakis, M.C. Kyrtsonis, P. Tsirkinidis, 
Z. Galanis, P. Tsaftaridis, E. Variamis, P. Michail, P. Panayiotidis, 
G.A. Pangalis
1stDept of Internal Medicine, Laikon General Hospital, National and Kapodis-
trian University of Athens, Greece
Introduction. ABVD-based CMT is currently considered the standard of
care for early stage HL. However, risk stratification is still based on con-
ventional prognostic factors, mainly derived from radiotherapy (RT)
treated patient populations. Since we have adopted ABVD-based CMT
for the treatment of all patients (pts) with early-stage HL since 1988, we
evaluated the role of conventional demographic, clinical, and laborato-
ry factors in the prognosis of patients with CS IA/IIA HL under current
standard therapy. 
Methods. We analyzed the clinical data of 462 consecutive pts with CS
IA/IIA HL, who were scheduled to receive ABVD-based CMT in our
Unit between 1988 and 2007. In brief the median age of the pts was 30
years (14-82), 57% were males, 38% and 62% had CS IA and IIA, and
65% had nodular sclerosis. The ABVD and EBVD (E=Epirubicine) regi-
mens were administered in 62% and 38% of the pts respectively. A
minority of pts (6%) did not actually receive RT because of refusal or ear-
ly progression. Involved field RT was administered in most of the pts at
a median dose of 2880 cGy. Results: At 5 and 10 years failure free sur-
vival (FFS) rates were 88±2% and 85±2% respectively. Multivariate
analysis demonstrated that independent adverse prognostic factors for
FFS were: Age ≥45 years (p=0.01), extranodal extension (p=0.01), leuko-
cytes ≥10x109/L (p=0.02), and involvement of ≥3 nodal sites (p=0.02).
The percentages of pts with 0, 1, 2 or 3-4 adverse factors were 36%,
41%, 21%, and 2%, respectively. The 10-year FFS rates for these groups
were 90±3%, 89±3%, 70±5%, and 50±23% (p<0.0001). ESR≥30 also
provided independent prognostic information, but limited the evaluable
population to 385 pts. When ESR was included, 29%, 38%, 24%, and
10% of pts had 0, 1, 2, or 3-5 adverse factors respectively. The 10-year
FFS rates for these groups were 90±4%, 89±3%, 79±5%, and 60±9%
(p<0.0001). Using either model, the 10-year HL specific survival was
≥95% for pts with 0-1 adverse features, although the differences com-
pared with the other groups were less marked than those of FFS. 
Discussion. After ABVD-based CMT, more than 2/3 of pts with CS
IA/IIA HL - those with 0 or 1 adverse factors- have a very favorable out-
come. In contrast, 10-23% of pts, those with multiple adverse features,
have more aggressive disease with a prognosis similar to that of
advanced stages. If ESR is taken into account, an intermediate group
including 3/4 of pts with approximately 80% cure rate can be identified.
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PET/CT SCAN GUIDED TREATMENT OF LIMITED STAGE HODGKIN LYMPHOMA 
ELIMINATES ALMOST ALL NEED FOR RADIATION
J.M. Connors, B. Campbell, P. Hoskins, R. Klasa, L.H. Sehn, 
T. Shenkier, N. Voss, D. Wilson, R.D. Gascoyne, K.J. Savage
BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada
Background. Based on results of the NCIC CTG/ECOG HD6 study
radiation can be eliminated from the management of most patients with
limited stage Hodgkin lymphoma. We postulated that PET/CT scan-
ning could identify the small minority of patients who still require radi-
ation, sparing the large majority from the risks of late complications of
such treatment. We predicted that approximately 10% of patients would
have a positive mid-treatment PET/CT scan after 2 cycles of ABVD
based on the HD6 experience and, therefore, 90% of patients could
avoid radiation.
Methods. Since November 2004 we have offered PET/CT scan guid-
ed management to adult (>15 y old) British Columbia patients with lim-
ited stage (stage IA or IIA, low bulk (<10 cm)) Hodgkin lymphoma. The
treatment plan is to give 2 cycles of ABVD then perform a PET/CT scan
2 weeks after the cycle 2B dose of chemotherapy. Patients with a nega-
tive scan are then treated with 2 more cycles of ABVD. Patients with a
positive scan receive involved nodal radiotherapy INRT (30-35 Gy; larg-
er radiation fields are treated with 1.75-2.0 Gy per fraction; at the radi-
ation oncologist's discretion, small radiation fields can be treated with
a shorter and more hyper-fractionated radiation schedule to a total dose
of 30 Gy, with 3 Gy per fraction).
Patient characteristics. n = 40; age 20-80 y (median 33 y); males 58%; his-
tology NS 55%, MC 15%; LD 2.5%, LR 5%, NOS 5%, N-LP 17.5%; stage
IA 32.5%, IIA 67.5%; largest mass 2-9 cm (median 4 cm); hemoglobin 108-
161 g/L (median 144 g/L); serum albumin 27-51 g/L (median 45 g/L). 
Results. All 40 patients have completed planned treatment with follow-
up of 3-32 months (median 19 months). Planned PET/CT scan re-assess-
ment was performed after 2 cycles of ABVD: PET/CT negative: 35
(87.5%) patients 34 completed treatment with 2 additional cycles of
ABVD; 1 received INRT at the referring physician's insistence; PET/CT
positive: 5 (12.5%) all 5 completed treatment with INRT. One of the
PET/CT negative patients and none of the PET/CT positive patients has
relapsed. One death has occurred in a 72 y old man with pre-existing car-
diac disease while still in complete remission, due to myocardial infarc-
tion 8 months after completing 2 cycles of ABVD followed, because of
a positive PET/CT, by INRT.
Conclusions. A planned PET/CT after 2 cycles of ABVD chemothera-
py distinguishes two groups of patients. Most (~90%) are PET/CT neg-
ative and can successfully complete treatment with 2 more cycles of
ABVD, avoiding radiation and preserving a high likelihood of progres-
sion free survival; a small minority (~10%) are found to have a positive
PET/CT scan allowing recommended radiation to be to be confined to
this small group who are most likely to benefit from it.
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PREDICTION OF POOR OUTCOME IN EARLY UNFAVOURABLE STAGE HODGKIN'S 
LYMPHOMA: A META-ANALYSIS BASED ON INDIVIDUAL PATIENT DATA 
J. Bohlius,1 H. Haverkamp,1 V. Diehl,1 H. Eghbali,2 C. Fermé,3
J. Franklin,1 B. Pfistner,1 J. Raemaekers,4 A. Engert,1 M. Henry-Amar5 on
behalf of German Hodgkin Study Group, EORTC Lymphoma Group
& Gela Groupe d'Études des Lymphomes de l'Adulte
1German Hodgkin Study Group, Cologne, Germany, 2Institut Bergonié, Bor-
deaux, France, 3Institut Gustave Roussy, Villejuif, France, 4Radboud Universi-
ty Nijmegen Medical Centre, The Netherlands, 5Centre François Baclesse, Caen,
France 
Introduction. Progression-free-survival (PFS) is unsatisfactory in patients
(pts) with early unfavourable stage Hodgkin's lymphoma (HL, stage I
and II with one or more risk factors mediastinal tumour, elevated ery-
throcyte sedimentation rate (ESR), ≥3 involved nodal regions, older age
or extranodal involvement). This might be caused by clinical hetero-
geneity within this patient group possibly leading to suboptimal treat-
ment strategies. An international collaboration was initiated to identify
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factors that may predict poor outcome.
Methods. We systematically searched for randomised controlled trials
(n>100 pts per study arm) in early unfavourable stage HL pts receiving
4-6 cycles of ABVD or similar chemotherapy plus radiotherapy in med-
ical databases (Medline, Cochrane Library). Individual patient data on
age, sex, tumour related factors, laboratory parameters, treatment and
outcome were collected and prognostic factors for PFS (disease progres-
sion, relapse or death) identified using multivariable proportional haz-
ards regression stratified by study.
Results. Data from six studies with 4,490 adult pts enrolled between
08/1982 and 01/2003 were available for analysis. 663 pts experienced an
event leading to an overall 5-year PFS rate of 85% (95% CI 83%-88%,
median follow-up 64 months). 4,078 cases were available for a complete
case analysis. Exploratory modelling showed that 5 factors defining ear-
ly unfavourable disease are significant predictors for poor outcome in a
multivariable model (mediastinal tumour >1/3 of thoracic diameter, ele-
vated ESR, ≥3 involved nodal regions, age ≥45 yrs, extranodal involve-
ment). Prediction is improved when adding age >60 and male sex as fac-
tors for poor outcome. A model stratified by study using these factors
produced the following hazard ratios: Age >60 HR 2.4 (95%-CI [1.8,
3.1], p<0.001), Age ≥45 HR 1.5 ([1.2, 1.8], p<0.001), large mediastinal
tumour HR 1.6 ([1.3, 1.9], p<0.001), sex HR 1.6 ([1.3, 1.9], p<0.001), high
ESR HR 1.5 ([1.3, 1.8], p<0.001), extranodal disease HR 1.4 ([1.1, 1.8],
p=0.013) and ≥3 involved nodal regions HR 1.3 ([1.1, 1.5], p=0.009).
Discussion. In addition to known prognostic such as mediastinal
tumour, elevated ESR, e3 involved nodal regions, older age and extran-
odal involvement male sex and age over 60 predict poor PFS in pts receiv-
ing 4-6 cycles of ABVD or similar chemotherapy plus radiotherapy. For
these pts, treatment has to be optimized.
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SEVERE BLEOMYCIN INDUCED PNEUMONITIS IN PATIENTS WITH 
HODGKIN’S LYMPHOMA
J. Markova, K. Klaskova, J. Vydra, J. Polivka, L. Zikavska, F. Cap, 
A. Vlachova, Z. Vernerova, J. Sturma, T. Kozak
University Hospital Kralovske Vinohrady, 3 th Medical School Charles Univer-
sity, Prague, Czech Republic
Introduction. Bleomycin-induced pneumonitis (BIP) has been well
described in Hodgkin s lymphoma (HL) patients (pts) treated with
bleomycin containing chemotherapy regimens. The central event in the
development of BIP is endothelial damage of lung vasculature caused by
release of cytokines and free radicals. Acute BIP may either resolve
copletely or progress into pulmonary fibrosis with irreversible damage to
pulmonary parenchyma.
Methods. We report on a retrospective study of 331 pts treated for new-
ly diagnosed HL from January 1995 to December 2006 with bleomycin
containing chemotherapy. Severe BIP was defined by the presence of pul-
monary symptoms, bilateral interstitial infiltrates, no evidence of infec-
tion initially and need for intensive care.
Results. Median age of pts was 31 years. 50% were males, the histol-
ogy was nodular sclerosis in 67%, advanced stages in 61%, B-symp-
toms in 72% pts. Frontline chemotherapy included BEACOPP in 61%,
ABVD in 22%, BEACOPP + ABVD in 9%, COPP + ABVD in 7%, ABV
in 1%. Sixty two percent of pts received radiation. 17 (5%) pts died.
Median folow - up of living pts is 50 months. Bleomycin dose 0-40
mg/m2 in 14%, 41-80 in 82%, 81-120 in 1% , 120< in 3%. G-CSF was
administered to 71% (236/331) of pts. Severe BIP was observed in 4
(1,2%) pts, the mortality rate was 0,6% in all pts and 50% (in two pts)
who developed the severe pulmonary syndrome. The four patients who
developed BIP were all older than 40 years, clinical stage was IVB, all
received G-CSF, were non-smokers and had normal renal functions.
Bleomycin dose was 72-150 mg/m2, BIP developed before the end of
chemotherapy in all patients (in three pts within 8 th, in one patient
within 7th cycle of BEACOPP or ABVD).
Conclusions. BIP is a severe and potentially fatal side effect of bleomycin
therapy. The ocurrence of BIP is unpredictable, BIP can develop even
after first dose of bleomycin. According to literature reports, the inci-
dence of BIP increases when cummulative dose of bleomycin exceeds
400 mg, in patients older than 40 years, smokers or patients with other
pulmonary disease or renal insuficiency. G-CSF and combination with
other chemotherapeutic agents also increase the incidence of BIP. Simi-
lar trends were observed in our patients. Genetic polymorphism which
might be responsible for increased risk of BIP in some patients are under
investigation. Supported by Grant MZ CR IGA NR 8033-6/2004
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CLINICAL SIGNIFICANCE OF INTRACYTOPLASMIC NM23-H1 EXPRESSION IN HODGKIN
LYMPHOMA
N. Niitsu,1,2 H. Nakamine,2 M. Okamoto,2 J.I. Tamaru,2 Y. Hagiwara,1
K. Tanae,1 S. Aoki,2 S. Nakamura,2 M. Hirano2
1Department of Hematology, Comprehensive Cancer Center, International Med-
ical Center, Saitama Medical University; 2The Adult Lymphoma Treatment
Study Group: ALTSG 2, Japan
Introduction. Recently, we established an ELISA technique for measur-
ing nm23-H1 protein in serum, and found that the serum nm23-H1 lev-
el is a potential prognostic factor for patients with lymphoma. We exam-
ined nm23-H1 expression in Hodgkin lymphoma (HL) in order to eval-
uate whether lymphoma cells produce the protein. 
Methods. We collected consecutive and untreated patients with
Hodgkin lymphoma (n=102), who were managed by the Adult Lym-
phoma Treatment Study Group in Japan from 1997 to 2006. Of the 102
patients with HL, 31 had MC and 71 had NS. We used immunohisto-
chemistry to examine the expression of nm23-H1, CD15, CD20, CD30,
Ki-67, and TIA-1 by the Hodgkin's and Reed-Sternberg (H-RS) lym-
phoma cells in patients with HL.
Results. nm23-H1 was positive in 86 of 102 (84.3%) cases, and posi-
tive frequencies according to lymphoma type were; 85% in NS, 81% in
MC, and 20% in nodular lymphocyte-predominant HL (NLP). CD15
was positive to 79% in NS, 77% in MC, and 0% in NLP. The expression
of Ki-67 or TIA-1 were 94% or 10%. The cytoplasmic nm23 expression
in lymphoma cells correlated significantly with the serum nm23-H1 lev-
el. There was a significant correlation between patients with cytoplas-
mic nm23-positive lymphoma and those with stage III/IV, bulky mass,
B symptoms, elevated serum level of sIL-2R, and elevated serum level of
CRP. Overall and progression-free survival rates were significantly low-
er in patients with nm23-H1-positive HL than in those with nm23-H1-
negative HL. Similar difference was seen between patients with high and
low serum levels of nm23-H1. Thus, the correlation between presence
or absence of cytoplasmic nm23-H1 expression and serum nm23-H1
levels suggests that serum nm23-H1 is produced directly by lymphoma
cells. 
Conclusions. Serum nm23-H1 is a rather stable protein that is easily and
rapidly measurable using only a small serum volume before initiating
treatment. Cytoplasmic nm23-H1 can be more easily examined at the
time of conventional phenotypic examinations for diagnosis of lym-
phoma, but quantitative evaluation of immunohistochemical staining is
difficult. Thus, the methods to examine serum nm23-H1 levels and cyto-
plasmic nm23-H1 expression have their own merits and demerits. We
suggest that nm23-H1 expression is a prognostic factor for HL, and that
it is as important as serum nm23-H1, both of which are useful for plan-
ning a treatment strategy.
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GONANDAL DAMAGE BEFORE AND AFTER TREATMENT OF FEMALE WITH HODGKIN'S
LYMPHOMA (HL). EXPERIENCE OF N.N. BLOKHIN RUSSIAN CANCER RESEARCH CENTER
(RCRC) 
I.V. Pylova, E.A. Demina, N.V. Lubimova, E.E. Perilova, R.G. Shmakov
N.N. Blokhin Russian Cancer Research Center, Moscow, Russia
Background. With success in treatment and high survival of young
women with HL the significance of treatment late effects is increasing.
Gonadal damage is not fatal but serious complication of the HD treat-
ment.
Patients and methods. Gonadal function was study in 146 female with
HL (age 14-44) who were treated in RCRC. Before the treatment gonadal
damage was occurred in 16 (11%) female and was determined of B-
symptoms (p=0.004), fever (p=0.003), anemia (p=0.009), weight loss
(p=0.04) and advanced stages (p=0.01). After the treatment gonandal
damage was higher -41.7% and in addition to B-symptoms and
advanced stages was correlate with age older 25 (p=0.0002), albumine-
mia (p=0.003), number of courses with cyclophosphamide if cumulative
dose was more than 6 gr. (p=0.02). During chemotherapy 58 female
received ovarian protection: 47 - oral contraceptives and 11 - Zoladex.
Dismenorrhea occurred in 11 (21.3%) female received oral contracep-
tives and none of female received Zoladex. Between female received 6
gr cyclophosphamide and more the frequency of amenorrhea was less
if oral contraceptives protection was -17.2% and 25.6% without contra-
ceptives. Gonadal hormones were study in 63 female and regular men-
strual cycle was in 55 (86.3%) of them. From 55 female with regular
menstrual cycle different changes in ovarian hormonal status before
treatment were in 22 (40%): hypoestrogenia -22.2%, low rate of prog-
esteron - 28.6% and low rate of ingibin-B - 15.9%. After treatment irreg-
ular menstrual cycle or amenorrhea were occurred in 41.7% female.
Gonadal damage was significantly frequent in female with changes in
ovarian hormonal status before treatment -50% and in 21.8% female
without hormonal changes (p=0.007).
Conclusions. Female after 25 years with advanced stages, B-symptoms
and anemia have high risk for gonadal damage after treatment with
cumulative dose of cyclophosphamide more than 6 gr. Oral contracep-
tives can protect gonadal damage, but Zoladex is best protector. Changes
in ovarian hormonal status before treatment - low rates of estrogen,
progesteron and ingibin-B can predict gonadal damage after treatment.
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TREATMENT OF HIV-ASSOCIATED HODGKIN’S DISEASE (HIV-HD): 
INTERIM ANALYSIS OF A PROSPECTIVE MULTICENTER TRIAL 
M. Hentrich,1 A. Masuhr,2 C. Hoffmann,3 D. Schuermann,4
J. Rockstroh,5 U. Kloenne,6 R. Weiss,7 D. Fong,8 H. Knechten,9
T. Wolf,10 F. Mosthaf,11 K. Arasteh,2 G. Faetkenheuer,12 A. Engert,12
P. Mitrou,10 C. Wyen12
1Harlaching Hospital, Munich; 2Auguste Victoria Hospital, Berlin; 3Private Prac-
tice, Hamburg; 4Charité University Medicine, Berlin; 5University Hospital Bonn;
6University Hospital Münster; 7Oncology Practice, Bremen; 8University of Inns-
bruck, Austria; 9Private Practice, Aachen; 10University Hospital Frankfurt; 11Pri-
vate Practice, Karlsruhe; 12University Hospital Cologne, Germany 
Introduction. Hodgkin’s disease (HD) is one of the most common non-
AIDS defining malignancies. Recent data indicate an improved outcome
of pts with HIV-HD treated since the introduction of highly active anti-
retroviral therapy (HAART). This trial was initiated to investigate a risk
adapted treatment strategy in pts with HIV-HD in accordance with stan-
dard treatment procedures established for HIV-negative pts with HD.
Methods. Pts with HIV-infection and histologically proven HD are
included in the ongoing study. Pts are planned to receive 2x ABVD + 30
Gy involved field (IF) radiation for early stage (ES) favourable HD, 4x
BEACOPP baseline +30 Gy IF for ES unfavourable HD (extranodal
involvement, large mediastinal mass, 3 or more lymph node areas
involved), and 6-8 x BEACOPP baseline for advanced stage HD. BEA-
COPP should be replaced by ABVD in pts with far advanced HIV-infec-
tion presenting with at least two of the following criteria: performance
status >2, CD4 cell counts <50/µL, prior opportunistic infection. HAART
is given to all patients in parallel to chemotherapy.
Results. Since March 2004, 43 males (median age 44 yrs, range 30-58)
were included in (n=38) or treated according to the ongoing trial (n=5).
To date baseline characteristics are available in 40 pts. Pts were diag-
nosed with stage I (n=4), stage II (n=8), stage III (n=15) and stage IV dis-
ease (n=13). B-symptoms were present in 24 of 40 cases (60%). In 33 of
38 pts (87%) HAART was given prior to HD and 10/37 pts (27%) had
a prior AIDS defining illness. The median CD4 counts at HD diagnosis
was 195/microl with a median viral load of <50/mL (range 0-454.000).
Pts received/are receiving ABVD (n=16) or BEACOPP baseline (n=20).
No data are yet available in 8 pts. Grade 3/4 toxicity was reported in 20
of 30 pts (67%) and 14 pts developed a documented infection. Response
data are available in 25 pts [CR 21 (84%), PR 1 (4%), SD 1 (4%), PD 2
(8%)]. After a median follow up of 11.7 months 5 pts have died, all of
them diagnosed with stage IVB HD. Causes of death were neutropenic
sepsis during the 7th course of BEACOPP (n=1), progressive HD (n=2),
progressive HD and HIV-infection (n=1) and not yet reported (n=1).
Discussion. In pts with HIV-HD risk-adapted CT and concomitant
HAART is safe and effective. However, pts are at increased risk for neu-
tropenic and opportunistic infections. These preliminary data suggest
that the prognosis of HIV-HD might approach results achieved in the
HIV-negative population with HD.
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HODGKIN LYMPHOMA IN TUNISIA: FIRST EVALUATION OF A PROSPECTIVE HODGKIN
LYMPHOMA STUDY: MDH 2002 (MONOCENTRIC EXPERIENCE OF 102 PATIENTS)
R. Ben Lakhal , M. Zarrouk, K. Zahra, R. Jeddi, L. Aissaoui, R. Ben Amor,
K. Kacem, Z. Belhadj Ali, H. Ben Abid, B. Meddeb
Department of Haematology, Aziza Othmana Hospital, Tunis, Tunisia
Introduction. Hodgkin lymphoma is a highly curable disease. Two chal-
lenges confrent the clinician treating Hodgkin lymphoma today: achiev-
ing a high level of effectiveness while minimizing toxicity.
Aim. to evaluate the clinical characteristics and the treatment results
of Hodgkin lymphoma in a Tunisian haematology department.
Patients and methods. From 2002 to 2005, 102 eligible patients who had
newly diagnosed hodgkin's lymphoma were included in the MDH2002
treatment strategy at the haematology department of Aziza Othmana
Hospital (Tunis-Tunisia). The Tunisian treatment strategy (MDH 2002)
is based on: a) the use of the EORTC prognostic factors in early stages
and the international prognostic scoring ( IPS ) in advanced stages; b) the
use of ABVD regimen: 3 cycles for favourable early stages, 6 cycles for
unfavourable early stage and 8 cycles for favourable advanced stages (IPS
<3). Involved fields radiotherapy is combined to chemotherapy for ear-
ly stages; c) the use of intensive chemotherapy (escalated BEACOPP
regimen level 4) for unfavourable advanced stages (IPS ≥3). 
Results. Median age was 35 years (16-68 years ) and advanced stages
(III, IV) were present at diagnostic in 63% of cases ( IPS >3 in 43% of
cases). 72% of our patients were B. The response rate is 79% The 5
years overall survival (OS) and relapse free survival (RFS) in (responders
patients) are respectively 85% and 90%.
Treatment results correlated to prognostic factors (Table 1). 
Table 1. Treatment results correlated to prognostic factors.
Early stages Advanced stages
Favourable Unfavourable IPS<3 IPS≥3
Response rate (>75%) 100% 81% 64% 71 %
Primary failure 0% 18% 35% 28%
Toxic deaths 0 0 0 N=2
OS 100% 96% 84% 73%
RFS (in responders patients) 100% 96% 62% 91%
Relapses 0 N=1 N=4 N=2
Conclusions. 2 problems still not solved: high rate of primary failure
treatment and high number of relapses in advanced stages and some
unfavourable early stages. The question to be answered: do we need the
use of escalated BEACOPP regimen in all advanced stages and some
unfavourable early stages (Bulky mass). 
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VALIDATION OF A NEW PROGNOSTIC SCORING SYSTEM (PSS) IN HODGKIN LYMPHOMA
ON DATA FROM THE GERMAN HODGKIN STUDY GROUP
C. Brillant,1 J. Franklin,1 M. Pfreundschuh,1 R. Duehmke,1 H. Tesch,1
L. Lathan,1 M. Sieber,1 D. Hasenclever,1 M. Loeffler,1 M. Georgi,1
M. Henry-Amar,2 B. Pfistner,1 V. Diehl,1 A. Engert1
1German Hodgkin Study Group, Department I Internal Medicine, University of
Cologne, Germany, 2EORTC Lymphoma Group
Introduction. The new three-risk-group Prognostic Scoring System (PSS)
established by the GOELAMS for staging Hodgkin Lymphoma (HL)
(Maucort-Boulch, Cancer 2007) is based on 4 variables: age, number of
involved areas, disseminated involvement of extralymphatic organs and
B-symptoms. The aim of this work is to validate this PSS-score on data
from the German Hodgkin Study Group (GHSG) and to compare it to
other currently used scores.
Methods. 4972 patients with a first diagnosis of HL were randomised
in the trials HD4-HD9 of the GHSG in 1988-1998 and received GHSG-
stage adapted treatment: patients with early stage received only radio-
therapy (RT) or 2xABVD+RT, patients with intermediate stage 2xCOPP-
ABVD or 2xCOPP-ABV-IMEP +RT and patients with advanced stage
4xCOPP-ABV-IMEP, 4xCOPP-ABVD or 8xBEACOPP ±RT. The PSS was
evaluable for 4859 patients.The PSS is a sum of the values of following
variables: age (0 for <40; 1 for ≥40); number of involved areas (0 for 1-
2; 1 for 3-4;2 for ≥5); disseminated involvement of extralymphatic organs
(0 for absence, else 1); B-symptoms (0 for absence, else1). The result
was pooled into 3 groups: stage1 (sum=0-1), stage2 (sum=2-3), and
stage3 (sum=4-5). The PSS was compared to the 3-class Ann Arbor stag-
ing system (AASS) (IA-IIA; IB-IIB-IIIA; IIIB-IV) and the classification of
the GHSG based on the Ann Arbor classification with 5 risk factors.
Results. The 3 systems have different distributions between their 3
groups. According to the PSS, 2936 patients (60%) were in stage1, 1652
(34%) in stage2 and 271 (6%) in stage3. According to the AASS, 2074
patients (43%) were in stage1, 1412 (29%) in stage2 and 1373 (28%) in
stage3. According to the GHSG-system, 930 patients (19%) were in
stage1 (early stage), 2088 (43%) were in stage2 (intermediate stage) and
1841 (38%) were in stage3 (advanced stage). Only few GHSG-patients
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were in stage3 for PSS. The GHSG-system had the lowest portion of
patients in stage1 and the highest in stage3. This distribution of GHSG-
and of GOELAMS-patients is similar. 
Discussion. In this group of patients, the effect of therapies should be con-
sidered in subgroup analyses. Overall Survival and Progression Free Survival
will be compared between different groups for each system. Analyses of
the time to progression and the EORTC-staging-system as well as addition-
al methodological analyses will be performed to determine the best prog-
nostic system. Furthermore EORTC data will be added to this dataset.
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EXPERIENCE WITH R-CHOP IN PATIENTS WITH LYMPHOCYTE PREDOMINANT HODGKIN
LYMPHOMA (LPHL)
M.A. Fanale, L.E. Fayad, J.E. Romaguera, P.W. McLaughlin, 
F.B. Hagemeister, B. Pro, B.S. Dabaja, L.J. Medeiros, M. Gilliam, 
A.R. Wedgwood, A. Younes
UT MD Anderson Cancer Center, Departments of Lymphoma/ Myeloma, Radi-
ation Oncology, and Hematopathology, Houston, TX, USA
Introduction. Given the rarity of the diagnosis of LPHL few publications are
available which describe treatment algorithms and predict short and long-
term outcomes. In order to provide further rationale for the best treatment
strategies we examined the outcomes of patients treated at our center.
Methods. A retrospective study was conducted to evaluate patients with
newly diagnosed LPHL treated at UT MDACC from 1996 to 2006.
Figure 1. Event free survival for all stages of LPHL.
Figure 2. Event free survival for stage 3 and 4 of LPHL.
Results. 51 patients were referred. Median age was 39 with a male:
female ratio of 2.4. Median follow-up was 61 months. 31 patients were
evaluable for response (3 had alternative diagnoses, 6 left during staging,
11 lacked full immunophenotyping). Also 3 patients were lost to follow-
up. 19 were stage I/II and 12 were stage III/IV. 4 patients had EN disease
(bone marrow/cortex, lung, breast) and 2 had spleen involvement. 2 trans-
formed to LCL (1 to DLBCL, 1 to TCR-LBCL). 3 patients died (1 from
AML-M6 with deletion 7, 1 from DLBCL, 1 from unrelated causes). 2
patients underwent ASCT (1 for relapsed LPHL with ASCT in CR3 with
no PD 15 months from ASCT, 1 for transformation to TCR-LBCL with no
PD 22 months from ASCT). For stage I/II patients there were 17 CRs and
2 PRs. Regimens included: STNI, mantle RT, IFRT, ABVD + STNI, R +
IFRT, COPP + IFRT, R-CHOP ± IFRT, and R-ABVD. For stage III/IV there
were 12 CRs. Regimens included: mantle RT, NOVP + mantle RT, R-
CHOP ± IFRT, ABVD, and R-ABVD. 9 patients received R-CHOP: 3 stage
I/II, 6 stage III/IV with 9/9 CRs and no relapses. R-CHOP compared to oth-
er treatments has a trend towards improved EFS (Figures 1 and 2).Discus-
sion. Our data demonstrates that LPHL patients have excellent respons-
es to treatment with a CR rate of 94% and reflects the heterogeneity of
treatment approaches over the past 10 years. In addition, it highlights the
risk of transformation to LBCL upon relapse. Finally, the EFS analysis pro-
vides support for a prospective investigation of R-CHOP as a front-line
treatment for LPHL.
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RITUXIMAB IN RELAPSED LYMPHOCYTE-PREDOMINANT HODGKIN’S LYMPHOMA: 
LONG-TERM RESULTS OF A PHASE-II TRIAL BY THE GERMAN HODGKIN LYMPHOMA
STUDY GROUP (GHSG)
H. Schulz,1 U. Rehwald,1 F. Morschhauser,2 T. Elter,1 C. Driessen,3
T. Rüdiger,4 P. Borchmann,1 R. Schnell,1 V. Diehl,1 A. Engert,1
M. Reiser1
1Department I of Internal Medicine, University of Cologne, Cologne, Germany;
2Hospitalier de Universitaire Lille; 3Medizinische Klinik und Poliklinik II, Uni-
versitätsklinikum Tübingen; 4Department of Pathology, University Wuerzburg,
Germany
Since nodular lymphocyte-predominant Hodgkin's lymphoma
(NLPHL) express CD20, rituximab may be used as a non-mutagenic
treatment option to avoid late toxicities in this rather indolent entity.
Between 1999-2004 the German Hodgkin Study Group investigated the
activity of rituximab (375 mg/m2 x 4) in a phase-II trial in 21 relapsed or
refractory NLPHL patients. The initial diagnosis of NLPHL was con-
firmed in 15/21 enrolled patients by reference pathology. The remain-
ing cases were reclassified as Hodgkin’s lymphoma transformed to T-cell
rich B-cell lymphoma (TCRBCL) (2) or CD20+ classical Hodgkin´s lym-
phoma (cHL) (4). In NLPHL patients the overall response rate was 94%,
including 8 CR and 6 PR. With a median follow-up of 63 months (range
3-84), the median time to progression was 33 months, whereas the medi-
an OS was not reached. Both TCRBCL were found in continous remis-
sion (73 ms+, 70 ms+) and 3/4 cHL patients reached CR. Thus, rituximab
is highly effective in relapsed and refractory NLPHL with efficacy in
CD20+ cHL and TCRBCL.
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CHEST X-RAY (CXR) AND THORACIC CT SCAN EVALUATION OF MEDIASTINAL 
LYMPHADENOPATHY IN PATIENTS WITH HODGKIN'S LYMPHOMA REVISITED
M.P.K. Angelopoulos, M.K. Angelopoulou, G.A. Pangalis, 
A.D. Gouliamos, M.P. Siakantaris, S. Kokoris, E. Dimitriadou, 
M.C. Kirtsonis, P. Tsaftaridis, E. Variamis, C. Kalpadakis, S. Sachanas,
S. Masouridis, T.P. Vassilakopoulos
1stDepartment of Internal Medicine, Department of Haematology; 2ndDepartment
of Radiology National and Kapodistrian University of Athens, Greece
Introduction. Bulky disease, especially in the mediastinum, has been
traditionally considered as an adverse prognostic factor for early stage
Hodgkin's Lymphoma (HL). Its significance is not clearly defined in
advanced disease. Bulky mediastinal masses also constitute an indication
for additional radiotherapy. However the definition of bulky mediasti-
nal disease is not uniform, when based on chest X-ray (CXR) findings.
Furthermore the relationship between CXR-defined and CT-defined
bulky disease has not been adequately investigated. 
Methods. We retrospectively evaluated CXR and thoracic CT findings
in 168 patients with HL involving the mediastinum from the files of
1100 HL patients diagnosed and followed up in our Departments the last
28 years. Bulky mediastinal masses were defined by determining the
madiastinal mass ratio (MMR) in posteroanterior CXR films taken in
maximal inspiration, by two methods: Method 1, (MMR1) as the ratio
between the maximal transverse diameter of the mass to the internal
transverse diameter of the thorax at the level of the T5-6 interspace.
Method 2, (MMR2) as the ratio between the maximal transverse diam-
eter of the mass and the maximal internal transverse diameter of the
thorax, usually close to the diaphragm. CXR-bulk, according to either
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method, was classified when MMR1 or MMR2 was ≥0.33. CT scans
were measured at the level where the mediastinal mass was appearing
in its maximal diameter and taking posteroanterior and transverse meas-
urements. According to CT findings, bulky disease was defined as the
presence of a mass ≥7 cm (CT-bulk7) or ≥10 cm (CT-bulk10). 
Results. MMR1 and MMR2 were ≥0.33 in 63% and 36% of the
patients respectively. According to CT findings, 60% and 26% had bulky
disease at the cutoff of 7 cm and 10 cm respectively. There was a signif-
icant correlation between MMR1 or MMR2 and the maximal diameter
of mediastinal lymphadenopathy in CT (Spearman's rho 0.589 and 0.568
respectively, p<0.001). Bulky MMR1 correlated better with CT-bulk7
(concordance rate 75%) than with CT-bulk10 (concordance rate 60%).
On the contrary bulky MMR2 correlated better with CT-bulk10 (con-
cordance rate 78%) than with CT-bulk7 (concordance rate 64%). 
Discussion. Different definitions of mediastinal bulky disease result to
substantially different patient classification. MMR2 correlated better
than MMR1 with the Cotswolds definition of bulky disease (cutoff set
at 10 cm by CT). The use of different approaches may affect the prog-
nostic significance attributed to bulky mediastinal disease.
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PROPHYLAXIS OF INFECTION USING GRANULOCYTE COLONY-STIMULATING FACTORS
OR ANTIBIOTICS IN PATIENTS RECEIVING MYELOSUPRESSIVE CHEMOTHERAPY FOR
HODGKIN LYMPHOMA. WHAT IS THE EVIDENCE?
C. Herbst, F. Naumann, I. Knauel, J. Bohlius, O. Weingart, A. Engert
Department I for Haematology and Oncology, Cochrane Haematological Malig-
nancies Group (CHMG), University of Cologne, Cologne, Germany
Information. Infections and fever are a common cause of morbidity
and mortality in patients receiving myelosuppressive chemotherapy for
Hodgkin lymphoma. Both prophylactic antibiotics and granulocyte or
granulocyte-macrophage colony-stimulating factors (G-CSF/GM-CSF)
are used. While G-CSF/GM-CSF is very expensive, the routine use of
antibiotics may be associated with an increase in antibiotic resistant
infections. Ideally the choice of prophylactic agent should be based on
the results of randomised trials examining the reduction of infection or
overall survival. The need for evidence-based and cost-effective strate-
gies is high.
Methods. A search of Medline, Embase and Cochrane Central was
done for the years 1980 to June 2007. Randomised controlled studies
were included in this study if they included at least 10 patients with
Hodgkin lymphoma and presented: i) a direct comparison of G-
CSF/GM-CSF and antibiotics, ii) G-CSF/GM-CSF vs. placebo or no treat-
ment, or c) antibiotics vs. placebo or no treatment. Both trials of primary
and secondary prophylaxis were included.
Results. The extensive literature search (~9000 abstracts) revealed few
randomised trials. There are no randomised trials for secondary pro-
phylaxis, ie. prophylaxis after a first infection or episode of febrile neu-
tropaenia. There are also no trials comparing G-CSF/GM-CSF with
antibiotics in patients with Hodgkin lymphoma. For primary prophylax-
is, a total of seven studies looking at G-CSF/GM-CSF vs. placebo or no
treatment were retrieved; 5 after haematological stem cell transplanta-
tion. Most of these trials have a mixed patient population and do not
present results by tumour entity. G-CSF/GM-CSF reduced the length of
neutropaenia and incidence of febrile neutropaenia, while the incidence
of fever or documented infections was usually not reduced. Two stud-
ies examining antibiotics vs. placebo with a mixed patient population
showed a reduction in the number of documented infections.
Discussion. The best strategy for the reduction of infections due to
myelosuppressive chemotherapy in patients with Hodgkin lymphoma
is unclear. Future trials incorporating a direct comparison between G-
CSF and antibiotics or between G-CSF and placebo would be of great
interest.
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PLASMA HEPARANASE AS A SIGNIFICANT MARKER OF TREATMENT RESPONSE 
IN CHILDREN WITH HODGKIN DISEASE: PILOT STUDY
M. Weyl Ben Arush,1,4 I. Shafat,2,4 A. Ben Barak,1 R. Bar Shalom,3
I. Vlodavsky,2,4 N. Ilan2,4
1Pediatric Hematology Oncology Department, Meyer Children’s Hospital, Ram-
bam Health Care Campus; 2Cancer and Vascular Biology Research Center;
3Nuclear Medicine Department; 4The Bruce Rappaport Faculty of Medicine,
Technion, Haifa, Israel
Introduction. The aim of this pilot study was to determine heparanase
plasma levels (HP) at diagnosis and at restaging in children diagnosed
with Hodgkin disease and to investigate whether this parameter pro-
vides prognostic information for response to treatment after induction
therapy.
Patients and Methods. Heparanase plasma levels of 17 consecutive pedi-
atric patients (pts) with Hodgkin disease were assayed at diagnosis and
at restaging. Mean age: 10.3 years (y) (4y-18y), 7 girls, 10 boys. Levels
of Heparanase were determined using an ELISA anti-human Heparanase
immunoassay kit. According to diagnosis, CAT scan, FDG/ PET-CT
fusion were performed to assess response to treatment after 2 to 3 cours-
es of chemotherapy. Two patients (pts) received VAMP protocol ( 1 pt
stage IA, 1 pt stage IIA), 4 pts received COPP/ABV ( 3 pts stage IIA bulky,
1 pt stage IIIA non bulky), 4 pts received ABVE-PC ( 2 pts stage IIB, 1 pt
stage IIA bulky, 1 pt stage IIIA bulky), 2 pts received ABVD (1 pt stage
IIA bulky, 1 pt stage IIIA), and 5 pts received escalated BEACOPP ( 1 pt
stage IIIB, 3 pts stage IVA, 1 pt stage IVB). 
Results. Changes in HP levels were found to correlate with response
to treatment for most of the children. At diagnosis, average HP level
was 1096 pg/mL (range, 141 pg/mL -5733 pg/mL) and decreased at
restaging to 630 pg/mL (range, 62 pg/mL -3267 pg/mL) (p=0.063). At
diagnosis, the average HP of the 13 patients in CR or VGPR was 1209
pg/mL and at restaging decreased to 626 pg/mL (p=0.034). At diagnosis,
the average HP level for the 4 pts with TP or PR was 1704 pg/mL and
increased to 1938 pg/mL at restaging.(p=0.08). Due to the small number
of patients we did not observe any correlation between the level of HP
at diagnosis, staging of the patients or any other clinical prognostic fac-
tor.
Conclusions. Changes in plasma heparanase levels correlated with
response to treatment for children diagnosed with Hodgkin disease.
This provides a rationale for exploring clinical interest in plasma
heparanase measurements of a larger group and using the test for clini-
cal trials of antiangiogenic therapies.
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AHOD0321: A COG PHASE II STUDY OF WEEKLY GEMCITABINE AND VINORELBINE IN
CHILDREN WITH RECURRENT OR REFRACTORY HODGKIN DISEASE
P.D. Cole, T.M. Trippett, R.A. Drachtman, P. DeAlarcon, L. Chen, 
R. Sposto, C.L. Schwartz
The Children's Oncology Group, Arcadia, CA, USA
Introduction. This COG Phase II study was conducted to assess the
efficacy and toxicity of gemcitabine/vinorelbine (GV) in pediatric
patients with heavily pre-treated relapsed/refractory Hodgkin disease. 
Methods. GV was given on days 1 and 8 of each 21d treatment cycle:
vinorelbine 25 mg/m2/dose IV and gemcitabine 1000 mg/m2/dose IV
over 100 minutes. Filgrastim 5 mg/kg/dose was started on Day 9 and
continued for a minimum of 7 days, until ANC was greater than
1500/µL. Response was evaluated after every two cycles. Patients with
measurable response after two cycles were given the option of going off
protocol therapy for stem cell transplantation (SCT). A minimum of two
additional cycles was mandated for those with stable disease after two
cycles. 
Results. Thirty-one eligible patients with a median age of 17.8 years
(range 10.7-29) were enrolled. Fourteen were female (45%). All patients
had received at least 2 prior chemotherapy regimens; 17 had prior autol-
ogous SCT. Toxicity and response data are currently available for 24
patients who completed at least two cycles and 16 who completed four
cycles of GV. Among those who completed two cycles, hematologic
toxicity was predominant, including grade 3-4 anemia (50%), leukope-
nia (71%), neutropenia (79%), and thrombocytopenia (83%). Nonhema-
tologic grade 3-4 toxicity included elevated SGPT (38%) or SGOT (21%)
and hyperbilirubinemia (4%). No patients developed non-cardiogenic
pulmonary edema. There have been three documented infectious com-
plications, including febrile neutropenia, sinusitis, and a urinary tract
infection. One patient, with a history of prior mediastinal irradiation,
developed pericardial and pleural effusions following cycles 4 and 5 of
GV, consistent with gemcitabine-induced radiation recall. There were no
toxic deaths. Response data are available for 23 patients of whom 17
(74%) have had measurable responses: 5 CRs, 10 VGPRs, and 2 PRs. All
radiographic evaluations of treatment response are undergoing central-
ized review and full response data for all enrolled patients will be avail-
able for presentation.
Conclusions. GV is an effective and well-tolerated re-induction regimen
for children with relapsed or refractory Hodgkin disease. 
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THE RESULTS OF TREATMENT OF HODGKINS DISEASE OF CHILDREN AND ADOLESCENT
N.R. Tyukalova
Federal Research Center for Pediatric Hematology, Oncology, and Immunology,
Moscow
Patiens and methods. Over a period of 15 years, since 1992 to 2007, 180
children and adolescents with Hodgkin s disease have entered this trial.
The chemotherapy was an equivalent to DAL HD 90. All patients (180
patients) were treated in Russian Pediatric Clinical Hospital (Moskow).
The age of the patients ranged from 2 to 18 years old. Average age was
12 years old; 103 boys, 77 girls. The distribution of the histological sub-
types according to the WHO-classification was analyzed: 24% had
nodular sclerotic type (NS), 68,5% mixed cellularity type (MCT), 0,5%
- lymphocyte predominant HL, 6% lymphocyte rich classical HL and 1%
lymphocyte depleted type. The distribution of the patients into disease
stages and treatment groups was as follows: TG I-16 (8,9%) patients; TG
II-114 (63,3%) patients; TG III-50 (27,7%) patients. Stage B symptoms
were detected in 80,5% cases, and extra nodal involvement in 24,6% cas-
es. All patients were treated by DAL HD 90. Four patients died while
receiving chemoradiotherapy: 3 due to sepsis, one from pneumocystic
pneumonia. Nine patients had relapse (4 early relapse and 5 late). One
(0,5%) patient suffered from secondary malignancies of Ewing s sarco-
ma in the irradiated field 7 years after the treatment was over. The esti-
mated probability of overall survival (OS) was 94,4% (Kaplan-Meier
analyses). The OS of patients sex: for boys 94,17%, for girls 94,81%,
p=0,84098. The OS for histogic variant was: LRCHL-100%, NS-97,9%,
MCT 92,5%, p=0,27928. The OS for stage: I AB -100%, II ABE-97%, III
ABE 92,4%, IV 83,5%, p=0,17554. The OS four B symptoms: OS
patients with B symptoms was 93,1%, with out B symptoms 100%,
p=0,9589. The OS for patiens with extra nodal involvement was 93,23%,
with out extra nodal involvement 93,75%, p=0,8010. The OS for treat-
ment group was: TG I 100%, TG II 96,%, TG III 89,8%, p=0,28591.
The OS does not depend on a sex , histologic variant, B symptoms, extra
nodal involvement, a stage and group of risk.
Late effects. The risk of secondary malignancies after diagnosis of
Hodgkin s disease during 15 years for patients treated according to the
DAL HD was 0,5%.
Conclusions. Protocol DAL HD is a gold standard for treating children
and adolescent with HD. 
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RESULTS OF THE MODIFIED PROTOCOL OF DAL-HD-90 FOR ADOLESCENT AND YOUNG
ADULT HODGKIN'S LYMPHOMA
S.V. Semochkin,1 S.S. Loriya,1 A.G. Rumiantsev,1 V.M. Sotnikov2
1Federal Scientific Clinical Center for Pediatric Hematology, Oncology and
Immunology, Moscow; 2Russian Scientific Center of Roentgeno-Radiology,
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Introduction. To improve results of therapy adolescents and young
adults with Hodgkin's lymphoma (HL) we were developed the modified
protocol of DAL-HD-90. This study was conducted to review the risk
factors, treatments and outcomes of this therapy. Methods: Retrospec-
tive review of 89 adolescents and young adults 15-33 years old (median
of 18 years; m-33, f-56) treated from 1995-2006 was performed. Origi-
nal separation of patients on therapeutic groups (TG) has been used.
Modification of the original protocol DAL-HD-90 consisted in replace-
ment of a vincrictine by a vinblastine the patient is more senior 20 years
and in change of doses of radiation therapy. All patients were received
involved-fields radiation therapy of 30 Gy plus boost of 6-10 Gy on
residual tumors. In TG 3 all patients were received an OPPA cycles with-
out dependence from a sex. For risk factor analyses, the Cox regression
models were used, involving sex, age, histology, B-symptoms, mediasti-
nal bulk with MTR >0.33, any bulky >50 sm3, number of nodal sites 4
and more, early response to therapy (CR/CRu after 2 cycles
OPPA/OEPA), E lesions, eryrthrocyte sedimentathion rate 50 mm/h and
more for A-stages and 30 mm/h and more for B-stages, International
Prognostic Index (IPI) for advanced HL and TG. 
Results. 11 (12%) patients have received therapy for TG 1 and 30 (34%)
for TG 2 and the most part-48 (54%) for TG 3. CR has reached 91% of
patients: TG 1-91%; TG 2 - 93% and TG 3-90%. At 8 (9%) patients there
was a progression on the first line of therapy: 1 (9%); 2 (7%) and 5
(10%), accordingly. Relapses have arisen at 7 (8%) patients TG 2 and TG
3: 2 (7%) and 5 (10%), accordingly. About time of occurrence 2 (29%)
relapse were early and 5 (71%) were late. 6y-OS was 0.93±0.03: TG 1-
0.91±0.10; TG 2-0.93±0.06 and TG 3-0.94±0.05 (p>0.05). 6y-EFS was
0.84±0.06: TG 1-0.91±0.10; TG 2-0.87±0.10 and TG 3-0.77±0.08
(p>0.05). The analysis of prognostic factor indicating progression and
relapse showed significant results for two parameters: absent of CR/CRu
after 2 cycles OPPA/OEPA (EFS 0.68 vs. 0.94, p<0.001) and IPS 4 and
more for patients of TG 2 and TG 3 (EFS 0.50 vs. 0.83, p=0.024). Discus-
sion: The modified protocol DAL-HD-90 is the highly effective approach
for treatment of adolescent and young adult HL. The early response to
therapy after 2 cycles OPPA/OEPA has shown itself as the powerful
prognostic factor of failures in treatment. 
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FOURTH ITALIAN MULTICENTRIC STUDY AIEOP LH 2004 FOR HODGKIN'S LYMPHOMA IN
CHILDHOOD: INTERIM ANALYSIS OF THE RESULTS
R. Burnelli, A. Todesco, A. Sala, L. Russo, F. Locatelli, M. Bianchi, 
S. Buffardi, S. D’Amico, A. Garaventa, N. Santoro, P. Farruggia, 
P. Cornelli, C. Favre, L. Notarangelo, A. Lippi, F. Fedeli, P. Bertolini, 
R. Pericoli, A. D’Ambrosio
Italian Association of Pediatric Hematology and Oncology (AIEOP)
The AIEOP-LH 2004 protocol was opened in June 2004 with the fol-
lowing main objectives: - to reduce toxicity in pts without negative prog-
nostic factors (group 1: stage IA and IIA with <4 nodal regions of disease,
without mediastinal mass or with M/T <0.33, no hilar adenopathy)
avoiding RT in pts in CR after 3 cycles of ABVD; - to increase the CR
rate and the Freedom from Progression (FFP) rate of pts with intermedi-
ate prognosis (group 2: pts not included in group 1 or 3) intensifying
therapy with 2 cycles of IEP if PR after initial 4 cycles of COPP/ABV fol-
lowed by RT; - to increase the CR and FFP rates of high risk pts (group
3: pts with M/T >0.33 and stage IIIB and IV) intensifying therapy with
2 cycles of IEP + 2 further cycles of COPP/ABV if PR after initial 4 cycles
of COPP/ABV followed by RT; - to reduce RT side effects utilizing low-
dose (14.4 Gy) irradiation only to the site of the disease (local field) in
group 2& 3 pts in CR after CT; - to improve the FFP rate of all pts in PR
after CT utilizing 25.2 Gy-local field-RT.Results As of February 2007, 220
pts were registered and 179 (81%) were evaluable for analysis (100 M,
79 F). 38 pts were included in group 1, 33 pts in group 2 (13 stage I-IIA
pts with >4 nodal sites and/or hilar involvement) and 108 pts in group
3 (46 pts because M/T >0.33). Group 1: After 3 ABVD 12 (31.5%) pts
were in CR and stopped therapy while 21 received 25.2 Gy RT; 1 pt
showed progression of disease (PD) and 4 were too early. Group 2: 19
(57.5%) pts received 14.4 Gy after 4 COPP/ABV; 9 (27%) reinforced
therapy with 2 IEP because in PR before RT and 5 were too early. Group
3: after initial 4 COPP/ABV, 89 (82%) pts were in CR, 9 (8.3%) intensi-
fied therapy with 2 IEP±2 COPP/ABV because in PR; 8 were too early
and 2 showed PD.The overall Survival and FFP rates at 2 years were
94.8% (96-100) and 83.7% (77-91), after a median observation time of
13 mos (38 days-34 mos). The FFP rates at 2 yrs of group 1, 2 and 3 were
93.5%, 89.1% and 78.4% respectively. Two (group 3) out of 20
relapsed/PD pts presented a mediastinal large B cell lymphoma at relapse;
the first histological diagnosis of HL was confirmed by the reviewer.
Conclusion Satisfactory results were registered in group 1, avoiding RT
in 1/3 of pts, and in group 2, utilizing low dose RT in 57.5%. The uncer-
tain results achieved in the group 3 pts need a more appropriate analy-
sis with a longer follow-up and the evaluation of all recruited pts. 
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OUTCOME OF CHILDREN WITH FIRST RELAPSE OF HODGKIN'S DISEASE. A REPORT
FROM THE SOCIÉTÉ FRANÇAISE DES CANCERS DE L’ENFANT (SFCE)
S. Gorde-Grosjean,1 S. Ansoborlo,2 H. Pacquement,3 A. Lambilliotte,4
G. Michel,5 O. Oberlin,6 T. Leblanc,7 Y. Perel,8 M. Schell,9 G. Leverger,10
J. Landman-Parker10
1Service d'hématologie pédiatrique, CHU Reims; 2Service de pédiatrie, CH
Saintes; 3Service de pédiatrie, Institut Curie Paris; 4Service d'hématologie pédi-
atrique, CHU Lille; 5Service d'hématologie pédiatrique, CHU Marseille; 6Ser-
vice de pédiatre, Institut Gustave Roussy Villejuif; 7Service de Pédiatrie, CHU
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Introduction. Pediatric patients with Hodgkin's disease (HD) relapsing
after primary chemotherapy have substantial chance of cure but the sal-
vage therapy is not consensual.
Purpose. To evaluate the outcome of paediatrics' patients with pro-
gressive or relapsing HD after primary treatment.
Patients. From 1987 to 2006, 69 patients were identified by the SFCE
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group, with progressive (refractory to treatment) (n=24) or first relapse
(n=45). Clinical presentation was: 38/69 male; median age 13.4 years (4
to 17.7); stage at relapse: Stage I n=8, Stage II n=27, Stage III n=8 and Stage
IV n=26. The median time from initial diagnosis to progression/relapse
was 5 months (0 to 56). 49/69 relapses occurred in irradiated area. 
Treatment. Salvage therapy consisted of chemotherapy in 68/69 cases
(with MINE n=43, IVA n=10, OPPA n=8, ABVD n=3, other n=4) and
radiotherapy in 1 case. High dose chemotherapy with autologous stem
cell transplantation (SCT) after salvage therapy was done for 49 patients;
double SCT was done for 5 patients. 
Results. 49/69 patients achieved second remission. Of 69 patients, 26
suffered seconds events, 18 died. With a median follow-up to 39 months
(1 to 140) global DFS and OS are 60% (±6) and 69% (±6) respectively.
The risk factor analysis revealed the time to progression/relapse as strong
prognostic factor. The DFS of patients with progression or early relapse
(<3 months) is 38% (±9%) whereas DFS of patients with late relapse
(>12 months) are 78% (±9) (p=0,008). Among the patients having SCT,
the outcome is better if the initial response of salvage therapy is good
(>70%) (DFS: 77% vs 22%, p<0,001). The following factors had no sig-
nificant impact on DFS in univariate analysis: sex, stage at relapse,
relapse in irradiated area, SCT or not.
Conclusions. After primary relapse patients have substantial chance of
second remission particularly in case of late relapse (>12 months). For
patients with progression or early relapse, novel approaches are needed. 
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PEDIATRIC HODGKIN LYMPHOMA (HL): 30-YEAR EXPERIENCE OF THE ISTITUTO
NAZIONALE TUMORI OF MILAN
G. Cefalo, L. Gandola, M. Terenziani, M. Massimino, R. Luksch, 
F. Spreafico, A. Ferrari, M. Casanova, D. Polastri, M. Podda, 
C. Meazza, S. Catania, E. Pecori, A. Marchianò, F. Fossati-Bellani
Fondazione IRCCS Istituto Nazionale Tumori Milano, Italy
Introduction. To evaluate both survival (S) and therapy-related seque-
lae, we reviewed our experience of 3 subsequent treatment programs for
stage I-III and a single study for stage IV.
Methods. From 1971 to 1999, 256 consecutive children ≤18 years of age
with newly diagnosed HL were treated at the Pediatric Unit of Istituto
Nazionale Tumori in Milan. Stage I-III. Study 1: before 1979 72 children,
staged by laparotomy with splenectomy, received extended-field RT (35-
45 Gy) without (stage IA-IIA) or with CT (6 MOPP). Study 2: from 1979
to 1989, 85 children staged with liver and spleen biopsies in laparoscopy
were treated with CT (3 ABVD) followed by limited-field RT (30-35 Gy
to involved nodal areas and 25 to adjacent ones), plus 3 additional ABVD
only to patients (pts) with B symptoms or stage III. Study 3: from 1989 to
1999, 51 children clinically staged were treated with CT (4-6 APVD, Pred-
nisone instead of Bleomycin) followed by involved-field (IF) RT (25-30 Gy
to involved nodal areas). Stage IV. From 1971 to 1999, 48 children with
stage IV were treated with CT (6 MOPP/ABVD) followed by IF-RT. 
Figure.
Results. After a median follow-up of 18 yrs, the 15-yr S was 74% for
72 children in Study 1, 96% for 85 pts in Study 2 and 95% for 51 pts in
Study 3. The 15-yr survival rate of the 48 stage IV pts was 86%. We eval-
uated type and severity of late effects (LE) in 243 long-term survivors.
In Study 1, 9 iatrogenic deaths occurred (sepsis 2, heart failure 2, second
tumour 5); 16 pts developed second malignant neoplasms, 7 severe car-
diac dysfunction and 5 heavily diminished pulmonary function. In Study
2, 7 pts developed second tumour (fatal 3), 4 severe cardiac dysfunction
and 5 pulmonary sequelae. In the Study 3, 2 pts developed second
tumour (1 exitus) and no other severe sequelae have been reported so
far. Considering the 48 stage IV pts, 5 developed second tumour (1 exi-
tus) and 3 major cardio-pulmonary sequelae. Fertility, thyroid and somat-
ic LE were also evaluated for the whole group. 
Discussion. A significant improvement in S and reduced morbidity
occurred for study 3 compared to the prior studies. Continued long-
term follow-up is needed for all patients.
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INITIAL RESPONSE TO SALVAGE THERAPY IS THE BEST PREDICTOR OF OUTCOME AFTER
PRIMARY RELAPSED OR REFRACTORY PEDIATRIC HODGKIN LYMPHOMA
M.L. Metzger,1,2 M.M. Hudson,1,2 M.J. Krasin,3 S. Kaste,3 L.E. Kun,3
S.C. Howard1,2
1Department of Oncology, St. Jude Children’s Research Hospital, Memphis,
TN, USA; 2Department of Pediatrics, University of Tennessee Center for Health
Sciences, Memphis, TN, USA; 3Department of Radiological Sciences, St. Jude
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Purpose. To evaluate the best predictor of outcome after primary
relapsed or refractory pediatric Hodgkin lymphoma. 
Methods. From 1990 to 2005, 313 patients with HL were treated with
risk-adapted chemotherapy ± involved field radiation therapy at St. Jude
Children's Research Hospital. We report outcomes of 47 patients that
either developed progressive or refractory disease during therapy or
relapsed. 
Results. The median age at diagnosis was 15.4 years (range 4.9 to 19.8
years); 30 patients were male; 32 were white and 15 black. Fourteen
patients presented initially with localized disease (1 stage IA, 13 stage
IIA) and 33 with advanced disease (IIB in 7, IIIA in 5, IIIB in 4, IVA in 7
and IVB in 10 patients). Initial therapy varied according to protocol and
stage. The median time to progression/relapse was 1.3 years (range 0.1
to 10 years). Ten patients had progressive disease, 9 early relapse (with-
in 12 months of diagnosis) and 28 late relapse (>12 months from diag-
nosis). Salvage therapy included multi-agent, intensive chemotherapy
(MIED, methotrexate, ifosfamide, etoposide, dexamethasone; ICE, ifos-
famide, carboplatin, etoposide; others) followed by autologous trans-
plant for patients with chemosensitive disease followed by radiation
therapy where possible. The 5-year overall survival (OS) for all the
patients was 67.2% (±7.9%). Of 11 patients whose disease progressed
on initial salvage therapy, only one remains alive without disease 3.6
years after primary relapse. Of the remaining 36 patients, who had sta-
ble disease (n=2), PR or CR (n=34) after initial salvage therapy, 31 (86%)
are alive with no disease (25 in second CR; 6 in 3rd or greater CR), 2 are
alive with disease and 5 have died (OS=90% at 5 years). Surviving
patients have been followed a median of 3.9 years (range, 0.4 to 15.4
years) since first relapse. Neither sex, age at diagnosis, timing of first
relapse (progressive disease, early relapse, late relapse) nor salvage
chemotherapy regimen (MIED, ICE, others) predicted response to sal-
vage therapy. Only response to initial salvage therapy was prognostic (p<
0.001 for progression vs. stable disease, PR, or CR).
Conclusions. Pediatric patients with relapsed or refractory HL that pro-
gresses during primary salvage therapy are rarely salvageable and should
be considered for experimental targeted therapy. In contrast, patients
that achieve a complete or partial response after initial salvage therapy
often achieve long-term survival.
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EVALUATION OF CARDIAC STATUS IN CHILDREN AND ADOLESCENTS WITH HODGKIN'S
LYMPHOMA: DATA OF A MONOCENTER STUDY
R. Feoktistov, O. Schurova, Y. Abugova, Y. Dyakonova, O. Makarova,
N. Myakova, N. Senyakovich, E. Samochatova
1Research Center for Pediatric Hematology, Oncology, Immunology, Moscow;
2Russian Children's Clinical Hospital, Moscow, Russia
Introduction. During the last decade in clinics of Russian Federation sig-
nificant success was achived in treatment children with Hodgkin's lym-
phoma (HL) with using DAL-HD-90. According our data a 5-year prob-
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ability of event-free survival was 84% and overall survival was 92%.
However, the using of doxorubicin in combination with mediastinal
radiotherapy in cases of initial mediastinal tumor predisposes the occur-
rence of early and late cardiomyopathy. 
Patients. We have evaluated the cardiac status in pediatric patients,
treated according to protocol DAL-HD-90. The study population consist-
ed of 27 patients with HL (m-16, f-11), mean age at the time of the study
was 14,1 years (range 4,2 to 17,9 years), follow-up after therapy 0,2 to
9,1 years. The cumulative dose of anthracyclines was 160 mg/m2. Dose
of the mediastinal radiotherapy was 25 Gy-4 patients, 30Gy-14 patients,
35Gy-7 patients, and 2 patients didn't received radiotherapy.
Method. Evaluation of cardiac function was performed using standard
M-mode echocardiography (with calculation ejection fraction-EF, left
ventricular shortening fraction-FS) and electrocardiography (with eval-
uation rate, rhythm and QTc). 
Results. No clinical signs of cardiac insufficiency were observed. Sig-
nificant decrease of contractility (FS<30%, EF<60%) occurred in 4 of the
27 patients (14,8%), in 3 of them was detected dilation of the left ven-
tricle and in 2 of them received the mediastinal radiotherapy in dose 35
Gy. 4 patients (14,8%) had hydropericardium (more than 5 mm) and it
was associated with decreased of voltage QRS. The postradiation peri-
carditis was often observed during 6 months after completing radiother-
apy but it was detected also after 1,8-3,5 years of treatment. 2 patients
(7,4%) had prolonged QTc, 2 patients (7,4%) had signs of overloading
of the left ventricle and in 4 patients (14,8%)-of the right atrium. We
found correlation of development of myocardiopathy and the dose of
irradiation, initial involvement of the lungs or pleura. 
Discussion. Although the protocol DAL-HD-90 includes low dose of
the anthracyclines we observed the cardiac dysfunction in children after
chemoradiotherapy. It demands of the monitoring of cardiac function
and cardiologist's consultation if necessary during long period of follow-
up.
P090
INTENSIVE CHEMOTHERAPY (E-BEACOPP) IN CHILDREN WITH ADVANCED STAGE
HODGKIN'S LYMPHOMA - EXCELLENT RESULTS AND ACCEPTABLE TOXICITY
G. Avrahami, S. Elitzur, H. Toledano, Z. Bar-Sever, B. Stark, I. Yaniv
Pediatric Hematology Oncology, Nuclear Medicine, Schneider Children's Med-
ical Center of Israel, Petah-Tikva, Sackler Faculty of Medicine, Tel Aviv Uni-
versity, Israel
Introduction. E-BEACOPP regimen is highly effective treatment for
advanced stage Hodgkin's Lymphoma, however dose intensive therapy
is associated with increased acute and late toxicity. The reported expe-
rience with this protocol in pediatric patients is limited.
Patients and methods. We report our experience in 15 children and ado-
lescents with advanced disease. Out of 50 children diagnosed with
Hodgkin's Lymphoma at the Schneider Children’s Medical Center of
Israel from October 2002 till May 2007, 15 were diagnosed with
advanced stage=3b or 4(a/b). Induction consisted of 4 cycles of E-BEA-
COPP. The response was assessed after 2 cycles by CT and gallium scan
in 3 patients and by PET CT in the remainder. Rapid response was
defined as reduction >70% in tumor size and no uptake of FDG or Gal-
ium. Consolidation therapy included E- BEACOPP/ABVE based proto-
cols in 3 and12 pts respectively. All pts received a total of 8 cycles of treat-
ment. Two pts received IF radiotherapy. 
Discussion. 15 children were enrolled, 8 girls and 7 boys. Age 6-17
years (mean -13 years). Fourteen had nodular sclerosis and one mixed cel-
lularity histology. All responded rapidly and there have been no recur-
rences to date-follow up 1-63 months (median 24 mos). Myelosuppres-
sion was observed in all patients. Other toxicities included: typhlitis in
two patients, mucositis in four patients and transient macroscopic hema-
turia in one patient. One girl died of sepsis during grade 4 neutropenia,
6 months on treatment following ABVE. During follow up one child
developed avascular necrosis of the femur and one girl partial ovarian
failure.
Conclusions. In our small group of patients E-BEACOPP protocol was
feasible, resulted in very good and rapid response and acceptable short
term toxicity. Assessment of the late sequella will require longer follow
up.
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Over last 10 years, treatment failures (progression, relapse) in
Hodgkins lymphoma (HL) occurred mainly in older children treated in
PPLLSG participating centers. That is why analysis of the influence of age
on the treatment outcome in children and adolescents treated with the
treatment program introduced in 1997 was performed. From 1997 to
2005, in 14 our centers, 568 patients (age from 2 to 19 years) were treat-
ed for HL. In all children MVPP and B-DOPA chemotherapy with or
without radiotherapy was introduced. The first remission was achieved
in 544 patients (97.5%). Relapses occurred in 22 patients (4%). They
had 6-19 (median: 14.7.) years of age at the time of diagnosis. The 5-year
probability of overall survival, relapse-free survival (RFS) and event-free
survival (EFS) was 96%, 95,5% and 92%, respectively. The logistic
regression analysis of age did not reveal the border value for increasing
the probability of relapse or event. Despite of that we have done com-
parison of results treatment in following 3 age groups: I under the
(n=108), II- 10-14,9 (n=233) and III-15-19 (n=227) years of age. The prob-
ability of 5-year EFS and RFS for children belonging to I, II and III group
was 95%, 92%, 91% and 97%, 95%, 91%, respectively. The differences
were not statistically significant. Among children over 10 year of age
some features of the disease occurred more frequently: presence of medi-
astinal tumor, IIIB and IV stage of the disease, NS histopathological type,
presence of general signs and ESR over 50 mm/1 h, greater tumor bur-
den and higher number of involved lymphatic regions. Among the
patients over 10 year of age, the presence of mediastinal tumor, more
advanced disease and ESR over 50 mm/1h significantly influenced the
occurrence of relapses (p=0.016; 0.05 and 0.05, respectively). The aim of
the further treatment modifications ought to comprise the need of bet-
ter treatment outcome in HL, especially in patients over 10 years of age
in which unfavorable prognostic factors are identified.
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OUTCOMES OF TREATMENT OF CHILDREN AND ADOLESCENTS WITH HODGKIN’S 
DISEASE WITH COMBINED MODALITY THERAPY. FIFTEEN YEARS EXPERIENCE
T. Stepanova,1 A. Pozdniakov,1 E. Sitnikova,1 G. Trubnikova,1
N. Judina,1 I. Kurilova,2 E. Basharova,3 V. Zlobina,4 K. Matushenko,5
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Purpose. Evaluation of treating results and toxic effects in children and
adolescents with Hodgkin's disease (HD) cured by Dal-HD-90 protocol
and it's modifications.
Materials and methods. From 1990 to 2005 years 339 patients with clin-
ical stages 1 to 1V HD treated with chemotherapy and low dose involved
fields radiotherapy in 7 institutions. Results evaluated by 5 year event free
survival (EFS) and overall survival rate (OS); toxic effects were observed.
The male/female ratio was 1,6/1. The median age - 10,6 years. 243
patients treated by the original Dal-HD-90 protocol with chemotherapy
(OPPA, COPP) and low dose involved fields radiotherapy up to 25 Gy;
46 pts. underwent Dal-HD-90 with the additional chemo (COPP, CVPP,
MOPP, CHVPP, PCVP ); 50 pts. received alternating chemotherapy with
the increasing radiation exposure up to 40 Gy. Consequently we had
three clinical groups: I. 243 - children treated according to the original
DAL-HD- 90 protocol; II. DAL-HD- 90 CT protocol with additional
chemotherapy; III- DAL-HD- 90 RT with increasing radiation exposure.
Results. After induction chemotherapy the response rate was 94%.
The overall survival - OS was 0,91, event free survival (EFS) - 0,86 of all
patients; 5,7% relapsed. The OS and EFS on the original protocol were
0,91 and 0,89 respectively. Survival rate of children and adolescents
depends on the stage of the disease. However, OS and EFS in patients
of the second and third groups were: OS=0,85, EFS=0,80 and OS=0,80,
EFS=0,78 respectively. Toxic effects after induction were: neutropenia
(66%), systemic infections (31%), and late effects: second malignancies-
OML (5%); cardiac toxicity (46%), scoliosis (5%) frequently observed
in patients, received overdoses of chemo- and radiotherapy. Early relaps-
es observed in 11% of patients (after 10 years old with primary advanced
HD), required intensified chemotherapy regimen BEACOPP, well
responded 3% patients died.
Conclusions. The DAL-HD-90 protocol is an effective universal, risk-
adapted, treating program. The escalating of DAL-HD-90 with addi-
tional chemo- and radiotherapy did not improve OS and EFS but
increased toxic effects. Relapsed Hodgkin's disease requires new clini-
cal approaches.
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CT45 EXPRESSION IN PEDIATRIC HODGKIN'S LYMPHOMA IS ASSOCIATED WITH 
NODULAR SCLEROSIS SUBTYPE, PRESENCE OF B SYMPTOMS AND ADVANCED DISEASE
STAGES
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1Department of Pediatrics and 2Hematopathology, University of Schleswig-Hol-
stein Campus Kiel, 3HELIOS Klinikum Berlin-Buch, 4Institute of Hematopathol-
ogy, Hamburg
Introduction. CT45 is a member of the Cancer Testis Antigens (CTA)
family characterized by a restricted expression pattern in normal testis
and a variety of malignant diseases. The CT45 gene family is located on
chromosome Xq26.3. The nuclear protein of 25/22 kDa can be detect-
ed in archived paraffin-embedded tissue specimens by a monoclonal
antibody generated after immunization of mice with HL-derived cell
line L428. So far, only few data on the expression of CTA in Hodgkin's
lymphoma (HL) are available. 
Material and Methods. We performed an immunohistochemical study
on diagnostic biopsy specimens from 477 pediatric and adolescent
patients (median age 14 years, 55% male) enrolled in the pediatric mul-
ticenter trial GPOH HD95 between 1996 and 2000 with respect to the
expression pattern of CT45. Immunohistochemical results of CT45
expression were correlated with histological subtype, immunopheno-
type and clinical data.
Results. Classical HL (cHL) was diagnosed in 426 patients (89%) and
nodular lymphocyte predominant HL (NLPHL) in 51 patients (11%).
The group of cHL included 314 cases of nodular sclerosis HL (NSHL), 103
cases of mixed cellularity HL (MCHL), three cases of lymphocyte-rich
cHL, four cases of lymphocyte-depleted HL (LDHL) and two not classi-
fiable cases. Nuclear CT45 expression was found in 239 cases (50%)
with striking differences among histological subtypes and unrelated to
CD30, CD20 and latent EBV infection. In NLPHL, 8% of cases scored
CT45 positive in contrast to 55% of cases in cHL (p<.001). Within cHL,
60% of cases with NSHL were CT45 positive compared to 42% with
MCHL (p=.001). Of aggressive histological variants of cHL (NSHL Ben-
nett 2, LDHL) 64% stained were CT45 positive. CT45 expression was
associated with stage (p=.001) and presence of B symptoms (p=.02).
More patients from treatment group (TG) 2 and 3 (intermediate and
advanced disease) were CT45 positive than patients from TG1 (localized
disease; 57% vs. 40%, p<.001). With a median follow-up of 5.5 years,
97% of patients are alive. No significant differences were observed for
overall survival, failure-free survival and event-free survival with respect
to CT45 status.
Conclusions. CT45, which is restricted to Hodgkin and Reed-Sternberg
cells, was found in about half of the patients. The high expression in
patients with more aggressive histological subtypes, B symptoms and
advanced stages indicates that CT45 might be a marker of biological
behavior of HL. Moreover, the expression pattern of CT45 in H&RS
cells makes it an additional valuable tool in the differential diagnosis of
HL from similar appearing reactive lesions.
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TOPOISOMERASE IIALPHA (TOPOIIα) EXPRESSION IN HODGKIN’S LYMPHOMA (HL):
PROGNOSTIC SIGNIFICANCE AND CORRELATIONS WITH CONVENTIONAL 
PROGNOSTIC FACTORS AND BIOLOGICAL MARKERS RELATED TO ANGIOGENESIS AND
APOPTOSIS
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Introduction. TopoIIalpha is a target for several cytotoxic agents used
in HL, such as doxorubicine, epirubicine, etoposide, and mitoxantrone,
but it may also serve as a proliferation marker. High TopoIIalpha expres-
sion has been associated with adverse prognosis in some neoplasms, but
in the single study of 42 patients (pts) with HL, it was a favorable fea-
ture. 
Methods. We report the final results on the immunohistochemical
(IHC) expression of TopoIIalpha and its association with demographic,
clinical and laboratory features and prognosis in 238 pts with HL, who
had been treated with ABVD or equivalents ± RT. IHC was performed
using the monoclonal antibody KiS1 (DAKO, Denmark). The prolifera-
tion marker Ki-67 was evaluated in 211 patients [MIB1 (YLEM)]. TopoI-
Ialpha was also evaluated in comparison with IHC biological markers:
Morphometric parameters reflecting angiogenesis, as microvascular den-
sity (MVD), total vascular area (TVA), and shape factor (SF) (n=226), bcl-
2 (n=175) and activated caspase-3 (aC3) expression (n=97). The median
age of the pts was 30 years (15-82), 49% were males and 97% had clas-
sical HL. 
Results. The median percentage of TopoIIα+ Hodgkin-Reed-Sternberg
(HRS) cells was 64% (5-98%; interquartile range: 51-78%), being 76%
(8-99%) for Ki-67. TopoIIα and Ki-67 were loosely correlated (S-rho
0.255, p<0.001). TopoIIα expression was neither correlated with conven-
tional prognostic factors nor with MVD, TVA, SF or expression of bcl-
2 and aC3. At a median follow-up of 111 months, the 10-year failure free
survival (FFS) and disease specific survival (DSS) for patients with TopoI-
Iα expression within the upper 3 (Q1-3) and the 4th quartile (Q4) was
82±3% vs. 68±7% (p=0.02) and 94±2% vs. 83±5% (p=0.005) respective-
ly. In multivariate analysis, TopoIIα expression within Q4 was an inde-
pendent prognostic factor for FFS (p=0.02) and DSS (p=0.01), even after
adjustment for the International Prognostic Score. The inclusion of SF did
not alter its prognostic impact (p=0.04 for FFS and DSS). 
Discussion. TopoIIα expression appears to be a primary prognostic vari-
able in HL, because it is not statistically associated with established con-
ventional and biological markers. Under standard anthracycline-based
treatment, high TopoIIα expression provided independent prognostic
information. Patients with high TopoIIα expression might benefit from
first-line chemotherapy regimens including another TopoIIalpha
inhibitor in addition to doxorubicine, such as BEACOPP-escalated.
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SERUM PROFILING OF ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS AT HIGH
RISK FOR TREATMENT FAILURE
R. Rautert,1 J. Franklin,2 M. Weihrauch,2 I. Hartlapp,2 T. Schober,2
V. Diehl,2 D. Re2
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Rationale. Although Hodgkin Lymphoma patients can be cured nowa-
days in a high percentage, early relapses and progressive disease remain
a therapeutic challenge. Clinical scores such as the International Prog-
nostic Score (IPS) were designed to predict the outcome of advanced
stage HL patients but fail to identify this very high risk population. We
therefore aim to identify biological serum factors that might be of prog-
nostic relevance in advanced stage HL.
Method. Hodgkin Lymphoma patients with advanced stage disease
treated within the second, third and fifth generation of the German
Hodgkin Study Group phase III trials were included in this retrospective
case-control study. 56 advanced stage patients with progressive disease
or early relapse within 12 months after the end of disease specific treat-
ment were matched with patients in continuous complete remission.
Patients were matched according to stage, age, sex, IPS and histological
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subtype. Pretherapeutic sera of those 112 patients were analyzed for
expression of 28 cytokines and chemokines. The amount of protein
expression was quantified using immunoassays including the bead based
FlexSet technology (Becton Dickinson) and conventional sandwich
ELISA technology.
Results and Conclusions. Univariate and multivariate analysis are cur-
rently underway. Results of this test cohort will be presented at the
meeting. In addition to the 56 individuals with advanced stage disease,
pretherapeutic sera of 38 intermediate stage patients suffering from pro-
gressive disease or early relapse will be available to validate results.
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TIPIFARNIB AS DOXORUBICIN-CHEMOSENSITIZER IN HODGKIN LYMPHOMA TUMOR
CELLS
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Introduction. The severe acute and late toxicities of chemotherapy in
Hodgkin lymphoma (HL) patients demand new therapeutic combina-
tions. Tipifarnib is a farnesyl transferase inhibitor with an excellent tox-
icity profile and clinical activity in hematologic malignancies. Recently,
tipifarnib has also been shown to potentiate the cytotoxicity of anthra-
cyclines in leukemia cells via the inhibition of the multidrug resistance
transporter P-glycoprotein. To date, nothing is known about a function-
al role of drug resistance transporters or the effects of tipifarnib in HL.
Methods. To test the anti-tumor effects of tipifarnib in HL cell lines, tip-
ifarnib was evaluated in the XTT cytotoxicity assay and the Annexin V
binding assay. The combination efficacy of tipifarnib with the anthra-
cycline doxorubicine was monitored using the Chou and Talalay com-
bination index method. Flow cytometry was applied to assess the effects
of tipifarnib on drug transporter mediated anthracycline efflux.
Results. First, tipifarnib displayed high single agent toxicity in HL cell
lines with an average IC50 of <0.1 µM. Second, the combination of tip-
ifarnib and doxorubicine was highly synergistic at clinically relevant
concentrations (1-3 µM and 0.02-0.2 µM, respectively). Third, measure-
ment of residual doxorubicine after incubation with doxorubicine and
tipifarnib indicated the inhibition of doxorubicine efflux by tipifarnib
suggesting a mechanism for the synergy of the two drugs.
Discussion. Tipifarnib exhibits a dual targeting mechanism in HL cells:
Potent cytotoxicity as single agent and drug transporter dependent
chemosensitization leading to a strong synergy with doxorubicine. The
synergistic combinations of tipifarnib with doxorubicine correspond to
plasma levels of the two drugs in cancer patients. Doxorubicine is one
of the most effective but also most toxic drugs in the standard HL poly-
chemotherapies whereas tipifarnib has a very favourable toxicity profile.
Consequently, tipifarnib should be evaluated as a combination drug for
HL polychemotherapy to save on doxorubicine dose and to lower acute
and long-term toxicities. Tipifarnib might also be examined as a
chemosensitizer for the combination therapy of patients with refracto-
ry disease.
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HUMANIZED ANTI-VEGF MONOCLONAL ANTIBODY (BEVACIZUMAB) THERAPY IN 
COMBINATION WITH CHEMOTHERAPY - A NEW OPTION FOR HODGKIN LYMPHOMA
TREATMENT?
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Introduction. For most patients Hodgkin Lymphoma (HL) has become
a curable disease after the introduction of improved treatment strategies
such as polychemotherapy regimens and extended-field radiation. But
for patients with advanced refractory or relapsed disease there are cur-
rently no curative treatment options available. Vascular endothelial
growth factor (VEGF) is highly expressed by Reed-Sternberg and
Hodgkin cells and is known to be secreted by HL cell lines when put
under hypoxic stress. HL cells also express the VEGF-R2 receptor that
mediates growth stimulation. Thus, it is most likely that VEGF con-
tributes to the development and growth of HL not only by stimulating
the malignant phenotype in an autokrine fashion but also by induction
of neoangiogenesis. Therefore, the application of anti-VEGF therapy
might be beneficial for the treatment of HL. On this account, we tested
the humanized monoclonal anti-VEGF antibody Bevacizumab (Avastin)
(BV) in an off-label use in combination with Gemcitabine.
Methods and results. Six patients with multiple relapsed or progressive
disease were treated two courses with monotherapy BV (10-15 mg/kg
body weight), followed by two courses BV plus Gemcitabine (1000
mg/m2). PET, NMR, CT, serology (VEGF, sCD30, TARC, TGFbeta, IL-8)
and FACS analysis of circulating endothelial cells (CEC) were performed
for each patient before administration of BV (day 0), after two courses
of BV (day 14+28) and after 4xBV+2x Gemcitabine (day 56). Adminis-
tration of BV alone or in combination with Gemcitabine led to partial or
even complete remission in four of seven cases. Changes in sera levels
of TARC, sCD30 and VEGF as well as in the amount of CEC are consis-
tent with the treatment response according to PET, CT and NMR.
Conclusions. These preliminary results indicate that anti-VEGF thera-
py sensitizes HL for chemotherapeutic treatment. Thus, the humanized
anti-VEGF monoclonal antibody Bevacizumab seems to be a promising
therapeutic option to enhance the efficacy of conventional chemother-
apy in HL. Final results will be presented.
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HODGKIN’S LYMPHOMA IN ADOLESCENTS AND ADULTS
H. Bredenfeld, H. Haverkamp, E. Gilman, V. Diehl, A. Engert, on
behalf of German Hodgkin Study Group (GHSG)
German Hodgkin Study Group (GHSG)
Introduction. Wether adults patients (pts) and adolescents with HL do
reflect distinct patient groups requiring different treatment regimens is
still a matter of debate. For the purpose of comparing clinical presenta-
tion, treatment outcome, and long term sequelae, pts aged 16 to 20 years
(yrs) and pts aged 21 to 45 yrs were evaluated from six different GHSG
trials for first-line treatment in early, intermediate and advanced stages
of HL.
Methods. Differences in patient characteristics were compared using
Fisher´s exact test. Univariate survival analysis was made with the
Kaplan-Meier method, freedom from treatment failure (FFTF) and over-
all survival (OS) were compared with the log-rank test. The effects of age
group, gender, stage, risk factors, and treatment modality on FFTF and
OS were estimated using Cox proportional hazards regression with dura-
tion response as dependend variable. 
Results. A total of 3.756 pts aged from 16 to 45 yrs were included in
this analysis, 562 adolescents and 3.194 adults. Significant differences
between the two groups concerned the presence of risk factors large
mediastinal mass, three or more lymphnode areas involved (p<0.001
each, shown more frequently in adolescents than in adults) and second-
ary neoplasias (p=0.04, more frequently in adults). After a median obser-
vation time of 6 years, FFTF rates for adolescents and adults were 80.1
and 79.8 percent respectively (log-rank test not significant, p=0.589). 6-
year OS rates were 93.1 and 91.0 (log-rank test also shows no significant
difference, p=0.057). 
Evaluating the role of age group on FFTF and OS, Cox regression analy-
sis identified Ann Arbor stage, B symptoms, large mediastinal mass and
allocated treatment as significant predictors with identical models for for-
ward and backward selection, with patients in Ann Arbor stage>II or with
B symptoms or large mediastinal mass having poorer outcome. Adding age
group to the final models, the prediction of the model including age
improved significantly for OS (p=0.013) with a higher risk for the older age
group (HR 1.51, 95%-CI [1.07, 2.14]). The model for FFTF including age
group did not perform better than the model without (p=0.4).
Discussion. Treatment outcome in terms of FFTF and OS after 6 years
median follow up shows no significant differences for both adolescent
and adult pts with HL. But, single patient characteristics are variant
between the two subgroups. Evaluation of the impact of age to OS
showed a significant higher risk for the adults group compared to the
adolescent. 
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RESULTS OF THE RANDOMISED PHASE II TRIAL FOR THE REDUCTION OF OVARIAN 
FAILURE WITH THE USE OF GNRH-ANALOGUES AND ORAL CONTRACEPTIVES IN YOUNG
WOMEN (18-40 YEARS) TREATED WITH INTENSIVE CHEMOTHERAPY FOR 
ADVANCED-STAGE HODGKIN LYMPHOMA (HL)
K. Behringer,1 L. Wildt,2 H. Haverkamp,1 V. Diehl,1 B. Pfistner,1
A. Engert,1 on behalf of German Hodgkin Study Group
1German Hodgkin Study Group, Cologne, Germany; 2University Hospital for
Gynecology and Reproduction medicine, University Hospital Innsbruck, Austria
Introduction. For the ongoing trials of the German Hodgkin Study
Group (GHSG), the reduction of treatment-related toxicities is of major
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importance. The prevention of ovarian failure in young women with
oral contraceptives and Gonadotropin-releasing hormone agonistic
analoges (GnRH-a) is due to the decline of serum gonadotropin levels
inhibiting follicular growth in the ovary. As contradictory results on the
effects have been published, the GHSG started a randomised phase-II
trial (PROFE) for the reduction of ovarian failure with the use of GnRH-
a and oral contraceptives in young women treated with intensive
chemotherapy for advanced-stage HL. The aim of the trial was to define
a standard co-treatment for the reduction of infertility rates in young
female patients during chemotherapy for HL. 
Patients and Methods. The study was designed for young female
patients (18-40 years) with advanced-stage HL, including stage II with
B symptoms and one of the following risk factors: extranodal disease
and/or large mediastinal mass, stage III, and IV. The patients were ran-
domly assigned either to receive daily oral contraceptive (Microgynon)
or to receive the GnRH-analogue (Zoladex) given monthly during 8
cycles of polychemotherapy with escalated BEACOPP. Blood samples
were drawn for determination of hormonal levels once before the begin-
ning of therapy, monthly during therapy, and 6, 12, and 18 months after
therapy. Hormonal profiles including follicle-stimulating hormone (FSH),
luteinizing hormone (LH), E2, AMH, prolactin, testosterone, DHEAS,
SHBG, Inhibin A, Inhibin B, progesterone), and AMH were measured to
document fertility status. The primary endpoint were FSH levels 6
months after the end of therapy (FSH: <15 mLU/mL: normal ovarian
function, FSH: >15 mLU/mL: ovarian failure)
Results and Conclusions. The recruitment of the trial was stopped
because of the following major reasons: first, the application of the more
intensive 8 cycles of escalated BEACOPP instead of 6 cycles, or 8 cycles
of BEACOPP-14. Second, to date, mostly all female patients in advanced
stages already receive GnRH-analogue co-treatment, as recommended
by their gynaecologists, and could therefore not be included into the
PROFE trial. Consequently, only a total of 23 patients are now evaluable
for the final analysis of blood samples 6 months after the completion of
therapy, 12 were enrolled into arm A (oral contraceptives) and 11 into
arm B (GnRH-analogue). At randomisation, the youngest women was
19, the oldest 41 years. Results of hormonal levels before, during, and
after therapy will be presented.
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A NOVEL ANTIBODY-DRUG CONJUGATE, SGN-35 (ANTI-CD30-AURISTATIN), INDUCES
OBJECTIVE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN 
LYMPHOMA: PRELIMINARY RESULTS OF A PHASE I TOLERABILITY STUDY
A. Younes,1 A. Forero-Torres,2 N. Bartlett,3 J.P. Leonard,4
B. Rege,5 D.A. Kennedy,5 J. Lorenz,5 E.L. Sievers5
1Houston, Texas, USA; 2Birmingham, AL; 3St. Louis, MO; 4New York, NY;
5Seattle Genetics, Inc. Bothell, WA, USA
Background. Expression of CD30 by malignant Reed-Sternberg cells
is a defining feature of Hodgkin lymphoma (HL).  Unconjugated anti-
CD30 monotherapy in HL patients has been well-tolerated and associ-
ated with modest clinical activity. SGN-35 is an antibody-drug conjugate
(ADC) consisting of the anti-CD30 antibody cAC10 chemically conju-
gated to the antitubulin agent monomethylauristatin E (MMAE). The
proposed SGN-35 mechanism of action involves binding to CD30 on the
surface of tumor cells, internalization of the ADC, and release of MMAE
from the conjugate through enzymatic degradation of the drug linker in
the lysosomes. Binding of released MMAE to tubulin disrupts the micro-
tubule network, leading to G2/M phase cell cycle arrest and apoptosis.
Methods: A multicenter phase I, open label, dose escalation study is
being conducted in patients with refractory or recurrent CD30-positive
hematologic malignancies. Twenty patients, 18 with HL, 1 with CD30+
angioimmunoblastic T-cell lymphoma, and 1 with systemic anaplastic
large cell lymphoma, have been enrolled. The median age was 32 (range
22-87) and patients had received a median of 4 prior therapies. Fifteen
patients had previously received an autologous hematopoietic stem cell
transplant. SGN-35 was administered to cohorts of patients at dose lev-
els including 0.1, 0.2, 0.4, 0.6, 0.8, and 1.2 mg/kg/dose (2-hour intra-
venous infusion, premedications were not required) every 3 weeks.
Patients with stable disease or objective response after 2 doses were eli-
gible to receive additional doses of SGN-35 every 3 weeks.
Results. No dose-limiting toxicities (DLT) and no infusion reactions
have been observed through the 1.2 mg/kg cohort. One patient experi-
enced Grade 3 hypercalcemia and 1 patient had Grade 3 urticaria, both
considered possibly drug related. After the 4th dose at 0.4 mg/kg, 1
patient with an anatomic high-grade coronary artery narrowing experi-
enced a possibly related myocardial infarction that resolved without
sequalae and was not considered a DLT. No other clinically meaningful,
related adverse events have been observed. Pharmacokinetic data sug-
gest that ADC is the major component of the total circulating antibody.
Exposure (AUC) to ADC increased relative to dose increment, and no
accumulation was documented with repeat dosing. Preliminary inves-
tigator assessed restaging included the following: Objective responses
(CR/PR) (n=4), stable disease (n=9), and progressive disease (n=7). In
the 1.2 mg/kg dose cohort, tumor reduction occurred in all 4 patients,
of whom 2 have achieved partial responses. Ten patients are continuing
to receive treatment with stable disease or better. Enrollment continues
at the 1.8 mg/kg dose level.   
Conclusions. Infrequent outpatient infusions of SGN-35 have been well
tolerated and have resulted in multiple objective responses in patients
with CD30+ lymphoma refractory to conventional therapy. These pre-
liminary results suggest that SGN-35, a novel antibody-drug conjugate
targeting CD30, may be an active, targeted therapy for patients with HL. 
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BREAST CANCER RISK IN 5-YEAR SURVIVORS OF HODGKIN'S LYMPHOMA,
THE INFLUENCE OF TREATMENT AND PREMATURE MENOPAUSE
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Introduction. Female Hodgkin's lymphoma (HL) survivors are at
increased risk of breast cancer (BC) up to 25 years after treatment, espe-
cially those irradiated to the breast area at young ages. We assessed the
cumulative risk after 25 years and the influence of gonadotoxic therapy
on the risk of BC in patients irradiated to the breast area.
Methods. We performed a cohort study in 1155 women, treated for HL
in the period 1965-1995 before age 51 (32% (RT), 8% CT, 60% RT+CT).
We compared the incidence of BC with the general population and cal-
culated standardized incidence ratios (SIRs) and absolute excess risks
(AERs). We assessed absolute risk at 30 years using Kaplan-Meier risk
estimation and competing risk techniques. Cox regression analyses was
performed to study therapy-effects in relation to gonadotoxicity.
Results. During follow-up (median 18.2 years), 100 women, of whom
99 were irradiated to the breast area, developed BC (SIR 5.4 [95%CI 4.4-
6.6], AER 54 per 10,000 patients per year). The risk remained high after
prolonged follow-up (>30 years after treatment SIR 8.7 [4.2-16.0]).
Although women treated before age 21 experienced the highest risk
(SIR 16.9 [11.1-24.9], the risk among women aged 31-40 at treatment
was still elevated (SIR 2.9 [1.8-4.5]). The cumulative risk (Kaplan-Meier)
for BC 30 years after first treatment was 22%, whereas the cumulative
incidence accounting for death as a competing risk was 17% at that
time. Among women irradiated to the breast area, treatment with pro-
carbazine (≤8.4 g/m2: HR 0.6 [0.3-1.1], >8.4 g/m2: HR 0.4 [ 0.1-1.0]), as
well as RT to the ovaries (HR 0.3 [0.0-1.1]) lowered the risk for BC. In
addition, women who retained normal ovarian function ≥16 years after
treatment were at an increased risk for BC compared to those with <8
years of intact ovarian function (HR 5.4 [2.1-13.8]). Smoking and use of
oral contraceptives did not influence the risk of BC, whereas obese
women had a higher risk for BC (HR 1.8 [1.0-2.9]). 
Conclusions. The risk of BC remains elevated up to >30 years after
treatment, which suggests need for lifetime surveillance. The Kaplan-
Meier method highly overestimated the absolute risk of BC after HL
compared with the method accounting for death as a competing risk.
Gonadotoxic therapy lowers the risk of BC in patients irradiated to the
breast area.
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RISK ADAPTED BEACOPP REGIMEN BASED ON EARLY SCINTIGRAPHY CAN REDUCE THE
CUMULATIVE DOSE OF CHEMOTHERAPY FOR STANDARD AND HIGH RISK HODGKIN
LYMPHOMA (HD) WITH NO IMPAIRMENT OF OUTCOME
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This prospective study evaluated the outcome of HD patients whose
chemotherapy was tailored based on the results of scans performed after
one or 2 cycles of chemotherapy, thus reducing the cumulative
chemotherapy for early responders and maximizing the dose for late
responders. The study was initiated in 1999 for patients with classical
HD aged 18-65 years. Eligibility criteria were either stages I, II with
unfavorable features or any stage III or IV HD. Disease stage was defined
according to the International Prognostic Score (IPS). Patients with stan-
dard risk were treated with 2 cycles of standard BEACOPP (SB), while
those with high risk received 2 cycles of escalated BEACOPP (EB). Base-
line GA67 or hybrid PET/CT scan was performed at diagnosis and after
the 1st or 2nd cycle for 58 and 66 patients, respectively. If the early inter-
im scan remained positive, then additional 4 cycles of EB were admin-
istered; otherwise, SB was given. One hundred and twenty four patients
- 52 females and 72 males aged 18-63 years (median 31; mean34±11)
who had at least one year of follow up are reported. The CR rate was
97%. The 5-year event-free (EFS) and overall survival (OS) was 87%
and 92%, respectively at a median follow-up of 55-months (5-95). The
5-year EFS and OS were similar for standard and high risk patients. The
disease progressed in 3/12 patients with an interim positive PET/CT
versus 1/54 with negative scans (p<0.02) and in 1/13 (8%) patients with
an interim positive Ga67scan versus 7/44(16%) with negative scan (NS).
Negative predictive value of early normal PET and GA67 scans are 98%
and 84%, respectively p<0.03. Only one patient developed secondary
leukemia following salvage therapy and high-dose chemotherapy. One
patient died during therapy from unrelated cause. 35 female patients
younger than 40 years old who had no disease progression were
assessed for fertility status: 9 conceived during the follow-up, deliver-
ing 9 healthy offspring, 21 had cyclic ovarian function and 5 had prema-
ture ovarian failure. Conclusion: PET/CT is a useful tool for making an
early interim decision regarding the dose of chemotherapy on an indi-
vidual basis. Early PET allowed for chemotherapy reduction in 78% of
high-risk patients. Only 18% of standard-risk patients required dose
intensification. Six cycles of risk-adapted BEACOPP were found to be
as effective as reported 8 cycles of EB. 
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Introduction. Dose-intensity is important in the treatment of lymphoma
and granulocyte colony stimulating factor (G-CSF) is commonly used to
maintain it. The dose intensity and related need of empiric G-CSF with
adriamycin, bleomycin, vinblastine, dacarabazine (ABVD) for the treat-
ment of Hodgkin lymphoma (HL) is not well defined. 
Methods. We reviewed all newly diagnosed HL patients from 1996-
2005 who received all treatment at our institution. Sixty-one patients
were identified who received ABVD chemotherapy with no dose reduc-
tions, treatment delays, and without empiric G-CSF, regardless of the
treatment-day absolute neutrophil count (ANC). 
Results. Among the 61 patients who received ABVD without empiric
G-CSF, the median ANC on all ABVD treatment days (n=658) was
925/µL (Figure 1), while the ANC was <500/µL on 26% of treatment
days (Figure 2). Median normalized ABVD dose-intensity was 99.1%
(range, 93%-100%) and median cycle duration was 28.2 days. Incidence
of bleomycin lung toxicity was 1.6%, 0.44% treatments were compli-
cated by febrile neutropenia, and no secondary malignancies have
occurred (median follow-up 48 months; range, 11-130 months). Five-
year event-free (EFS) and overall survival (OS) were 92.9% and 97.4%,
respectively. Furthermore, the 5-year EFS of 87.4% and OS 94.1% for
advanced stage patients compared favorably with a similar ABVD
patient group who received routine prophylactic G-CSF (n=23) with
EFS 80.0% and OS 91.3% (p=0.46 and 0.67, respectively). 
Figure 1. Treatment-day complete blood count data for patients treated
with full-dose ABVD without G-CSF. The median white blood count (WBC),
absolute neutrophil count (ANC), and percentage of monocytes for each
cycle and day ABVD was given to patients who did not receive G-CSF (n=61).
WBC and ANC displayed on left vertical axis and percentage of monocytes
(from same-day WBC) on right vertical axis. High limit of normal for percent-
age monocytes is 15%. Abbreviations: C, cycle; D, day.
Figure 2. Frequency of grade 3 and 4 neutropenia on the ABVD treatment-
day (without G-CSF). The percent of patients with grade 3 and grade 4 neu-
tropenia on the day treated each cycle with full-dose ABVD (without delay
or G-CSF support) was administered is shown (n=61). Beginning with cycle
1/day 15 through cycle 6/day 15, 47% to 63% of patients had grade 3 neu-
tropenia on the day ABVD was given; while 17% to 32% of patients had
grade 4 neutropenia (ANC ≤500 cells/µL) on the day that treatment was
administered.
Discussion. Our experience suggests that ABVD may be safely and
effectively administered at >99% dose-intensity without G-CSF sup-
port, regardless of treatment-day ANC. This treatment strategy needs
to be tested in prospective multicenter trials.
66 | haematologica/the hematology journal | 2007; 92(s5)
7th International Symposium on Hodgkin Lymphoma, 3-7 November 2007 – Cologne, Germany
P102
COMBINED ESCBEACOPP-ABVD THERAPY FOR ADVANCED HODGKIN'S LYMPHOMA
PATIENTS WITH HIGH IPS SCORE: AN EFFECTIVE REGIMEN AND LOW POSITIVE 
PREDICTIVE VALUE OF EARLY FDG-PET/CT
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Background. The expected 5-year freedom from progression of
advanced stage Hodgkin's lymphoma (HL) patients (pts) with IPS 3 or
more, treated with COPP-ABVD, was reported as 55%. While the supe-
riority of escalated (esc) BEACOPP regimen over COPP-ABVD was
shown for all risk groups, it was more pronounced in pts with a poor
IPS. However, pts receiving escBEACOPP had more acute and long-term
toxicities. In an attempt to reduce this toxicity, while preserving
improved initial tumor control in this high risk group of pts, we conduct-
ed a phase II study, which utilized the combination of escBEACOPP
and ABVD. 
Methods. Newly diagnosed HL pts, with unfavorable stage IIB or
stages III-IV with IPS 3 or more were initially received two cycles of
escBEACOPP followed by reevaluation with PET/CT scans. When com-
plete or partial response (CR, PR) was achieved, pts then continued to
receive four cycles of ABVD, while pts who failed to obtain this response
received salvage therapy. 
Results. Since 2001, 40 eligible pts received this regimen. Median age
at diagnosis was 27 years (range 18-56) and 29 (73%) were males. Fol-
lowing the first two cycles of escBEACOPP the overall response rate
(CR+PR) was 100% and at the end of all therapy 36 (90%) pts were in
CR, 2 (5%) in PR and 2 (5%) pts had progressive disease. After a medi-
an follow-up of 30 months (range 7-61), 38 pts are alive while two pts
died from progressive HL. The estimated 5-year event free survival (EFS)
and overall survival rates were 78% (95% CI, 64-92%) and 91% (95%
CI, 78-100%), respectively. The 5-year cumulative incidence of relapse
is 13% (95% CI, 5-33%). These survival rates are higher than those
expected for ABVD containing regimens and comparable with the
reported estimated long term survival rates achieved with the poor prog-
nostic subgroup of pts, receiving eight cycles of escBEACOPP in the
GHLSG HD9 trial. Furthermore, the estimated 5-year EFS rate for early
PET negative pts (n=27) and for early PET positive pts (n=11) was 82%
(95% CI, 66-98%) and 64% (95%, CI 35-92%), respectively (p=0.14) (in
2 pts early PET results were not conclusive). As expected, the incidence
of acute hematologic toxicities was more common in the escBEACOPP
than in the ABVD phase. 
Conclusions. Combined escBEACOPP-ABVD therapy is well tolerated
and may improve the outcome in pts with advanced HL who have high
IPS scores. Larger scale randomized studies are required in order to ver-
ify its true merit in this high risk subgroup of pts.
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Introduction. To test the efficacy and toxicity of a new-generation,
vinorelbine-containing, VEBEP regimen in Hodgkin's lymphoma (HL)
with low-doses radiotherapy (RT) with the primary aim to reduce short
and long-term toxicity and, if possible, to improve therapeutic outcome. 
Methods. From November 1997 to February 2004, 121 consecutive
adult patients with newly diagnosed biopsy-proven HL, classified as
stage IIAX, IIB, III (A and B), and IV (A and B) according to the Ann
Arbor criteria, were enrolled into this prospective nonrandomized study.
The regimen consisted in epidoxorubicin 30 mg/mq iv day 1-3,
cyclophosphamide 1000 mg/mq iv on day 1, VNR 25 mg/mq iv on day
2, bleomycin 10 mg/mq iv on day 3, and prednisone 100 mg iv day 1-3.
Treatment plan varied on the basis of Ann Arbor/Cotswold stage: local-
ly extensive disease were given four courses of VEBEP and involved
field (IF) RT at same doses, whereas advanced stages were given six
courses of VEBEP with RT only on bulky sites. 
Results. A total of 105 patients (87%) entered complete response (CR)
at the end of the treatment program. CR rate was significantly worse in
patients with stage IV compared with patients with stage II and III (67%
vs 95% vs 92, p=0.004) and in patients with B-symptoms (p= 0.02). Tox-
icity was globally mild, with neither toxic-deaths or hospitalisation.
Eighteen(17%) out of 105 complete responders showed lymphoma
relapse within six years from the starting chemotherapy. With a medi-
an follow-up of 57 months, 72% patients were free from lymphoma pro-
gression (FFP). FFP was significant inferior in patients with stage III and
IV compared with patients with locally extensive disease (63% vs 78%
p=0.009) and B-symptoms, (62% vs 84% p=0.01), respectively A total of
10 patients have died within six years from starting VEBEP: nine of dis-
ease progression and one of second tumor, for an overall survival rate of
91%. Among the 111 patients alive, all but one are disease free, 87 in first
CR, and 23 in second or further CR with an FF2P of 74% at 31 months
from relapse.
Conclusions. Despite VEBEP regimen show a FF1P probability lower
than other common new regimens, the very low toxicity allows a full
salvage therapy with an optimal FF2P. An increase in dose-intensity is
planned for patients at higher risk.
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PRECLINICAL PHARMACOLOGY OF XMAB™2513 AN FC ENGINEERED 
HUMANIZED ANTI-CD30 MAB
P. Hammond, G. Lazar, S. Karki, D. Carmichael, S. Chu
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XmAb2513 is a new humanized monoclonal antibody (mAb), to the
human cell surface antigen CD30, with an engineered Fc region to
enhance recruitment of effector cells and potentiate anti-tumor effica-
cy. It is being developed for CD30-positive (CD30+) diseases such as
Hodgkin Lymphoma (HL) and anaplastic large cell lymphoma (ALCL).
XmAb2513 was derived from the murine mAb AC10 by humanizing the
variable domain using the method of human sequence content opti-
mization while retaining high binding affinity for CD30. In addition, the
Fc region was engineered to increase the binding affinity for all Fcγ recep-
tors (FcγRs). Using biacore measurements, XmAb2513 was determined
to have a binding affinity of 465 pM for CD30. The Fc engineering
increased the binding affinity of XmAb2513 for FcγRI, FcγRIIa. FcγRIIb,
and FcgammaRIIIa by between 3- and 26-fold when compared to the
binding affinity of an unengineered comparator mAb. XmAb2513
retains the potent anti-proliferative activity exhibited by the parental
antibody against HL and ALCL cell lines. In addition, as a result of the
Fc engineering, XmAb2513 exhibited superior antibody-dependent cell-
mediated cytotoxicity (ADCC), mediated by NK cells that primarily
express FcγRIIIa, when compared to the unengineered mAb. The mean
efficacy (percentage of cells specifically lysed) improvement was 4.7-fold
and the mean potency (concentration giving 50% of maximal lysis)
improvement was 2.4-fold over the unengineered mAb. XmAb2513 was
also 2.1-fold more efficacious than the unengineered mAb in antibody-
dependent cell-mediated phagocytosis (ADCP) assays using FcγRIIa/b
and FcγRIIIa expressing macrophages. The in vivo anti-tumor activity of
XmAb2513 was evaluated using subcutaneous xenograft models in
SCID mice. Statistically significant reductions in tumor growth, togeth-
er with enhanced survival, were observed at 3 mg/kg while at 10 and
30 mg/kg XmAb2513 was even able to eliminate established tumors.
XmAb2513 has been successfully engineered to possess multiple mech-
anisms of action, including ADCC and ADCP, with significant improve-
ment over those of an unengineered IgG1 mAb comparator. Addition-
ally, XmAb2513 has potent anti-proliferative effects and was efficacious
against HL xenografts. These in vitro and in vivo pharmacology data pro-
vide a rationale for the clinical testing of XmAb2513 in patients with
CD30+ hematologic malignancies.
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PREDICTION OF OUTCOME ACCORDING TO INTERNATIONAL PROGNOSTIC SCORE (IPS)
IN PATIENTS WITH ADVANCED STAGE HUMAN IMMUNODEFICIENCY VIRUS INFECTION
(HIV)-RELATED HODGKIN'S LYMPHOMA (HL) TREATED WITH DOXORUBICIN,
BLEOMYCIN, VINBLASTINE AND DACARBAZINE (ABVD) AND HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY (HAART)
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Introduction. In our experience treatment with ABVD and HAART with
advanced-stage HIV-related HL is feasible, with a similar response rate
and survival to that of immunocompetent patients. Immunological
response to HAART has a positive impact on OS and EFS (Haematolog-
ica 2007;92:191-8). The IPS is a seven-factor prognostic score useful for
prediction of outcome in newly diagnosed patients with HL in advanced
stages, but patients with HIV-related HL were excluded from the prog-
nostic model. This study aimed to evaluate IPS as a predictor of outcome
in patients with advanced stage HIV-related HL treated with ABVD and
HAART. 
Methods. From 1996 to 2005 53 pts. with newly diagnosed HIV-relat-
ed HL in advanced stage were treated with 6-8 cycles of ABVD and
HAART since diagnosis in 15 Spanish hospitals. Parameters included in
IPS (serum albumin level <4 g/dL, hemoglobin <10.5 g/dL, male sex, age
45 years or older, stage IV, WBC 15×109/L, lymphocyte count <0.6×109/L
or <8% of the WBC, or both) were retrospectively collected from each
patient. IPS score was defined as the number of adverse prognostic fac-
tors at diagnosis, and patients were classified in two groups: IPS 0-3 vs
4 or higher. CR rate OS and EFS were analyzed. 
Results. Twenty seven pts. (51%) had IPS 0-3 and 26 (49%) IPS 4 or
higher. CR rate was 93% in group with a prognostic score 0-3 com-
pared to 81% in group with a prognostic score 4 or higher (p=0.19). 5-
year (95%CI) OS probabilities were 84% (69-99%) and 62% (42-82%)
for groups with IPS 0-3 and with IPS 4 or higher, respectively (p=0.07),
whereas 5-year (95%CI) EFS probabilities were 84% (70-98%) and 62%
(42-82%) for pts. with IPS 0-3 and with IPS 4 or higher, respectively
(p=0.05).
Discussion. In our series of patients with advanced stage HIV-related
HL treated with ABVD together with HAART the proportion of cases
with advanced IPS Score is higher than that observed in the original IPS
series. IPS score had prognostic relevance in those patients (poor EFS and
OS in patients with high IPS score). 
Supported by grants 3690-02 and 36606/06 from FIPSE, 021210 from Fun-
dacio La Marato TV3 and P-EF-06 from FIJC Jose Carreras International
Leukemia Foundation)
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Introduction. Central nervous system (CNS) involvement in patients
with Hodgkin's disease (HD) is rare (approximately 0,2-0,5% of cases).
Involvement of CNS could be seen in primary disease and during relaps-
es. Usually it is combined with other lesions.
Materials and methods. From May 2001 to April 2007 8 patients with
HD and primary CNS involvement were treated in our departments
(man/woman - 5/3, age from 20 to 44 years, median - 29 years). 
Results. Without taking into account involvement CNS, II stage of HD
was marked at 2 patients, III stage at 1 patient, IV stage at 3 patients, the
isolated involvement in vertebral channel with involvement of vertebrae
- at 2 patients. One of 8 patients had diffuse involvement of meningeal
membrane and the tissue of a brain, the others 7 patients (88%) had
marked involvement in the spinal channel with involving vertebrae. In
3 patients there was involving a chest part of spine, in 2 - a lumbar part,
1 - sacrum, and another 1 - chest and lumbar part of spine. At all patients
there was an expressed neurological symptoms accordingly the place of
involvement of a different degree - from a painful syndrome with pare-
sis, up to plegia and disfunction of pelvis organs; in the case of involve-
ment of the brain unilateral decrease in visual acuity, narrowing of fields
of vision, rough bilateral accomodation, exoftalm was marked. In all
patients diagnosis HD was confirmed by histological and immonohis-
tochemistry exammenatin, at 5 patients biopsy of the place of involve-
ment CNS was done with histological acknowledgement in it HD ori-
gin. All patients received treatment by BEACOPP escalated from 4 up
to 6 cycles with radiation therapy on area of CNS defeat from 34 up to
40 Gr was spent. All patients achieved complete remission by duration
from 3 up to 66 months, relapses by the present moment aren’t noted.
Conclusions. BEACOPP escalated is highly efficient in cases of HD
with primary CNS involvement.
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Introduction. The prognosis for patients with liver disease as the initial
manifestation of Hodgkin's disease is poor. Patients died of disease pro-
gression or infectious complications during the first chemotherapy
course. 
Methods. We report a retrospective analysis of 15 patients between
1993 and 2007presenting with Hodgkin's disease primary involving the
liver. In all cases except 3 patients liver involvement was revealed by liv-
er biopsy with subsequent histological and immunohisto-chemistry. In
8 from 15 patients (53.3%) involvement of liver carries diffuse charac-
ter, in 7(46.%) cases - nodular involvement. Attributes of cholestasis
(increased levels of conjugated bilirubin, alkaline phosphatase) were
observed mainly in group with diffuse involvement of liver (6 patients
from 8 -75%) and in 2 cases from 7 with nodular involvement (28.5%).
The lead therapy ABVD, MOPP-ABVD, BECOPPbas, STANFORD-V,
CHOP, and in relapse/progression - DHAP, ChLAD, BEACOPPbas, Dex-
aBEAM.
Results. From 15 patients with primary involvement of liver in 6 cas-
es (40%) were reached complete remission (CR), 5 of these with diffuse
involvement. Relapses in this group during supervision fro£m 1 month
till 13 years (median 7 years) doesn't revealed. In 2 cases CR reached
after first line therapy. In 4 cases partial remission reached, 2 of these
patients threated with DexaBEAM in relapse and complete response
were reached in two cases. 2 patients have received DexaBEAM as a
stage of continuous therapy. This cases presented with severe liver fail-
ure. In connection therapy has been begun with less toxic courses of
chemotherapy. Consistently leaded 1 course ABVD, 2 courses BEA-
COPP-bas, 4 courses DexaBEAM. In 1 cases duration of remission - 13
months, and in second case - 1 month.
Discussion. Involvement of a liver at Hodgkin’s disease has the differ-
ent forecast depending on character of involvement. Patients with nodu-
lar involvement have the worst forecast. Therapy with MOPP, ABVD,
STANFORD-V, BEACOPP-bas were low effective in liver involvement.
The early intensification is impossible because of serious of disease.
Tactics of a consecutive intensification of therapy is represented to us
rational, but greater term of supervision however is required. 
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Introduction. Evaluation of treatment of clinical staged IIB advanced
Hodgkin disease (HD), according to the German Hodgkin Study Group
(GHSG) criteria, with ABVD (Adriamycin, Bleomycin, Vinblastine, Det-
icene) and radiotherapy (RT). 
Methods. We evaluated 16 patients with median age 23 years (range
15-59) and median follow-up 45 months (range 9-117). Fifteen patients
had bulky mediastinal and one had extranodal disease. Eleven patients
were treated with 6 cycles of ABVD, and five patients received 8 cycles
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of ABVD. Eleven patients received involved field (IF) radiation (median
dose 30 Gy, range 25-39) and five received extended field (EF) (median
dose 36 Gy, range 34-37). 
Results. Twelve patients are still in complete response (CR), three
patients relapsed and were rescued with salvage chemotherapy and
underwent autologous stem cell transplantation (ASCT), and one patient
died from disease. Disease free survival (DFS) was 71% at 5 years, and
overall survival (OS) was 93%. No patients developed secondary solid
tumor or hematological malignancy. 
Discussion. Despite the small number of patients and the short time of
follow-up, as also the existing arguments for more aggressive therapy,
ABVD with RT can be an effective and well-tolerated therapy for this
group of patients, given that relapsed patients can be rescued with
ASCT.
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CASABLANCA EXPERIENCE
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Backgroun and aim. ABVD is accepted as standard chemotherapy in
combined modality strategy for the treatment of advanced Hodgkin's
Lymphoma (HL), OS and DFS after 5 years are about 70-80% and 65-
70%, respectively. The ABVP protocol used in our institution is a mod-
ification of ABVD in which prednisone substitute Dacarbazine which
is unavailable in Morocco. The aim of this retrospective study is to pres-
ent our results in treatment of adults with advanced HL by ABVP.
Patients and Methods. Patients with newly diagnosed HL (stage III-IV),
aged from 16-60 years old were treated with 8 cycles ABVP protocol
(doxorubicin 25 mg/m2, bleomycin 10U/m2, Vinblastin 6 mg/m2 were
administered on days 1 and 8 of each cycle, Prednisone 40 mg/m2 for the
first 14 days, a new cycle is began on day 28), followed by radiothera-
py to involved Bulky areas or residual masses (36 Gy). 
Results. 103 patients were enrolled from 2001 to July 2005, the medi-
an age was 36 years, and there were 65 males and 38 females. The medi-
an time to diagnosis was 9 months. The Nodular Sclerosis was predom-
inant in 66 patients (64%) followed by mixed cellularity in 17 patients
(16.5%). The B symptoms were present in 86 patients (83.5%). LDH was
elevated in 60%. 23 patients (22.5%) had bulky mediastinal,. The
haemoglobin was ≤10.5g/dL in 47 patients (45.5%), hypoalbuminemia
in 13.5%. 35 patients (34%) had stage III, 68 patients stage IV (66%) The
bone marrow was involved in 11 patients (10.5%). The spleen was
nodular in 45.5%; the infradiaphragmatic involvement was seen in 9
patients (8.5%). The rate of involved extra nodal sites ≥2 was 36%. The
IPS score ≥3 was noted in 60% of patients. The treatment was respect-
ed in 57% of patients and the radiotherapy was received by 33.7% of
patients. Only 96 patients were assessed for results; the CR is achieved
in 73 patients (76%), the rate of failure is 15.5%, 3 patients (3.5%) died,
5% were lost of follow-up and 24 patients relapsed (32.5%) with early
relapse in 58.5%. With a median follow up of 26.8 months the CR is
66%, 7 patients (7.5%) died, 3 patients are alive with PD. At 5 years, the
OS is 78%, and EFS is 55%.
Conclusions. Our data suggest that the ABVP protocol is insufficient to
treat advanced Hodgkin lymphoma with such strong tumor burden.
ABVD is now using in the treatment of HL at our department but more
aggressive first line treatment is needed to treat advanced HL with unfa-
vorable prognostics. 
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ARE FOUR CYCLES OF BEACOPP ESCALATED PLUS FOUR CYCLES OF BEACOPP 
BASELINE AN APPROPRIATE TREATMENT OPTION FOR PATIENTS WITH ADVANCED STAGE
HODGKIN’S LYMPHOMA? A SINGLE-CENTER RETROSPECTIVE ANALYSIS
P. Stepankova, D. Belada, A. Zavrelova, A. Sykorova, L. Smolej, 
J. Maly
2ndDepartment of Internal Medicine,Department of Clinical Hematology, Uni-
versity Hospital and Medical School, Hradec Kralove, Czech Republic
Introduction. Although ABVD regimen has been standard in patients
with advanced Hodgkin’s lymphoma (HL) for many years, about 30%
relapsed. HD-12 trial of the German Hodgkin’s Lymphoma Study Group
de-escalated therapy of advanced stage of HL comparing 8 cycles of esca-
lated BEACOPP with 4 cycles of escalated BEACOPP and 4 cycles of base-
line BEACOPP. We evaluated efficacy and toxicity of this reduced regimen.
Patients and methods. Fourty-four patients (pts) with newly diagnosed
advanced stage HL were treated between December 2001 and Decem-
ber 2006. 38/44 pts (median age, 32 years; range 18 to 59) with minimal
follow-up of 12 months were finally evaluated. Patients with stage II plus
one of the unfavourable prognostic factors: large mediastinal mass or
extranodal involvement, and stage III-IV pts were eligible for this treat-
ment strategy. Initial stage II/III/IV disease was present in 8/20/10 pts,
respectively. We analyzed this group for outcome based on intent-to-
treat principle and for toxicity. 
Results. 36 pts (95%) achieved complete remission (CR). One patient
progressed on treatment, one had stable disease. Radiotherapy was used
in 9 pts with residual PET acitivity. Only two pts relapsed (14 and 22
months after therapy). With the median of follow-up (FU) 31 months,
the estimated 2-year event-free survival (EFS) is 92%, and overall sur-
vival (OS) at 2 years is 100%.
Toxicity. 31 pts (82%) completed preplanned 8 cycles of the therapy.
The treatment was not completed in 5 pts (all were over 50 years) due
to adverse events (AE), in 2 pts due to non-compliance. Major toxicities
were hematological. Grade 3-4 anemia occured in 18 pts (47%), grade
3-4 neutropenia in 34 (89%) and grade 3-4 thrombocytopenia in 13
(34%) pts. G-CSF support in baseline BEACOPP was needed in 20 (53%)
pts. Other toxicities included: aseptic necrosis of the head of femur (1x),
deep vein thrombosis (3x), soft tissue abscess (2x), osteomyelitis (1x),
peripheral neuropathy (5x), pneumonitis (3x) and osteoporosis with
compressive fracture (2x). One patient developed secondary Non-
Hodgkin’s lymphoma, and 1 patient myelodysplasia following salvage
and high-dose chemotherapy with stem cell rescue. 
Conclusions. This study shows that combination of escalated and base-
line BEACOPP chemotherapy might be very effective treatment for
patients with advanced HL with acceptable acute toxicity. Longer follow-
up is needed for evaluation of late toxicities of this treatment approach.
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INITIAL DOSE INTENSITY HAS LIMITED IMPACT ON THE OUTCOME OF ABVD
CHEMOTHERAPY FOR ADVANCED HODGKIN'S LYMPHOMA (HL): 
DATA FROM UKLG LY09 (ISRCTN97144519)
P.W.M. Johnson,1 M.R. Sydes,2 S.P. Stenning,2 M.H. Cullen,3
J.A. Radford,4 B.W. Hancock,5 for the LY09 Trial Management Group
and LY09 investigators 
1Cancer Research UK Clinical Centre, Southampton General Hospital,
Southampton; 2Medical Research Council Clinical Trials Unit, London,; 3Depart-
ment of Medical Oncology, Queen Elizabeth Hospital, Birmingham; 4Cancer
Research UK Department of Medical Oncology, Christie Hospital, Manches-
ter; 5Yorkshire Cancer Research Academic Unit of Clinical Oncology, Weston
Park Hospital, Sheffield, UK
Background. Response-adjusted therapy is attractive in the treatment
of HL, to avoid over-treatment of patients with a good prognosis and to
maximise the chance of cure. However, it is not clear whether the inten-
sity of initial therapy prior to early response assessment is critical to the
outcome, or whether subsequent intensification may compensate for
less intense initial treatment. We investigated whether dose intensity in
the first two cycles of standard ABVD chemotherapy is predictive of pro-
gression-free survival (PFS).
Methods. Data for 379 eligible patients allocated to receive ABVD in
the UKLG LY09 trial and who received at least two cycles of chemother-
apy were included. All patients were planned to have 6 cycles of
chemotherapy, extended to 8 where there was evidence of continuing
response at 6. Growth factor support was permitted following delays or
reductions in treatment. Radiotherapy was recommended for residual
masses or at the sites of prior bulk disease. Patients were recruited
between 1998 and 2002 with median follow-up of 52 months. Observed
dose was standardised by dividing by expected dose for the first two
cycles. Dose intensity was defined as standardised dose divided by
[observed duration for two cycles divided by expected duration for two
cycles]. These were calculated separately for doxorubicin, bleomycin,
dacarbazine and vinblastine and averaged. Landmark analyses were
timed from the start of cycle 3. The analyses include 96 PFS events: dis-
ease progression or death from HL.
Results. 93/397 (25%) of patients received treatment at >97% intend-
ed DI (averaged across all 4 drugs) for cycles 1-2, whilst 137 (37%)
received 86-97% and 147 (39%) less than 86%. Dose and dose intensi-
ty in cycles 1-2 correlated well with dose and dose intensity in the
remaining cycles 3-6 for all drugs. There was no good evidence from
unadjusted univariate analyses of the four drugs individually and their
average, that higher dose intensity in the first two cycles was associated
with better PFS. Adjusting for baseline IPI score, the strongest effect of a
10% increase in DI in cycles 1-2 was from Doxorubicin. This was asso-
ciated with a hazard ratio of 0.90 (95%CI 0.78, 1.02); bleomycin HR=0.90
(95%CI 0.78, 1.05), dacarbazine HR=0.92 (95%CI 0.79, 1.06), vinblastine
HR=0.94 (95%CI 0.81, 1.09). Among 82 patients who had cycles 3-6
delivered at over 97% DI on average, patients who received average DI
below 86% in cycles 1-2 had the same long-term PFS as those patients
who received average DI over 97% in cycles 1-2. Poorer DI in cycles 1-2
was associated with increased use of G-CSF during subsequent cycles. 
Discussion. We have found no evidence of improved PFS with higher
dose intensity in the first two cycles of ABVD. This is a non-randomised
comparison and caution is needed in the interpretation of such retrospec-
tive data. However, the data comes from a large cohort of patients fol-
lowing a standard treatment regimen, ABVD, in the context of a ran-
domised controlled trial. It is possible that following initial low dose
intensity, growth factors were effectively used to restore the efficacy of
treatment and/or chemotherapy was continued for more cycles and/or
consolidation radiotherapy used. This does not appear to support the
introduction of a policy of maximising initial dose intensity without
testing in a further prospective study.
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BACOPP-D AS TREATMENT IN PATIENTS WITH ADVANCED HODGKIN LYMPHOMA
R. Naumann,1 K. Wetzko,1 A. Haenel,2 K. Friedrichsen,2 E. Zschuppe,3
H. Schmidt,4 M. Moelle,5 M. Dawel,6 B. Beuthien-Baumann,7
U. Schwanebeck,8 G. Ehninger,1 M. Haenel2
1Department of Internal Medicine I, University Hospital Carl Gustav Carus,
Dresden University of Technology, Dresden; 2Department of
Haematology/Oncology, Clinic of Internal Medicine III, Chemnitz Medical Cen-
ter, Chemnitz; 3Department of Internal Medicine I, Friedrichstadt Hospital, Dres-
den; 4Department of Haematology/Oncology, Hameln Hospital, Hameln; 5Inter-
nal Medicine, Practice Altstrehlen, Dresden; 6Department of Radiotherapy, Uni-
versity Hospital Carl Gustav Carus, Dresden University of Technology, Dres-
den; 7Department of Nuclear Medicine/PET centre Rossendorf, University Hos-
pital Carl Gustav Carus, Dresden University of Technology, Dresden; 8Coordi-
nating Centre for Clinical Trials, Faculty of Medicine Carl Gustav Carus, Dres-
den University of Technology, Dresden, Germany
Introduction. The development of the escalated BEACOPP regimen let
to an improved outcome in patients with advanced Hodgkin Lymphoma
(HD9 study of the GHSG). However, the application of high dose etopo-
side (cumulative 4,8 g/m2 per 8 cycles) seems to be associated with an
increased incidence of secondary MDS and AML, respectively. There-
fore, the aim of our ongoing multicenter pilot study is to evaluate the effi-
cacy and toxicity of the etoposide free as well as dose intensified
BACOPP-D protocol.
Methods. Since May 2000 a total of 115 patients with Hodgkin Lym-
phoma (HL) stage IIB, III, and IV were treated with BACOPP-D which
included cyclophosphamide 1250 mg/m2 (d1), adriamycin 25
mg/m2(d1+2), dacarbazine 250 mg/m2 (d1-3), procarbazine 100 mg/m2
(d1-7), prednisolone 40 mg/m2 (d1-14), bleomycin 10 mg/m2(d8) and vin-
cristine 1,4 mg/m2 (maximum 2 mg, d8) at three-weekly intervals with
granulocyte colony-stimulating factor (G-CSF). A consolidating involved
field radiation (30 Gy) was performed only in patients who achieved less
than CR following chemotherapy. Initial staging and post-treatment con-
trol included PET monitoring.
Results. Until now 97 patients (median age 35 years, range 17-65; 61
male, 36 female) are assessable for toxicity and treatment outcome. We
analyzed the acute toxicity for 728 cycles of BACOPP-D. CTC/WHO
grade III/IV haematological toxicities per patient were observed as fol-
lows: leukopenia 93%, anemia 39%, and thrombocytopenia 33%. CTC
grade III/IV non-haematological side effects included documented infec-
tion (4%) and lung toxicity (one patient with reversible bleomycin-
induced pneumonitis). A total of 85 patients (88%) achieved complete
remission, 9 patients (9%) achieved partial remission, three patients (3%)
had progressive disease. At a median observation time of 39 months
(0,9-77 months), six patients have relapsed, and nine deaths were doc-
umented (4 HL-specific and 3 treatment related deaths, 1 death due to
ruptured Meckel diverticulum with peritonitis, one 65 year-old woman
died in CR following myocardial infarction caused by coronary heart dis-
ease). One patient developed a second neoplasia (hypopharyngeal car-
cinoma in an alcoholic). The overall survival and freedom from treatment
failure rates at 39 months were 91% and 85%, respectively.
Discussion. BACOPP-D regimen appears as a feasible and safe treat-
ment protocol with moderate acute toxicity in patients with advanced
HL. No secondary AML or MDS occurred until now.
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ADVANCED HODGKIN’S DISEASE AND DEESCALATED BEACOPP. FIRST EXPERIENCE IN
ADULTS IN VENEZUELA 
M.A. Torres,2 M. Morales,1 R. Somoza,1 J. R. Ordonez,1 A. Möller,1
G. Acquatella
Instituto de Oncologia and Hematologia M.S.D.S, 1Oncologia y Hematologia
360; 2Badan Foundation; Caracas, Venezuela
Objectives. The intention of this study was to evaluate Overall Survival
(OS), event free survival (EFS) and toxicity of the deescalated BEACOPP
regimen to treat advance Hodgkin's disease (HD). 
Material and Methods. 29 patients with HD non previously treated) CS
IIB, IIIA-B, IVA-B with adverse prognostic factors (PF) and medium age
of 30y, received deescalated BEACOPP for 8 cycles and 30 cGY RT to
residual disease 
Results. medium follow-up was 24 months. 
Table.
CR PR>50% PROGR RELAPSE EFS 36 m OS 36 m
19 (66%) 8 (28%) 9 (31%) 3/19 (16%) 53% 88%
Conclusions. a) Although the follow-up period is short, our results with
BEACOPP regimen differ and are inferior to the one published in the
International Literature; b) 19/29 ptes (66%) achieved a RC. All patients
in PR>50% that did not receive RT progressed (5/18); and all those in PR
that received RT 10/10, achieved a RC, which suggests that all patient
in PR>50% should receive RT to residual disease. All patients that
achieved PR<50%(4/29)progressed.Eigth autologous transplants (28%)
as salvage treatment were completed and all patients achieved a 2nd
CR. The EFS rate was 36%; c) The use of EPO, G-CSF, and prophylac-
tic antibioticotherapy for pnemocistis C. and fungi, makes this regimen
feasible and well tolerated; d) A major difference was observed in the rate
of primary progressive disease and relasep rate, (31% and 16% respec-
tively),between international reports and our series. Also if we com-
pared our historical controls, patients with advanced HD and 3 adverse
PF, treated with COPP/ABV reported in the 2002: CR rate 79%, Prima-
ry Progression rate 14%, Relapsed rate 22% and EFS rate at 36 m 74%
we observed we had a better results in the past; d) We think this big dif-
ference could have its reason in the routine utilization of generic and
copy drugs to treat our oncology patients. So we must alert to the sci-
entific world on the necessity to formally evaluate the roll of generics
and copy drugs into this setting, since biology changes of this tumor have
not been reported. 
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10-YEAR RESULTS OF THE HD9 TRIAL OF THE GERMAN HODGKIN STUDY GROUP 
COMPARING BASELINE AND ESCALATED BEACOPP CHEMOTHERAPY FOR ADVANCED
HODGKIN LYMPHOMA 
V. Diehl,1 J. Franklin,1 B. Pfistner,1 A. Engert2 for the German Hodgkin
Study Group 
1German Hodgkin Study Group, Cologne;  2University of Cologne, Department
of Internal Medicine I, Cologne, Germany
Introduction. The HD9 trial compared baseline and dose escalated ver-
sions of the novel chemotherapy regimen BEACOPP in advanced
Hodgkin lymphoma. The previous analysis with a median follow-up of
5 years showed improved tumor control and overall survival for BEA-
COPPescalated. The present 10 year analysis in March 2007 aimed to
update and confirm these results and to monitor late effects.
Methods. Patients aged 16-65 years with previously untreated
advanced Hodgkin lymphoma (stage IIB/IIIA and risk factors or stage
IIIB/IV) were randomized to (A) 4 double cycles COPP/ABVD, (B) 8
cycles BEACOPPbaseline or (C) 8 cycles BEACOPPescalated (doxoru-
bicin, cyclophosphamide and etoposide at 140%, 192% and 200% of
standard doses, respectively). For all treatment arms the chemotherapy
was followed by irradiation of initial bulky and/or residual disease. The
trial was planned so as to detect a 9-10% improvement in the primary
endpoint, freedom from treatment failure (FFTF), by accrual of at least
900 patients.
Results. 1196 of 1201 eligible, randomized patients were evaluable
(261, 469 and 466 in arms A, B and C, respectively). The median follow-
up times were 122, 111 and 107 months in arms A, B and C, respective-
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ly (29-32 months longer than in 2004). Corresponding 10-year FFTF rates
were 64%, 70% and 82% respectively (p<0.0001). FFTF was significant-
ly better in the BEACOPPescalated arm than in the BEACOPPbaseline
arm (p<0.0001). 10-year overall survival rates were 75%, 80% and 86%
respectively (p<0.001). Overall survival was also significantly better in
the BEACOPPescalated arm than in the BEACOPPbaseline arm
(p=0.0053). The death rates for HL were 11,5%, 8,1% and 2,8% in arms
A, B and C respectively. A total of 74 second malignancies were docu-
mented: 1, 7 and 14 acute myeloid leukemias (AML); 7, 8 and 5 non-
Hodgkin lymphomas (NHL); 7, 16 and 9 solid tumors/others in arms A,
B and C respectively. The corresponding overall secondary malignancy
rates were 6,7%, 8,9% and 6,8%. 
Conclusions. After 10 years of follow-up dose escalation of BEACOPP
chemotherapy results in a stabilized significant improvement in long-
term FFTF and OS. The risk of secondary AML, although increased in
this study after BEACOPPescalated, amounts to 0.9% in the succeeding
HD12 study with BEACOPPescalated in 1502 randomized patients and
4 years median follow-up.
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NOVEL HSP90 INHIBITOR CNF2024 SELECTIVELY KILLS HODGKIN LYMPHOMA CELLS
BY DEPLETING NFKB AND INHIBITS HL TUMOR GROWTH IN VIVO
B. Böll, F. Eltaib, K. Lundgren,1 K. Reiners, S. Tawadros, 
B. von Tresckow, F. Burrows,1 A. Engert, E. Pogge von Strandmann
University Hospital of Cologne, Department of Internal Medicine I, Laboratory
for Immunotherapy, Kerpener, Cologne, Germany; 1Biogen Idec., San Diego,
CA, USA
To date, the majority of Hodgkin Lymphoma (HL) Patients can be
cured with chemo- and radiotherapy, but intensified treatment is asso-
ciated with severe side effects and secondary malignancies. Moreover,
treatment options for relapsed or progressive patients remain insuffi-
cient. Thus novel more selective and efficient therapies are needed. The
chaperone Heat shock protein 90 (HSP90) promotes cancer cells by sta-
bilizing client proteins: regulators of cell cycle, transcription and cell sur-
vival. Client proteins include several key regulators of HL growth (e.g.
cFLIP, XIAP, PI3K/AKT) and recently, HSP90 has been implicated in the
activation of NFκB in HL cells. To investigate the effects of HSP90 inhi-
bition on NFκB activity and on HL growth in vivo, we tested the activi-
ty of CNF2024, a novel orally available HSP90 inhibitor in HL. We ana-
lyzed cell viability and NFκB activity in HL cells and the therapeutic
efficacy of CNF2024 alone and in combination with Gemcitabine (GC)
in a HL xenograft model.
Methods and results. Cell viability in response to HSP90 inhibition was
tested with XTT-assays and combination experiments (Calcusyn
method). CNF2024 is highly effective in all tested HL cell lines with
IC50s 0.2-0.6 µM and combination with GC is synergistic (CIs 0.96-
0.19). HSP90 inhibition selectively induces apoptosis in HL cells with-
out effect on healthy lymphocytes as shown by Annexin-V-staining and
anti-PARP Western Blots. Recent reports suggest functional IκBa is
required for depletion of NFkB in response to HSP90 inhibitors. About
40% of HL exhibit defective IkBa and we tested HL cells with function-
al or mutated IkBa for their response to HSP90 inhibition with the
TransAm p65-Assay. Inhibition of constitutive NFκB activity using 1
µM CNF2024 ranges between 19.68% and 82.14% after 24h and is irre-
spective of IκBa mutations. Applying CNF2024 in a subcutaneous
L540cy HL xenograft model, we revealed that biweekly oral applica-
tion of CNF2024 results in 58.9% inhibited tumour-growth and combi-
nation with GC almost completely inhibits tumour-growth (inhibition
95% vs. 65.18% GC alone).
Conclusions. CNF2024 selectively inhibits HL cell viability irrespective
of origin (T- vs B-cell), EBV-status and histological subtype; and depletes
constitutively active NFκB independent of IκBa. CNF2024 exhibits in
vivo activity and synergy with conventional chemotherapy in HL and
therefore is a promising new compound for the treatment of Hodgkin
Lymphoma.
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RISK- AND TOXICITY-TAILORED PROGRAM FOR ADVANCED HODGKIN'S LYMPHOMA: 
SINGLE - CENTER EXPERIENCE (1998-2004)
T.I. Bogatyreva, S. Yu. Scoropad, T.O. Nestaiko, E.I. Strelnikova, 
O.A. Konova
Medical Radiological Research Centre, Obninsk, Russian Federation 
Introduction. At MRRC, COPP-based trials of 1974-97 in 1048 patients
(pts) with advanced HL showed three risk factors (RF) to be associated
with early induction failure (EIF): i) lymphoid depletion histology, ii)
pericardial effusion, iii) bones or bone marrow involvement in combi-
nation with splenic lesions. This prospective trial was aimed: 1) to test
BEACOPP baseline in improving the control of EIF in pts with RF; 2) to
minimize over-treatment by prescribing COPP/ABV hybrid (1998-1999)
or ABVD (2000-2004) induction for pts without RF; 3) to reduce cumu-
lative cardiopulmonary toxicity by change for COPP in 1-2 cycles pre-
ceding mediastinal irradiation. 
Patients and methods. Between 1998 and 2004, 181 consecutive pts with
advanced HL aged 14-63 (median, 26 years) in stages IIBXE or III/IY
were enrolled for receiving chemotherapy (CT) tailored to RF and fol-
lowed by IF-RT (20-30 Gy). Total 73 pts (RF+, 61 pts) received 4 to 6 BEA-
COPP+2 COPP (BEA arm); 33 pts (RF-,21 pts) 6 to 8 COPP/ABV±1
COPP; 75 pts (RF–,61 pts) 6 to 8 ABVD± 1 COPP. Six cycles were given
for supradiaphragmatic disease, 8 cycles for involvement on both sides
of the diaphragm. Five-year overall survival (OS) and freedom from pro-
gression (FFP) were evaluated with regard to the International Prognos-
tic Score (IPS) with 3 risk subgroups: A, 0-1; B, 2-3; C, 4+score. 
Results. A/B/C subgroups included 55/102/24 pts, respectively. RF of
EIF were found in 48% pts; A/B/C/:18/60/67%. Thirteen of 16 pts in
subgroup C had RF iii. In an intention-to-treat analysis 5-year OS was
95/86/76% and FFP was 85/69/51%. Due to evident inferiority of
COPP/ABV for advanced HL even without RF (FFP 75 and 71% in A/B)
these data were excluded from further analysis. In the evaluable pts of
BEA (RF+) and ABVD (RF–) arms, EIF rate within A/B/C strata was
0/10/23% and 3/7/33%. In pts of BEA arm, actuarial 5-year OS and FFP
are 100,92,91% and 100, 73, 67%, respectively. For ABVD arm, OS and
FFP are 100,93,100% and 93,77,75%. 
Conclusions. Our data demonstrate that discriminating patients with
favorable advanced stage for less toxic treatment is feasible mainly
among those with score 0-3. As a result, half of advanced stage patients
received ABVD with the outcome similar to that reported for baseline
BEACOPP. High EIF in patients with score 4+ suggests that 4 x BEA-
COPP-14 might be more appropriate for this subgroup than baseline. 
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ARSENIC TRIOXIDE (AS2O3) INDUCES SIGNIFICANT APOPTOSIS IN NON-HODGKINS
LYMPHOMA (NHL) AND HODGKIN LYMPHOMA (HL) CELLS: REACTIVE OXYGEN SPECIES
(ROS)-RELATED CELL DEATH THAT IS CASPASE-INDEPENDENT AND THROUGH 
MAP-KINASE PATHWAYS 
A.M. Evens,1 S. Bhalla,1 A. Singh,1 S. Prachand,1 T.V. O’Halloran,2
J.N. Winter,1 P.T. Schumacker,3 L.I. Gordon1
1Division of Hematology/Oncology, 2Department of Chemistry, 3Division of Pul-
monary and Critical Care; Translational Lymphoma Program, Northwestern
University Feinberg School of Medicine and the Robert H. Lurie Comprehensive
Cancer Center of Northwestern University, Chicago, Ill, USA
Introduction. Continued development of targeted agents with associat-
ed discovery of cell death pathways/mechanisms for NHL and HL is
needed. The cytotoxic activity of As2O3 in leukemia and myeloma has
been shown to occur through apoptosis and ROS-related pathways. We
assessed the cytotoxicity of As2O3 in NHL and HL cell lines with inves-
tigation of associated cell death pathways.
Methods. Ramos Burkitt-NHL and L428-HL cells were cultured with
increasing As2O3 concentrations (1.0 µm-10 µm) at 24-72 hours
with/without the reducing agent, buthionine sulfoxime (BSO, 100 µm).
Cell death/apoptosis were assessed by Annexin-V-propidium iodine (PI)
flow cytometric analysis. ROS was measured by flow cytometric fluo-
rescence intensity. Western blot analysis was performed for bcl-2, PARP,
caspase activation (caspases-8, 9, and 3), caspase inhibition (Z-VAD-
FMK and Z-IETD), and mitogen activated protein kinase (MAPK) path-
ways (ERK, JNK, and p38 activation).
Results. Single-agent As2O3 induced dose- and time-dependent apop-
tosis in Ramos and L428 cells with >75% +Annexin/PI at 48 hours and
72 hours, respectively, with 10 µm As2O3. Moreover, combination
As2O3/BSO therapy caused significant synergistic apoptotic cell death in
Ramos and L428 cell lines (2 µm As2O3 or BSO alone <15% +Annexin/PI
versus >80% when combined, p=0.001). Four-fold increase in ROS was
seen in both Ramos and L428 with As2O3/BSO treatment, but not fol-
lowing single-agent As2O3. Furthermore, N-acetylcysteine blocked ROS
and As2O3/BSO-related apoptosis in Ramos and L428. In terms of caspase
activation, As2O3/BSO treatment induced PARP cleavage and caspase-3
activation in Ramos cells, but not L428. In Ramos, Z-VAD-FMK blocked
single-agent As2O3-induced apoptosis, but had no effect in blocking
As2O3/BSO cell death. Z-VAD-FMK did not inhibit the cytotoxicity of
either single-agent As2O3 or As2O3/BSO. In terms of MAPK analysis,
As2O3/BSO treatment induced strong upregulation of phospo-p38 in
Ramos cells, while in L428 phospho-ERK was activated following
As2O3/BSO incubation. Analysis with MAPK inhibitors (antibody and
siRNA) is underway. 
Discussion. Single-agent As2O3 induces dose- and time-dependent
apoptosis in Ramos-NHL and L428-HL cells, while As2O3/BSO combi-
nation treatment results in synergistic cell death. As2O3/BSO induced
ROS-dependent apoptosis that occurred was caspase-independent. In
addition, MAPK pathways are activated in NHL and HL cell lines (p38
and ERK, respectively).
P118
PET FINDINGS AFTER THERAPY DURING FOLLOW-UP IN PATIENTS WITH 
HODGKIN LYMPHOMA - A RETROSPECTIVE STUDY
H. Mocikova,1 P. Obrtlikova,1 M. Skopalova,2 B. Vackova,1 R. Pytlik,1
J. Salkova,1 J. Haber,1 E. Koleskova,1 E. Zikesova,1 J. Straub,1 E. Cmunt,1
M. Siskova,1 J. Karban,1 V. Campr,3 J. Stritesky,4 M. Trneny1
11st Department of Internal Medicine, General Faculty Hospital, Charles Unver-
sity, Prague, Czech Republic; 2PET centre, Na Homolce Hospital, Prague, Czech
Republic; 3Institute of Pathology and Molecular Medicine, 2nd Medical Faculty,
Charles University, Prague, Czech Republic; 4Institute of Pathology, General
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Introduction. PET is not recommended for routine posttreatment sur-
veillance in Hodgkin lymphoma (HL) due to inadequate data to support
this issue. Methods The aim of this retrospective study was to evaluate
PET findings in 82patients (pts) with HL during the long-term follow-up
after therapy (70 pts treated with 1st line therapy and 12pts treated with
subsequent lines of therapy). 41pts received chemotherapy and 41pts
chemotherapy and radiotherapy. Median follow- up of the group since
end of therapy until December 2006 is 39 months. Results 301 PET
examinations were evaluated in 82 pts (mean 4 PET scans per patient).
80 of 82 pts are alive, 2 of 82(2,4%) pts died (1 lymphoma progression,
1 treatment toxicity). At the end of therapy 70 (85,3%) pts were PET neg-
ative and 12 (14,7%) pts PET positive. During the follow-up in the group
of 70 PET negative pts 39 had sustained complete remission with PET
negative scans. In 31/70 pts subsequent PET positivity was observed:
19/31pts (61,3%) had transient nonspecific PET positivity (6 biopsy
proven non neoplastic findings): postchemotherapeutic and postradia-
tion changes, inflammation, osteonecrosis, thymus hyperplasia. None of
these 19 pts relapsed. In 12/31 cases biopsy confirmed tumor: 9 relaps-
es of HL, 2 transformed HL into B NHL (1DLBCL and 1FL),1 second
tumor: pulmonary adenocarcinoma. In the group of 12/82 (14,6%) pts
with positive PET at the end of therapy: 5/12 (41,7%) suffered from pri-
mary progressive HL and 7/12 (58,3%) pts had transient nonspecific PET
positivity without a relapse (1 biopsy proven reactive changes).
Conclusions. In our retrospective stude we observed high ratio of false
positive PET results during the long-term follow-up. Positive predictive
value of PET is still controversial and all PET positive cases should be
carefully evaluated. 
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PET SCAN AFTER FOUR CYCLES OF BEACOPP IN THERAPY OF ADVANCED STAGE OF
HODGKIN S LYMPHOMA (TREATED WITHIN HD15 STUDY OF GERMAN HODGKIN 
LYMPHOMA STUDY GROUP)
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Introduction. Several recent studies have suggested that PET scanning
is an indicator of early treatment response and interim PET scanning
correlates with prognosis. The potential value of this information is that
treatment could be tailored to the response, i.e., intensified among those
who still have positive PET scans or reduced in patiens (pts) who have
an early conversion to a negative scan. 358 pts with primary Hodgkin s
lymphoma (HL) were treated within GHSG trials since 1995 at our cen-
ter, out of them 205 (57%) with advanced stage.
Methods. The aim of this study is to assess predictive value of PET after
four cycles of BEACOPP escalated (esc) or BEACOPP14 in the therapy
of advanced stage of HL treated within HD15 study of GHSG. Total of
44 pts were evaluated: 32/44 pts were treated with BEACOPP esc (arm
A + arm B) and 12/44 pts with BEACOPP14 (arm C). Median follow up
of living pts is 19 months (r5-33). One patient died due to acute toxici-
ty of treatment (bleomycin induced pneumonitis) in the last cycle of
therapy.
Results. Patients characteristics: median age 29 y (r 19-59), male/ female
19/25. Histology: NS 80% (n=35), MC 16% (n =7), LD + unc 4% (n=2).
Median number of PET scan for patient was 4 (r 2 - 6): PET 0, PET 4, PET
6 or PET 8, PET 3 m after the end of therapy and PET follow -up. 33 /
44 pts had negative and 11/44 pts (25%) had positive PET after four
cycles of BEACOPP (PET4). Pts with PET4 positive scan: 11/11 nodular
sclerosis, 10/11 had initially a large mediastinal mass (>1/3 maximum
transverse thorax diameter), IPS 3-6 four, 0-2 seven pts. 9/11 pts were
scheduled for the intensive therapy BEACOPP esc (arm A + B) and 2/11
pts to the arm C (BEACOPP14). 42/44 pts were in complete remission
(CR or CRr), 2/44 pts in PR or NR and salvage chemotherapy is ongoing
at the time of this report, in both cases PET was positive after four cycles
of BEACOPP esc.
Conclusions. Eleven out of fourty four pts (25%) treated within HD15
study GHSG had positive PET scan after 4 cycles of the chemothera-
py. Ten of these had initially a large mediastinal mass and two of them
are treated by salvage therapy because of tumor inadequate response.
Definite conclusion regarding the prognostic impact of this finding is
pending.
Supported by Grant MZ CR IGA NR 8033-6/2004
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ment, Az. Ospedaliera S. Antonio e Biagio, Alessandria; 4Hematology Chair
Universita’ di Catania, Catania; 5Hematology Department Arcispeale S. Maria
Nuova, Reggio Emilia; 6Hematology Department Az. Ospedaliera S. Giovanni
Battista, Torino; 7Hematology Department, Ospedale S. Gerardo, Monza; 8Bio-
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Background. FDG-PET scan performed early during standard ABVD
chemotherapy for Hodgkin's disease (HD) is a powerful prognostic tool,
but no data exist on the role of early FDG-PET in HD patients treated
with BEACOPP. Patients Starting from November 2002, 30 new HD
patients were enrolled in a prospective multicenter clinical trial to study
the predictive role on treatment outcome of early interim FDG - PET scan
during BEACOPP therapy (4 escalated + 4 baseline cycles). The mean age
was 35,0 years (18-60); advanced disease (stages IIB-IVB) was present in
27, and stage IIA with adverse prognostic factor in 3. All pts were staged
at baseline, after 2 courses of chemotherapy at the end of treatment by
FDG-PET scan (PET-0, PET-2, PET-8, respectively). All the PET-2 positive
studies were reviewed. The mean interval between the end of the 2nd
BEACOPP course and PET-2 was 11.6 (5-20). At the end of chemother-
apy in 15/30 pts. with bulky disease consolidation radiotherapy was
given. All patients were given the therapy programmed at baseline. No
treatment change depending on PET-2 result was allowed, except in case
of overt progression. Results: the mean follow-up was 731 days (276-
1707). Twenty-six pts attained CR while 4 were chemoresistant and
showed disease progression during therapy; 2 patients relapsed + 224
and +266 days after CR entry. In univariate analysis besides PET-2
(p<0.05), the clinical factors that were significantly associated with a
higher probability of treatment failure were age older than 45 (p<0.05)
and hemoglobin <10.5 g/dL (p< 0.05). In multivariate analysis only age
and hemoglobin retained their significance (p<0.05). In terms of treat-
ment failure, the Positive Predictive Value (PPV) and Negative Predictive
Value (NPV) were 60% and 88%, respectively. The sensitivity, specifici-
ty and overall accuracy of PET-2 were 50%, 92% and 83%, respective-
ly. The 2-y Failure-Free Survival (FFS) probability for PET-2 negative was
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88% while no PET-2 positive patient reached 2 y (Log Rank test=4.5,
p<0.05). Conclusions: this study seems to indicate that early interim
PET during intensified BEACOPP chemotherapy has a similar prognos-
tic meaning than during standard ABVD therapy. However, PET-2 dur-
ing BEACOPP showed a lower sensitivity and PPV (50% versus 86% and
60% vs. 93%, respectively, p<0.05) probably for some false negative
PET-2 studies. Updated results, as more patients with an adequate fol-
low-up become available for analysis will be presented.
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USE 18 F-FDG PET OF ALL BODY IN MONITORING OF PRIMARY PATIENTS WITH
HODGKIN’S DISEASE (HD)
N.V. Ilyin, E.I. Ivanova, M.S. Tlostanova, J.N. Vinogradova, 
L.A. Tyutin
Central Research Institute for Radiology, St.Petersburg, Russia
The aim of the investigation. The increase of the effectiveness of treat-
ment of patients with primary HD by means of the usage of PET of the
whole body. 
Materials and methods. There were included 19 patients with HD
receiving the primary treatment from May 2006 tile March 2007, the age
of the patients being from 18 to 79 years old (the average age - 48,5
years) stages II-I\/ AB. The patients were distributed according to the
stage: II A-5; II B-2; III A-7; III B-1; I\/ A-1; I\/ B-3; 16 females and 3
males. All the patients received chemotherapy (CT) ABVD or BEACOPP
and the radiation therapy (RT) on the primary involved zones (stages II
and III) or initially bulks and/or extra nodal and residual involved
zones(stage IV). RT was performed on the linear electron accelerator SL
75-5 energy 6 MeV twice fractions per day 1,2 Gy*2, the total one 30-
36 Gy. All patients underwent PET before treatment, after 2 cycles of CT
ABVD in the favorable variants and 3 cycles of ABVD in the unfavor-
able variants. When the metabolic response was not full the patients
received the 1 additional cycle of CT ABVD, then the RT. At III A stage
PET was repeated after the 4 cycles of CT ABVD, under the partial meta-
bolic response the patients received the 5th cycle of ABVD, then RT. At
III B-I\/ stages PET was repeated after 6 cycles of CT BEACOPP, under
the partial metabolic response the patients received 2 cycles more of
CT BEACOPP and then RT. 
Results. According to Chesson's criterias 10(52,6%) of 19 patients
demonstrated partial metabolic response, in connection with this they
received additional CT and the volume of antitumour treatment was
increased, as a result all 19 patients came into the clinical remission.
Thus, PET of whole body changed the tactics of the treatment in 10
patients (52,6%) from 19 ones. 
P122
ADDICTIVE VALUE OF PET/CT IN STAGING AND TREATMENT RESPONSE IN HODGKIN'S
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Aim. Confronting PET/CT and contrast enhancementCT(ceCT) for
staging and final therapy response in Hodgkin’s Lymphoma (HL) and
evaluating PET/CT2 to predict treatment outcome.
Methods. 12 pts with histologically proven HL underwent ceCT and
PET/CT at initial staging of disease and after therapy. ceCT and PET/CT
were confronted regarding the sensitivity and response to therapy. Pts
underwent also PET/CT after 2 cycles of therapy (PET/CT2).
Results. Staging:globally 113 sites of disease were identified; ceCT and
PET/CT sensitivity were respectively 84%(95/113) and 82% (93/113),
with 66% of concordant sites. For nodal sites ceCT and PET/CT sensi-
tivity were respectively 89%(92/103) and 82% (84/103). For extranodal
sites PET/CT sensitivity was 90%(9/10) and ceCT sensitivity was 30%
(3/10). ceCT staged 4 pts in stage II, 8 in stage III. PET/CT staged 6 pts
in stage II, 3 in stage III and 3 in stage IV.PET/CT and ceCT staging were
concordant in 6/12 pts (50%): 3 pts in stage II and 3 in stage III. In 6 pts
staging was discordant: 3 pts with ceCT stage III had PET/CT stage II,
2 pts with ceCT stage III had PET/CT stage IV,1 pts with ceCT stage II
had PET/CT stage IV. 
Therapy Response. PET/CT2 was positive for disease in 3 pts (25%) and
negative in 9(75%). At the end of therapy using the International Work-
shop Criteria(IWC) 2 pts (16%) had CR, 4 uCR(33%), 5 PR (42%) and
only 1 pt had PD. Using the recently published International Harmoniza-
tion Project Response Criteria only 3 pts (25%) had PR, 8 (87%) had CR,
1 pt had PD (8%). PET/CT and ceCT agreed in defining the response to
therapy in 6 cases (50%). All the uCR and 2 of 5 PR (40%) at ceCT are
CR at PET/CT. Of the 6 discordant cases we considered the PET/CT
response to define the effective clinical outcome. The 3 pts with posi-
tive PET/CT2 were positive also at the end of treatment; 8 of the 9 pts
with PET/CT2 negative remained negative and 1 became positive. Up
to date all the 8 pts(100%) with CR at post-treatment PET/CT are clin-
ically disease free(followup: mean 6 months, range 3-12).
Discussion. PET/CT and ceCT seem quite similar in diagnosing nodal
site of disease, but PET/CT is superior for extranodal sites and for final
staging. For evaluation of response to therapy PET/CT is much more bet-
ter than ceCT, particularly for negative predictive value. If these data will
be confirmed by greater patients population, it should be considered to
use both ceCT and PET/CT for staging, and only PET/CT for evaluation
of therapy response. 
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ORGANISATION OF NATIONAL CENTRAL REVIEW OF FDG-PET IMAGING IN A UK 
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Introduction. Prospective randomised trials are desirable to answer
questions about the role of positron emission tomography (PET) in the
management of lymphoma. Successful recruitment requires patients to
have access to PET close to where they are treated but consistency in
scan acquisition, quality control and interpretation is important for
results to be comparable where scans are performed at different centres.
We describe the organisation of a national randomised trial in patients
with stages IA/IIA Hodgkin lymphoma involving central review of PET
in the UK. Patients with complete response by PET criteria after 3 cycles
of ABVD are randomised to receive either involved field radiotherapy
or no further treatment. The primary outcome measure is disease-free
survival 
Methods. All centres used dedicated PET or PET-CT cameras. Prior to
inclusion, all centres agreed to the same method for regular quality con-
trol. A physicist from the central reporting facility in London (Core Lab)
visited each centre to cross calibrate cameras by scanning a standard
phantom. Phantom data/patient scans were assessed for image quality
and the data transfer process was tested to ensure confidentiality and
reliability. Centres were then eligible to take part in the trial. At the
Core Lab visual interpretation is used to score scans using a 5 point scale
(score 1, 2, negative; score 3, 4, 5, positive). Two readers scored scans inde-
pendently with differences resolved by consensus. The result is faxed to
the trials office where a negative score from the Core Lab is a require-
ment for randomisation. 
Results. At the time of analysis 229 eligible patients from 76 sites
entered into the study have been scanned at 12 UK PET Centres. The
current rate of accrual is 9 patients per month. 215 of 229 (94%) scans
have been centrally reviewed. 76% of patients were scanned at least 8
days after day 15 of cycle 3 ABVD, but 24% were scanned earlier sug-
gesting problems with re-scheduling scans when chemotherapy was
delayed. The percentage of scans scored as negative has been consistent
over 6 monthly periods, varying between 76% and 85%. 
Conclusions. The way in which PET is performed and interpreted can
be successfully co-ordinated across geographically distant locations using
a central Core Lab and leads to consistently high standards. Similar
methods could be employed in the design of international trials in
patients with lymphoma.
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Introduction. Approximately 30% of patients (pts) with HL fail primary
ABVD chemotherapy (CHT) or relapse after an initial remission. Further-
more many pts have residual masses, but do not progress in the long-
term. PET scan is a new functional imaging technique, which can detect
the presence of viable tumor post treatment. Mid-CHT and post treat-
ment PET results appear to highly affect prognosis. The predictive val-
ue of post-CHT PET findings in patients scheduled to receive addition-
al RT is not clearly established. 
Methods. Between Dec 2004 and Dec 2006, 106 pts were treated with
4-8 ABVD cycles, representing the total HL pt population in our Unit: 60
underwent PET/CT after the end of ABVD, 35 were not evaluated with
PET/CT (mainly due to cost issues), one died early and 10 experienced
early disease progression detected by conventional methods prior to
PET/CT. All 60 pts who underwent PET/CT had achieved CR/CRu or
PR with ABVD. We retrospectively analyzed PET/CT findings after the
end of ABVD and their impact on the risk of subsequent progression. 
Results. The median age of the 60 pts was 27.5 years (18-78), 62%
were males, 97% had classical HL and 58% had clinical stages (CS) I/II.
PET/CT was negative in 39/60 pts (65%) and positive in 21 (35%),
including 2 patients with indeterminate results (positivity exclusively
detected in atypical, unexpected, not previously involved sites). All PET
(-) pts remained progression free for a median of 9 months (1-23) from
the end of ABVD: 30/39 pts, all CS I/II, received RT at a median dose of
2935 cGy, while the 9 CS III/IV pts did not receive RT. Among 21 PET(+)
pts, 17 received RT at a median dose of 3650 cGy, 2 were simply fol-
lowed without further treatment, 1 progressed rapidly and 1 declined RT.
After a median follow-up of 9.4 months (2-23), 5/21 pts experienced dis-
ease progression. The 12- and 18- month progression free survival was
100% for PET– and 74% and 59% for PET+< pts (p=0.003). For CS I/II
pts these figures were 74% and 49% (p=0.008), while for CSIII/IV 75%
(p=0.13). 
Discussion. A negative PET/CT result after ABVD was associated with
excellent short term outcome. Pts with positive PET/CT were in
increased risk of progression, but most of them had not progressed at the
time of the analysis. Longer follow-up is needed to accurately assess the
positive predictive value of PET/CT after ABVD and the potential mod-
ulatory effect of subsequent RT. More mature follow-up data will be pre-
sented at the Meeting.
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Background. Approximately two-thirds of Hodgkin lymphoma (HL)
patients have a residual mass on CT scan after completion of first line
therapy. The assesment of these masses is one of the greatest dilemma
of physicians dealing with lymphoma, because only about 20-30%
relapse. 18-FDG-PET is a useful method to distinguishe malignant resid-
ual disease from benign tissue (necrosis or fibrosis). 
Patients and methods. FDG-PET was performed between November
1995 and November 2005 in 168 patients, who had residual masses on
their posttreatment CT scans after the first-line treatment. PET results
was evaluated using clinical follow-up data or pathological examina-
tions. Seven patiens was lost of follow-up. The sensitivity of the FDG-
PET was 79%, specificity 87%, the positive predictive value 55% and
the negative predictive value 95%. 
Conclusions. FDG-PET is a useful method in the posttreatment evalu-
ation of HL patients with high sensitivity, specificity and negativ predic-
tive value, clearly showing the ability of FDG-PET to identify patients
are cured with the first-line treatment. Positiv results must be carefully
analised, false positive rates are high, probably decrease with using
PET/CT scans and with increasing experience. In PET positive cases oth-
er confirmation of disease persistence should be done before further
treatment is indicated.
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Aim of the study. To examine the accuracy of 18FDG PET-CT compared
with conventional imaging modalities (CIM: CT/MRI/US) in staging
adolescents with CHL and its role in assessment of early response to
chemotherapy. Can PET-CT identify patients in whom radiotherapy can
be avoided based on response to chemotherapy?
Patients and methods. The records of 24 adolescents with CHL diag-
nosed between April 2005 and Dec 2006 were reviewed retrospective-
ly. Age range at diagnosis 12-18 yrs, median age 15 yrs 11months, 11
males and 13 females. All patients had disease assessed by FDG PET-CT
and CIM at diagnosis and after 2 cycles of OEPA chemotherapy (OEPA
- Oncovin, Etoposide, Prednisolone, Adriamycin). Patients were risk
stratified based on stage into three treatment groups TG1, 2 and 3 receiv-
ing 2 OEPA, 2 OEPA plus 2 COPP and 2 OEPA plus 4 COPP respective-
ly. Results of staging and early response assessment were reported inde-
pendently by radiology for CIM and nuclear medicine for PET-CT.
Patients who had a good early response (CR or PR and PET negative)
after 2 OEPA did not receive radiotherapy. All other patients had
involved field radiotherapy. 
Results at initial staging.
Table 1.
Stage I II III IV
By PET-CT 0 12 7 5
By CIM 0 12 7 5
There was 100% concordance in staging and treatment group alloca-
tion between PET CT and CIM. 
Results at early response assessment. 11/24 patients were PET-CT Nega-
tive: of these all 11 had residual disease on CIM.
Table 2.
Treatment group TG1 TG2 TG3
Number of patients 6 9 9
Number PET negative 3 (50%) 5 (57%) 3 (33%)
post 2 OEPA
12 / 24 patients were PET-CT Positive: of these all 12 had residual dis-
ease on CIM - 11 had partial response and 1 had disease progression. 1
patient had equivocal PET result treated as PET positive. 
Current Clinical Status. All but 1 patient is currently in clinical remis-
sion with a maximum follow up 20 months (range 1-20 months). 22 of
24 are more than 6 months off treatment. 
Discussion. This study shows that PET-CT is 100% concordant in allo-
cation of stage and treatment group compared with CIM in adolescents
with HL. The results of early response assessment showed 11/24 patients
had a negative PET-CT and all 11 avoided radiotherapy. In contrast all
24 had residual disease on CIM at this stage which demonstrates the lim-
itations of CIM for response assessment in CHL. Although follow up is
short there has only been 1 treatment failure. PET-CT shows huge prom-
ise in identifying adolescent patients who may avoid radiotherapy with-
out compromising treatment success.
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Introduction. The purpose of this study was to evaluate if early FDG-
PET scan combined with a clinical risk score can provide a better sys-
tem to predict outcome of patients with recurred Hodgkin's lymphoma
(rHL).
Methods. Between 1998 and 2006, 26 patients (pts) with rHL after the
front-line therapy were observed in our Centre. By using a recent Ger-
man prognostic score, based on duration of first remission, clinical stage
and anemia at relapse (Josting A, JCO 2002), we considered 4 categories
of risk: low (score=0), low-intermediated (score=1), high-intermediated
(score=2) and high (score=3). In the most of pts, PET scans performed
before and after salvage therapy were compared. The response was clas-
sified in complete remission (CR), if all lesions disappeared, partial remis-
sion (PR) for residual abnormalities, and no response (NR) in case of no
change or progression of lesions volume. Finally, we evaluated overall
survival (OS) and progression free survival (PFS) for different groups
stratified according to the risk score and the PET response.
Results. The median age of the 26 pts was 40 years (range 19-78). 3 pts
showed no risk factors (11,5% risk 0), 8 pts were included in risk 1
(31%), 12 pts in risk 2 (46%) and 3 pts in risk 4 (11,5%). Before and after
reinduction therapy, 15 pts (58%) were evaluated by PET. The PET
responses were 40% CR, 26,6% PR, 33,4% NR. The median OS and PFS
for all pts were 43 and 20 months, respectively. Five-years OS was 38%
and PFS 46%. Even if there were no statistically significant differences
in OS in according to risk score (p=0.12), an evident trend for longer OS
and PFS was observed in low risk score group vs other categories: 3-year
OS 100% vs 50%, 3-year PFS 100% vs 38% (p=0,09). Median OS was
28 months for not responder pts vs 50 months for pts that achieved CR
or PR (p= 0,04). Median PFS was 8 months for resistant cases vs not
reached for the sensitive group (p= 0,016).
Figure 1. OS for all patients.
Figure 2. PFS for all patients.
Figure 3. OS low risk vs others (p=0.12).
Figure 4. PFS low risk vs others (p=0.09)
Figure 5. OS and PET response (CR o PR vs NR) p=0.04
Figure 6. PFS & PET response (CR + PR vs NR) p=0.016
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Discussion. Patients with recurrence of HL usually have few chance of
cure. The combinated use of early assessment of response by PET with
a risk score calculated on anemia, advanced stage at recurrence and pro-
gression/relapse by 12 months, can be considered a valid tool to strati-
fy patients with poorest prognosis. These observations would be rele-
vant in order to plan an intensified treatment already in the early phase
of recurrent disease. In these selected patients, autologous transplant
can be considered as option of potentially curative therapy.
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Introduction. PET/CT with [18F]fluorodeoxyglucose (FDG) has a well-
established role in managing lymphoma patients as concerns staging,
early evaluation of disease response, re-staging at the end of therapy
and modelling radiotherapy field; however, less is known about its role
during follow-up, especially its potential to detect relapse relatively to
conventional imaging. The aim of the present study is to assess the role
of FDG PET/CT in follow-up of patients affected by Hodgkin's lym-
phoma who reached complete remission status after one or more treat-
ment lines. 
Methods. We retrospectively analyzed 26 patients with diagnosis of
Hodgkin's lymphoma in complete remission after chemotherapy with
or without radiotherapy for newly diagnosed (n=19) or relapsed/refrac-
tory disease (n=7), who had at least two FDG PET/CT scans in the fol-
low-up. Patients were all treated at our institution between July 1999 and
March 2006. In addition to PET/CT, most patients underwent contrast
enhancement (c.e.) CT scans. Median age of patients was 35 years old
(range: 17-83); lymphoma was diagnosed as a stage I in 4% (n=1), II in
48% (n=12), III in 30% (n=8) and IV in 18% (n=5) of cases; most used
first-line chemotherapy was ABVD (n=19) with or without involved
field radiotherapy; second-line treatment was high-dose chemotherapy
and autologous stem cell transplantation (n=6 patients); one patient
received allogeneic stem cell transplantation. One hundred thirty-four
FDG PET/CT scans were performed (median per patient: 4, range 2-15)
with a median follow-up of 17 months (range: 8-60). In case of FDG
PET/CT positivity, a confirmatory biopsy, clinical symptoms assessment
or CT studies were used to document relapse.
Results. Eleven patients showed increased FDG activity in lymph
nodes. Six of these patients were true positive: two patients had posi-
tive and two patients had negative c.e. CT; two patients did not have c.e.
CT and received node biopsy confirming relapse. Five out of eleven
patients were false positive findings and absence of relapse was docu-
mented by node biopsy (n=3) and further follow-up (n=2) that showed
normalization of FDG PET/CT imaging. Four out of five patients had
abnormal c.e. CT findings. No patients with negative FDG PET/CT scan
relapsed so far. Sensitivity, specificity, negative and positive predictive
values were 100%, 75%, 100% and 55% respectively. 
Discussion. this study suggests that PET/CT with FDG is more accu-
rate than c.e. CT for the follow-up of patients with Hodgkin's lym-
phoma in complete remission after one or more treatment lines. How-
ever, because of the low specificity, caution must be adopted when inter-
preting positive FDG PET findings, and either node biopsy or follow-up
are necessary. Use of FDG PET/CT could allow starting salvage treat-
ment at the time of preclinical relapse. Further studies are warranted to
determine if this results in an improvement of patients' outcome. 
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RITUXIMAB+ABVD IMPROVES EVENT FREE SURVIVAL IN PATIENTS WITH CLASSICAL
HODGKIN LYMPHOMA WHO HAVE PET POSITIVE DISEASE AFTER 2-3 CYCLES OF 
THERAPY 
A. Wedgwood, M. Fanale, L. Fayad, P. McLaughlin, F. Hagemeister, 
B. Pro, J. Romaguera, A. Younes
MD Anderson Cancer Center, Houston, TX, USA
Introduction. PET after 2-3 cycles of ABVD has been shown to confer
poor prognosis and therefore proposed to guide future therapy. Hutch-
ings et al. (Blood, 2006) reported a negative PET scan after two cycles of
ABVD to be a good predictor of outcome with 96% 2-year progression
free survival (PFS). Those with PET positive after 2 cycles had a 0% PFS
at 2 years. We have recently reported that Rituximab + ABVD (RABVD),
improved event free survival (EFS) compared to patients treated with
ABVD irrespective of IPS. In this study, we examined the effect of RAB-
VD on early PET imaging and determined whether PET status remains
predictive of treatment outcome in patients receiving RABVD. 
Methods. 65 evaluable patients were treated with RABVD with at least
a 12 month follow-up. Of those, 55 had PET after 2-3 cycles and were
included in this analysis. 
Results. PET became negative in 43 patients (78%) after completing 2-
3 cycles of RABVD and positive in the remaining 12 patients (22%). 5-
year EFS for those with negative PET was 93% and 75% for those who
remained PET positive (p=0.05). (Figure 1)
Figure 1. EFS by PET after 2-3 cycles of R-ABVD.
Discussion. In this prospective phase II study, we confirmed prior
reports that patients who remain PET positive after 2-3 cycles have
worse prognosis when compared to those that achieve PET negativity.
However, the outcome for those who remained PET positive after 2-3
cycles is better than what has been previously reported when using
ABVD alone. Our data suggests the addition of rituximab to ABVD may
be superior to ABVD alone when patients remain PET positive after 2-
3 cycles. A randomized trial will be needed to confirm this observation. 
P130
ACCELERATED HYPERFRACTIONATION IN RADIATION THERAPY HODGKIN'S DISEASE
N.V. Ilyin, E.N. Nikolaeva
Central Research Institute for Radiology, St.Petersburg, Russia
Introduction. Radiobiologically based improvements in the scheduling
of conventional radiotherapy (CF) made a progress in the effectiveness
of radiation therapy (RT). In our studies we have developed accelerated
hyperfraction (AHF) versus CF radiotherapylorHD.
Methods. We examined 145 patients with HD II-IIIAB who received
AHF within 1985-1997. A comparison was carried out with the compa-
rable groups of 110 patients given CF. The AHF schedule was carried out
by admission of the single dose 1,35 Gy twice a day with interval 3,5-4
hs to basic registration points (bifurcation of trachea and paraaortal lym-
phatic nodes). The total doses in clinically involved nodes were approx-
imately 40 Gy; zones of subclinical involvement received ~ 36 Gy.
Results. Objective response was obtained in 87,4% patients in the AHF
group and in 90,0% patients in the CF group. Median follow-up was 144
months: AHF - 144 months, CF-150 months. Quantity of recurrences
was higher in patients with CF than in those with AHF - 28,3% and
16,5% (p=0,02), respectively. 10-years overall survival was 82,8% in
AHF group and 72,1% in the CF group. 10-year recurrence-free survival
was 81,5% in the AHF group and 69,8% in the CF group (p=0,04). Analy-
sis of clinical date showed essential reduction of radiation pneumonitis
rate at AHF in comparison with CF: 13,1% versus 25,4% (p=0,01),
postradiation pericarditis was observed in comparison with CF 2,1%
versus 7,3% (p=0,04).
Conclusions. Clinical analysis revealed the benefits of single dose
decrease from 2 Gy to 1,35 Gy at the twice a day irradiation scheme. The
AHF is an effective schedule of RT and promotes to the recurrence fre-
quency reduction, increases recurrence-free survival, decreases of the
cardiopulmonary complication risk.
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SIGNIFICANCE OF RADIOTHERAPY IN THE TREATMENT OF HODGKIN’S LYMPHOMA
RELAPSES
N.V. Ilyin, I.A. Shenderova, E.N. Nikolaeva
Central Research Institute of Radiology, St.-Petersburg, Russia
Methods. in 653 newly -admitted patients this Hodgkin’s Lymphoma
(HL) I-IV stages who were receiving radiotherapy and combination ther-
apy from 1980 up to 1993 we developed 112 (17,2%) relapses. The aver-
age monitoring period for this group was 96 months. The first relapses
were early with 20,5% of patients, late - with 79,5%; relapses in the
stage RS I-II - 36,6%, RS III AB - 22,3%, RS IVB - 41,1%. When combi-
nation primary therapy was applied, the recurrence rate was much low-
er (15,3%) than when only chemotherapy (26,8%) or only radiothera-
py (22,4%) were applied. 
Results. The radiotherapy was applied just by itself or in combination
in 72 out of 112 relapse cases (64,9%). Re-irradiation in the case of
relapses at different stage was applied to 64 out of 112 patients (57,1%),
to previously irradiated zones - with 42 out of 64 (65,6%) patients under-
going re-irradiation treatment of relapses in the period of 6-108 months
from the previous radiotherapy. It was ascertained that re-irradiation,
regardless of relapse stage, is safe, effective and can be recommended in
combination treatment. Subtotal body irradiation in single dose 1 Gy
and summary dose 5-6 Gy were used as salvage therapy in case of inef-
fectiveness of chemotherapy standard for 20 patients: first relapse with
14 patients, second relapse - with 6 patients (with one of the patients
subtotal body irradiation was applied in treatment of the first and sec-
ond relapse). In relapse treatments subtotal body irradiation was used
together with chemotherapy in case of insufficient effectiveness of
chemotherapy to reach second and third remission. In case of success-
ful combined subtotal body irradiation and chemotherapy antitumoral
treatment the local re-irradiation was supplementally applied. As a
result, 12 (85,7%) out of 14 patients with the first relapse were brought
into the second remission (complete - with 8 , partial - with 4 patients).
The total 10 -year survival in case of 112 patients with relapses made
71,6±4,3 %, corrected survival -73,7±4,2 %, free of second failure -
28,6±5,4 %. The last one did not depend either on gender or age of the
patients, but was significantly higher with RS I - II AB.
Discussion. radiation therapy is an important component of HL relapse
treatment.
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RADIOTHERAPY DOES NOT INFLUENCE THE SEVERE PULMONARY TOXICITY OBSERVED
WITH THE ADMINISTRATION OF GEMCITABINE AND BLEOMYCIN IN PATIENTS WITH
ADVANCED STAGE HODGKINS LYMPHOMA TREATED WITH THE BAGCOPP REGIMEN: 
A REPORT BY THE GERMAN HODGKINS LYMPHOMA STUDY GROUP
H.T. Eich,1 A. Macann,2 H. Bredenfeld,3 K. Hansemann,1
R. Skripnitchenko,1 V. Diehl,3 A. Engert,3 R.P. Mueller1
1Department of Radiation Oncology, University of Cologne, Germany; 2Depart-
ment of Radiation Oncology, Auckland Regional Cancer and Blood Service, New
Zealand; 3Department of Medical Oncology, University of Cologne, Germany
Purpose. To evaluate the effect of radiotherapy (RT) on severe pul-
monary toxicity observed in the pilot study of BAGCOPP (bleomycin,
doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone,
and gemcitabine) for advanced stage Hodgkin’s lymphoma (HL).
Methods. Patients with stage III or IV HL, or stage IIB with risk factors
participated in this single arm multicentre pilot study. The intention had
been to determine the maximum tolerated dose of gemcitabine within
a modified escalated BEACOPP regimen. Consolidative RT was admin-
istered to sites of initial bulk disease (>5 cm) or sites of residual tumour
after chemotherapy.
Results. Twenty seven patients were enrolled on the study before its
premature closure as a result of the development of serious pulmonary
toxicity (mainly pneumonitis) in eight patients. All the cases of pul-
monary toxicity occured either during or immediately after the BAG-
COPP chemotherapy course. The pulmonary toxicity contributed to
one early fatality but resolved in the other 7 patients after cessation of
gemcitabine and bleomycin, allowing continuation of therapy. Fifteen
patients received consolidative RT including 4 who previously had pul-
monary toxicity. Transient grade 2 oesophagitis developed in 2 patients
and grade 2 mucositis in one patient. There were no reported cases of
radiation pneumonitis and no exacerbation of pulmonary symptoms in
the 4 patients who had had previous pulmonary toxicity.
Conclusions. The severe pulmonary toxicity observed in this study has
been attributed to an interaction between gemcitabine and bleomycin.
Gemcitabine (when administered without bleomycin) remains of inter-
est in Hodgkins lymphoma and is being incorporated into a new GHSG
protocol that also includes consolidative RT. This study supports the
concept of the integration of RT in gemcitabine containing regimens in
HL if there is an interval of at least 4 weeks between the 2 modalities
and with a schedule where RT follows the chemotherapy.
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RESULTS OF THE MULTIDISCIPLINARY PANEL OF THE GHSG TRIAL HD12 - A QUALITY
CONTROL PROGRAM INITIATED BY THE RADIOTHERAPY REFERENCE CENTER COLOGNE
J. Kriz,1 H.T. Eich,1 A. Gossmann,2 K. Hansemann,1 J. Franklin,3
R. Skripnitchenko,1 H. Bredenfeld,3 A. Engert,3 V. Diehl,3 R.P. Mueller1
1Department of Radiation Oncology, University of Cologne; 2Department of
Radiology, University of Cologne; 3Department of Medical Oncology, Universi-
ty of Cologne, Germany
Purpose. The role of radiotherapy (RT) after intensive chemotherapy
in patients with advanced stage Hodgkin's lymphoma (HL) is still
unclear. The HD12 trial was designed to test whether consolidative RT
in the region of initial bulky disease and of residual disease is necessary
following effective chemotherapy. A quality control program based on
a multidisciplinary panel of radiation oncologists, radiologists and med-
ical oncologists who reviewed all patients’ staging and restaging imag-
ing was initiated. For patients with poor response to chemotherapy, the
panel recommended RT independent of the randomization. This proce-
dure ensured that patients with a poor response to chemotherapy
received additive RT. Further the panel evaluated the imaging quality by
the guidelines of the German association of radiology.
Methods. A total of 1661 patients aged 16-65 with HL in stage IIB
(large mediastinal mass and/or E-lesions) or stage III-IV were random-
ized from 01/1999-01/2003 according to a factorial design between: 8
esc.BEACOPP + RT (arm A), 8 esc.BEACOPP no RT (arm B), 4+4BEA-
COPP + RT (arm C), 4+4BEACOPP no RT (arm D).
Results. At the 5th interim analysis 1449 patients were eligible and
1084 had been evaluated by the multidisciplinary panel. The panel
defined initially bulky disease in 800/1084 reviewed patients (74%) and
residual disease in 600/1084 reviewed patients (56%). The panel recom-
mended continuation of therapy according to the randomization for
934/1084 patients and additive RT independently from the randomza-
tion arm for 145/1084. For the first 371 consecutive patients the panel
evalueted the imaging quality of 2607 CT scans according to the guide-
lines of the German Radiological Society concerning the quality of tech-
nique and contrast enhancement. Helical CT showed a significantly
higher contrast enhancement and imaging quality than conventional CT
(p<0.001). CT-imaging from university hospitals was assessed as supe-
rior to that from other institutions (p<0.001).
Conclusions. RT can be reduced substantially after effective chemother-
apy. However, due to the irradiation of 10% of patients in the no-RT
arms, equivalent effectiveness of a no-RT strategy cannot be proven. A
substantial limitation of consolidative RT according to expert panel rec-
ommendations appears to be possible without reducing effectiveness. 
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DO WE NEED A RADIOTHERAPY REFERENCE CENTER IN COOPERATIVE GROUP TRIALS
WITHIN THE MULTIDISCIPLINARY TREATMENT OF HODGKINS LYMPHOMA?
H.T. Eich,1 K. Hansemann,1 A. Gossmann,2 A. Engert,3
R. Skripnitchenko,1 A. Schneeweiss,1 V. Diehl,3 R.P. Mueller1
1Department of Radiation Oncology, University of Cologne; 2Department of
Radiology, University of Cologne; 3Department of Medical Oncology, Universi-
ty of Cologne, Germany
Purpose. The GHSG set up a radiotherapy reference center within the
Department of Radiation Oncology at the University of Cologne to
undertake quality assurance (QA) of the groups clinical studies. The
HD4 study demonstrated the importance of this. Major protocol viola-
tions (with particular reference to the design of the radiotherapy fields)
were associated with a statistically significant reduction in FFTF. The QA
program in this trial was of retrospective manner after treatment and
highlighted two key factors: 1) The need for a real time QA program
which could influence the actual delivery of treatment; 2) The close inte-
gration required between the diagnostic radiology and radiotherapy
components of the QA program given that decisions on radiotherapy
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field designs are determined by diagnostic radiology parameters.
Material. Between 1998-2003, 1371 pts were enrolled into the HD10
and 1570 pts into the HD11. All study centers were required to score dis-
ease involvement at a total of 34 possible sites on case report forms
(CRF) and sent them with all diagnostic imaging to the RT reference
center. Here, the images were reviewed and compared with the CRF.
Complete sets of documentation of 89% of pts both in HD10 and HD11
were submitted to the reference center.
Results. A considerable proportion of involved sites, were not or incor-
rect recorded on the CRF. For pts in HD10 there was a correction of the
disease involvement in 49%, for pts in HD11 in 67%. This resulted in a
change of disease stage in 41 pts. 93 pts had to be treated in a different
protocol, due to changes of stage and risk factors. Due to the incorrect
lymph node documentation the RT treatment volume had to be enlarged
in 891 pts and reduced in 82 pts.
Conclusions. A central prospective review of pts data has a significant
impact on the correctness of stage definition, allocation to treatment
groups and extension of the IF treatment volume. Recent results of this
QA program in the trials HD13 and HD14 will be presented.
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INTRODUCTION OF DICOM-EMAIL AS A TOOL FOR ELECTRONIC IMAGING 
COMMUNICATION WITHIN THE QUALITY CONTROL PROGRAMS OF THE RADIOTHERAPY
REFERENCE CENTER OF THE GHSG
H.T. Eich, A. Schneeweiss, K. Hansemann, R. Skripnitchenko, 
R.P. Mueller
Deparment Of Radiation Oncology University of Cologne, Germany
Introduction. The subproject Radiotherapy is part of the competence
network malignant lymphoma and funded by the Federal German Min-
istry of Education and Research (BMBF). A teleradiotherapeutic network
between different departments of Radiation Oncology was established.
Transfer of digital imaging between participating study centers and the
radiotherapy reference center allows immediate or short-term evaluation
of adequacy of treatment fields by expert radiation oncologists before the
start of radiotherapy. This improves dialogue and consensus between
radiotherapy reference centers and participating centers and thus con-
tributes towards high radiotherapy quality for lymphoma patients.
Material und Method. For cooperating departments with different tel-
eradiological systems, the possibility for digital imaging data exchange
was confined to send in CD-ROM or DVD. DICOM-email for digital
imaging transfer to the reference center could recently be introduced in
the network. This method is producer independent and save with the
help of GPG/PGP.
Results: By means of this standard the circle of cooperating partners,
who are able to communicate medical imaging data, can be considerably
expanded. We expect the communication mode to be changed in more
than 30% of the partners and thus the number of digital sendings will
significant increase. This will additionally improve the workflow of the
radiotherapeutic quality assurance programs.
Conclusions. The introduction of DICOM-email will increase the exist-
ing teleradiotherapeutic network and is an important step to involve fur-
ther European partners.
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OUTCOME OF GEMCITABINE-BASED SALVAGE CHEMOTHERAPY AND AUTOLOGOUS STEM
CELL TRANSPLANTATION FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
J. Kuruvilla,1,2 T. Nagy,1,2 S. Zadeh,2 N. Puig,1,2 T. Seshadri,2 R. Tsang, 
A. Keating,2 M. Crump1,2
1Lymphoma Program and 2Autologous Blood and Marrow Transplant Program,
Princess Margaret Hospital, Toronto, Canada
Objectives. To assess the response rate, progression-free (PFS) and over-
all survival (OS) following second-line chemotherapy with GDP fol-
lowed by high-dose therapy and autologous stem cell support (ASCT)
for patients (pts) with relapsed (REL) or primary refractory (REF) Hodgkin
lymphoma (HL).
Patients and methods. 91 consecutive pts referred for salvage therapy
between 1999 and 2006 were retrospectively analyzed. REF disease was
defined as progression on initial treatment or within 90 days. GDP (gem-
citabine 1000 mg/m2 IV d1 and 8, dexamethasone 40 mg PO d1-4, cis-
platin 75 mg/m2 day 1) was administered as an outpatient every 3 weeks
with pts typically receiving 2 cycles of salvage therapy to assess
chemotherapy sensitivity (Cheson, JCO 1999; 17:1244). Responding pts
had PBSCs mobilized with cyclophosphamide 2 g/m2 day 1, etoposide
200 mg/m2 days 1-3 and filgrastim 10 µg/kg. The conditioning regimen
consisted of high-dose VP16 60 mg/kg day -4 and melphalan180 mg/m2
day -3 with PBSC infusion day 0. Pts with bulk disease at relapse (>5 cm)
received involved field radiation post-ASCT.
Results. Initial treatment: ABVD: 93%, radiotherapy: 27%. Patients
characteristics: median age at salvage therapy: 40 (range 18 to 65), Sex:
male:female=55:36, REF disease: 53%, Stage at relapse - IA or IIA: 27%
Stage III/IV or B symptoms: 73%. A median of 2 cycles of GDP was giv-
en (range 1-3). The overall response rate (ORR) to GDP was 67%
(CR/CRu: 14%, PR: 53%). ORR for REF HL: 58% (CR/CRu 5, PR: 23, SD:
13, PD:7); ORR for REL HL: 77% (CR/CRu: 8, PR: 25, SD:9, PD:1). 23%
of pts had chemosensitive stable disease (SD) and underwent ASCT. 2/5
pts with PD responded to second salvage with mini-BEAM. 81 of 91 pts
(89%) were able to proceed to ASCT. PBSC mobilization was success-
ful in 80/81 (99%) pts. Consolidative post-ASCT radiotherapy was giv-
en in 24%. With a median follow-up of 21 months (range 6-61) post-
ASCT, the PFS and OS are 67% and 87%. There were no treatment-relat-
ed deaths due to salvage therapy or ASCT. One pt has developed sec-
ondary MDS.
Conclusions. GDP salvage chemotherapy compares favourably to cur-
rent, more toxic regimens in response rate, ability to collect stem cells
and proceed to ASCT. A phase III comparison of a gemcitabine-based
therapy to current standards such as dexa-BEAM+ASCT or high-dose
sequential therapy is warranted. 
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LONG TERM ABSOLUTE LYMPHOCYTE COUNT (ALC) RECOVERY IS CORRELATED WITH
PROGRESSION FREE SURVIVAL (PFS) OF PATIENTS WITH HODGKIN LYMPHOMA (HL)
UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
T. Seshadri, J. Kuruvilla, M. Pintile, A. Keating, M. Crump
Autologous Blood and Marrow Transplant Programme, Princess Margaret Hos-
pital, University of Toronto, Toronto, Canada
Introduction. Prior studies in patients (pts) with lymphoid malignan-
cies, including a small study of pts with HL (Porrata L, 2002), have report-
ed an association between day 15 ALC post ASCT and PFS. The aim of
our study was to validate these findings in a cohort of pts with relapsed
and primary refractory HL undergoing ASCT, and to review factors asso-
ciates with outcome.
Methods. We retrospectively reviewed consecutive pts with HL under-
going ASCT from Jan 1999 to Dec 2006 at Princess Margaret Hospital.
Pts received 2-3 cycles of salvage chemotherapy, followed in respond-
ing pts by stem cell mobilization using cyclophosphamide, etoposide and
G-CSF. High dose therapy: etoposide 60 mg/kg + melphalan 180mg/m2,
followed by ASCT, with involved field radiation to initial sites of disease
>5 cm. Variables analyzed: pre-transplant characteristics, infused CD34
cells, pre-apheresis ALC, day 15 and 90 ALC post ASCT (ALC 15, ACL
90) and engraftment times. ALC 15 and ALC 90 values were analyzed
as continuous variables.
Results. 146 pts were identified and 143 analyzed. Median age: 38
years (range 18-67); 38% female; 81% nodular sclerosis histology; 43%
had primary refractory disease, 57% relapsed. Salvage chemotherapy
pre-transplant: GDP 62%, miniBEAM 29%, other 9%. After a median
follow-up of 2.0 years, 50 pts have relapsed between 1.4-29.6 months
(median 6.7months) post ASCT. Median 2 year overall (OS) and PFS are
94% and 60%. There was no association between PFS and stage at
relapse, or time to recurrence (refractory vs early relapse [3-12 m] or late
relapse [>12 m]). Two year PFS for patients achieving a CR, PR, or SD
post-salvage therapy was 68%, 62% and 42% (p=0.09). Median ALC15
and ALC 90 were 0.6×109/L (n=129) and 1.1×109/L (n=87). There was no
association between PFS and ALC15, infused CD34 cell number, or
engraftment times. Pre-apheresis ALC (HR=0.76, p=0.04) and day 90
ALC (HR =0.62, p=0.036) were significantly correlated with PFS in uni-
variate analysis. Pts with ALC 90>0.5×109/L had 2 year PFS of 67% com-
pared to 34% for ALC 90<0.5×109/L (p=0.04).
Conclusions. Pre-apheresis ALC and ALC90 are associated with
improved PFS, suggesting infused lymphoid cells as well as long-term
lymphoid reconstitution may be important factors in determining PFS.
Prospective evaluation of lymphocyte subset recovery is underway to
clarify the relationship between lymphoid recovery and disease control,
and in planning post-transplant interventions to prevent recurrence.
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A PHASE I/II TRIAL OF TOTAL LYMPHOID IRRADIATION-BASED THERAPY WITH 
AUTOLOGOUS STEM CELL TRANSPLANTATION: EXCELLENT LONG-TERM SURVIVAL IN
HIGH RISK RELAPSED/REFRACTORY HODGKIN LYMPHOMA 
A.M. Evens,1 J.K. Altman,1 B.B. Mittal,2 N. Hou,3 A. Rademaker,3
D. Patton,1 L. Kaminer,1 S. Williams,1 S. Duffey,1 D. Variakojis,4
S. Singhal,1 M.S. Tallman,1 J. Mehta,1 J.N. Winter,1 L.I. Gordon1
1Division of Hematology/Oncology, Hematopoietic Stem Cell Transplant Pro-
gram and Lymphoma Program, Northwestern University Feinberg School of
Medicine, and the Robert H. Lurie Comprehensive Cancer Center of North-
western University, Chicago, Illinois; 2Department of Radiation Oncology;
3Department of Preventive Medicine; and 4Department of Pathology; all from
Northwestern University Feinberg School of Medicine, USA
Introduction. The standard approach to treatment for relapsed/refrac-
tory Hodgkin lymphoma (HL) is high-dose chemotherapy conditioning
followed by autologous hematopoietic stem cell transplantation
(aHSCT). We report the results of a prospective phase I/II clinical trial
of accelerated hyperfractionated total lymphoid irradiation (TLI) imme-
diately followed by high-dose chemotherapy for relapsed/refractory HL. 
Methods. Forty-eight patients underwent aHSCT with either sequen-
tial TLI/chemotherapy (n=32) or chemotherapy-alone conditioning
(n=16), based on prior radiation exposure. The first 22 patients enrolled
on the Phase I component of the clinical trial received escalating doses
of etoposide (1600 mg/m2 to 2100 mg/m2) with high-dose carboplatin
and cyclophosphamide. 
Results. Among the chemotherapy-alone conditioning group, 19% of
patients had primary induction failure (PIF) and 50% were resistant to
salvage chemotherapy prior to aHSCT; while 84% of patients from the
TLI/chemotherapy group had either PIF or short initial remission (<12
months). No dose-limiting toxicity was seen and TLI/chemotherapy
was overall well-tolerated. The 5-year event-free survival (EFS) for all
patients was 44% with overall survival (OS) of 48%. Five-year EFS and
OS for patients who received TLI/chemotherapy was 63% and 61%,
respectively, compared with 6% and 27%, respectively, for the
chemotherapy-alone group (p<0.0001 and p=0.04, respectively). HL
patients with PIF who received TLI/chemotherapy had 5-year EFS and
OS rate of 83%. The 100-day treatment related mortality was 4.2% and
two secondary cancers were seen. Significant factors predicting survival
by multivariate analysis included TLI/chemotherapy and B symptoms
at relapse. 
Discussion. Sequential TLI/chemotherapy conditioning for relapsed/
refractory HL is safe and associated with excellent long-term survival
rates. 
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A MULTICENTER STUDY OF A GEMCITABINE-BASED REGIMEN IN RELAPSED OR
REFRACTORY HODGKIN'S LYMPHOMA PATIENTS 
P. Validire,1 C. Fermé,2 P. Brice,3 M. Diviné,4 J. Gabarre,5
K. Bouabdallah,6 O. Fitoussi,7 D. Chaoui,8 H. Pacquement,9
C. Soussain,10 P. Carde,2 R. Salhi,1 D. Decaudin1
1Institut Curie, Paris; 2Institut Gustave Roussy, Villejuif; 3Hopital Saint-Louis,
Paris; 4Hopital Henri Mondor, Créteil; 5Hopital de la Pitié-Salpetriére, Paris;
6Hopital Haut l’Eveque, Pessac; 7Polyclinique Bordeaux Nord Aquitaine, Bor-
deaux; 8Hopital Victor Dupouy, Argenteuil; 9Institut Curie, Paris; 10Centre René
Huguenin, Saint-Cloud, France
Introduction. The aim of this study was to assess the efficacy of a gem-
citabine-based regimen in pretreated Hodgkin's lymphoma (HL)
patients. 
Patients and methods. Relapsed or refractory HL patients treated with
gemcitabine, used alone or in combination with other cytotoxic agents,
were retrospectively reviewed. 
Results. Fifty-five patients were included in the study. Initial character-
istics before gemcitabine administration were: Ann Arbor stage III-IV:
84%; International Prognostic Score less than 3 in 20/43 cases (47%);
thirty-one primary refractory patients at the end of first-line therapy
(56%); median number of previous chemotherapy regimens of 3. Twen-
ty-nine patients received gemcitabine alone with a median starting dose
of 750 mg/m2 per injection (range: 180-1250 mg/m2); Gemcitabine was
administered at a starting dose of 1000 mg/m2 per injection (range: 500-
1250) in combination with vinorelbine in 10 patients, oxaliplatin in 13
patients, and other drugs in 3 patients, with a median of 6 injections
(range: 1-18). Overall response rate was 20% with 11% of complete
remission. On univariate analysis, two adverse factors at progression
were significant for response to gemcitabine-based regimen: stage III-IV
disease and hemoglobin level less than 10.5 g/dL.
Discussion. The two identified prognostic factors for response to gem-
citabine are part of the International Prognostic Score of HL, suggesting
that response to gemcitabine is mainly influenced by the specific prog-
nostic factors of HL. Moreover, with an ORR of 29%, our results of the
gemcitabine administered alone regimen are not different from those
reported in the literature. In contrast, the results of the various series of
HL patients treated by gemcitabine-combined regimens, mainly with
cisplatin or derivatives, vinorelbine, ifosfamide, doxorubicin, and pred-
nisone, are very different due to different patient characteristics. In heav-
ily pretreated cases, as in our study, the ORR was 26%; inversely, in
patients who had received only one or two lines of chemotherapy, the
ORR varied between 64% and 82% with 9% to 54% of complete remis-
sions. This discordance can probably be explained by the prognostic
impact of previous treatment lines in the response to gemcitabine. This
observation emphasizes the possible interest of using gemcitabine ear-
lier in the treatment of Hodgkin's lymphoma, namely at the time of first
relapse or after first-line treatment in primary refractory HL patients. 
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LONG TERM FOLLOW-UP AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN
REFRACTORY OR RELAPSED HODGKIN LYMPHOMA
A. Stamatoullas, H. Lanic, N. Contentin, K. Nunes, J.M. Picquenot, 
C. Bastard, H. Tilly
Département d'Hématologie, Centre Henri Becquerel, Rouen, France
Autologous stem cell transplantation (ASCT) is an effective treatment
for patients with relapsed or primary refractory Hodgkin lymphoma
(HL). More than half of these patients eventually relapse and die of their
disease. Some predictive factors for long term survival were previously
described, mainly chemosensitivity and duration of prior complete
remission (CR). Recently, tandem ASCT were performed and looked
favourably, especially for those patients with primary refractory dis-
ease. Long term toxicity after BMT is also an important issue. We ret-
rospectively analysed 38 patients who received ASCT from May 1992
to October 2005, in Centre Henri Becquerel for relapsed or primary
refractory HL. The median age at diagnosis was 27 years (16-58), 20
were males, 19 had relapse (11 first relapse, 13 relapses <12 months) and
19 had refractory disease. At transplantation, 9 patients were refracto-
ry to salvage chemotherapy, 4 patients were in stable disease, 10 patients
were in PR and 15 patients were in CR. Tandem ASCT were performed
in 12 patients, 7 with refractory disease and 5 with early relapse. The
first conditioning regimen consisted to CBVN. The second was TAM (8)
(TBI: 12 Gy, cytarabine 6 g/m2, melphalan: 140 mg/m2) and BAM (3)
(busulfan: 12 mg/Kg, cytarabine, melphalan). For patients with one trans-
plant, conditioning regimen was BEAM. Among the group with only one
transplantation (26): 20 patients achieved CR+CRu, 1 PR and 5 failed to
respond. Fifteen patients are alive in CR. Eleven patients relapsed and 3
of them underwent subsequent allogeneic bmt. From these patients, 2
died: one from GVHD, and one from relapse. The third patient relapsed
and is alive with active disease. Among the group with tandem trans-
plantations (12): after the first transplant: 5 patients achieved CR, 4 Cru,
2 PR and 1 had stable disease. Eight patients are alive in CR. Four patients
died: 1 toxic death, 2 relapses and one GVHD after allogeneic BMT.
With a median follow up of 74 months (19-163), 22 patients are current-
ly alive, one with active disease. The overall survival at 5 years is 59%
(95CI: 43-73). The incidence of late toxicity is low: 1 coronary artery dis-
ease, 1 HTA; 1 PNH, one melanoma relapse, 1 MDS. Regarding fertili-
ty: two women became pregnant. In conclusions: our series confirm the
effectiveness of ASCT for relapsed or primary refractory HL. Tandem
ASCT can be performed with acceptable early and late toxicity. 
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RADIOIMMUNOTHERAPY (RIT) OF REFRACTORY OR RELAPSED HODGKIN’S LYMPHOMA
(HL) WITH 90YTTRIUM-LABELLED ANTIFERRITIN ANTIBODY 
D. Decaudin,1 R. Levy,2 F. Lokiec,3 O. Madar,3 R. Brossel,4
F. Morschhauser,5 V. Songeur,1 M. Djeridane,2 J. Kadouche,2
A. Pecking3
1Institut Curie, Paris; 2MATBioPharma, Evry; 3Centre René Huguenin, Saint-
Cloud; 4Biologie & Industrie, Montreuil; 5CHRU, Lille; France
Introduction. The aim of this study was to evaluate the safety and effi-
cacy of radiolabelled DTPA-chelated rabbit polyclonal antiferritin anti-
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body (Ab) in relapsed or refractory HL.
Patients and methods. The protocol included a first intravenous injection
of 111Indium-labelled antiferritin Ab followed by immunoscintigraphy at
4, 48, and 72 hours and intravenous injection of 90Yttrium-labelled anti-
ferritin Ab in the case of tumour targeting.
Results. Ten patients were included in the study: median number of
chemotherapy regimens: 3; number of autografted pts: 8; number of pre-
viously irradiated pts: 9; response to last chemotherapy: 6 PR and 4 pro-
gressions. All immunoscintigraphies showed tumour targeting. Nine
patients were treated, as the last patient died from progressive HL before
therapeutic injection. Median injected activity was 12 MBq/kg (0.32
mCi/kg). Among the ten patients who were included in the study, 1 CR
and 6 PR were observed (ORR 70%) with a median duration of response
of 8 months (range: 7-12 months). Toxicity was mainly haematological,
with grade 1 or 2 neutropenia and anaemia, and grade 2 and 3 throm-
bocytopenia. The pharmacokinetic study showed that the half-lives of
111Indium and 90Yttrium were almost identical.
Discussion. These results confirm those previously reported in the liter-
ature and show the therapeutic potential of rabbit polyclonal antiferritin
Ab in relapsed or refractory HL. On the basis of all these results, MATBio-
Pharma proposed to test a radioimmunotherapy with polyclonal antifer-
ritin antibodies (Abs) in patients with refractory or relapsed HL. The treat-
ment is constituted with chelated rabbit polyclonal antiferritin Abs to be
loaded with 111Indium for the diagnosis of the tumour(s) by immuno-
scintigraphy and with 90Yttrium for the treatment of the tumour(s). A
phase I study is still ongoing at the Institut Curie/Centre René Huguenin
(France) to evaluate the safety and tolerability of ascending doses of 90Yttri-
um antiferritin until the maximum tolerated dose (MTD) is reached and
to select a dose for further investigation (one dose step below MTD). A
pharmacokinetics is concomitantly performed to determine dose lineari-
ty and pharmacokinetic parameters of increasing 90Y-Ab and Ab. The sec-
ond dose level will be completed in the third quarter 2007 and available
data on immunoscintigraphy, safety, and efficacy of included HL patients
will be provided for the 7th International Symposium on HL. 
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SERUM TARC AND THE DIAGNOSIS OF RELAPSED HODGKIN LYMPHOMA
K. Farrell,1 C. Cannon,2 P. Tansey,1 R. Jackson,3 R.F. Jarrett2
Department of Haematology, Victoria Infirmary, Glasgow; LRF Virus Centre,
Institute of Comparative Medicine, University of Glasgow; Department of Pathol-
ogy, Glasgow Royal Infirmary, Glasgow, UK
Introduction. The chemokine TARC (CCL17) is expressed at high lev-
els by Hodgkin and Reed-Sternberg (HRS) cells and high levels of TARC
have been detected in pre-treatment serum samples from Hodgkin lym-
phoma (HL) patients (see accompanying abstract by Niens et al.;
Weihrauch et al., Cancer Res 2005;65: 5516). Small studies have demon-
strated that TARC may be a useful prognostic marker. In this case study,
we investigated the usefulness of serum TARC measurement in the diag-
nosis of relapsed HL.
Case history. The patient, a previously fit 42-year old man, originally
presented in February 2005 with stage 3B, nodular sclerosis HL. He was
treated with 6 cycles of ABVD chemotherapy and achieved clinical, radi-
ological and PET remission. He re-presented in April 2007, complaining
of weight loss and drenching night sweats. Clinical examination con-
firmed widespread lymphadenopathy, with palpable nodes present in
the left cervical chain and bilateral inguinal areas. CT scanning confirmed
multiple intra-abdominal nodes, thought to be less accessible to biopsy.
Clinically there was a strong suspicion of relapsed HL; however, inguinal
lymph node excision biopsy demonstrated only reactive changes, with
no pathognomonic HRS cells. Due to the delay in reaching a diagnosis,
a serum TARC measurement was performed. 
Methods. Serum TARC measurements were performed using a com-
mercially available ELISA (R&D Systems) according to the manufactur-
er’s instructions. 
Results. Serum TARC levels at initial presentation and suspected
relapse were high at 8904 and 5768 pg/mL, respectively (cut-off 1094
pg/mL). A further lymph node biopsy was subsequently carried out and
confirmed the diagnosis of relapsed nodular-sclerosis HL. The patient is
undergoing salvage chemotherapy.
Discussion. A small, but significant minority of HL proves difficult to
diagnose on initial biopsy, leading to delays in treatment. The above
case demonstrates the concept that TARC levels may help in reaching a
diagnosis. Further studies into the sensitivity and specificity are required
to validate this concept. In conclusion, TARC may prove to be a useful
diagnostic tool, particularly in expediting treatment in this difficult sub-
group of patients.
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ESHAP VS GIN AS SALVAGE AND MOBILIZING REGIMENS IN RELAPSED OR REFRACTORY
HODGKIN LYMPHOMA (HL)
P. Tsirkinidis, T.P. Vassilakopoulos, M. Moschoyiannis, Z. Galanis, 
K. Anargyrou, E. Dimitriadou, S. Masouridis, V. Pappis, N. Gratsias, 
E. Chatzileonidas, S. Sachanas, V. Kalotychou, K. Kostandoudakis, 
S. Kokoris, M. Siakantaris, I. Rombos, G.A. Pangalis, 
M.K. Angelopoulou
1stDepartment of Internal Medicine and Hematology, National and Kapodistri-
an University of Athens, Laikon General Hospital, Athens, Greece
Introduction. Relapsed or refractory HL patients are treated with salvage
chemotherapy followed by high dose therapy and autologous stem cell
transplantation (HDT/ASCT). Salvage chemotherapy aims to disease
debulking, testing of chemosensitivity, as well as mobilization of periph-
eral blood stem cells. Platinum-based regimens (DHAP, ESHAP, ICE) are
the frequently used for this purpose. However, studies comparing dif-
ferent salvage chemotherapy regimens are lacking. Recently the combi-
nation of gemcitabine, ifosphamide and vinorelbine (GIN) has been
shown to be an effective salvage regimen in HL. The aim of the present
study is the comparison of ESHAP (etoposide, methylprednisolone, high
dose cytarabine and cis-platinum) vs GIN chemotherapy as 2nd line treat-
ment for relapsed or refractory HL patients eligible for HDT/ASCT. 
Methods. Between 2001 and 2006 most patients scheduled for ASCT
received ESHAP as first salvage (n=37), while GIN was introduced as first
salvage during the last year (n=13). We retrospectively compared these
two regimens regarding mobilization parameters, disease control (over-
all response rate) and a combined endpoint, including both successful
mobilization and disease control prior to ASCT. 
Results. Patients' characteristics did not differ between ESHAP and
GIN groups, with the exception of bulk and advanced disease stage at
relapse/progression, which were more frequent in the latter. GIN was
more effective as a mobilizing regimen: peak circulating CD34+ cells was
higher (median 217.9 vs 75.2, p<0.001), the number of total CD34+ col-
lected cells was higher (median 15.2×106/kg vs 4.32×106/kg, p<0.001),
while all patients were successfully mobilized with GIN vs 90% in the
ESHAP group. The median time to apheresis was shorter with GIN (12
vs 16 days, p<0.001). In addition, time to neutrophil engraftment follow-
ing ASCT was faster with GIN (median 9 vs 10 days, p=0.002). Response
rates were similar with both regimens (38% vs 50% with GIN vs
ESHAP). The combined endpoint of successful mobilization and disease
control was achieved in a similar percentage of patients with both regi-
mens (38% vs 49%). 
Discussion. GIN appears to be a more effective mobilizing regimen
compared to ESHAP in relapsed/refractory HL. More patients are need-
ed for a meaningful comparison of efficacy.
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HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDT/ASCT) IN
HODGKIN'S LYMPHOMA (HL). OUTCOME AND PROGNOSTIC FACTORS
M.K. Angelopoulou, Z. Galanis, T.P. Vassilakopoulos, P. Tsirkinidis, 
M. Moschogiannis, E. Dimitriadou, V. Pappis, S. Masouridis, 
E. Chatzileonida, D. Chasiotis, K. Katsandris, V. Kalotychou, 
D. Boutsis, K. Anargyrou, S. Sachanas, M.N. Dimopoulou, 
S. Kokoris, M.C. Kyrtsonis, M.P. Siakantaris, I. Rombos, G.A. Pangalis
1stDepartment Of Internal Medicine And Hematology, National And Kapodis-
trian University Of Athens, Greece 
Introduction. HL is a potentially curable disease in at least 75% of the
patients (pts) treated with ABVD chemotherapy±radiotherapy. For
relapsed or refractory HL pts, HDT/ASCT is the most widely accepted
option with curative intent. The aim of the present study is outcome and
prognostic factor analysis for relapsed or refractory HL pts treated with
HDT/ASCT. 
Methods. We retrospectively analyzed 58 pts with refractory or
relapsed HL treated with HDT/ASCT between 1996 and 2006 in a sin-
gle Hematology Unit. Several pts’ characteristics, disease status and
remission status pre-transplant, early vs late relapse and number of pri-
or regimens were analyzed as possible prognostic factors. 
Results. Median age at ASCT was 29 years (19-57) and 71% were
males. At diagnosis 14%, 52%, 19% and 16% of the pts had clinical
stage I, II, III and IV respectively, 43% had B symptoms, 36% bulky dis-
ease and 97% received an anthracycline-based regimen. At relapse 21%,
42%, 5% and 32% had clinical stage I, II, III and IV respectively, 18% B
symptoms and 6% bulky disease. Half of the pts were transplanted in
first relapse, 17% after multiple relapses and 33% were primary refrac-
80 | haematologica/the hematology journal | 2007; 92(s5)
7th International Symposium on Hodgkin Lymphoma, 3-7 November 2007 – Cologne, Germany
tory. All pts received salvage chemotherapy (CT) before ASCT, mostly
ESHAP or GIN. The median number of CT regimens prior to ASCT was
2 (2-5). At ASCT 36% of the pts were in complete remission (CR), 43%
in partial remission (PR) and 22% were chemoresistant. The condition-
ing regimen was BEAM. The median time to neutrophil and platelet
recovery was 10 (8-19) and 15 days (10-102) respectively. Treatment
related mortality (TRM) rate was 2%. 27 pts experienced an event at a
median of 5.5 months (0.7-45.5) after ASCT. At a median follow-up of
25 months (0.5-104) for surviving pts the 3- and 6- year event-free sur-
vival (EFS) were 49±7% and 39±9% respectively. The corresponding 3-
and 6- year overall survival (OS) rates were 73±8% and 66±10% respec-
tively. Chemosemsitivity (p=0.03) and CR prior to ASCT (p=0.02) were
identified as significant factors for OS. There was a trend for inferior EFS
and OS in primary refractory pts. 
Discussion. HDT/ASCT can salvage 40% of relapsed/refractory HL pts
with a low TRM. Chemosensitive pts, especially those transplanted in
CR have a superior outcome, while primary refractory pts tend to do
worse. 
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VERY LATE RELAPSES IN PATIENTS WITH HODGKIN’S LYMPHOMA (HL)
T.P. Vassilakopoulos, G.A. Pangalis, S. Masouridis, S. Sachanas, 
M.P. Siakantaris, S.I. Kokoris, E.M. Dimitriadou, M.N. Dimopoulou,
M.C. Kyrtsonis, C. Kalpadakis, P. Tsaftaridis, E. Plata, Z. Galanis, 
P. Tsirkinidis, P. Michail, E. Variamis, N.A. Viniou, P. Panayiotidis,
M.K. Angelopoulou
1st Department of Internal Medicine and Department of Haematology, Nation-
al and Kapodistrian University of Athens, Greece
Introduction. Most relapses in patients (pts) with HL occur within 5
years from diagnosis. However occasional pts relapse later on. The inci-
dence of these very late relapses (VLR) is not precisely known. Although
''late'' relapses have a relatively favorable outcome, the prognosis of pts
with VLR has not been established. 
Methods. We evaluated the actuarial incidence and risk factors for
relapse in HL pts, who had been in complete remission (CR) for 5 years
after first-line treatment initiation with chemotherapy (CT) or com-
bined modality therapy (CMT), as well as the outcome of these VLR
after salvage therapy. CT was anthracycline-based in 81% of pts.
RESULTS: Among 545 HL pts, who achieved a CR lasting for 5 years,
493 remain in CR, 20 died from second malignancies and 32 experi-
enced VLR. The 10, 15, and 20-year relapse rate (RR) was 4.4±1.0%,
8.4±1.6% and 10.6±2.3%, respectively. A higher risk of VLR was predict-
ed in univariate analysis by a number of involved sites (NIS) 5 (p=0.02),
non-nodular sclerosing histology (non-NS, p=0.02), stage IV (p=0.04)
and use of CT alone vs CMT (p=0.01). In multivariate analysis non-NS
histology (p=0.03) was independently associated with the incidence of
VLR, while a NIS≥5 (p=0.08) and use of CT alone (p=0.09) were of bor-
derline significance. The 15-year RR for pts with 0, 1 or 2-3 of these fac-
tors was 3.6±1.4%, 8.8±2.7% and 19.7±6.1%, respectively. Among
patients with VLR, 30 were treated with conventional salvage therapy
(19 with non-cross resistant CT, 7 with the same CT regimen and 4
with RT alone), 1 received a transplant and 1 has not been treated yet.
Two pts died of toxicity of salvage therapy. The 5-year freedom from
second progression rate (FF2P) was 36±10% and the 5- and 10-year sur-
vival after relapse (SAR) was 69±9% and 49±11%. B-symptoms and
extranodal involvement at relapse were independently associated with
inferior outcome after salvage therapy. All subsequent relapses occurred
within 4 years from salvage therapy initiation. 
Discussion. Among pts with HL, who remain in CR1 for 5 years after
the initiation of CT/CMT, approximately 8% relapse during the subse-
quent 10 years. NS pts with relatively low tumor burden, who received
CMT had the lowest risk of VLR (3.6%). The outcome of VLR was not
satisfactory after conventional salvage therapy, with only 1/3 of pts
achieving a durable CR2. Thus, high-dose therapy should not probably
be spared in this subgroup based simply on the length of CR1.
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TEN-YEAR RESULTS OF HIGH-DOSE CHEMOTHERAPY (HDCT) WITH AUTOLOGOUS BONE
MARROW (ABMT) OR PERIPHERAL STEM CELLS TRANSPLANTATION (ASCT) AS FIRST
SALVAGE TREATMENT FOR RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
S. Viviani, M. Di Nicola, V. Bonfante, C. Carlostella, P. Valagussa, 
G. Bonadonna, A.M. Gianni
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Background. HDCT +ASCT or ABMT has significantly improved the
prognosis of refractory or relapsed HL over conventional- dose salvage
chemotherapy (CT) and therefore has become standard treatment in
this setting, however only few data are available on long-term outcome.
Methods. To evaluate the outcome of adult HL patients (pts) who failed
or relapsed after first-line CT± radiotherapy, we report the results of a
retrospective analysis in 74 patients treated at a single institution with
HDCT + ABMT or ASCT between 10/1984 and 12/2006 and followed
for at least 5 years. Seventeen pts had late relapse (CR≥12 months), 27
had early relapse (CR<12 months) while 30 never achieved CR or pro-
gressed during first-line CT (Induction failure). The main pts character-
istics at relapse/progression were as follows: M/F: 39/35; median age 28
years; Nodular Sclerosis histology :78%, stage III-IV/ I-II: 41/33, B symp-
toms: 27%, bulky disease 13%; extranodal ± nodal disease 49%; IPI≥ 3
32%. Induction treatment consisted in sequential HDCT (Cyclophos-
phamide 7 gr/mq followed by ASC or BM harvest, Methotrexate 8
gr/mq+ Vincristine 1,4 mg/mq, VP16 2 gr/mq) in 31 cases; 3-4 courses
of Ifosfamide (3 gr/mq x 4 days)+ Vinorelbine (25 mg/mq day 1+5) in
36 cases; other regimens in 7 cases. Final myeloablative course was
BEAM, or high-dose Melphalan combined with Mitoxantrone or with
Carmustine followed by ABMT or ASCT.
Results. Sixty-five pts underwent the myeloablative phase, while nine
pts progressed during induction CT. Toxicity was mild. After a median
follow-up of 66 months both 10-year freedom from second progression
(FF2P) and overall survival (OS) were 61% for all pts. According to
response to first-line treatment, FF2P and OS were respectively 46%
and 79% for pts with CR≥12; 48% and 50% for pts with CR<12; 48%
and 52% for pts with induction failure. In multivariate analysis bulky
disease was the most important prognostic factor for FF2P, whereas for
OS no factor reached the statistical significance but there was only a
trend in favour of pts achieving a long-lasting CR with first-line treat-
ment. 
Conclusions. These long-term results confirm that HDCT + ASCT or
ABMT was a feasible, safe and very effective approach even in the
unfavourable group of patients with refractory disease and should be
employed at first relapse or in the case of induction failure after first-line
therapy. 
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BEACOPP REGIMEN IN REFRACTORY AND RELAPSED HODGKIN’S LYMPHOMA: 
PRELIMINARY RESULTS 
E. Cavalieri, A. Matturro, N. Frattarelli, R. Foà, A. Pulsoni
Department of Hematology, La Sapienza University, Rome, Italy
Background. 25-30% of Hodgkin's lymphoma (HL) patients relapse or
do not respond to first line chemotherapy. A well-known experience
demonstrates the efficacy of the BEACOPP regimen as first-line treat-
ment for advanced stage HL, while no data are available for relapsed or
refractory HL patients. 
Aims. To retrospectively evaluate the efficacy of the BEACOPP regi-
men in refractory or relapsed HL patients after first-line therapy or after
high dose therapy (HDT). Response rate, overall survival (OS), progres-
sion-free survival (PFS) and toxicity were analyzed.
Methods. Nineteen HL patients, admitted between December 2005
and May 2006, were studied. Eight patients (group 1) were refractory or
relapsed after first-line therapies and 11 patients (group 2) were refrac-
tory or relapsed after HDT. All patients received salvage chemotherapy
with BEACOPP (4-8 cycles) at standard or escalated dose on the basis
of previous treatment, medical history, disease status and the general
conditions of patients.
Results. Of the 8 group 1 patients, 7 were treated in first relapse and 1
was partially responder to first-line treatment. All patients achieved CR.
After a median follow-up of 19 months, 5 patients (62.5%) are in con-
tinuous CR, 2 patients (25%) have relapsed, one patient died in CR 12
months later due to acute leukaemia. Of the 11 patients treated after
HDT (group 2), eight patients (73%) achieved CR and 2 proved refrac-
tory. After a median follow-up of 36 months (range 26-44), 4 patients
(43%) are in CR, 3 patients are alive with disease and 4 patients died.
OS and PFS are 87.5% and 62.5% for group 1 and 50% and 40% for
group 2, respectively. All patients had hematologic toxicity (WHO 3-4);
one patient presented an aspergillary pneumonia during severe neutrope-
nia and 1 patient suffered from an acute pericarditis. One patient had a
congestive heart failure 10 months off-therapy. Two patients had an
aseptic osteonecrosis caput femoris.
Conclusions. BEACOPP regimen is effective as second line therapy pro-
ducing results comparable to HDT. This regimen should be considered
also in patients relapsing after HDT.
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PREDICTORS OF OUTCOME OF HODGKIN'S LYMPHOMA IN PATIENTS WITH 
PROGRESSIVE DISEASE FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT)
K. Al-Farsi,1 C. Ma,2 S. Zadeh,1 T. Nagy,1 J. Kuruvilla,1 A. Keating,1
M. Crump1
1Division of Hematology/Oncology and 2Department of Biostatistics, Princess
Margaret Hospital, University Health Network, Toronto, Canada
Introduction. ASCT has become the standard treatment for patients
(pts) with relapsed/primary refractory Hodgkin’s Lymphoma (HL). For
pts who relapse after ASCT, there is little information on the predictors
of outcome and optimal treatment strategies. We reviewed pts with
relapsed HL after ASCT at our institution in an attempt to identify pre-
dictors of subsequent outcome.
Method. We retrospectively reviewed our computerized database and
charts of pts undergoing ASCT for relapsed or primary refractory HL
from Dec 1986 - Jun 2006. Of 330 pts, 139 relapsed after ASCT; 118 had
adequate data on subsequent therapy and were analyzed for factors
influencing progression free survival (PFS) and overall survival (OS) using
univariate Kaplan-Meier and multivariate Cox Proportional Hazards
(Cox-PH) analyses.
Figure.
Results. Pt characteristics: 34% had ASCT for primary refractory HL,
68% had advanced stage at relapse post-ASCT, 30% had B-symptoms
and 41% had involvement of extra-nodal (EN) sites by imaging. Medi-
an time to relapse post-ASCT was 6.5 months (m). From time of relapse,
median PFS and OS were 7.5 m and 27.6 m respectively. For PFS, uni-
variate analysis identified need for >2 cycles or alternate salvage thera-
py (Salvage) prior to ASCT (p=0.006), involvement of EN sites (p=0.001)
and stage 4 (p=0.03) at relapse as statistically significant; the first two
variables remained significant in a multivariate model. Risk groups were
created by identifying patients who had 0, 1 or 2 risk factors. These
three groups had significantly different PFS (p<0.0001): low risk with a
median PFS of 13.9 m, intermediate 6.4 m and high risk 3.9 m. Time to
relapse did not influence PFS or OS. For OS, Salvage (p=0.02) and ane-
mia at relapse post-ASCT (p=0.0001) were significant on univariate
analysis, and remained significant on multivariate analysis. Pts had sig-
nificantly different OS according to number of variables present at
relapse: low risk (no risk factors) with median OS 35.8 m; intermediate
(1): 21.1 m; high risk (2): 9.4 m. Conclusions. Through this retrospective
analysis, we were able to identify variables that can stratify patients
with relapsed HL after ASCT into prognostic groups with significantly
different PFS and OS. This information can be used to guide the choice
of treatment and to understand the results of novel therapeutic approach-
es, ranging from the evaluation of investigational agents to reduced
intensity allogeneic stem cell transplantation.
P149
HODGKIN'S LYMPHOMA OF THE UTERINE CERVIX
B. Mihaljevic, M. Perunicic, L.J. Jakovic, A. Sretenovic, T. Terzic, 
B. Andjelic, D. Boskovic
Institute of Hematology, Clinical Center of Serbia, Belgrade, Serbia
Uterine cervix is uncommon site for Hodgkin's lymphoma (HL) pres-
entation and therefore maybe misdiagnosed. The therapy of this unusu-
al extranodal HL presentation is still controversal: irradiation alone or
combination either with surgery or chemotherapy. We present the case
of 62 years (yrs) old postmenopausal multipara who developed unusu-
al cervical relapse of HL, with per continuitatem propagation to the vagi-
nal wall. The patient (pt) relapsed 15 yrs after achievement complete
remission of HL, CS IV B, initially treated with MOPP regimen and sub-
diaphragmal irradiation. During the follow-up period, she developed
renal failure and asepttic necrosis od acetabulum. Suspected neoplastic
process on the uterine cervix was verified upon routine abdominal ultra-
sound, and gynecological examination. Cervical and vaginal biopsy was
performed as well as curettage of the cervical canal. In the obtained uter-
ine cervix tissue samples nodular growth of the tumor tissue is observed
in the stroma with marked proliferation of the connective tissue. The
nodules contain numerous classical Reed-Sternberg cells, multinuclear
variants, numerous mononuclear and lacunar cells. Individual large cells
are mummified the nuclei are markedly condensed, hyperchromatic, lack-
ing the visible nucleolus. The neoplastic cells are surrounded by moder-
ately numerous lymphocytes, eosinophilic granulocytes, histocytes and
plasmocytes. Blood vessels are showing the characteristic onion-skin
fibrosis. The tumours cells were CD30+, CD15+, MUM-1+, CD20+/-, CD3,
CD45RO–, EMA–, ALK-1–, Bcl-2–. Ki-67 was positive in 50% of tumor
cells. The diagnosis of cHL relapse was obtained. This late relapse of HL
was in CS I BE, and the patient was treated with ABVD regimen. After
the second course of chemotherapy lethal outcome ensued due to pro-
gression of the renal failure. Although uncommon, lymphoma should be
included in the differential diagnosis of gynecological malignancies
because of a possible favorable outcome when properly diagnosed and
treated. We speculate weather this rare relapse of our pt is consequence
of initial combined therapy 15 yrs ago.
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ALLOGENEIC STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN’S
LYMPHOMA: A REPORT OF 9 PATIENTS TREATED AT A SINGLE CENTER
M. Villalobos, S. Schonland, J. Meissner, M. Rieger, U. Hegenbart, 
P. Dreger, A.D. Ho
Department of Hematology and Oncology, University of Heidelberg, Germany
Introduction. Prognosis of Hodgkin’s Lymphoma (HL) with chemother-
apy-refractory relapse and relapse after autologous stem cell transplan-
tation is poor. The role of allogeneic stem cell transplantation in this sit-
uation is still controversial.
Methods. Since 2001 nine patients with relapsed or refractory HL
underwent allogeneic stem cell transplantation at our department. The
median age was 39 years (range 24-50). The median number of
chemotherapies received prior to the allogeneic stem cell transplantation
was 3 (range 3-5). 6 patients had received prior autologous stem cell
transplantation. Disease status at allogeneic stem cell transplantation
was sensitive relapse in 7 patients and refractory relapse in 2. 4 patients
had an unrelated donor, 5 patients had a related donor. The condition-
ing regimens employed were TBI (12 Gy) with cyclophosphamide (120
mg/kg BW) in 3 patients, melphalan (100-140 mg/m2) with fludarabine
(75-150 mg/m2) in 5 patients and TBI (2 Gy) with fludarabine (90 mg/m2)
in 1 patient following autologous transplantation.
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Results. 6 patients are alive (all in complete remission) with a median
follow-up of 58 months (range 1-77). The incidence of acute GvHD
(grade I-IV) in 6 of 9 patients eligible was 66,6% and of chronic GvHD
(limited and extensive) was 80%. 100-day mortality was 14,3% and 1-
year-mortality was 50%. One patient died at day +33 due to pneumo-
nia (refractory relapse, conditioning with TBI/Cy), the other two patients
at day +119 and +246 due to progressive disease (both were sensitive
relapses, conditioning with TBI/Cy and Mel/Flu respectively). 
Discussion. The 1-year mortality rate is comparable to reported data
on allogeneic stem cell transplantation in heavily pretreated or refracto-
ry HL patients. All three long-term survivors developed chronic GvHD,
suggesting the presence and curative potential of a GvHL effect. The val-
ue of allogeneic stem cell transplantation should be further explored in
prospective clinical trials
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TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN PRIMARY REFRACTORY
HODGKIN LYMPHOMA AFTER SALVAGE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL
TRANSPLANTATION
N. Puig,1 M. Pintilie,2 T. Nagy,1 S. Zadeh,1 R. Tsang,3 A. Keating,1
M. Crump,1 J. Kuruvilla1
1Autologous Blood and Marrow Transplant Program, 2Clinical Study Coordina-
tion and Biostatistics; 3Department of Radiation Oncology, Princess Margaret
Hospital, Toronto, Canada
Introduction. Duration of response to primary therapy is recognized as
a predictor of outcome for patients (pts) with relapsed Hodgkin Lym-
phoma (REL-HL). Primary refractory HL (REF-HL) has a particularly poor
prognosis. High-dose chemotherapy (HDCT) followed by autologous
stem cell transplantation (ASCT) is frequently performed, but the impact
of patient selection on reports of outcome with this approach is not
clear. 
Patients and methods. We evaluated 81 consecutive pts with REF-HL
referred for consideration of ASCT between 1999 and 2006. REF-HL
was defined as progression during or within 3 months primary treatment
(ABVD: 93%). Response to salvage therapy (mini-BEAM: 24, DHAP: 7,
GDP: 43) was assessed after 2-3 cycles. A second regimen was used in
cases of disease progression. HDCT consisted in etoposide (60 mg/kg)
and melphalan (180 mg/m2). Pts with disease >5 cm at relapse received
involved field radiation post-ASCT. 
Results. Pts characteristics: 54 males (67%); median age: 33 years
(range: 18-68); histology: nodular sclerosis: 62 (77%); stage at diagnosis:
I/II: 35 (44%), III/IV: 45 (56%); presented with B symptoms at diagno-
sis: 49 (61%); received combined modality therapy: 15(19%). 58 (72%)
had disease progression during first line treatment. 39 (51%) of pts were
stage III/IV and 21 (28%) had B symptoms at the time of disease pro-
gression. Overall response rate to salvage chemotherapy was 53% (GDP:
54%, mini-BEAM: 52%). 19 pts (26%) had stable disease. 66 (81%) pts
received HDCT and ASCT, 7 after 2nd line salvage. The 3-year DFS and
OS after ASCT were 50% and 84% respectively, compared to 63% and
90% for pts with remission>3 months following primary therapy
(p=0.097 and p=0.36 respectively). OS for all 81 pts at 3 years was and
77%. In multivariate analysis, sensitivity to salvage treatment was the
only significant prognostic factor for OS (p=0.0068). B symptoms at time
of progression, response at time of diagnosis and response for salvage
were significant for DFS (p=0.026, 0.040, 0.025).
Conclusions. 3-year DFS and OS are acceptable and justify the use of
HDCT and ASCT for this group of PTS. Future trials should focus on
mechanisms of drug resistance and addition of novel agents to salvage
chemotherapy.
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CLINICAL AND EPIDEMIOLOGICAL FEATURES OF HODKINS LYMPHOMA PATIENTS 
SUBMITTED TO AUTOLOGOUS BONE MARROW TRANSPLANT, CARRIED OUT AT THE
ONCOLOGICAL REASERCH CENTER (CEPON) OF THE STATE OF SANTA CATARINA,
BRAZIL, IN THE PERIOD FROM 3RD OF AUGUST 2000 UP TO 7TH OF APRIL 2007
A.C. Sepetiba Ribas, J.A. Pagnoncelli Bortolini, I.H. Bezerra Massaut,
M.A. da Silva Rotolo
Centro de Pesquisas Oncologicas, CEPON, Florianapolis, Brazil
Introduction. Hodgkins Lymphoma (HL) is a lymphoid originated can-
cer, typified by the proliferation of neoplastic cells of variable morphol-
ogy, named Reed-Sternberg cells. Hystological classification proposed by
the World Health Organization, suggests 2 different cases of HL, i.e., the
nodular lymphocitical predominant HL and the classical HL (WHO).
Chemotherapy with substantial doses, followed by autologous bone
marrow transplant is an alternative indicated to recurrence diseased
patients, once treated with chemotherapy and/or radiotherapy.
Purpose. Description of clinical and epidemiological characteristics of
patients with HL based on a bone marrow transplant treatment.
Methods. CEPON is the unique medical center of the State of Santa
Catarina available to offer a bone marrow transplant to the patients suf-
fering HL. A retrospective record analysis of all patients transplanted
within the time span of 7 years, i.e., from 3rd of August 200 to 7th of
April 2007. 
Results. Up to April 2007, 36 patients were treated with autologous
transplant. Most of them male patients (58,3%). The diagnostic denotes
an average age of 26,5 years old.The classical HL prevailed (94,5%) and
the Ann Arbor clinical condition with grade IV has prevailed over all oth-
ers (27,8%), followed by grade II (41,7%), grade III (25%) and grade I
(5,5%) accordingly. B symptoms occurred in 22 patients, making up
61,1% and absence of symptoms the remaining 38,9% of patients. As
far as the prior prognostic is concerned, the patients were divided into
3 groups (GHSG): favorable precocious condition (5,5%), unfavorable
precocious (intermediate) 41,7% and advanced (52,8%). Most of them
were transplanted on the second partial remission (33,3%), followed by
the second complete remission (19,4%). A group of 6 patients were pri-
marily refractory (16,6%) and 5 patients have shown third partial remis-
sion (13,8%). The average infused CD cells 34/kg was 7,8×106. The
engraftment of neutrophyls occurred in 100% of patients, with average
time intervals of 9,45 days. The engraftment of platelets occurred in
13,8 days.There are currently 77,8% of alive patients (28). From all 8
remaining patients that passed away, one unique has the death been
related to the transplant itself and the other 6 have their deaths result-
ed by the progression of the disease or due to its recurrency. From the
28 alive patients, 69,7% are remissive and 8,4% recurred. The overall
survival average noticed was 33,9 months.
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FOURTH INTERIM ANALYSIS OF THE HD-R2 STUDY - A EUROPEAN MULTICENTER TRIAL
FOR PATIENTS WITH RELAPSED HODGKIN LYMPHOMA
A. Josting,1 H. Haverkamp,1 P. Borchmann,1 H. Döhner,2 B. Metzner,3
A. Franke,4 L. Smardova,5 D. Niederwieser,6 M.Wilhelm,7
M.E. Goebeler,8 B. Pfistner,1 N. Schmitz,9 A. Sureda,10 J. Raemaekers,11
J.W. Baars,12 V. Diehl,1 A. Engert1
1German Hodgkin Study Group, Cologne, Germany, 2University Hospital Ulm,
Germany, 3Klinikum Oldenburg, Germany, 4University Hospital Magdeburg,
Germany, 5University Hospital Brno, Czech Republic, 6University Hospital
Leipzig, Germany, 7Klinikum Nürnberg, Germany, 8University Hospital
Würzburg, Germany, 9AK St. Georg, Hamburg, Germany, 10Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain; 11Radboud University Nijmegen Med-
ical Centre, The Netherlands; 12Netherland Cancer Institute, Amsterdam, The
Netherlands
Introduction. In patients with relapsed Hodgkin lymphoma (HL), high
dose chemotherapy (HDCT) followed by autologous stem cell trans-
plant is being regarded as standard of care resulting in significantly
improved progression-free survival. However, the best approach and
the amount of chemotherapy needed are unclear. A prior phase-II study
indicated that DHAP is feasible and very effective also when combined
with single agent high dose chemotherapy followed by BEAM (Josting
et al., A. Oncol 2005). 
Methods. Based on these data, a European intergroup study (HD-R2)
for patients in histologically confirmed relapse of HL (first relapse with
CR>3 months or second relapse without prior HDCT) was initiated
from GHSG, EORTC and EBMT. Responding patients after two cycles
of DHAP were randomized between BEAM vs. sequential high dose
(CTX, MTX, VP-16) and BEAM. Sample size was chosen to detect a
20% difference in 2-year freedom-from-treatment-failure (FFTF) for ran-
domized patients.
Results. Between 1/2001 and 12/2006 (end of recruitment) a total of
284 patients were included in this trial of whom 176 recruited to 8/2005
were included in the forth interim analysis being presented here. Eight
patients were not randomized due to progression and 9 for different
other reasons resulting in 159 responding patients randomized after two
cycles of DHAP. In this group the median follow-up was 28 months.
There were no major differences in patient characteristics between the
two arms with most of the patients being in late first relapse (CR>12
months). Major toxicity (WHO grade 3, 4) of randomized treatment
was thrombocytopenia in 91% of patients, leukopenia in 90%, mucosi-
tis in 65%, anemia in 59%, infection in 39%, nausea in 42% and fever
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in 14%, respectively with 93% of patients receiving at least one toxici-
ty of WHO grade 4. There were 85% of patients achieving CR/CRu.
After 30 months, overall survival for randomized patients was 86%
(95%-CI [80%, 92%]) and FFTF was 69% (95%-CI [61%, 77%]) with
no difference between treatment arms (p = 0,82 for survival, p=0,36 for
FFTF). 
Discussion. The treatment was feasible and effective with no sequen-
tial significant differences between arms at this forth interim analysis.
Thus, unequivocal conclusions will only be available after the final
analysis expected for 2008.
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